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Acute	   optic	   neuritis	   is	   a	   common	   and	   often	   presenting	   feature	   of	  multiple	   sclerosis,	   and	  
attacks	   can	   lead	   to	  persistent	   visual	   impairment	   through	  neurodegeneration	   in	   the	   retina	  
and	   optic	   nerve.	   The	   acute	   inflammatory	   lesion	   in	   the	   optic	   nerve	   resembles	   the	  
demyelinating	  plaques	  elsewhere	  in	  the	  CNS.	  	  
As	  with	  other	  MS	  relapses,	  corticosteroids	  have	  no	  or	   little	   impact	  on	  the	  extent	  to	  which	  
vision	   recovers	   nor	   do	   they	   prevent	   optic	   nerve	   atrophy	   on	  MRI	   or	   improve	   VEP	   latency	  
after	  an	  attack	  of	  optic	  neuritis.	  There	  is	  currently	  no	  treatment	  for	  the	  acute	  phase	  of	  the	  
disease	  to	  improve	  long-­‐term	  visual	  outcome,	  and	  in	  this	  context	  neuroprotection	  remains	  a	  
major	  unmet	  need.	  
Progress	  in	  the	  development	  of	  potential	  neuroprotective	  therapies	  in	  optic	  neuritis	  and	  MS	  
relies	  upon	  the	  identification	  of	  key	  mechanisms	  and	  treatment	  targets.	  	  
Among	  possible	  mechanisms	  of	  neurodegeneration,	  there	  is	  growing	  evidence	  of	  a	  cascade	  
of	   accumulation	   of	   sodium	   ions	   in	   demyelinated	   axons	   that	   arises	   from	   neuronal	   energy	  
failure	   leading	   to	   the	   reverse	   operation	   of	   the	   Na+/Ca2+	   exchanger	   and	   subsequent	   toxic	  
accumulation	   of	   injurious	   calcium	   ions.	   Inhibition	   of	   voltage-­‐gated	   sodium	   channels	   is	  
neuroprotective	  in	  preclinical	  models	  of	  inflammatory	  demyelination.	  
The	  anterior	  visual	  system	  has	  many	  advantages	  for	  testing	  neuroprotective	  treatments	   in	  
MS.	   In	   particular,	   the	   retinal	   nerve	   fibre	   layer	   is	   a	   relatively	   pure	   compartment	   of	  
unmyelinated	  axons	  whose	  thickness	  can	  be	  measured	  sensitively	  and	  non-­‐invasively	  using	  
optical	  coherence	  tomography	  making	  it	  an	  attractive	  biomarker	  of	  axonal	  loss.	  
In	   this	   thesis	   I	   investigated	   whether	   early	   and	   sustained	   sodium	   channel	   inhibition	   with	  
phenytoin	   is	  neuroprotective	   in	  acute	  optic	  neuritis.	  86	  people	  were	   randomized	  within	  2	  
weeks	   of	   optic	   neuritis	   symptom	   onset	   to	   receive	   phenytoin	   or	   placebo	   for	   3	   months.	  
Retinal	   nerve	   fibre	   layer	   (RNFL)	   thickness	   and	   macular	   volume	   (MV)	   were	   measured	   at	  
baseline,	   then	  6	  months	   later,	   using	  optical	   coherence	   tomography.	  Visual	   function,	   optic	  
nerve	  MRI,	   and	   visual	   evoked	   potentials	   were	   also	  measured.	   The	   primary	   outcome	  was	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mean	   RNFL	   thickness	   in	   the	   affected	   eye	   at	   6	   months,	   adjusted	   for	   fellow	   eye	   RNFL	  
thickness	  at	  baseline.	  
	  
In	  the	  intention	  to	  treat	  comparison,	  average	  affected	  eye	  RNFL	  thickness	  at	  6	  months	  was	  
7.15	  µm	  greater	  in	  the	  active	  group	  (n=39)	  vs.	  placebo	  (n=42),	  a	  30%	  protective	  treatment	  
effect	  (p=0.021).	  Adjusted	  MV	  was	  0.20	  mm3	  greater	  in	  the	  active	  group,	  a	  34%	  treatment	  
effect	   (p=0.005).	   There	  was	   also	   a	   near	   significant	   treatment	   effect	   on	   optic	   nerve	   cross-­‐
sectional	   area	   (p=0.06).	   Per	   protocol	   comparisons	   showed	   similar	   treatment	   effects.	  
Treatment	  did	  not	  affect	  visual	  outcome.	  	  	  
	  
These	   findings	   support	   the	   concept	   of	   neuroprotection	   with	   phenytoin	   in	   acute	   optic	  
neuritis.	  Inhibition	  of	  voltage-­‐gated	  sodium	  channels	  could	  also	  be	  neuroprotective	  in	  other	  
relapses	   of	   multiple	   sclerosis,	   and	   further	   investigation	   of	   its	   effect	   is	   warranted	   in	   this	  














I,	   Rhian	   Raftopoulos	   confirm	   that	   the	   work	   presented	   in	   this	   thesis	   is	   my	   own.	   Where	  
information	  has	  been	  derived	  from	  other	  sources	   I	  confirm	  that	  this	  has	  been	   indicated	   in	  
the	  thesis.	  
I	  performed	  the	  following:	  assisted	  in	  writing	  of	  applications	  for	  ethics	  approval,	  setting	  up	  
the	  trial	  infrastructure	  and	  advertising	  the	  trial	  to	  the	  patient	  identification	  centres,	  writing	  
of	  the	  trial	  standard	  operating	  procedures,	  screening	  and	  recruitment	  of	  all	  patients	  at	  the	  
London	   site,	  development	  of	  MRI	  protocols	  with	   the	  assistance	   from	   the	  physicists.	   I	  was	  
also	   responsible	   for	  arranging	  all	   visits	  at	   the	  London	  site,	  baseline,	  one	  month	  and	   three	  
month	  clinical	  assessments,	  pharmocovigilence,	  maintaining	  case	  record	  forms	  and	   liaising	  
with	   the	   trial	   monitor,	   performing	   the	   baseline	   retinal	   imaging,	   taking	   and	   processing	   of	  
blood	   and	   urine	   samples	   for	   the	   biomarker	   sub	   study,	   data	   acquisition	   and	   entry,	   data	  
analysis	  (with	  the	  exception	  of	  the	  MTR	  analysis)	  and	  the	  writing	  of	  this	  thesis.	  	  
The	   study	  was	   designed	   by	   the	   trial	   working	   group	  who	   included:	   Dr	   Simon	  Hickman,	   Dr	  
Ahmed	   Toosy,	   Dr	   Basil	   Sharrack,	   Daniel	   R	   Altmann,	   Dr	   Rose	   Sheridan,	   Professor	   Martin	  
Koltzenburg,	  Professor	  Claudia	  AM	  Gandini	  Wheeler-­‐Kingshott,	  Professor	  Klaus	  Schmierer,	  
Professor	  Gavin	  Giovannoni,	  Professor	  David	  H	  Miller	  and	  Dr	  Raju	  Kapoor	  
Dr	   Rose	   Sheridan	   was	   the	   project	   manager	   for	   the	   trial	   and	   assisted	   in	   the	   writing	   of	  
applications	  for	  ethics,	  MHRA	  and	  R+D	  approval	  as	  well	  as	  obtaining	  R+D	  approval	  at	  all	  of	  
the	  patients	  identicication	  centres.	  	  
Dr	   Simon	   Hickman	   and	   Dr	   Basil	   Sharrack	   were	   responsible	   for	   patient	   screening,	  
recruitment,	  clinical	  assessments	  and	  pharmacovigilence	  at	  the	  Sheffield	  site.	  The	  Sheffield	  
trial	  nurses	  were	  responsible	  for	  maintenance	  of	  case	  record	  forms	  taking	  and	  processing	  of	  
blood	  and	  urine	  samples	  for	  the	  biomarker	  sub	  study	  and	  data	  acquisition	  at	  the	  Sheffield	  
site.	  
The	  patients	  were	  identified	  and	  referred	  by	  colleagues	  in	  a	  number	  of	  patient	  identification	  
sites	   across	   the	   country	   including:	  Mr.	   James	   Acheson	   and	   the	   Ophthalmology	   Specialist	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Registrars	   (Moorfields	   Eye	   Hospital	   NHS	   Foundation	   Trust,)	   Dr	   Richard	   Nicholas	   (Western	  
Eye	  Hospital,	   Imperial	  College	  Healthcare	  NHS	  Trust)	  Dr	  Luke	  Bennetto	   (North	  Bristol	  NHS	  
Trust),	  Mr.	  Mike	   Burdon	   (University	   Hospitals	   Birmingham	   NHS	   Trust),	   Dr	   Jeremy	   Hobart	  
(Plymouth	  Hospitals	  NHS	  Trust),	  Dr	  Edward	  Hughes,	  Dr	  Waqar	  Rashid,	  Dr	  Sarah	  Vickers	  and	  
Dr	   Dominic	   Heath	   (Brighton	   and	   Sussex	   University	   Hospitals	   NHS	   Trust),	   Professor	   Cris	  
Constantinescu	   	   (Nottingham	   University	   Hospitals	   NHS	   Trust),	   Professor	   Irene	   Gottlob	  
(University	  Hospitals	  of	  Leicester	  NHS	  Trust),	  Dr	  Matt	  Craner	  and	  Dr	   Jackie	  Palace	   (Oxford	  
University	   Hospitals),	   Professor	   Keith	   Martin	   and	   Professor	   Alasdair	   Coles	   (Cambridge	  
University	   Hospitals	   NHS	   Trust),	   Professor	   Clive	   Hawkins	   (University	   Hospitals	   of	   North	  
Midlands	  NHS	  Trust),	  and	  Mr	  David	  Bessant	  (London	  North	  West	  Healthcare	  NHS	  Trust).	  
Six-­‐month	  visual	  assessments	  and	  retinal	   imaging	  were	  performed	  by	  Dr	  Shahruckh	  Mallik	  
(at	   the	   London	   site)	   and	   retinal	   imaging	   at	   the	   Sheffield	   site	   was	   performed	   by	   the	   OCT	  
technicians,	  all	  of	  whom	  were	  blinded	  to	  treatment	  allocation.	  	  	  
Blinded	   electrophysiological	   testing	   was	   performed	   by	   Prasad	   Malladi	   and	   analysed	   by	  
Professor	  Martin	   Koltzenburg	   at	   the	   London	   site	   and	   Dr	   Ptolemaios	   G	   Sarrigiannis	   at	   the	  
Sheffield	  site.	  	  
Professor	   Claudia	   Wheeler-­‐kingshott,	   Dr	   Rebecca	   Samson	   and	   Marios	   Yiannakas	   assisted	  
with	  the	  development	  of	  the	  MRI	  protocol.	  
Dr	  Ahmed	  Toosy	  and	  Marios	  Yiannakas	  assisted	  with	  lesion	  identification	  and	  location	  in	  the	  
optic	  nerve.	  	  	  	  	  
Dr	  Katherine	  Miszkiel	  and	  Dr	  Nigel	  Hoggard	  reported	  on	  the	  brain	  MRI	  of	  the	  patients	  at	  the	  
London	  Sheffield	  sites	  respectively	  both	  of	  whom	  were	  blinded	  to	  treatment	  allocation.	  
Dr	  Vincente	  performed	  the	  MTR	  analysis	  of	  the	  optic	  nerve	  imaging	  at	  the	  London	  site	  and	  
was	  blinded	  to	  treatment	  allocation.	  	  
Dr	  Daniel	  Altmann	  performed	  the	  statistical	  analysis	  for	  the	  trial.	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There	  are	  a	  many	  people	  who	   I	  would	   like	   to	   thank	   for	   their	   invaluable	  help	  and	   support	  
during	  this	  PhD	  project.	  
First	  and	  foremost	  I	  would	  like	  to	  thank	  the	  patients	  for	  agreeing	  to	  participate	  in	  the	  trial	  
and	  giving	  up	  so	  much	  of	  their	  time	  to	  return	  for	  follow	  up	  visits.	  This	  work	  would	  not	  have	  
been	  possible	  without	  them.	  
I	  would	  also	   like	   to	   thank	   to	  Dr	  Simon	  Hickman	  and	   the	   rest	  of	   the	   trial	   team	   in	  Sheffield	  
who	  were	  responsible	  for	  the	  recruitment	  and	  care	  of	  the	  patients	  at	  the	  Sheffield	  trial	  site.	  
Without	  their	  commitment	  and	  collaboration	  this	  project	  would	  not	  have	  been	  possible.	  	  	  
Special	   thanks	  also	  goes	   to	  Dr	  Ahmed	  Toosy	  who	  was	  extremely	  helpful	   in	   setting	  up	   the	  
recruitment	  pathway	  in	  Moorfields	  that	  has	  been	  so	  instrumental	  to	  the	  success	  of	  the	  trial.	  	  
I	  learnt	  a	  huge	  amount	  about	  neuro-­‐opthalmology	  thanks	  to	  his	  tutelage.	  	  In	  addition	  to	  this	  
he	  helped	  teach	  me	  about	  MRI	  analysis	  of	  the	  optic	  nerve.	  
I	  am	  also	  extremely	  grateful	  to	  Mr	  Acheson	  and	  the	  ophthalmology	  registrars	  at	  Moorfields	  
eye	  hospital	  who	  were	  so	  helpful	  in	  contacting	  me	  every	  time	  a	  patient	  with	  optic	  neuritis	  
was	  seen	  in	  eye	  casualty.	  Without	  this	  recruitment	  of	  sufficient	  numbers	  of	  patients	  into	  the	  
trial	  would	  have	  been	  extremely	  difficult	  if	  not	  impossible.	  	  
I	  would	  also	  like	  to	  give	  special	  mention	  to	  Dr	  Rose	  Sheridan	  who	  was	  project	  manager	  and	  
responsible	  for	  overseeing	  all	  aspects	  of	  the	  trial.	  She	  really	  was	  indispensible	  and	  this	  
project	  would	  not	  have	  got	  off	  the	  ground	  without	  her.	  
In	  addition,	  I	  would	  like	  to	  thank	  the	  radiographers	  in	  the	  NMR	  unit	  who	  performed	  the	  MRI	  
scans	  for	  the	  patients	  with	  particular	  thanks	  to	  Marios	  Yiannakos	  who	  also	  assisted	  with	  the	  
development	  of	  the	  MRI	  protocols	  as	  well	  as	  helping	  identify	  the	  lesion	  on	  the	  optic	  nerve	  
imaging.	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Prasad	  Malladi	  performed	  the	  electrophysiology	  for	  the	  trial	  patients	  and	  was	  so	  
accommodating	  in	  fitting	  them	  in	  at	  the	  last	  minute.	  
I	  am	  also	  indebted	  to	  the	  physicists	  in	  particular	  Professor	  Claudia	  Wheeler-­‐kingshott	  and	  Dr	  
Rebecca	  Samson	  for	  the	  development	  of	  the	  MRI	  protocol	  for	  the	  trial.	  	  
Dr	  Daniel	  Altmann	  developed	  the	  statistical	  analysis	  plan	  and	  performed	  all	  the	  statistics	  for	  
the	  trial.	  I	  am	  extremely	  grateful	  for	  his	  patience,	  precision	  and	  attention	  to	  detail	  as	  well	  as	  
his	  pragmatic	  approach	  to	  explaining	  statistical	  concepts.	  	  
I	  have	  been	  lucky	  enough	  work	  alongside	  some	  fantastic	  clinical	  fellows	  in	  the	  NMR	  unit	  and	  
would	  like	  to	  thanks	  Dr	  David	  Paling	  for	  his	  assistance	  with	  visual	  testing	  as	  well	  as	  Dr	  
Shahruckh	  Mallik	  for	  performing	  the	  six-­‐month	  OCT	  scans.	  Thanks	  also	  to	  Dr	  Hugh	  Kearney,	  
Dr	  Varun	  Sethi,	  Dr	  Nils	  Mulhert,	  Dr	  Wallace	  Brownlee	  and	  Niamh	  Cawley	  for	  making	  my	  time	  
at	  Queen	  Square	  such	  an	  enjoyable	  and	  fulfilling	  experience	  and	  for	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Chapter	  1 Anatomy	  and	  Physiology	  of	  the	  Anterior	  Visual	  System	  
1.1 Histology	  of	  the	  Retina	  
The	  sensory	  retina	  is	  part	  of	  the	  central	  nervous	  system	  and	  develops	  from	  the	  optic	  cup.	  It	  
is	  approximately	  0.5mm	  thick	  and	  lines	  the	  back	  of	  the	  eye.	  It	  is	  a	  unique	  CNS	  structure	  as	  it	  
contains	  axons	  and	  glia	  in	  the	  absence	  of	  myelin.	  
The	  central	  retina	  is	  a	  circular	  field	  approximately	  6	  mm	  around	  the	  fovea	  and	  beyond	  that	  
the	   peripheral	   retina	   extends	   to	   the	   ora	   serrata	  which	   is	   approximately	   21	  mm	   from	   the	  
fovea(Polyak,	  1941)	  .	  
The	  macula	   is	   a	   circular	   area	  approximately	  1.5	  mm	   in	  diameter	  with	  a	   centre	   located	  17	  
degrees	  or	  4.0-­‐5.0mm	  temporal	  to	  and	  0.53-­‐0.8	  mm	  inferior	  to	  the	  centre	  of	  the	  optic	  disc	  T	  
(Kincaid	   and	  Green,	   1999).	   It	   is	   easily	   identified	   due	   to	   the	   oval	   shaped	   depression	   at	   its	  
centre	  called	  the	  fovea.	  The	  foveal	  part	  of	  the	  macula	  confers	  the	  greatest	  visual	  acuity	  and	  
has	  the	  highest	  density	  of	  cone	  receptors	  (199,000/mm2),	  which	  are	  elongated	  to	  maximize	  
light	  detection	  (Oyster,	  1999;	  Curcio	  et	  al.,	  1990).	  
	  There	   are	   no	   rods	   in	   the	   foveola	   but	   these	   are	   the	   predominant	   photoreceptor	   in	   the	  
peripheral	  retina.	  	  
The	   neurosensory	   retina	   consists	   of	   three	   layers	   of	   nerve	   cell	   bodies	   and	   two	   layers	   of	  
synapses.	  The	  ganglion	  cell	  layer	  lies	  innermost,	  proximal	  to	  the	  lens	  and	  anterior	  chamber	  
of	  the	  eye	  and	  the	  photoreceptor	  layer	  is	  outermost	  next	  to	  the	  retinal	  pigment	  epithelium.	  
Light	  must	  therefore	  travel	  the	  entire	  thickness	  of	  the	  inner	  retina	  before	  reaching	  the	  rods	  




1.2 The	  Retinal	  Layers.	  
Bruch’s	  membrane	  
Is	  an	  elastic	  membrane	  extending	  from	  the	  optic	  disc	  posteriorly,	  where	  it	  is	  thickest,	  to	  the	  
ora	   serrata	   anteriorly.	   It	   is	   located	   between	   the	   retinal	   pigment	   epithelium	   RPE	   and	   the	  
choriocapillaris.	  	  
The	  Retinal	  Pigment	  Epithelium	  (RPE)	  
Provides	   structural	   and	   metabolic	   support	   to	   the	   photoreceptors	   primarily	   via	   vitamin	   A	  
metabolism.	  The	  tight	  junctions	  between	  RPE	  cells	  help	  maintain	  the	  selective	  blood	  retina	  
barrier.	  	  
The	  Photoreceptor	  Layer	  (The	  Outer	  Nuclear	  Layer)	  
Photoreceptors	  (rods	  and	  cones)	  contain	  a	  visual	  pigment	  that	  absorbs	  photons	  of	  light	  and	  
converts	  them	  into	  an	  electrochemical	  signal.	  	  
The	  human	  retina	  contains	  three	  types	  of	  cone	  and	  rods.	  The	  three	  types	  of	  cone	  operate	  at	  
different	  wavelengths:	   short	   (blue),	  middle	   (green)	   and	   long	   (red).	   Rods	   are	   saturated	   by	  
natural	   light	   and	   cannot	   distinguish	   colours	   but	   are	   effective	   for	   scotopic	   vision.	   Humans	  
have	  a	  rod:	  cone	  ratio	  of	  20:1	  and	  approximately	  50%	  of	  cones	  are	  located	  within	  the	  central	  
30	   degrees	   of	   visual	   field.	   (Rizzo,	   1994).	   The	   density	   of	   rods	   is	   highest	   in	   the	   ‘rod	   ring’	  
approximately	  4.5mm	  from	  the	  foveola.	  	  (Rizzo,	  1994).	  
The	  Outer	  Plexiform	  Layer	  
This	  is	  where	  the	  photoreceptors	  form	  synaptic	  connections	  with	  the	  bipolar	  and	  horizontal	  




The	  Inner	  Nuclear	  Layer	  
This	   layer	   consists	   of	   bipolar,	   horizontal	   and	   amacrine	   cells.	   These	   form	   complex	  
neuroretinal	   connections	   in	   the	   inner	   and	   outer	   plexiform	   layers	   that	   modify	   the	  
photoreceptor	  signal	  and	  transmit	  it	  to	  the	  ganglion	  cells.	  
Photoreceptors	  connect	  to	  bipolar	  cells	  that	  relay	  messages	  to	  ganglion	  cells.	  Amacrine	  and	  
horizontal	   cells	   form	   lateral	   connections	   between	   these	   layers	   and	   may	   contribute	   to	  
contrast	  enhancement.	  In	  the	  fovea	  cone	  bipolar	  cells	  may	  receive	  input	  from	  a	  single	  cone	  
photoreceptor	   that	   allows	   a	   high	   degree	   of	   spatial	   acuity.	   Conversely,	   in	   the	   peripheral	  
retina	  up	  to	  70	  rods	  may	  converge	  and	  provide	  information	  to	  a	  bipolar	  cell	  (Sharma	  et	  al,	  
2003).	  
The	  Inner	  Plexiform	  Layer	  
This	   is	  where	   the	   second	   stage	  of	   retinal	  processing	  occurs	  and	  acts	  as	  a	   relay	   station	   for	  
vertical	  information.	  It	  is	  the	  neuropil	  layer	  where	  bipolar	  cells	  synapse	  with	  the	  dendrites	  of	  
ganglion	   cells.	   In	   addition	   to	   this	   different	   varieties	   of	   horizontally	   and	   vertically	   directed	  
amacrine	  cells	  interact	  to	  integrate	  and	  influence	  bipolar	  cell	  outputs.	  There	  are	  around	  40	  
types	  of	  amacrine	  cell	  and	  each	  type	  has	  a	  particular	  neurotransmitter	  and	  connects	  with	  a	  
particular	  type	  of	  bipolar	  cell.	  	  (Kolb	  et	  al.,	  1995)	  
The	  Ganglion	  Cell	  Layer	  
The	  ganglion	  cells	   transfer	  visual	   information	   from	  the	   retina	   to	   the	  brain.	  Adults	  have	  on	  
average	  1.2	  million	  retinal	  ganglion	  cells	  and	  approximately	  70%	  of	  these	  sub	  serve	  central	  
vision	  (Rizzo,	  1994).	  Although	  up	  to	  20	  different	  types	  of	  ganglion	  cell	  have	  been	  described	  
the	  most	  common	  (80%)	  are	  midget	  (parvocellular	  cells)	  and	  10%	  are	  parasol	  (magnocellular	  
cells)	  that	  are	  named	  after	  their	  target	  locations	  in	  the	  lateral	  geniculate	  nucleus.	  (Wurtz	  et	  
al,	  2000).	  The	  Midget	  pathways	  consist	  of	  midget	  bipolar	  cells	  and	  midget	  ganglion	  cells.	  The	  
fovea	  has	  a	  high	  concentration	  of	  midget	  ganglion	  cells.	  Midget	  cells	  have	  cone	  opponent	  
receptive	  fields.	  They	  are	  high	  acuity	  cells	  and	  also	  carry	  red	  or	  green	  color	  specific	  signal.	  
This	  allows	  them	  to	  confer	  high	  spatial	  acuity,	  colour	  vision	  and	  fine	  stereopsis.	  Midget	  cells	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come	  in	  high	  branching	  varieties	  that	  are	  probably	  physiologically	  off	  centre	  as	  well	  as	  low	  
branching	   types	   that	   are	   probably	   ON	   centre	   physiologically.	   	   The	   connections	   between	  
midget	  bipolar	   and	  midget	   ganglion	   cells	  have	  previously	  been	   thought	   to	  be	  one	   to	  one.	  
Although	  this	  is	  likely	  to	  be	  the	  case	  in	  the	  foveal	  area	  it	  may	  not	  be	  true	  in	  the	  peripheral	  
retina	  where	  the	  midget	  ganglion	  cells	  have	  larger	  dendritic	  trees	  and	  can	  have	  input	  from	  
3-­‐5	  midge	  bipolar	  cells	  (Kolb	  and	  Marshak,	  2003).	  
Parasol	  (magnocellular	  cells),	  so	  called	  because	  of	  their	  resemblance	  to	  an	  open	  umbrella	  on	  
histological	  sections,	  have	  a	  much	  larger	  dendritic	  tree	  and	  make	  connections	  with	  several	  
bipolar	  cells	  receiving	  convergent	  input	  from	  a	  much	  larger	  area	  of	  the	  retina.	  They	  are	  more	  
numerous	   in	   the	   peripheral	   retina.	   They	   have	   a	   larger	   receptive	   field	   and	   lower	   spatial	  
resolution	   than	   midget	   cells	   and	   transmit	   signals	   from	   many	   rods	   and	   cones.	   They	  
demonstrate	  spatial	  but	  not	  spectral	  opponency.	  They	  confer	  low	  spatial	  resolution,	  motion	  
detection	  and	  coarse	  stereopsis	  but	  do	  not	  detect	  colour	  (Livingstone	  and	  Hubel,	  1988).	  	  
The	   smallest	   ganglion	   cells	   are	   koniocellular.	   They	   have	   a	   small	   cell	   body	   but	   diffuse	  
dendritic	   tree.	   They	   include	   bistratified	   cells	   that	  make	   contact	   at	   both	   upper	   and	   lower	  
sublaminae	   of	   the	   inner	   plexiform	   layer.	   They	   project	   to	   intercalated	   layers	   (koniocellular	  
layers)	  in	  the	  LGN.	  They	  have	  S	  (Short-­‐length)	  cone	  ON	  receptive	  fields	  and	  one	  of	  the	  major	  
roles	  of	  the	  koniocellular	  pathway	  may	  be	  to	  serve	  the	  blue	  yellow	  axis	  of	  colour	  vision.	  The	  
koniocellular	   layer	   of	   the	   LGN	   comprises	   a	   diffuse	   layer	   of	   mostly	   small	   cell	   codes	  
intercalated	  between	  the	  main	  laminae	  (Dacey	  and	  Lee,	  1994)	  (Hendry	  and	  Yoshioka,	  1994)	  
The	  ganglion	  cell	  layer	  also	  contains	  displaced	  amacrine	  cells	  and	  astrocytes.	  	  
The	  Retinal	  Nerve	  Fibre	  Layer	  
Retinal	  ganglion	  cell	  axons	  travel	  towards	  the	  optic	  nerve	  head	  within	  the	  nerve	  fibre	  layer.	  
The	   retinal	   nerve	   fibre	   layer	   is	   located	   between	   the	   inner	   limiting	   membrane	   and	   the	  
ganglion	   cell	   layer.	   It	   is	   composed	   of	   ganglion	   cell	   axons,	   astrocytes,	   retinal	   vessels	   and	  
Muller	   cells.	   Astrocytes	   and	   Muller	   cells	   comprise	   a	   neuroglial	   system	   that	   provides	  
structural	   and	   nutritional	   support	   to	   the	   nerve	   fibres.	   Muller	   cells	   occupy	   nearly	   all	   the	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intracellular	   retinal	   space	   and	   form	   the	   inner	   limiting	  membrane	   covering	   the	   nerve	   fibre	  
layer	  on	   its	  vitreal	   surface.	  The	  astrocytic	  processes	  partially	  envelope	  all	  nerve	   fibres	  and	  
also	  cover	  the	  retinal	  capillaries	  isolating	  the	  axons	  from	  retinal	  blood	  flow.	  The	  large	  retinal	  
arterioles	  and	  venules	  lie	  in	  the	  superficial	  part	  of	  the	  nerve	  fibre	  layer.	  A	  previous	  study	  in	  
primates	  demonstrated	  that	  glia	  occupies	  at	   least	  18%	  of	  the	  cross-­‐sectional	  area	  of	  every	  
nerve	   fibre	  bundle	  but	   this	  varies	  with	   location	  across	   the	  retina	  and	   in	  some	  areas	   (nasal	  
retina)	  was	   as	  much	   as	   42%	   (Ogden,	   1983).	   Another	   study	   in	   humans	   demonstrated	   that	  
retinal	  nerve	  fibre	  layer	  (RNFL)	  thickness,	  measured	  histomorphometrically	  at	  the	  optic	  disc	  
border	   in	  patients	  with	  absolute	  glaucoma,	  was	  40	  µms	  which	  would	  be	  consistent	  with	  a	  
glial	   content	   of	   around	   23-­‐30%	   of	   the	   total	   RNFL	   thickness	   (Dichtl	   et	   al.,	   1999).	   The	   glial	  
content	  of	  the	  retinal	  nerve	  fibre	  layer	  may	  increase	  with	  disease.	  In	  a	  histological	  study	  on	  
eyes	  of	  82	  patients	  with	  multiple	   sclerosis	  gliosis	  with	  a	   related	  glial	  mesodermal	   reaction	  
was	   seen	   in	   more	   than	   70%	   of	   optic	   nerves	   and	   immunohistochemistry	   demonstrated	  
perivenular	   astrocytic	   gliosis	   in	   the	   optic	   disc	   and	   intense	   gliomesodermal	   reaction	   in	   the	  
optic	  nerve	  (Green	  et	  al.,	  2010).	  This	  is	  important	  to	  highlight	  given	  that	  OCT	  measured	  RNFL	  
thickness	   measures	   do	   not	   give	   cytological	   detail	   and	   therefore	   may	   not	   be	   purely	  
measuring	  axonal	  loss	  after	  optic	  neuritis	  but	  may	  also	  be	  affected	  by	  gliosis.	  
The	  RNFL	  is	  thinnest	  in	  the	  peripheral	  retina	  and	  thickest	  towards	  the	  superior	  and	  inferior	  
margins	   of	   the	   optic	   disc	  where	   it	  measures	   approximately	   200	  µms	   (Dichtl	   et	   al.,	   1999).	  
Retinal	  nerve	   fibre	   layer	   thickness	   is	   known	   to	  decrease	  gradually	  with	  age	   (Alamouti	   and	  
Funk,	  2003).This	  occurs	  diffusely	  without	   the	  development	  of	   localised	  defects	   (Jonas	  and	  
Schiro,	  1994).	  	  
The	  axons	  are	  separated	  into	  bundles	  by	  the	  cell	  processes	  of	  the	  Muller	  cells.	  The	  axons	  of	  
the	   foveal	   ganglion	   cells	   project	   directly	   to	   the	   temporal	   aspect	   of	   the	   optic	   disc	   via	   the	  
papillomacular	   bundle.	   The	   remaining	   axons	   from	   the	   temporal	   retina	   form	   the	   arcuate	  
bundle	  around	  the	  papillomacular	  bundle	  on	  either	  side	  of	   the	  horizontal	   raphe	  and	  enter	  
the	  superior	  temporal	  and	  inferior	  temporal	  sections	  of	  the	  optic	  disc.	  Axons	  that	  originate	  
from	  the	  nasal	  retina	  project	  directly	  to	  the	  nasal	  aspect	  of	  the	  optic	  disc	  in	  a	  radial	  pattern.	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The	  horizontal	   raphe	  creates	  a	  physiological	   separation	  between	   the	   superior	  and	   inferior	  
hemi	  field	  of	  the	  nasal	  visual	  field	  (temporal	  retina).	  The	  vertical	  meridian	  that	  separates	  the	  
nasal	  and	  temporal	  retina	  is	  a	  vertical	  line	  that	  passes	  through	  the	  fovea.	  	  
The	  diameter	  of	  the	  nerve	  fibres	  in	  the	  temporal	  retina	  is	  smaller	  than	  in	  the	  nasal	  region	  or	  
vertical	  disc	  poles	  presumably	  due	  to	  the	  higher	  density	  of	  parvocellular	  ganglion	  cells	  in	  the	  
fovea	  (Jonas	  and	  Dichtl,	  1996)	  
Within	  the	  nerve	  fibre	   layer	  axons	  from	  central	  RGCs	   lie	  superior	  to	  those	  from	  peripheral	  
RGCs.	  Axons	   from	   the	  nasal	   retina	  decussate	  at	   the	  optic	   chiasm	  whereas	  axons	   from	   the	  
temporal	  retina	  remain	  ipsilateral.	  	  
Figure	  1-­‐1:	  Diagram	  illustrating	  RNFL	  axons	  as	  they	  project	  form	  RGCs	  to	  the	  optic	  disc	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
(Taken	  from	  Prasad	  and	  Galetta,	  2011	  (page	  9,	  Figure	  1.7))	  
	  





Figure	   1-­‐2:	   Diagram	   illustrating	   different	   retinal	   layers	   (ONL-­‐	   outer	   nuclear	   layer,	   OPL-­‐	  
outer	   plexiform	   layer,	   INL	   -­‐inner	   nuclear	   layer,	   GCL-­‐	   ganglion	   cell	   layer,	   RNFL	   –	   retinal	  
nerve	  fibre	  layer)	  
	  
(webvision.med.utah.edu)	  
1.3 The	  Optic	  Nerve	  
The	   optic	   nerves	   are	   phylogenetically	   an	   evagination	   of	   the	   brain	   and	   their	   histological	  








Each	   optic	   nerve	   consists	   of	   approximately	   1.2	   million	   retinal	   ganglion	   cell	   axons	   (Rizzo,	  
1994).	  There	  is	  a	  wide	  variation	  in	  the	  length	  of	  the	  optic	  nerve,	  even	  between	  the	  two	  eyes	  
of	  the	  same	  individual,	  with	  a	  range	  of	  35-­‐55mm	  from	  globe	  to	  chiasm	  (Hayreh,	  2011).	  	  	  	  
Each	  optic	  nerve	  can	  be	  segmented	  into	  four	  portions	  according	  to	  location	  along	  its	  course:	  
the	  intraocular,	  intraorbital,	  intracanalicular	  and	  intracranial	  portions.	  	  
Table	  1-­‐1:	  Approximate	  length	  of	  each	  segment	  of	  the	  optic	  nerve	  
Part	  of	  Optic	  Nerve	   Approximate	  Length	  
Intraocular	  (Optic	  nerve	  head)	   1mm	  
Intraorbital	  	   25	  mm	  
Intracanalicular	   4-­‐10mm	  
Intracranial	   10mm	  
	  
The	  Intraocular	  Portion	  
The	  optic	  nerve	  head	  is	  approximately	  4.5	  mm	  or	  15	  degrees	  nasal	  to	  the	  fovea.	  It	  contains	  
no	   retinal	   photoreceptors	   and	   is	   responsible	   for	   the	   blind	   spot.	   It	   is	   approximately	   1	  mm	  
deep	  and	  1.5mm	  in	  diameter	  (Hayreh,	  2011).	  It	  has	  a	  central	  depression	  called	  the	  optic	  cup.	  
The	  intraocular	  portion	  of	  the	  optic	  nerve	  head	  is	  visible	  on	  fundoscopy.	  Retinal	  axons	  enter	  
the	   optic	   disc	   at	   a	   90-­‐degree	   angle.	   The	   nerve	   fibres	   are	   arranged	   in	   bundles	   and	   are	  
unmyelinated	  at	  this	  point.	  
The	   topography	   of	   axons	  within	   the	   nerve	   fibre	   layer	   and	   optic	   nerve	   head	   is	   somewhat	  
controversial	  with	  conflicting	  reports	  of	  the	  positioning	  of	  ganglion	  cell	  axons.	  Some	  studies	  
have	  indicated	  that	  central	  retinal	  axons	  are	  positioned	  in	  the	  inner	  part	  of	  the	  optic	  nerve	  
head	   and	   the	   peripheral	   retinal	   axons	   in	   the	   outer	   part	   of	   the	   optic	   nerve	   head	  whereas	  
others	  have	  found	  the	  opposite	  (Garway-­‐Heath	  et	  al., 2000). These	  conflicting	  results	  may	  
be	   explained	   in	   part	   by	   inter-­‐species	   variation.	   A	   study	   in	   human	   eyes	   indicated	   that	   the	  
nerve	   fibre	   layer	   was	   not	   topographically	   organized	   with	   respect	   to	   eccentricity	   and	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peripheral	   nerve	   fibres	   were	   scattered	   throughout	   the	   thickness	   of	   the	   RNFL.	   However,	  
there	  was	  a	  rough	  topographic	  organization	  of	  nerve	  fibres	  within	  the	  optic	  nerve	  head	  with	  
respect	   to	   the	   circumferential	   origin	  of	   axons.	   Foveal	   fibres	  were	   found	   to	  occupy	  a	   large	  
proportion	   of	   the	   temporal	   aspect	   of	   the	   optic	   nerve	   head	   whereas	   fibres	   from	   areas	  
temporal	  to	  the	  fovea	  were	  displaced	  to	  more	  superior	  and	  inferior	  regions.	  Arcuate	  fibres	  
occupied	  a	  peripheral	  position	   in	   the	  optic	  nerve	  head.	  This	   topographic	  organization	  was	  
maintained	  going	  in	  to	  the	  optic	  nerve	  (Fitzgibbon	  and	  Taylor,	  1996).	  	  
Garway-­‐Heath	  et	  al	  produced	  a	  map	  relating	  regions	  of	  the	  visual	  field	  to	  sectors	  of	  the	  optic	  
disc	   using	   a	  Humphrey	  24-­‐2	   visual	   field	   grid	   superimposed	  onto	   the	  RNFL	  photographs	  of	  
patients	  with	  well-­‐defined	  RNFL	  defects.	  In	  their	  map	  the	  optic	  disc	  is	  divided	  into	  6	  sectors.	  
The	  central	  macular	   region	  of	   the	  visual	   field	  was	  associated	  with	   the	   temporal	   sectors	  of	  
the	  disc,	  the	  superior	  arcuate	  region	  of	  the	  field	  with	  the	  inferior	  temporal	  sector	  of	  the	  disc	  
and	  the	   inferior	  arcuate	  region	  of	   the	  visual	   field	  with	  the	  superior	  temporal	  sector	  of	   the	  
disc	  as	  well	  as	  three	  regions	  of	  the	  visual	  field	  corresponding	  to	  the	  nasal	  half	  of	  the	  optic	  










Figure	  1-­‐3:	  Diagram	  taken	  from	  Garway-­‐Heath	  et	  al	  demonstrating	  division	  of	  visual	  field	  
(A)	  and	  optic	  nerve	  (B)	  into	  sectors	  as	  described	  above.	  
	  
	  
The	  Optic	  nerve	  head	  is	  composed	  of:	  








The	  intraorbital	  optic	  nerve	  
The	  intraorbital	  part	  of	  the	  optic	  nerve	  begins	  where	  the	  nerve	  exits	  at	  the	  lamina	  cribrosa	  
and	  as	  it	  does	  so	  it	  becomes	  myelinated	  with	  oligodendrocytes	  and	  increases	  in	  diameter	  to	  
between	  3-­‐4	  mm.	  The	  acquisition	  of	  myelin	  at	  the	  lamina	  cribrosa	  allows	  the	  transformation	  
of	  action	  potentials	  from	  slow	  membrane	  to	  fast	  salutatory	  conduction.	  It	  is	  also	  at	  this	  point	  
that	   the	   optic	   nerve	   becomes	   ensheathed	   in	   the	  meninges	   and	   CSF	   fills	   the	   tube	   shaped	  
subarachnoid	  space	  between	  nerve	  and	  sheath.	  The	  subarachnoid	  space	  is	  continuous	  from	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the	  middle	   cranial	   fossa,	   along	   the	   nerve	   and	   into	   the	   posterior	   sclera.	   The	   subarachnoid	  
space	   of	   the	   optic	   nerve	   is	   widest	   near	   the	   globe	   and	   contains	   a	  multitude	   of	   arachnoid	  
trabeculae	   arranged	   in	   a	   reticular	   fashion.	   Some	   of	   the	   larger	   trabeculae	   contain	   blood	  
vessels.	  Elevated	  intracranial	  pressure	  is	  transmitted	  through	  the	  subarachnoid	  space	  to	  the	  
optic	  nerve	  head	  resulting	  in	  papilloedema.	  	  
The	  intraorbital	  portion	  of	  the	  optic	  nerve	  is	  between	  25	  –	  30	  mm	  in	  length	  and	  is	  at	  least	  
5mm	  longer	  than	  the	  direct	  distance	  from	  the	  globe	  to	  the	  orbital	  apex	  (Glaser	  and	  Sadun,	  
1990).	  This	  ‘slack	  in	  the	  system’	  allows	  movements	  of	  the	  eye.	  	  
Most	  of	  the	  optic	  nerve	  receives	  it	  blood	  supply	  from	  the	  ophthalmic	  artery	  that	  is	  a	  branch	  
of	  the	  internal	  carotid	  artery	  just	  after	  it	  has	  exited	  the	  cavernous	  sinus.	  In	  the	  cranial	  cavity	  
the	  ophthalmic	  artery	  lies	  mostly	  in	  the	  subdural	  space.	  The	  ophthalmic	  artery	  then	  passes	  
through	   the	   orbital	   canal	   below	   the	   optic	   nerve	   and	   gives	   rise	   to	   the	   posterior	   cililary	  
arteries	   and	   the	   central	   retinal	   artery.	   The	   central	   retinal	   artery	   pierces	   the	   optic	   nerve	  
approximately	  10-­‐15	  mm	  behind	  the	  globe	  and	  runs	  anteriorly	  within	  the	  optic	  nerve.	  The	  
blood	  supply	  to	  the	  orbital	  segment	  of	  the	  optic	  nerve	  is	  via	  the	  pial	  network	  that	  is	  supplied	  
either	  directly	  via	  branches	  of	  the	  ophthalmic	  artery	  or	  indirectly	  via	  branches	  of	  the	  short	  
posterior	   cilliary	   arteries	  or	   a	  branch	  of	   the	   central	   retinal	   artery.	  Branches	  of	   the	   central	  
retinal	   artery	  may	   also	   contribute	   to	   the	   optic	   nerve	   blood	   supply.	   Branches	   of	   the	   short	  
posterior	   cililary	   arteries	   provide	   the	  major	   blood	   supply	   to	   the	   optic	   nerve	   head	   via	   the	  
circle	  of	  Zinn-­‐	  Haller(Hayreh,	  2011).	  
The	  Intracanalicular	  Portion	  
Upon	  exiting	  the	  orbit	  the	  optic	  nerve	  enters	  the	  optic	  canal	  at	  the	  orbital	  apex.	  The	  optic	  
canal	  lies	  within	  the	  lesser	  wing	  of	  the	  sphenoid	  bone	  and	  is	  approximately	  10mm	  long	  and	  
3-­‐4mm	  wide	   (Rizzo,	  1994).	  The	  CSF	   filled	   subarachnoid	   space	   is	  markedly	  attenuated	  as	   it	  
passes	  through	  the	  optic	  canal	  and	  so	  is	  usually	  not	  seen	  on	  T2	  weighted	  MRI	  at	  this	  point.	  	  
The	   orbital	   canal	   makes	   an	   angle	   of	   45	   degrees	   with	   sagittal	   plane.	   The	   intracanalicular	  
portion	   of	   the	   optic	   nerve	   is	   fixed	   and	   immobile	   and	   may	   be	   particularly	   susceptible	   to	  
damage	  from	  trauma	  or	  swelling.	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The	  Intracranial	  portion	  
The	  intracranial	  portion	  of	  the	  optic	  nerve	  is	  approximately	  10	  mm	  long.	  It	  lies	  below	  the	  A1	  
segment	   of	   the	   anterior	   cerebral	   artery	   and	   lateral	   to	   the	   internal	   carotid	   artery.	   The	  
ophthalmic	   artery	   is	   a	   branch	   of	   the	   internal	   carotid.	   The	   ophthalmic	   artery	   enters	   the	  
subarachnoid	  space	  of	  the	  optic	  canal	  inferolaterally	  to	  the	  nerve.	  	  
The	  Optic	  Chiasm	  
The	  dumbbell	  shaped	  optic	  chiasm	  is	  where	  the	  two	  optic	  nerves	  merge.	  	  It	  is	  positioned	  in	  
the	   subarachnoid	   space	   of	   the	   suprasellar	   cistern	   above	   the	   diaphragma	   sella	   and	   the	  
pituitary	  gland.	  It	  lies	  inferior	  to	  the	  hypothalamus	  and	  anterior	  to	  the	  infundibulum.	  	  
The	  chiasm	  is	  usually	  around	  10mm	  above	  the	  pituitary	  gland.	  In	  15%	  of	  people	  the	  chiasm	  
is	   displaced	   anterior	   to	   the	   pituitary	   gland	   (a	   prefixed	   chiasm)	   and	   in	   5%	   is	   displaced	  
posteriorly	  (a	  post	  fixed	  chiasm)(Doyle,	  1990).	  	  
Within	   the	   chiasm,	   nerve	   fibres	   from	   the	   nasal	   retina	   of	   each	   eye	   decussate	   to	   join	   the	  
temporal	  fibres	  of	  the	  contralateral	  eye.	  In	  this	  way,	  fibres	  that	  carry	  information	  from	  the	  
same	  part	  half	  of	  the	  visual	  field	  are	  brought	  together.	  	  
The	  optic	  chiasm	  lies	  amongst	  the	  arteries	  that	  make	  up	  the	  circle	  of	  Willis	  and	  these	  vessels	  
provide	  an	  anastomotic	  supply	  to	  the	  chiasm.	  	  
1.4 Optic	  Nerve	  Fibres	  
Each	  optic	  nerve	   contains	  between	  770,000	  and	  1.7	  million	  nerve	   fibres.	   The	  nerve	   fibres	  
vary	   in	  diameter	   (between	  0.7µm	  and	  10µm)	  (Jonas	  and	  Dichtl,	  1996).	   In	  the	  retrolaminar	  
and	  orbital	  parts	  of	   the	  optic	  nerve	   they	  are	  arranged	   in	  bundles	   separated	  by	   septa.	  The	  
presence	   of	   these	   septa	   distinguishes	   the	   optic	   nerve	   from	   the	   other	   CNS	   white	   matter	  
tracts.	  Within	   the	  nerve	   fibre	  bundles	  are	  rows	  of	  supporting	  astrocytes,	  oligodendrocytes	  
and	  microglial	  cells.	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Hoyt	  et	  el	  studied	  the	  topographic	  organization	  of	  the	  nerve	  fibres	  in	  the	  anterior	  portion	  of	  
the	  optic	  nerve	  in	  primates.	  	  By	  photocoagulating	  different	  regions	  of	  the	  retina	  they	  were	  
able	   to	  histologically	   localize	  nerve	   fibre	  degeneration	   in	   the	  optic	  nerve.	  They	   found	   that	  	  	  
lesions	   in	   the	   superior	   and	   inferior	   temporal	   retina	   (sparing	   the	   macula)	   caused	  
degeneration	   of	   nerve	   fibres	   in	   the	   upper	   and	   lower	   temporal	   sectors	   of	   the	   intraorbital	  
optic	   nerve.	   Lesions	   in	   the	   macular	   region	   led	   to	   degeneration	   of	   fibres	   temporally	   in	   a	  
sector	  occupying	  at	   least	  one	   third	  of	   the	  cross-­‐sectional	  area	  of	   the	  anterior	  optic	  nerve.	  
Lesions	  in	  the	  nasal	  retina	  led	  to	  degeneration	  medially	  in	  the	  anterior	  optic	  nerve	  (Hayreh,	  
2011).	  
Due	   to	   the	   lack	  of	  pathological	   data	  on	  MS	  associated	  optic	  neuritis	   it	   is	   unclear	  whether	  
there	  is	  a	  predisposition	  for	  the	  location	  of	  MS	  lesions	  within	  the	  optic	  nerve	  (e.g.	  peripheral	  
rather	  than	  central).	  
.	  
 39 
Chapter	  2 An	  Overview	  of	  the	  clinical	  aspects	  of	  optic	  neuritis	  
Optic	   Neuritis	   is	   a	   generic	   term	   used	   to	   describe	   the	   pathophysiological	   process	   of	  
inflammation	   of	   the	   optic	   nerve.	   There	   are	   a	   variety	   of	   infectious,	   autoimmune,	  
inflammatory	  and	  vascular	  conditions	  that	  can	  cause	  optic	  neuritis.	  However,	   the	  majority	  
of	  cases	  are	  due	  to	  idiopathic	  inflammatory	  demyelination,	  which	  can	  occur	  in	  isolation	  or	  in	  
association	  with	  multiple	  sclerosis.	  	  
Acute	   idiopathic	   demyelinating	   optic	   neuritis	   is	   a	   relatively	   common	   condition	   with	   a	  
reported	   incidence	   of	   up	   to	   5	   in	   100,000	   per	   year	   in	   high-­‐risk	   populations	   for	   MS	   (1	   in	  
100,000	   in	   lower	  risk	  populations).	  Women	  are	  more	  commonly	  affected	  than	  men	  with	  a	  
ratio	  of	  approximately	  3:1.	  However	  there	  may	  be	  racial	  differences	  with	  a	  ratio	  of	  1:1.22	  in	  
a	   Japanese	   cohort	   (Wakakura	   et	   al.,	   1995).	   	   Although	   there	   is	   a	   wide	   variation	   in	   age	   of	  
onset	   it	   most	   commonly	   affects	   young	   people,	   between	   the	   ages	   of	   20-­‐50	   years.	   The	  
incidence	   is	   highest	   in	   Caucasians,	   in	   countries	   at	   higher	   latitude	   and	   lowest	   in	   regions	  
closer	   to	   the	   equator	   (Jin	   et	   al.,	   1998;	   Rodriguez	   et	   al.,	   1995).	   There	   is	   reported	   to	   be	   a	  
seasonal	  variation	  with	  a	  higher	  incidence	  in	  spring/	  early	  summer	  (Jin	  et	  al.,	  1999).	  	  
The	  inflammatory	  lesion	  in	  the	  optic	  nerve	  is	  similar	  to	  the	  acute	  plaques	  seen	  elsewhere	  in	  
the	  CNS	  in	  MS.	  The	  pathological	  process	  is	  thought	  to	  be	  immune	  mediated	  where	  there	  is	  
activation	  of	  systemic	  T	  lymphocytes	  that	  cross	  the	  blood	  brain	  barrier	  leading	  to	  a	  delayed	  
type	   hypersensitivity	   reaction	   with	   inflammation,	   demyelination	   and	   subsequent	   axonal	  
loss.	  The	  exact	  target	  antigen	  remains	  elusive.	  A	  genetic	  predisposition	  has	  been	  proposed	  
and	  this	  is	  supported	  by	  an	  over-­‐representation	  of	  certain	  HLA	  types	  (e.g.,	  HLA–DRB*1501)	  
amongst	  patients	  with	  Optic	  Neuritis	  (Hauser	  et	  al.,	  2000;	  Oksenberg	  et	  al.,	  2008).	  It	  is	  likely	  
that	  as	  yet	  unknown	  environmental	  factors	  trigger	  the	  condition	  in	  a	  genetically	  susceptible	  
individual.	  There	  is	  an	  association	  between	  higher	  incidence	  rates	  and	  previous	  exposure	  to	  
Epstein	   Barr	   virus	   (Lucas	   et	   al.,	   2011).	   In	   addition	   to	   this	   prospective	   studies	   have	   shown	  
that	  other	  common	  viral	   infections	  are	  probably	   risk	   factors	   for	  MS	  relapses	   (Sibley	  et	  al.,	  
1985)	   and	  one	   study	  demonstrated	  a	   significant	   correlation	  between	  adenovirus	  CSF	   titre	  
rises	  with	  the	  occurrence	  of	  a	  major	  MS	  relapse	  (Andersen	  et	  al.,	  1993).	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The	   Optic	   Neuritis	   treatment	   trial	   has	   provided	   a	   wealth	   of	   information	   on	   the	   clinical	  
presentation	  and	  course	  of	  acute	  demyelinating	  optic	  neuritis.	  	  
2.1 Clinical	  Features	  	  
Optic	   Neuritis	   is	   diagnosed	   clinically	   on	   the	   basis	   of	   history	   and	   clinical	   examination.	   It	  
usually	   presents	   with	   sub-­‐acute	   monocular	   visual	   loss,	   which	   progresses	   over	   7-­‐10	   days	  
before	  reaching	  a	  nadir.	  Continued	  deterioration	  in	  vision	  beyond	  two	  weeks	  is	  unusual	  and	  
may	   indicate	   an	   alternative	   diagnosis.	   It	   is	   unilateral	   in	   >90%	   of	   adults	   in	   contrast	   to	  
paediatric	  cases	  where	  it	  is	  bilateral	  in	  60-­‐70%	  of	  cases	  (Boomer	  and	  Siatkowski,	  2003).	  
Retro-­‐orbital	  pain,	  which	  is	  exacerbated	  by	  eye	  movements,	  is	  also	  typical	  and	  in	  the	  optic	  
neuritis	   treatment	   trial	   92%	   of	   patients	   experienced	   pain.	   	   The	   pain	   may	   proceed	   or	   be	  
concomitant	   with	   the	   visual	   loss	   (Optic	   Neuritis	   Study	   Group,	   1991).	   The	   pain	   varies	   in	  
severity	  but	  typically	  does	  not	  interfere	  with	  sleep	  and	  usually	  resolves	  within	  a	  week.	  	  Pain	  
can	   be	   absent	   or	   present	   as	   a	   headache	   particularly	   if	   the	   lesion	   is	   limited	   to	   the	  
intracanalicular	   or	   intracranial	   portion	   of	   the	   nerve.	   Patients	  may	   also	   report	   difficulty	   in	  
perceiving	  colours	  and	  may	  describe	  reds	  in	  particular	  as	  looking	  ‘washed	  out’.	  	  	  Phosphenes	  
(flashes	  of	  light)	  and	  positive	  visual	  phenomena	  on	  eye	  movements	  are	  also	  described,	  and	  
were	  reported	  in	  30%	  of	  patients	  in	  the	  ONTT.	  
Visual	  acuity	  in	  the	  affected	  eye	  ranges	  from	  6/6	  or	  better	  to	  no	  perception	  of	  light.	  In	  the	  
ONTT,	  median	  visual	  acuity	  was	  20/80	  at	  study	  entry.	  	  Colour	  vision	  is	  usually	  abnormal	  and	  
may	  be	  disproportionately	  affected	  compared	  to	  visual	  acuity.	   It	  would	  be	  very	  atypical	  to	  
have	  acute	  optic	  neuritis	  with	  poor	  visual	  acuity	  but	  retain	  colour	  vision.	  In	  the	  ONTT,	  colour	  
vision	  as	  assessed	  by	  Ishihara	  pseudo	  isochromatic	  plates	  was	  abnormal	  in	  88%	  of	  affected	  
eyes	  (Optic	  Neuritis	  Study	  Group,	  1991).	  The	  dyschromatopsia	  of	  optic	  neuritis	  has	  a	  mixed	  
spectral	  pattern	  with	  blue-­‐yellow	  defects	  more	  common	  in	  the	  acute	  phase	  and	  red-­‐green	  
more	  likely	  at	  6	  months	  (Katz,	  1995).	  
A	  visual	   field	  defect	   in	   the	  affected	  eye	   is	   frequently	  present.	  Although	  a	  central	   scotoma	  
with	  sloping	  border	  of	  the	  isopters	  is	  classically	  described,	  in	  reality	  almost	  any	  type	  of	  visual	  
field	  defect	  can	  occur.	  In	  the	  ONTT	  the	  most	  common	  visual	  field	  defect	  was	  ‘diffuse’	  with	  
 41 
generalised	   reduction	   of	   the	   entire	   central	   30	   degrees	   of	   visual	   field,	   which	   occurred	   in	  
48.2%	   of	   patients	   (Optic	   Neuritis	   Study	   Group,	   1991).	   Central	   defects	   including	   central	  
scotomas,	   paracentral	   defects	   and	   centrocaecal	   scotomas	   were	   also	   seen	   and	   imply	  
involvement	  of	   the	   central	  portion	  of	   the	  optic	  nerve.	  Nerve	   fibre	  bundle	  defects	   such	  as	  
altitudinal	  and	  arcuate	  defects	  can	  also	  occur	  and	  imply	  localization	  to	  a	  particular	  group	  of	  
nerve	  fibres	  (e.g.	  superior	  arcuate	  bundle).	  In	  general	  they	  respect	  the	  horizontal	  meridian	  
because	  of	  the	  anatomic	  boundary	  of	  the	  horizontal	  raphe	  (Lui	  et	  al.,	  2010).	  Involvement	  of	  
the	  chiasm	  can	  lead	  to	  bitemporal	  visual	  field	  defects.	  Sparing	  of	  central	  vision	  suggests	  an	  
optic	   perineuritis.	   	   The	   visual	   field	   defects	   usually	   resolve	   and	   in	   the	   ONTT	   56%	   had	  
normalised	  by	  1	  year	  and	  73%	  by	  10	  years.	  During	  the	   first	  year	  of	   follow	  up	   in	   the	  ONTT	  
diffuse	  central	  visual	  field	  loss	  changed	  to	  a	  more	  localised	  pattern	  in	  the	  form	  of	  nerve	  fibre	  
bundle	  defects	  and	  at	  1	  year	  these	  accounted	  for	  35.7%	  of	  abnormalities	  in	  the	  affected	  eye.	  
(Keltner	  et	  al.,	  1994;	  Kawasaki	  et	  al.,	  1996).	  	  
Low	  contrast	  acuity	   is	   reduced	  and	  can	  be	  demonstrated	  even	   in	  patients	  with	  acuities	  of	  
6/6	  or	  more.	  	  
A	  relative	  afferent	  pupillary	  defect	  is	  almost	  always	  present	  in	  the	  affected	  eye,	  although	  it	  
may	  be	  absent	   in	  mildly	  affected	  eyes,	   if	  there	  is	  bilateral	   involvement	  or	   if	  there	  is	  a	  pre-­‐
existing	  optic	  neuropathy	  in	  the	  fellow	  eye.	  Its	  absence	  may	  be	  a	  clue	  to	  a	  retinal	  cause	  for	  
the	  visual	   loss,	  e.g.	  central	  serous	  retinopathy.	   	  An	  RAPD	  can	  be	  exaggerated	  by	  holding	  a	  
0.3	  log	  unit	  density	  filter	  in	  front	  of	  the	  affected	  eye	  (Kawasaki	  et	  al.,	  1996).	  
Papillitis	  or	  disc	  swelling	  may	  be	  present	  in	  up	  to	  a	  third	  of	  patients	  and	  is	  diffuse.	  Marked	  
haemorrhages	   are	   unusual	   as	   are	   segmental	   or	   altitudinal	   swelling,	   disc	   pallor	   or	   arterial	  
attenuation	   and	   lipid	   maculopathy,	   and	   are	   more	   suggestive	   of	   other	   diagnoses	   (e.g.	  
anterior	   ischaemic	   optic	   neuropathy).	   Two	   thirds	   of	   patients	   have	   a	   retrobulbar	   optic	  
neuritis	  with	  normal	  fundoscopy	  in	  the	  acute	  phase	  (Optic	  Neuritis	  Study	  Group,	  1991).	  	  
Uveitis	  or	  cells	  in	  the	  anterior	  chamber	  would	  be	  atypical	  and	  are	  more	  commonly	  present	  
in	  other	  autoimmune	  diseases	  or	  infections.	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Retinal	  periphelibitis	  (perivenous	  sheathing)	  has	  been	  reported	  in	  up	  to	  12%	  of	  patients	  with	  
optic	  neuritis	  and	  their	  presence	  is	  associated	  with	  a	  higher	  risk	  of	  subsequent	  conversion	  to	  
clinically	  definite	  multiple	  sclerosis	  (Lightman	  et	  al.,	  1987).	  More	  detailed	  information	  of	  the	  
clinical	   features	   (typical	   and	  atypical)	   and	  differential	   diagnosis	   are	  provided	   in	   Table	  2-­‐1,	  
Table	  2-­‐2	  and	  Table	  2-­‐3.	  	  
Other	  associated	  symptomatology	  includes	  Uhthoff's	  and	  Pulfrich's	  phenomenon	  (these	  are	  
discussed	  in	  more	  detail	  later	  on	  see	  section	  2.9)	  
Table	  2-­‐1:	  Clinical	  features	  of	  typical	  optic	  neuritis	  (%	  taken	  from	  ONTT)	  
	  
Female	  (77%)	  	  
White	  (85%)	  
Young	  adult	  (mean	  age	  32+/-­‐	  6.7	  yrs.)	  
Periocular	  pain	  (92%)	  Exacerbated	  by	  eye	  movements	  (87%).	  
Progressive	  unilateral	  visual	  loss	  over	  days	  of	  variable	  severity	  	  
Spontaneous	  improvement	  within	  2	  weeks	  regardless	  treatment	  (>90%	  of	  patients)	  
Previous	  history	  of	  neurological	  symptoms	  
Uhthoff's	  phenomenon	  (exercise	  or	  heat-­‐induced	  deterioration	  of	  visual	  symptoms,	  occurs	  
in	  50%	  of	  patients)	  	  	  
Pulfrich's	  phenomenon:	  misperception	  of	  the	  direction	  of	  movement	  due	  to	  asymmetry	  of	  
conduction	  velocity	  in	  the	  optic	  nerves)	  
Photopsias	  	  
Dychromatopsia	  (85%)	  and	  reduced	  contrast	  vision	  
Swollen	  optic	  disc	  (35%),	  normal	  optic	  disc	  (65%).	  
Visual	  field	  defect	  (any	  type	  –	  most	  common	  in	  ONTT	  diffuse	  (48%))	  
Relative	  afferent	  pupillary	  defect	  
Normal	  macular	  and	  peripheral	  retina	  
Retinal	  periphlebitis/uveitis	  
Ancillary	  investigations	  suggestive	  of	  MS	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Table	   2-­‐2:	   Clinical	   features	  of	   atypical	   optic	   neuritis	   (Adapted	   from	  Hickman	  et	   al	   2002,	  
panel	  3)	  	  
(Hickman	  et	  al.,	  2002)	  
	  
Age>50	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Afro-­‐Caribbean	  
Bilateral	  simultaneous	  onset	  of	  optic	  neuritis	  or	  rapidly	  sequential	  optic	  neuritis	  in	  an	  adult	  
Chiasmitis	  
Severe	  visual	  loss	  to	  no	  perception	  of	  light	  without	  early	  recovery	  
Lack	  of	  pain	  
Severe	  pain	  that	  restricts	  eye	  movements	  or	  disrupts	  sleep	  	  
Persistent	  pain	  for	  >	  2	  weeks	  
Severe	  headache	  
Photophobia	  
Ocular	   findings	   suggestive	   of	   an	   inflammatory	   process	   e.g.	   anterior	   uveitis,	   macular	  
exudates,	  retinal	  inflammation	  
Severe	  disc	  swelling	  
Marked	  haemorrhage	  
Lack	  of	  significant	   improvement	  of	  visual	   function	  or	  worsening	  of	  visual	   function	  after	  30	  
days	  
Lack	   of	   at	   least	   one	   line	   of	   improvement	   in	   visual	   acuity	   within	   3	   weeks	   of	   onset	   of	  
symptoms	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neuritis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chronic	  relapsing	  
inflammatory	  optic	  
neuritis	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Optic	  Perineuritis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Behcet’s	  disease	  
Neuromyelitis	  Optica	  	  
Progressive	  severe	  visual	  
loss	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Recurrent	  episodes	  of	  ON	  
Pain	  may	  be	  severe	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Often	  bilateral	  
Multisystem	  
More	  common	  in	  Afro	  
Caribbeans	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
MRI	  brain	  and	  orbits	  with	  
contrast	  








Other	  inflammatory	   Bilateral	  
Often	  in	  children,	  
swollen	  discs,	  lipid	  
exudates,	  macular	  star	  	  	  
Good	  prognosis	  	  	  	  	  	  	  	  	  
MRI	  brain	  and	  orbits	  with	  
contrast	  
LP	  
Bartonella,	  borrelia	  and	  
syphilis	  serology	  
Post-­‐infectious	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Post-­‐vaccination	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ADEM	  
Neuroretinitis	  
Infectious	   	  
Progressive	  loss	  after	  	  	  	  	  
exposure	  to	  infectious	  
agent	  
Cells	  in	  the	  anterior	  
chamber	  	  	  
Severe	  disc	  swelling	  	  
	  	  	  	  	  	  	  	  	  	  
History	  of	  travel	  	  	  	  	  	  	  	  	  	  	  
	  
	  











Lyme	  disease	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Bartonella	  henselae	  (Cat	  
scratch	  disease)	  
Whipple’s	  disease	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Brucellosis	  	  	  
Fungal	   	  
Immunosuppressed	  
	  




History	  of	  exposure	  
	  


















Viral	   	  
Viral	  optic	  neuritis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
HIV	  related	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Local	  infection	  	  
Periorbital	  cellulitis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Paranasal	  sinusitis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Toxic	  and	  nutritional	  	  	  
Vitamin	  B12	  deficiency	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Tobacco-­‐alcohol	  
amblyopia	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Methanol	  intoxication	  
Ethambutol	  toxicity	  
Emerging	  evidence	  of	  
cobalt	  toxicity	  






History	  of	  alcohol/tobacco	  
excess	  
History	  of	  exposure	  to	  
toxin	  	  	  	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
History	  of	  brain	  irradiation	  





	   	  





Young	  male	  (80-­‐90%)	  	  	  	  	  	  	  
sequential,	  bilateral	  visual	  









Compressive	  optic	  	  
neuropathies	  
	   	  
Primary	  tumours	  e.g.	  
meningiomas,	  gliomas	  
Metastases	  
Tuberculomas	  	  	  	  	  	  	  	  	  
Thyroid	  opthalmopathy	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Arterial	  aneurysms	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Painless,	  progressive	  visual	  
loss	  
Optic	  atrophy	  at	  
presentation	  
History	  of	  Malignancy	  	  	  	  
Proptosis,	  diplopia	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
CT/MRI	  brain	  and	  orbits	  
with	  contrast	  
	  Consider	  biopsy	  
Thyroid	  function	  tests	  +	  
TPO	  antibodies	  
Cerebral	  angiogram	  
Ischaemic	  	  optic	  	  
neuropathies	  
	   	  
Anterior	  ischaemic	  optic	  	  
neuropathy	  	  	  	  	  	  	  	  	  
Giant	  cell	  arteritis	  (GCA)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Diabetic	  papillopathy	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Susac’s	  syndrome	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Older	  patient	  	  	  	  
Sudden	  onset	  
Painless	  (except	  GCA)	  
Altitudinal	  field	  defect	  	  	  	  	  
Disc	  swelling,	  
haemorrhages	  Fellow	  eye	  
crowded	  with	  small	  cup	  	  	  	  
Hearing	  loss,	  encephalitis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ESR,	  temporal	  artery	  
biopsy	  






Ocular	  or	  retinal	  disease	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Posterior	  scleritis	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Central	  serous	  
retinopathy	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
White	  dot	  syndromes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




retinopathies	  	  (melanoma	  
–associated	  retinopathy).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
severe	  pain,	  relatively	  	  
preserved	  vision,	  proptosis	  	  	  
painless,	  central	  blurring	  
metamorphopsia,	  young	  
male,	  good	  recovery	  	  	  	  	  	  	  	  
VF	  abnormality	  with	  	  
preserved	  colour	  vision	  	  	  	  	  	  	  	  	  	  
	  
History	  of	  malignancy	  
(melanoma)	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





Miscellaneous	   	   	  
Functional	  	  	  	  
	  
	  
May	  be	  associated	  with	  
other	  neurological	  
symptoms.	  	  	  	  	  
Inconsistencies	  between	  
symptoms	  &	  subjective	  
visual	  function	  tests	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Flash	  VEPS	  
Snake	  bite	   	   	  
Bee	  or	  wasp	  sting	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2.2 Investigations	  
Generally,	  optic	  neuritis	  is	  a	  clinical	  diagnosis	  based	  on	  history	  and	  examination	  findings	  and	  
an	  ophthalmic	  examination	   is	   an	  essential	  part	  of	   this.	  As	   such	  diagnostic	   tests	   should	  be	  
aimed	  at	  excluding	  atypical	  causes	  of	  optic	  neuritis	  and	  prognostication	  of	  future	  risk	  of	  MS.	  	  
With	  the	  exception	  of	  prognostic	  information,	  the	  yield	  from	  diagnostic	  tests	  in	  typical	  cases	  
of	  demyelinating	  optic	  neuritis	   is	  extremely	   low	  (Shams	  and	  Plant,	  2009).	  However,	   in	   the	  
presence	   of	   any	   atypical	   features	   suggestive	   of	   an	   alternative	   diagnosis	   investigations	  
should	  be	  initiated	  promptly	  and	  should	  be	  guided	  by	  the	  clinical	  presentation	  (See	  table	  3).	  
In	   atypical	   cases,	   delay	   in	   diagnosis	   and	   treatment	   can	   result	   in	   a	   much	   worse	   visual	  
outcome(Hickman	   et	   al.,	   2002b).	   Early	   follow	   up	   should	   be	   arranged	   to	   ensure	   visual	  
recovery	  has	  begun,	  and	  if	  not,	  the	  diagnosis	  revisited.	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2.2.1 Magnetic	  resonance	  Imaging	  
MRI	  of	   the	   brain	  may	  provide	   confirmation	  of	   the	   diagnosis	   of	  MS	  or	   identify	   patients	   at	  
higher	  risk	  of	  MS	  In	  the	  future.	  	  The	  McDonald	  2010	  criteria	  (Polman	  et	  al.,	  2011)	  	  	  require	  
evidence	   of	   dissemination	   in	   time	   and	   space	   to	   confirm	   a	   diagnosis	   of	   multiple	   sclerosis	  
using	  the	  following	  criteria:	  
Dissemination	  in	  space	  
	  
At	  least	  one	  lesion	  visible	  on	  a	  T2-­‐weighted	  scan	  in	  at	  least	  two	  of	  four	  locations:	  
juxtacortical,	  periventricular,	  infratentorial,	  and	  spinal	  cord	  
	  
Dissemination	  in	  time	  
	  
A	  new	  T2	  lesion	  or	  gadolinium-­‐enhancing	  lesion	  visible	  on	  a	  follow-­‐up	  MRI	  scan	  when	  
compared	  with	  a	  previous	  scan	  obtained	  at	  any	  time	  after	  the	  onset	  of	  symptoms;	  or	  
	  
An	  MRI	   scan	   showing	   both	   gadolinium-­‐enhancing	   and	   non-­‐enhancing	   lesions	   that	   do	   not	  
cause	  clinical	  signs	  (i.e.	  asymptomatic	  lesions)	  
These	   criteria	   have	   subsequently	   been	   updated	   further	   by	   the	  MAGNIMS	   network	   in	   Jan	  
2016	  (Filippi	  et	  al.,	  2016)	  based	  on	  the	  availability	  of	  new	  evidence	  on	  the	  application	  of	  MRI	  
to	  demonstrate	  dissemination	  in	  time	  and	  space	  as	  well	  as	  improvements	  in	  MRI	  technology	  
resulting	  in	  new	  acquisition	  sequences.	  The	  main	  revisions	  to	  the	  above	  criteria	  are	  detailed	  
below:	  
1)	   An	   increase	   in	   the	   number	   of	   lesions	   required	   in	   the	   periventricular	   area	   from	   one	   to	  
three	   in	  order	   to	  demonstrate	  dissemination	   in	   space	   (as	  a	   single	   lesion	  was	  not	  deemed	  
sufficiently	  specific	  for	  a	  demyelinating	  inflammatory	  event)	  
2)	  To	  include	  one	  or	  more	  lesions	  in	  the	  optic	  nerve	  as	  evidence	  of	  dissemination	  in	  space	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3)	   Expansion	   of	   the	   term	   ‘juxtacortical	   lesion’	   to	   cortical/juxtacortical	   lesions	   since	  
intracortical,	   leukocortical	   and	   juxtacortical	   lesions	   cannot	   be	   reliably	   distinguished	   using	  
conventional	  MRI	   scans.	  Where	  available	  advanced	   imaging	   techniques	   should	  be	  used	   to	  
visualise	  cortical	  lesions	  
4)	  No	  distinction	  between	  symptomatic	  and	  asymptomatic	  lesions	  for	  dissemination	  in	  time	  
and	   space	   as	   evidence	   suggests	   inclusion	   of	   the	   symptomatic	   lesion	   may	   increase	   the	  
sensitivity	  of	  MRI	  diagnostic	  criteria	  for	  MS	  without	  compromising	  specificity.	  	  
5)	   Imaging	   of	   the	   whole	   spinal	   cord	   is	   recommended	   to	   define	   dissemination	   in	   space	  
(especially	   in	  patients	  who	  do	  not	   fulfill	  brain	  MRI	   criteria	   for	  dissemination	   in	   space)	  but	  
spinal	  cord	  imaging	  has	  a	  limited	  role	  for	  identification	  of	  dissemination	  in	  time.	  
	  Although	   historically	   difficult	   to	   image	   due	   to	   its	   small	   size	   and	   propensity	   for	   motion	  
artifact,	  short	  tau	  inversion	  recovery,	  fast	  spin	  echo	  and	  fluid	  attenuated	  inversion	  recovery	  
with	  fat	  suppression	  techniques	  have	  improved	  imaging	  of	  the	  optic	  nerve.	  These	  sequences	  
allow	   identification	  of	   intrinsic	   lesions	  within	  the	  optic	  nerve	  as	  well	  as	  compressive	   (Gass	  
and	  Moseley,	  2000)	  .	  
Optic	   nerve	   inflammation,	   as	   suggested	   by	   high	   T2	  weighted	   signal	   abnormality,	   swelling	  
and	  contrast	  enhancement	  on	  T1	  weighted	  images,	  can	  be	  demonstrated	  in	  95%	  of	  patients	  
with	  acute	  optic	  neuritis	  (Kupersmith	  et	  al.,	  2002).	  The	  longitudinal	  extent	  of	  the	  optic	  nerve	  
lesion	   correlates	   with	   visual	   loss	   at	   presentation	   as	   well	   as	   overall	   visual	   outcome.	  
Gadolinium	  enhancement	  persists	  for	  a	  mean	  of	  30	  days	  	  (68	  days	  (median)	  with	  triple	  dose	  
gadolinium)(Hickman	   et	   al.,	   2004b)	   after	   onset	   of	   symptoms.	   Contrast	   enhancement	  
features	   have	   little	   impact	   on	   visual	   recovery	   and	   final	   visual	   outcome	   (Hickman	   et	   al.,	  
2004b).	  T2	  weighted	  signal	  abnormality	  persists	  even	  after	  visual	  recovery.	   	  Longer	   lesions	  
involving	   the	   intracranial	  optic	  nerve	  and	   chiasm	  are	  more	   typical	  of	  NM0	   (Khanna	  et	   al.,	  
2012).	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  In	   granulomatous	   disease,	   e.g.,	   sarcoidosis,	   an	   optic	   perineuritis	   may	   be	   seen	  
(enhancement	  of	  the	  optic	  nerve	  sheath)	  in	  addition	  to	  basal	  meningeal	  enhancement	  and	  
enhancing	  brain	  lesions.	  	  
White	  matter	  lesions	  on	  T2	  weighted	  and	  gadolinium	  enhanced	  MRI	  are	  usually	  seen	  in	  50-­‐
70%	  of	  demyelinating	  optic	  neuritis	  (Ormerod	  et	  al.,	  1986;	  Beck	  et	  al.,	  1993;	  Frederiksen	  et	  
al.,	   1989).	   Characteristic	   demyelinating	   lesions	   are	   typically	   ≥	   3mm	   in	   diameter,	   ovoid	   in	  
shape	  and	  often	  located	  in	  the	  periventricular	  white	  matter.	  Other	  typical	  locations	  of	  white	  
matter	  lesions	  include	  juxtacortical,	  infratentorial	  and	  the	  spinal	  cord.	  	  Flair	  sequences	  allow	  
for	  improved	  identification	  of	  periventricular	  lesions	  due	  to	  suppression	  of	  CSF.	  	  
It	   is	   important	   to	   note	   that	   T2	   weighted	   white	  matter	   abnormalities	   are	   not	   specific	   for	  
demyelination	  and	  can	  be	  due	  to	  other	  causes	  e.g.	  small	  vessel	  disease.	  	  
In	  the	  optic	  neuritis	  treatment	  trial	  the	  risk	  of	  developing	  multiple	  sclerosis	  within	  10	  years	  
of	   the	   first	   episode	   of	   optic	   neuritis	   was	   56%	   amongst	   patients	   with	   one	   or	  more	   white	  
matter	  lesions	  on	  MRI	  compared	  to	  22%	  of	  patients	  with	  no	  lesions	  (Beck	  et	  al.,	  2003).	  	  
The	  risk	  of	  conversion	  to	  clinically	  definite	  MS	  increases	  if	  asymptomatic	  spinal	  cord	  lesions	  
in	  addition	  to	  brain	   lesions	  are	  present	  at	  baseline.	   In	  one	  study	  of	  patients	  with	  clinically	  
isolated	   syndromes	   48%	   of	   patients	   with	   brain	   and	   spinal	   cord	   lesions	   developed	   MS	  
compared	  to	  18%	  of	  patients	  with	  brain	  lesions	  in	  isolation	  (Brex	  et	  al.,	  1999;	  Swanton	  et	  al.,	  
2010).	  However	  the	  yield	  of	  spinal	  cord	  imaging	  in	  unselected	  patients	  is	  low	  (Dalton	  et	  al.,	  
2003)	   it	   is	   therefore	   not	   recommended	   that	   imaging	   of	   the	   spinal	   cord	   is	   undertaken	  
routinely	  after	  an	  episode	  of	  optic	  neuritis.	  Swanton	  et	  al.,	  2010	  found	  that	  higher	  numbers	  
of	  baseline	  periventricular	  T2	  weighted	  lesions	  and	  new	  T2	  lesions	  on	  early	  follow	  up	  scan	  
were	  predictive	  of	  clinically	  definite	  MS	  after	  isolated	  optic	  neuritis.	  The	  same	  group	  found	  
that	   spinal	  cord,	   infratentorial	  and	  gadolinium	  enhancing	   lesions	  within	  3	  months	  of	  optic	  
neuritis	  was	  predictive	  of	  disability	  but	  only	  spinal	  cord	   lesions	  were	  predictive	   in	  patients	  
converting	  to	  clinically	  definite	  MS	  (Swanton	  et	  al.,	  2009).	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2.2.2 Lumbar	  puncture	  
Lumbar	   puncture	   should	   be	   considered	   if	   an	   atypical	   cause,	   particularly	   infectious	   or	  
inflammatory,	   is	   suspected.	   In	   typical	   demyelinating	   optic	   neuritis	   lumbar	   puncture	   as	   a	  
routine	   investigation	   is	   not	   generally	   required.	   In	   the	   optic	   neuritis	   treatment	   trial	   no	  
patient	  had	  the	  diagnosis	  or	  management	  altered	  as	  a	  result	  of	  CSF	  findings.	  Approximately	  
60-­‐80%	   of	   patients	  with	   acute	   optic	   neuritis	   have	   non-­‐specific	   CSF	   abnormalities	   (Jacobs,	  
1997).	   In	   the	  ONTT	  CSF	  abnormalities	   included	  raised	  WCC	   (36%	  of	  patients	  had	  >6	  white	  
cells	   per	   cubic	  mm,	   highest	  WCC	   27/ml),	   raised	   total	   protein	   (9.4%	   of	   patients	   had	   total	  
protein	   >	   50mg/dl),	   raised	   CSF	   Ig	   G	   concentration,	   oligoclonal	   bands	   (present	   in	   50%)	   of	  
patients	  and	  raised	  myelin	  basic	  protein	  levels.	  
In	   the	  ONTT	  the	  presence	  of	  oligoclonal	  bands	   in	   the	  CSF	  was	  correlated	  with	  subsequent	  
risk	  of	  developing	  MS	  but	  this	  was	  not	  independent	  of	  MRI	  abnormalities	  as	  these	  patients	  
also	   tended	   to	   have	   abnormal	   baseline	  MRI	   brain	   scans.	   CSF	   oligoclonal	   bands	  may	   be	   a	  
more	  useful	  predictor	  of	   future	  MS	   risk	   in	  patients	  with	  a	  normal	  MRI	  brain	   (Rolak	  et	   al.,	  
1996).	  
2.2.3 Visual	  Evoked	  Potentials	  
Are	   generally	   of	   limited	   utility	   in	   the	   diagnosis	   of	   optic	   neuritis	   and	   do	   not	   allow	  
differentiation	   between	   the	   different	   causes	   of	   an	   optic	   neuropathy	   in	   the	   acute	   phase	  
except	  in	  the	  case	  of	  functional	  visual	  loss.	  
The	   combination	   of	   visual	   evoked	   potentials	   (VEP)	   and	   pattern	   electroretinogram	   can	   be	  
helpful	  in	  distinguishing	  optic	  nerve	  from	  retinal	  disorders.	  In	  retinal	  disorders	  both	  the	  P50	  
(early)	   and	   (N95)	   late	   components	   of	   the	   PERG	   are	   abnormal	  whereas	   only	   the	   late	   N95	  
component	  is	  abnormal	  in	  optic	  nerve	  disorders	  (although	  both	  may	  be	  affected	  acutely).	  	  	  
In	  acute	  optic	  neuritis	  the	  VEP	  typically	  demonstrates	  a	  delayed	  P100	  response	  with	  a	  well	  
preserved	   waveform	   and	   only	   modestly	   reduced	   amplitude,	   which	   is	   a	   manifestation	   of	  
conduction	  slowing	  and	  partial	  block	   in	  the	  optic	  nerve	  as	  a	  result	  of	  demyelination.	  After	  
one	  year	  80-­‐90%	  of	  patients	  will	  have	   residual	  abnormalities	  on	  VEPs	   (Brusa	  et	  al.,	  2001).	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Mulitfocal	   VEPs	   appear	   to	   be	   more	   sensitive	   and	   specific	   than	   conventional	   VEPs	   for	  
diagnosing	  optic	  neuritis	  (Fraser	  et	  al.,	  2006)	  although	  they	  are	  technically	  more	  challenging.	  	  
2.2.4 Optical	  Coherence	  Tomography	  	  
This	  modality	  is	  the	  optical	  analogue	  of	  B	  mode	  ultrasound	  and	  uses	  the	  backscatter	  of	  near	  
infrared	  light	  to	  produce	  two	  and	  three-­‐dimensional	  images	  of	  retinal	  ultrastructure.	  	  It	  has	  
been	  used	  to	  demonstrate	  axonal	  loss	  in	  the	  optic	  nerve	  by	  taking	  measurements	  of	  retinal	  
nerve	  fibre	  layer	  (RNFL)	  thickness	  and	  is	  increasingly	  being	  used	  as	  an	  outcome	  measure	  for	  
axonal	   loss	   in	   MS	   and	   optic	   neuritis	   research.	   85	   %	   of	   patients	   will	   have	   demonstrable	  
retinal	  nerve	  fibre	  layer	  thinning	  after	  an	  episode	  of	  optic	  neuritis	  and	  lower	  RNFL	  thickness	  
measurements	   have	   been	   shown	   to	   correlate	  with	  worse	   visual	   outcome	   (Costello	   et	   al.,	  
2006;	  Trip	  et	  al.,	  2005).	  Acutely	  there	  may	  be	  RNFL	  swelling	  and	  this	  is	  much	  more	  common	  
than	  once	  thought,	  occurring	  in	  approximately	  82	  %	  of	  affected	  nerves	  and	  remains	  evident	  
in	  at	  least	  one	  quadrant	  in	  the	  majority	  of	  patients	  at	  12	  weeks	  (Costello	  et	  al.,	  2006).	  It	  is	  
therefore	  prudent	  to	  allow	  at	   least	   three	  months	  after	  an	  episode	  of	  optic	  neuritis	  before	  
attempting	  to	  quantify	  RNFL	  atrophy	  (Henderson	  et	  al.,	  2010).	  
Isolated	  thickening	  of	   the	   inner	  nuclear	   layer	  with	  associated	  microcystic	  macular	  oedema	  
has	  also	  been	  reported	   in	  association	  with	  MS	  related	  optic	  neuritis	   (Gelfand	  et	  al.,	  2012;	  
Gelfand	   et	   al.,	   2013).	   However	   this	   is	   much	   more	   common	   in	   NMO	   (20%	   of	   patients),	  
(Gelfand	  et	  al.,	  2013)	  than	  MSON	  (5%	  of	  patients)	  and	  should	  prompt	  testing	  with	  aquaporin	  







Figure	   2-­‐1:	   Optical	   coherence	   tomography	   scan	   demonstrating	   atrophy	   of	   the	   retinal	  
nerve	  fibre	  layer	  six	  months	  after	  optic	  neuritis	  	  
	  
Heidelberg	   Spectralis	   retinal	   nerve	   fibre	   layer	   scan.	   Top	   left	   image:	   Fundus	   photograph-­‐Retinal	   nerve	   fibre	   layer	  
measurements	  are	  taken	  from	  the	  peripapillary	  region,	  as	  delineated	  by	  the	  green	  circle	  of	  3.4mm	  diameter	  centered	  on	  
the	   optic	   disc,	   and	   compared	   to	   a	   normative	   database.	   Top	   right	   image:	   OCT	   image	   of	   the	   peripapillary	   retina.	   OCT	  
software	   automatically	   segments	   the	   retinal	   fibre	   layer	   delineated	   by	   the	   red	   lines.	   Bottom	   left	   image:	   Pie	   chart	  
demonstrating	  mean	  global	  and	  sectoral	  RNFL	  thickness	  measurements.	  Top	  value	  is	  the	  measured	  mean	  RNFL	  thickness	  
for	  each	  sector.	  Bottom	  value	  is	  the	  mean	  age	  adjusted	  normal	  value.	  If	  the	  RNFL	  thickness	  of	  the	  sector	  is	  above	  the	  5th	  
percentile	  of	  the	  normal	  distribution	  it	  is	  coloured	  green,	  between	  1st	  and	  5th	  percentile	  it’s	  coloured	  yellow	  and	  below	  the	  
1st	  percentile	  it’s	  coloured	  red.	  Bottom	  right:	  Graph	  demonstrating	  the	  RNFL	  thickness	  profile	  measured	  along	  the	  circular	  
scan	  (black	  line)	  and	  its	  comparison	  to	  the	  normal	  range.	  The	  green	  band	  represents	  the	  normal	  range	  of	  RNFL	  thickness	  
defined	  as	  between	  5th	  and	  95th	  percentile	  of	  normal	  distribution.	  	  Red	  area	  denotes	  range	  below	  1st	  percentile	  and	  yellow	  
band	  represents	  values	  below	  5th	  but	  above	  the	  1st	  percentile	  of	  normal	  distribution.	  
2.3 Treatment	  
2.3.1 Acute	  treatment	  
The	  findings	  of	  the	  optic	  neuritis	  treatment	  trial	  (ONTT)	  and	  its	  extension	  study	  have	  had	  a	  
major	   influence	  on	  current	   clinical	  practice	  of	   the	   treatment	  of	  acute	  demyelinating	  optic	  
neuritis.	   The	   primary	   aim	   of	   the	   ONTT	   was	   to	   evaluate	   the	   effect	   of	   intravenous	  
methylprednisolone	  and	  oral	  corticosteroid	  therapy	  on	  visual	  outcome.	  The	  secondary	  aim	  
was	  to	  assess	  the	  affect	  of	  corticosteroid	  treatment	  on	  future	  risk	  of	  conversion	  to	  clinically	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definite	  multiple	  sclerosis.	  457	  patients	  were	  enrolled	  within	  8	  days	  of	  visual	  loss	  and	  were	  
(Beck	  et	  al.,	  1992b)randomised	  to	  one	  of	  three	  arms	  (Beck	  et	  al.,	  1992b):	  
1) Oral	  prednisone	  1mg/kg/day	  for	  14	  days	  followed	  by	  a	  4	  day	  oral	  taper	  
2) Intravenous	  methylprednisolone	  250mg	  every	  6	  hours	  for	  3	  days	  followed	  by	  oral	  
prednisone	  1mg/kg/day	  for	  11	  days	  with	  4	  day	  taper.	  
3) Oral	  placebo	  for	  14	  days.	  	  
The	  trial	  was	  double	  blinded	  
Patients	   in	   the	   intravenous	   methyprednisolone	   arm	   experienced	   faster	   visual	   recovery	  
particularly	  during	  the	  first	  15	  days	  compared	  to	  the	  other	  arms.	  However	  at	  1	  year	  follow	  
up	   there	   was	   no	   significant	   difference	   in	   visual	   outcomes	   between	   the	   three	   treatment	  
groups.	  When	  the	  presenting	  visual	  acuity	  was	  	  6/12	  or	  better	  corticosteroids	  conferred	  no	  
benefit.	  
Patients	  randomised	  to	  the	  intravenous	  methylpredisolone	  arm	  were	  also	  at	  reduced	  risk	  of	  
conversion	   to	   clinically	   definite	   MS	   at	   2	   years	   compared	   to	   the	   other	   arms	   (7.5%	   IVMP	  
versus	  14.7%	  placebo)	  and	  16.7%	  prednisone).	  However,	  this	  effect	  was	  not	  born	  out	  after	  
five	  years	  (Optic	  Neuritis	  Study	  Group,	  1997).	  These	  findings	  were	  as	  a	  result	  of	  a	  post-­‐hoc	  
analysis	  and	  patients	  in	  the	  IV	  methylprednisolone	  group	  were	  not	  blinded	  to	  treatment.	  	  	  
In	  the	  ONTT	  the	  use	  of	  oral	  prednisone	  was	  associated	  with	  an	  increased	  rate	  of	  recurrent	  
optic	   neuritis	   in	   either	   eye	   compared	   with	   the	   other	   two	   treatment	   arms	   (30%	   vs.	   13%	  
methylprednisolone	  and	  16.7%	  placebo)	  within	   the	   first	   two	  years.	  At	  10	  years	   the	   risk	  of	  
recurrent	   optic	   neuritis	   remained	   higher	   in	   the	   oral	   prednisone	   group	   but	  was	   no	   longer	  
statistically	   significant	   (Beck	   et	   al.,	   2004).	   This	   result	   should	   be	   interpreted	   with	   caution	  
given	  that	  this	  effect	  has	  not	  been	  confirmed	  in	  other	  studies	  and	  the	  trial	  was	  not	  designed	  
to	  investigate	  this	  as	  an	  outcome	  measure.	  There	  is	  no	  definitive	  biological	  explanation	  and	  
it	  may	  therefore	  be	  a	  chance	  finding.	  	  
Findings	  in	  other	  trials	  of	  corticosteroids	  in	  optic	  neuritis	  are	  reported	  in	  Table	  2-­‐4.	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  Table	  2-­‐4:	  Trials	  of	  corticosteroids	   in	  acute	  optic	  neuritis	   	   (Adapted	  from	  Kaufman	  et	  al,	  
2000	  (Table	  2))	  
Study	   Treatment	  arms	  	  	  	  	  	  	  	  	  	   Visual	  Outcome	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rawson	  et	  al	  	  1966	  	  	  	  	  
(Class	  I)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
40	  units	  IM	  ACTH/	  IM	  	  	  
placebo	  a	  day	  for	  30	  days	  	  	  	  	  	  	  	  	  	  	  	  
Faster	  recovery	  of	  VA	  at	  30	  
days	  in	  active	  arm;	  	  
at	  1	  yr	  no	  significant	  
difference	  between	  arms;	  	  
small	  number	  of	  pts.	  (25	  per	  
arm)	  
Bowden	  et	  al	  1974	  	  (Class	  I)	   40	  units	  IM	  ACTH/IM	  
placebo	  a	  day	  for	  30	  days	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
No	  significant	  difference	  in	  
VA	  between	  treatment	  arms	  
at	  1	  year	  	  
small	  number	  of	  pts.	  (27	  per	  
arm)	  
Kapoor	  et	  al	  	  	  1998	  (Class	  I)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1g	  IV	  methylprednisnolone/	  
iv	  saline	  for	  3	  days	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
No	  significant	  treatment	  
affect	  at	  6	  months,	  no	  
treatment	  effect	  on	  lesion	  all	  
patients	  had	  optic	  canal	  
lesions	  (33	  pts	  per	  arm)	  	  
	  
Sellebjerg	  et	  al	  	  	  1999	  	  (Class	  







	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
500mg	  po	  
methylprednisolone/placebo	  
for	  5	  days	  with	  10	  day	  oral	  
taper	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  
Increased	  speed	  of	  recovery	  
in	  treated	  group	  (p=0.008),	  
no	  long	  term	  benefit	  
compared	  to	  placebo.	  
Increase	  in	  recurrence	  of	  ON	  
at	  1	  yr	  in	  
methylprednisolone	  group	  
(30	  pts	  per	  arm)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Gould	  et	  al	  1977	  	  (Class	  I)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  stat	  dose	  40mg	  retrobulbar	  
triamcinolone	  	  	  	  	  	  	  
No	  placebo	  group	  	  	  	  	  	  	  	  
Follow	  up	  at	  6	  months	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Treatment	  group	  faster	  
visual	  recovery	  but	  no	  
significant	  difference	  at	  6	  
months	  	  
31	  pts	  treatment	  arm	  30	  
controls)	  
	  
Wakakura	  et	  al	  1990	  
	  	  (Class	  II)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1g	  1VMP	  for	  3	  days/	  iv	  
mecobalamin	  500	  μ	  for	  3	  
days	  followed	  by	  oral	  taper	  
for	  7	  days	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
IVMP	  group	  faster	  rate	  of	  
visual	  recovery	  but	  no	  	  
significant	  difference	  at	  
12wks/	  1	  yr	  (33	  pts	  per	  arm)	  
(33	  pts	  per	  arm)	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
Trauzettel-­‐Klosinski	  et	  al	  	  
1991	  (Class	  II)	  	  
100mg	  po	  MP	  per	  day/	  
followed	  by	  tapering	  dose	  
for	  24d	  or	  po	  thiamine	  	  	  	  	  	  	  	  	  	  	  
Faster	  visual	  recovery	  in	  	  MP	  
group	  but	  no	  significant	  




Spoor	  and	  Rockwell	  et	  al	  	  
1988	  (Class	  III)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
1-­‐2	  g	  IVMP,	  not	  randomised	  
or	  placebo	  controlled	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Rapid	  rate	  of	  recovery	  in	  12	  
pts	  given	  IVMP	  
	  
	  
A	  meta-­‐analysis	  of	  12	  randomised	  controlled	  trials	  showed	  that	  corticosteroids	  reduced	  the	  
number	   of	   patients	   without	   clinical	   improvement	   at	   30	   days	   (odds	   ratio	   0.6,	   range	   0.42-­‐
0.85)	  but	  did	  not	  result	  in	  long-­‐term	  improvement	  of	  visual	  outcome	  even	  in	  patients	  with	  
severe	  visual	  loss	  (Brusaferri	  and	  Candelise,	  2000).	  	  
The	   report	   of	   the	   Quality	   Standards	   Committee	   of	   the	   American	   Academy	   of	   Neurology	  
states	   that	   the	   decision	   to	   use	   higher	   dose	   oral	   or	   parenteral	  methylprednisolone	   should	  
therefore	   be	   based	   on	   factors	   such	   as	   quality	   of	   life,	   visual	   function	   in	   the	   fellow	   eye	   or	  
other	  situations,	  e.g.	  in	  the	  case	  of	  severe	  or	  bilateral	  visual	  loss	  (Kaufman	  et	  al.,	  2000).	  	  
Acute	  immunomodulatory	  therapy	  
Intravenous	   immunoglobulin	   has	   not	   been	   shown	   to	   have	   a	   beneficial	   effect	   in	   the	  
treatment	  of	  optic	  neuritis.	  	  Two	  randomised	  controlled	  trials	  looking	  at	  the	  efficacy	  of	  IVIG	  
in	   the	   treatment	   of	   optic	   neuritis	   did	   not	   demonstrate	   any	   difference	   in	   visual	   or	   MRI	  
outcome	  or	  subsequent	  demyelinating	  events	  at	  6	  months	  (Noseworthy	  et	  al.,	  2001;	  Roed	  
et	  al.,	  2005).	  
Plasmapheresis	  
Evidence	   is	   currently	   from	   observational	   cohort	   studies	   of	   patients	   with	   steroid	   resistant	  
demyelinating	  optic	  neuritis	  and	  may	  be	  beneficial	  if	   instituted	  early.	  In	  a	  case	  series	  of	  23	  
patients	   (10	   with	   RRMS)	   70%	   improved	   with	   plasmapheresis	   given	   after	   two	   cycles	   of	  
intravenous	  methylprednisolone	  (Roesner	  et	  al.,	  2012).	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2.3.2 Long-­‐term	  immunomodulatory	  therapy	  
Guidelines	  on	  the	  use	  of	  immunomodulatory	  therapy	  after	  CIS	  vary	  internationally.	  In	  the	  US	  
DMD	  therapy	  is	  discussed	  with	  patients	  after	  an	  episode	  of	  demyelinating	  optic	  neuritis	  that	  
have	  at	   least	   two	   typical	  demyelinating	  white	  matter	   lesions	  on	  MRI.	  However,	   in	   the	  UK	  
DMDs	  are	  generally	  only	  used	   if	  a	  second	  clinical	  attack	  occurs	  within	  2	  years	  of	  the	  optic	  
neuritis.	  	  
Three	   trials	   have	   investigated	   the	   efficacy	   of	   beta	   interferons	   in	   reducing	   the	   risk	   of	  
developing	  MS	  after	  a	  clinically	  isolated	  syndrome.	  	  
The	   CHAMPS	   study	   (Jacobs	   et	   al.,	   2000)	   was	   a	   randomised	   placebo	   controlled	   trial	  
comparing	  early	  treatment	  with	  intramuscular	  interferon	  beta-­‐1a	  30	  μg	  once	  a	  week	  versus	  
placebo.	  383	  patients	  were	  randomised	  (50%	  with	   isolated	  optic	  neuritis).	  All	  patients	  had	  
two	  or	  more	   typical	   demyelinating	   lesions	  on	  MRI	   scan.	   Patients	   received	   treatment	  with	  
intravenous	  methylprednisolone	  within	  14	  days	  of	  symptom	  onset	  and	  were	  randomised	  to	  
commence	  intramuscular	  interferon	  beta-­‐1a/placebo	  within	  one	  month.	  	  	  
The	  study	  was	  terminated	  early	  because	  the	  cumulative	  probability	  of	  developing	  clinically	  
definite	  MS	  was	  35%	  in	  the	  treated	  group	  compared	  to	  50%	  on	  the	  placebo	  group	  (p=0.002).	  	  
There	  was	  also	  a	  reduction	  in	  new	  T2	  weighted	  lesions	  and	  T1	  gadolinium	  enhancing	  lesions	  
on	  MRI	  at	  18	  months	  in	  the	  treated	  group.	  	  
In	   the	   ETOMS	   (Comi	   et	   al.,	   2001)	   308	   patients	  were	   randomised	  within	   three	  months	   of	  
their	  first	  clinical	  demyelinating	  event	  to	  receive	  either	  interferon	  beta-­‐1a	  22μg	  once	  a	  week	  
or	  placebo.	  All	  patients	  had	  at	  least	  four	  white	  matter	  lesions	  or	  three	  with	  at	  least	  one	  that	  
enhanced	  with	   gadolinium.	   35%	  of	   patients	   had	   an	   acute	  optic	   neuritis.	   At	   two	   years	   the	  
proportion	  of	  patients	  who	  had	  developed	  clinically	  definite	  MS	  was	  34%	  in	  the	  active	  group	  
versus	  45%	  in	  the	  placebo	  group.	  Amongst	  those	  patients	  who	  did	  develop	  clinically	  definite	  
MS,	  onset	  was	  delayed	  in	  the	  active	  versus	  placebo	  group	  (569	  days	  versus	  252	  days	  (30th	  
centile)).	  Additionally	  there	  was	  a	  reduction	  in	  the	  new	  T2	  weighted	  lesions	  in	  the	  treatment	  
group.	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More	   recently	   the	   BENEFIT	   trial	   randomly	   assigned	   487	   patients	   with	   clinically	   isolated	  
syndromes	   to	   receive	   ether	   interferon-­‐1b	   250μg	   once	   every	   other	   day	   or	   placebo.	   The	  
results	  were	  consistent	  with	   the	  CHAMPS	  and	  ETOMs	  trials	  with	  a	   reduction	   in	   the	  risk	  of	  
developing	   clinically	   definite	  MS	   in	   the	   treatment	   group	   (28%	   versus	   45%	   in	   the	   placebo	  
group)	  as	  well	  as	  reducing	  the	  amount	  of	  disease	  activity	  as	  measured	  by	  new	  T2	  weighted	  
lesions	  at	  2	  years	  (Kappos	  et	  al.,	  2006).	  
These	  results	  are	  consistent	  with	  the	  effects	  of	  DMDs	  in	  relapsing	  remitting	  MS	  where	  they	  
reduce	  the	  number	  of	  relapses	  by	  a	  third.	  	  
In	  addition	  to	  these	  trials	  the	  PreCISe	  study	  investigated	  the	  effect	  on	  glatiramer	  acetate	  on	  
conversion	  to	  clinically	  definite	  MS.	  	  481	  with	  a	  unifocal	  clinically	  isolated	  syndrome	  and	  two	  
or	  more	   T2	  weighted	   brain	   lesions	  were	   randomly	   assigned	   to	   receive	   glatiramer	   acetate	  
20mg	  od	  or	  placebo	  for	  up	  to	  36	  months.	  The	  risk	  of	  developing	  clinically	  definite	  MS	  was	  
reduced	   by	   45%	   compared	   to	   placebo	   and	   for	   those	   who	   did	   convert	   the	   time	   clinically	  
definite	  disease	  was	  prolonged	  from	  366	  (placebo)	  to	  722	  days	  (glatiramer	  acetate)	  (Comi	  et	  
al.,	  2009).	  
Some	  of	   the	  newer	  oral	   therapies	  have	  also	  been	  trialed	   in	  CIS.	  The	  TOPIC	  study	  assessed	  
the	  efficacy	  and	  safety	  of	  teriflunomide	  in	  patients	  with	  a	  first	  clinical	  episode	  suggestive	  of	  
MS.	  A	  double	  blind-­‐placebo	  controlled	  trial	  that	  compared	  teriflunomide	  14mg	  and	  7	  mg	  to	  
placebo	   taken	   for	   up	   to	   18	   weeks.	   Teriflunomide	   significantly	   reduced	   the	   risk	   of	   a	  MS-­‐
defining	   relapse	   both	   at	   7mg	   and	   14mg	   (p=0.0271	   and	   p=0.0087	   respectively).	   Similarly,	  
Teriflunomide	   at	   both	  doses	   significantly	   reduced	   the	   risk	   of	   relapse	  or	   a	   new	  MRI	   lesion	  
compared	  to	  placebo	  (14mg,	  p=0.0003,	  7mg	  p=0.0020)(Miller	  et	  al.,	  2014).	  
Oral	  cladribine	  at	  5.25mg/kg	  and	  3.5	  mg/kg	  has	  also	  been	  shown	  to	  reduce	  the	  risk	  of	  time	  
to	   conversion	   to	   clinically	   definite	   MS	   when	   compared	   to	   placebo	   (p=<0.0001	   and	  
p=<0.0001	  respectively)	  (Leist	  et	  al.,	  2014).	  
When	  interpreting	  the	  results	  of	  these	  trials	  it	  is	  important	  to	  highlight	  that	  in	  the	  ONTT	  40%	  
of	  patients	  with	  abnormal	  scans	  had	  not	  progressed	  to	  clinically	  definite	  MS	  after	  10	  years.	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Therefore,	   there	   is	   a	   risk	   of	   committing	   patients	  with	   a	   benign	   course	   to	   expensive	   long-­‐
term	  therapy	  that	   is	  not	  without	  side	  effects.	   In	  addition	  these	  therapies	  are	  only	  partially	  
effective	   and	   according	   to	   the	   analysis	   of	   one	   study,	   in	   order	   to	   prevent	   one	   relapse	   a	  
patient	  needs	  to	  be	  treated	  for	  approximately	  six	  years	  (Shams	  and	  Plant,	  2009).	  Also	  there	  
is	   some	   evidence	   that	   the	   prognosis	   for	   patients	   presenting	   with	   optic	   neuritis	   as	   a	   first	  
manifestation	  of	  MS	   is	  relatively	  good	  (Ramsaransing	  et	  al.,	  2001).	   In	  the	  ONTT	  only	  17	  of	  
the	  105	  patients	  who	  developed	  clinically	  definite	  MS	  had	  an	  EDSS	  of	  3	  or	  more	  after	  5	  years	  
(Optic	  Neuritis	  Study	  Group,	  1997).	  
2.4 Neuroprotective	  and	  remyelinating	  trials	  
Current	   treatment	  of	   optic	   neuritis	  with	   corticosteroids	  does	  not	   improve	   visual	   outcome	  
and	   permanent	   visual	   disability	   after	   optic	   neuritis	   is	   largely	   due	   to	   axonal	   loss,	   as	   is	  
discussed	   in	  more	   detail	   in	   section	   2.11	   In	   this	   context	   neuroprotection	   remains	   a	  major	  
unmet	   need	   and	   identifying	   neuroprotective	   agents	   to	   prevent	   axonal	   loss	   along	   with	  
strategies	   to	   induce	   remyelination	   (which	   itself	  may	   be	   neuroprotective)	   is	   a	   key	   area	   of	  
therapeutic	  research.	  Several	  trials	  targeting	  potential	  mechanistic	  pathways	  of	  neuroaxonal	  
loss	  including	  sodium	  channels,	  acid	  sensing	  channels,	  NMDA	  receptors	  (see	  Table	  2-­‐5)	  are	  
underway	  or	  have	  been	  completed.	  Additionally	  an	  antibody	  against	  LING01,	  a	  CNS	  protein	  
that	  down	  regulates	  oligodendrocyte	  precursor	  differentiation	  has	  been	  developed	  and	  has	  
the	   potential	   to	   promote	  CNS	   remyelination.	   Trials	   are	   currently	   underway	   in	   acute	   optic	  





Table	  2-­‐5:	  	  Neuroprotective	  and	  remyelinating	  trials	  in	  optic	  neuritis	  
(Adapted	  from	  Table	  2,	  Balcer	  et	  al.,	  2015)	  
Agent	   Mechanism	   of	  
action	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Visual	  fields	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Trial	  in	  progress	  
	  
2.5 Recovery	  
Visual	   recovery	   usually	   commences	   within	   2-­‐4weeks	   and	   in	   the	   ONTT	   93%	   of	   patients	  
showed	  signs	  of	  improvement	  within	  the	  first	  five	  weeks	  (Optic	  Neuritis	  Study	  Group,	  1991).	  
Visual	  recovery	  can	  occur	  over	  months	  and	  in	  some	  patients	  can	  continue	  up	  to	  a	  year	  after	  
the	  initial	  episode	  of	  optic	  neuritis.	  In	  the	  ONTT	  at	  1	  year	  93%	  of	  patients	  had	  a	  visual	  acuity	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of	   20/40	  or	  better	   and	  only	   5%	  of	   patients	  had	  a	   visual	   acuity	  of	   20/200	  or	  worse	   (Optic	  
Neuritis	  Study	  Group,	  1997).	  	  
In	  the	  ONTT	  the	  best	  predictor	  of	  poor	  visual	  outcome	  was	  lower	  visual	  acuity	  at	  baseline.	  
Despite	   this,	   64%	   of	   patients	   with	   a	   visual	   acuity	   perception	   of	   light	   or	   worse	   recovered	  
vision	  to	  20/40	  or	  better	  (Optic	  Neuritis	  Study	  Group,	  1997).	  	  	  
Other	  prognostic	   indicators	   include	   lesion	   length	   in	  the	  optic	  nerve	  as	  measured	  with	  MRI	  
with	  more	  elongated	  lesions	  being	  associated	  with	  poorer	  visual	  outcome.	  Lesions	  occurring	  
in	  the	  optic	  canal	  are	  also	  associated	  with	  a	  worse	  visual	  prognosis	  (Hickman	  et	  al.,	  2004b).	  	  
Visual	  recovery	  may	  be	  worse	  in	  patients	  with	  MS	  than	  those	  without	  and	  in	  the	  ONTT	  older	  
age	  was	  also	  associated	  with	  a	   slightly	  worse	  visual	  outcome	   (Optic	  Neuritis	  Study	  Group,	  
2008).	  	  
Hickman	   et	   al.,	   2004	   found	   that	   the	   factors	   associated	   with	   a	   better	   prognosis	   included	  
having	   a	   shorter	   enhancing	   lesion	   on	   triple	   dose	   gadolinium	   enhanced	   MRI,	   higher	   VEP	  
amplitudes	   on	   follow	   up	   VEPs	   and	   a	   steeper	   gradient	   of	   initial	   visual	   improvement.	   They	  
proposed	  that	  the	  crucial	  period	  of	  recovery	  appeared	  to	  be	  in	  the	  first	  2	  months	  
No	  other	  demographic	  factors	  are	  predictive	  of	  visual	  outcome.	  	  
Even	   with	   a	   good	   visual	   recovery	   in	   terms	   of	   visual	   acuity	   it	   is	   common	   for	   patients	   to	  
continue	  to	  report	  subjective	  symptoms	  (Frederiksen	  et	  al.,	  1997).	  Patients	  often	  experience	  
residual	   symptoms	   of	   reduced	   vision	   in	   bright	   light	   and	   glare,	   visual	   fading	   and	   Uhtoff’s	  
phenomenon.	  
Optic	   atrophy	   occurs	   in	   virtually	   all	   patients,	   even	   those	   with	   good	   visual	   recovery,	   with	  
temporal	  pallor	  developing	  between	  four	  to	  six	  weeks	  (Shams	  and	  Plant,	  2009).	  
VEP	   latencies	   remain	  delayed	   in	  most	  patients	  even	  with	  visual	   recovery	  and	  80%	   remain	  
abnormal	  at	  two	  years.	  However	  progressive	  latency	  shortening	  probably	  occurs	  for	  at	  least	  
2	   years	   after	   presentation	   suggesting	   some	   degree	   of	   remyelination	   does	   occur	   for	   a	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prolonged	   period	   of	   time	   (Brusa	   et	   al.,	   2001)	   although	   a	   small	   amount	   of	   shortening	   of	  
latency	  might	  conceivably	  arise	  from	  central	  adaptation	  through	  synaptic	  plasticity.	  	  
The	  RAPD	  in	  the	  affected	  eye	  may	  disappear	  if	  vision	  recovers	  fully.	  	  
2.6 Recurrence	  
In	  the	  ONTT	  the	  rate	  of	  recurrence	  of	  optic	  neuritis	  was	  19%	  in	  the	  affected	  eye,	  17%	  for	  the	  
fellow	  eye	  and	  30%	  for	  either	  eye	  (Optic	  Neuritis	  Study	  Group,	  1997).	  Recurrences	  occurred	  
more	   frequently	   in	   patients	  who	   subsequently	  went	   on	   to	   develop	   clinically	   definite	  MS.	  
Similarly	  patients	  with	  recurrent	  optic	  neuritis	  have	  a	  greater	  risk	  of	  developing	  MS	  (Beck	  et	  
al.,	   2003).	   Recovery	   after	   recurrent	   optic	   neuritis	   is	   more	   variable	   than	   after	   isolated	  
episodes.	  
In	  one	  study,	  20-­‐30%	  of	  patients	  with	  recurrent	  optic	  neuritis	  will	  develop	  seropositivity	  for	  
NMO	  after	  a	  follow	  up	  period	  of	  up	  to	  12	  yrs.	  (de	  Seze	  et	  al.,	  2008)	  
2.7 Association	  with	  Multiple	  Sclerosis	  
The	   risk	   of	   developing	   clinically	   definite	   MS	   after	   an	   isolated	   episode	   of	   optic	   neuritis	  
increases	   over	   time.	   In	   the	  ONTT	   the	   five-­‐year	   proportion	   of	   patients	   diagnosed	  with	  MS	  
was	  30%	  and	  this	  increased	  to	  50%	  at	  15	  years	  (Optic	  Neuritis	  Study	  Group,	  2008)	  and	  the	  
median	  time	  to	  diagnosis	  of	  MS	  was	  three	  years.	  Other	  studies	  similarly	  report	  a	  25-­‐35%	  risk	  
of	   developing	   MS	   after	   an	   episode	   of	   demyelinating	   optic	   neuritis	   (Nilsson	   et	   al.,	   2005;	  
Rodriguez	  et	  al.,	  1995)	  
Females	  are	  more	  likely	  to	  develop	  MS	  than	  males.	  In	  one	  study	  by	  (Rizzo	  and	  Lessell,	  1988)	  
74%	   of	   women	   and	   34%	   of	   men	   developed	   MS	   15	   years	   post	   optic	   neuritis.	   In	   adults,	  
younger	   age	   at	   the	   time	   of	   the	   optic	   neuritis	   attack	   is	   associated	  with	   an	   increased	   risk.	  
Ethnicity	  also	  seems	  to	  play	  a	  role	  with	  Caucasians	  being	  at	   increased	  risk	  (14%	  versus	  5%	  
non-­‐Caucasians	  in	  the	  ONTT	  (Beck	  et	  al.,	  1993).	  Other	  factors	  that	  confer	  an	  increased	  risk	  
of	   subsequent	   MS	   include	   evidence	   of	   retinal	   periphlebitis	   (57%	   of	   patients	   with	  
periphlebitis	   developed	  MS	   at	   3.5	   year	   follow	   up	   in	   one	   study	   by	   (Lightman	   et	   al.,	   1987;	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Compston,	  1978)	  and	  unmatched	  oligoclonal	  bands	  on	  CSF	  examination	  and	  positive	  typing	  
for	  HLA	  BT101	  (Compston,	  1978).	  The	  presence	  of	  HLA	  DR2	  antigen	  may	  also	  be	  associated	  
with	  increased	  risk	  of	  conversion	  to	  MS	  and	  is	  over-­‐represented	  in	  certain	  MS	  populations	  
(Hely	  et	  al.,	  1986).	  	  
The	  strongest	  predictor	  of	  future	  risk	  of	  MS	  is	  the	  presence	  of	  asymptomatic	  demyelinating	  
lesions	  on	  brain	  MRI	   (Miller	   et	   al.,	   1988b).	   In	   the	  ONTT	   the	   risk	  of	  MS	  was	  72%	  amongst	  
patients	  with	  one	  or	  more	   lesions	  on	  MRI	   versus	  25%	  among	   those	  with	  no	   lesions	  at	  15	  
years.	   (Optic	   Neuritis	   Study	   Group,	   2008).	   The	   location	   of	   the	   lesions	   also	   appears	   to	   be	  
important	  with	  infratentorial	  lesions	  conferring	  a	  higher	  risk	  (Miller	  et	  al.,	  2005).	  	  
The	  presence	  of	  asymptomatic	  spinal	  cord	  lesions	  in	  addition	  to	  brain	  lesions	  is	  associated	  
with	  an	  increased	  risk	  of	  early	  MS	  at	  1	  year	  as	  is	  the	  appearance	  of	  new	  T2	  weighted	  lesions	  
and	  gadolinium-­‐enhancing	  lesions	  on	  repeat	  imaging	  at	  three	  months	  (Brex	  et	  al.,	  1999)	  .	  
Lesion	   load	   on	  MRI	   can	   also	   be	   predicative	   of	   future	   disability.	   In	   one	   CIS	   study	   baseline	  
lesion	   volume	   and	   change	   in	   lesion	   volume	   in	   the	   first	   five	   years	   correlated	   with	   future	  
disability	  (Brex	  et	  al.,	  2002).	  In	  another	  prospective	  study	  of	  patients	  presenting	  with	  optic	  
neuritis	  the	  presence	  and	  number	  of	  infratentorial	  and	  spinal	  cord	  lesions	  was	  predicative	  of	  
disability	  in	  those	  who	  subsequently	  developed	  MS	  (Swanton	  et	  al.,	  2009).	  	  
In	   2001	   the	   McDonald	   criteria	   for	   the	   diagnosis	   of	   MS	   were	   published	   to	   allow	   earlier	  
diagnosis	  of	  MS	  based	  on	  MRI	  evidence	  of	  dissemination	  in	  time	  and	  space	  before	  a	  second	  
clinical	  attack	  has	  occurred.	  When	  applied	  to	  a	  cohort	  of	  CIS	  patients	  with	  repeat	  imaging	  at	  
3	  months	   the	   criteria	  had	  a	   specificity	  of	  93%	  and	  a	  positive	  predicative	  value	  of	  83%	   for	  
developing	  clinically	  definite	  MS	  at	  3	  years	  (Dalton	  et	  al.,	  2002).	  	  
Normal	  MRI	  brain,	  male	  gender,	  onset	  in	  childhood,	  simultaneous	  bilateral	  optic	  neuritis,	  
papillitis	  (particularly	  if	  severe),	  and	  peripapillary	  haemorrhage	  are	  associated	  with	  a	  lower	  
risk	  of	  developing	  MS	  (Beck	  et	  al.,	  2003)
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2.8 Pathology	  and	  Pathophysiology	  of	  optic	  neuritis	  
Pathology	  of	  optic	  nerve	  in	  optic	  neuritis	  and	  MS	  	  
There	  are	  very	  few	  studies	  on	  the	  pathological	  findings	  in	  the	  optic	  nerves	  of	  isolated	  acute	  
optic	  neuritis.	   This	   is	  primarily	  due	   to	   the	   fact	   that	   the	  condition	   typically	  afflicts	  a	   young	  
patient	  group	  that	  naturally	  will	  not	  die	  until	  many	  years	  afterwards	  and	  only	  then	  offer	  the	  
possibility	  of	  post	  mortem	  data	  (biopsy	  of	  the	  acute	  lesion	  is	  not	  reasonable	  because	  of	  the	  
potential	  risk	  of	  visual	  damage	  in	  a	  condition	  that	  normally	  has	  a	  good	  visual	  recovery).	  	  	  
Data	  from	  pathological	  studies	  of	  the	  optic	  nerve	  in	  acute	  and	  advanced	  MS	  patients	  have	  
demonstrated	  that	   the	  demyelinating	  plaques	  are	  similar	   to	   those	   found	  elsewhere	   in	   the	  
brain	   in	  MS.	  MS	  lesions	   in	  the	  optic	  nerves	  are	  found	   in	  approximately	  94-­‐99%	  of	  autopsy	  
cases.	  Optic	  nerve	   lesions	  have	  been	  described	  as	  more	  diffuse	  and	   less	  well	   demarcated	  
than	  brain	  lesions	  and	  are	  often	  associated	  with	  atrophy.	  Lesions	  may	  affect	  the	  whole	  cross	  
section	   of	   the	   optic	   nerve	   or	   partial	   sections	   (Lumsden,	   1970).	   The	   optic	   chiasm	   is	   often	  
involved.	   Lesion	   lengths	   of	   3-­‐	   30	   mm	   have	   been	   reported	   in	   pathological	   studies.	  
(McDonald,	  1986).	  	  
Evangelou	  et	  al.,	  2001	  measured	  axonal	  loss	  and	  neuronal	  size	  changes	  in	  the	  anterior	  visual	  
pathways	  of	  eight	  patients	  who	  had	  died	  of	  MS	  and	  compared	  them	  to	  controls.	  They	  found	  
that	  the	  optic	  nerves	  from	  MS	  brains	  had	  a	  trend	  towards	  smaller	  mean	  cross-­‐sectional	  area	  
and	  estimated	  total	  axon	  counts	  were	  reduced	  by	  45%	  when	  compared	  to	  controls.	   In	  MS	  
brains	  the	  parvocellular	  cells	  of	  the	  lateral	  geniculate	  nucleus	  were	  significantly	  smaller	  than	  
controls	  and	  this	  correlated	  with	  the	  axonal	  loss	  in	  the	  optic	  nerves.	  This	  was	  not	  true	  of	  the	  
magnocellular	  cells	  that	  were	  similar	  in	  MS	  brains	  and	  controls.	  They	  concluded	  that	  there	  
appears	  to	  be	  selective	  atrophy	  of	  smaller	  neurons	  in	  the	  parvocellular	  nucleus	  as	  a	  result	  of	  
transynaptic	  atrophy	  preferentially	  affecting	  smaller	  axons.	  	  
Gartner,	   1953	   examined	   14	   eyes	   from	   10	   patients	   with	   advanced	   MS.	   They	   found	   optic	  
atrophy	  predominantly	   in	  the	  temporal	  portion	  of	  the	  optic	  nerve	  with	  the	  papillomacular	  
bundle	  predominantly	  affected	  in	  the	  retina.	  There	  was	  an	  increase	  in	  glial	  cells	  in	  the	  optic	  
nerve	   and	   gliosis	   of	   the	   optic	   discs.	   As	   mentioned	   in	   Chapter	   1	   this	   has	   implications	   for	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follow	  up	  retinal	  nerve	  fibre	   layer	  measurements	  which	  may	  not	   just	  be	  measuring	  axonal	  
loss	   but	   also	   gliosis	   (that	   could	   ‘falsely’	   increase	  RNFL	   thickness	  measurements	   giving	   the	  
impression	  of	  axonal	  preservation).	  	  	  
Histopathological	   studies	   of	   EAE	   models	   of	   optic	   neuritis	   in	   animals	   have	   demonstrated	  
inflammatory	  infiltrate,	  extensive	  demyelination	  and	  axonal	  loss	  in	  the	  affected	  optic	  nerves	  
(Rao	  et	  al.	  1977;	  Hayreh	  et	  al.,	  1981)	  
The	  Pathology	  of	  the	  acute	  active	  plaque	  in	  MS	  
It	  is	  believed	  that	  most	  plaques	  begin	  with	  the	  margination	  of	  activated	  autoreactive	  CD4+T	  
cells	  across	  breaches	  in	  the	  blood	  brain	  barrier.	  
Although	  patients	  with	  MS	  appear	  similar	  to	  healthy	  controls	   in	  the	  number	  of	  T	  cells	  that	  
react	   to	  myelin	   in	   their	  peripheral	  blood,	   they	  appear	   to	  be	  qualitatively	  different.	  Myelin	  
reactive	   T	   cells	   in	   MS	   patients	   exhibit	   an	   activated	   phenotype	   compared	   to	   a	   naïve	  
phenotype	   in	  healthy	   controls.	   There	  are	  also	   significant	  differences	   in	   the	  cytokines	   they	  
release	   with	   myelin	   reactive	   T	   cells	   in	   MS	   patients	   being	   relatively	   more	   inflammatory	  
(Frohman	  et	  al.,	  2006).	  
	  The	  existence	  of	   several	  putative	  myelin	  and	  non-­‐myelin	   target	  antigens	   including	  myelin	  
basic	  protein,	  myelin-­‐associated	  glycoprotein	  and	  αB	  crystallin	  have	  been	  proposed.	  	  This	  is	  
followed	  by	  amplification	  of	   the	   immune	   response	  after	   recognition	  of	   target	  antigens	  on	  
antigen	   presenting	   cells	   and	   the	   release	   of	   proinflammatory	   cytokines.	   Lymphocytes	   and	  
macrophages	   form	   perivascular	   cuffs	   around	   capillaries	   and	   venules.	   There	   is	   diffuse	  
parenchymal	   infiltration	   by	   inflammatory	   cells	   and	   oedema	  with	   loss	   of	   oligodendrocytes	  
and	   myelin.	   	   Demyelination	   may	   be	   due	   to	   an	   anti-­‐myelin	   antibody	   that	   enables	  
phagocytosis	  by	  macrophages	  in	  the	  presence	  of	  complement	  (Frohman	  et	  al.,	  2006).	  	  
There	  is	  inflammation,	  demyelination	  with	  variable	  gliosis	  and	  relative	  axonal	  preservation.	  
Although	  there	  is	  relatively	  less	  axonal	   injury	  it	  does	  occur	  and	  is	  most	  pronounced	  during	  
active	  inflammatory	  demyelination	  (Trapp	  et	  al.,	  1998).	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Early	  MS	   lesions	  demonstrate	  marked	  heterogeneity	   in	   their	  pathological	   appearance	  and	  
four	   distinct	   immune-­‐pathological	   patterns	   have	   been	   characterised	   (Lucchinetti	   et	   al.,	  
2000).	  Lucchinetti	  et	  al	  found	  that	  a	  single	  lesional	  type	  was	  common	  to	  all	  active	  plaques	  in	  
the	  same	  patient	  but	  there	  was	  major	  variation	  in	  the	  pathological	  appearance	  of	  plaques	  in	  
different	  patients.	  Others	  have	  not	   consistently	   confirmed	   this	   finding	  but	   it	  does	   suggest	  
that	  there	  are	  a	  variety	  of	  different	  immunological	  mechanisms	  and	  targets	  responsible	  for	  
inflammation	  and	  demyelination	   in	  MS	  and	  these	  may	  vary	   from	  patient	  to	  patient.	  The	  4	  
types	  are	  therefore	  summarized	  below.	  
	  Type	   I	   –	   characterised	   by	   active	   demyelination	   on	   a	   T	   lymphocyte	   and	   activated	  
macrophage/microglia	   inflammatory	   background	   with	   a	   lack	   of	   immunoglobulin	   and	  
complement	  deposition.	   	  There	   is	  variable	  oligodendrocyte	   loss	  most	  marked	  at	  the	  active	  
lesional	  border.	  There	  is	  a	  high	  incidence	  of	  remyelination	  (15%	  of	  active	  MS	  lesions).	  	  
Type	   II	   –	   characterised	   by	   active	   demyelination	   associated	   with	   immunoglobulin	   and	  
complement	   deposition	   on	  myelin	   and	  macrophage	   phagocytosis	   of	   myelin	   debris	   on	   an	  
inflammatory	  background.	  There	  is	  variable	  oligodendrocyte	  loss	  at	  the	  active	  border	  with	  a	  
high	  incidence	  of	  remyelinated	  shadow	  plaques.	  (58%	  of	  MS	  patients)	  
Type	  III	  –	  ill-­‐defined	  lesions	  show	  active	  demyelination	  with	  oligodendrocyte	  apoptosis	  and	  
preferential	   loss	   of	   periaxonal	   myelin	   components.	   Loss	   of	   oligodendrocytes	   is	   most	  
prominent	  at	  the	  active	  plaque	  border	  but	  extends	  into	  the	  normal	  appearing	  white	  matter.	  
The	  inactive	  plaque	  centre	  is	  also	  devoid	  of	  oligodendrocytes	  with	  no	  remyelination	  shadow	  
plaques	  (26%	  of	  MS	  patients	  biopsied).	  	  
Type	   IV	   lesions	  were	  very	   rare	  and	  exhibited	  profound	  oligodendrocyte	   loss	   in	  periplaque	  
white	  matter.	  	  
Barnett	  and	  Prineas,	  2004	  challenged	  this	  classification	  in	  their	  series	  of	  patients	  who	  died	  
during	  or	  shortly	  after	  and	  acute	  relapse.	  They	  propose	  that	  lesion	  heterogeneity	  is	  related	  
to	  differences	  in	  lesion	  age	  rather	  than	  inter	  patient	  differences.	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2.9 Pathophysiology	  of	  optic	  neuritis	  
To	  some	  extent	  we	  are	  able	  to	  visualise	  the	  pathology	  of	  the	  lesion	  in	  optic	  neuritis	  in	  vivo	  
with	  MRI	  studies.	  Gadolinium	  enhancement	  occurs	  where	  there	  is	  a	  breakdown	  in	  the	  blood	  
brain	  barrier	  and	   likely	   represents	   inflammation	  occurring	   in	   the	  acute	   lesion.	  Gadolinium	  
enhancement	  of	  the	  optic	  nerve	  is	  a	  sensitive	  (94%)	  finding	  in	  acute	  optic	  neuritis	  and	  does	  
not	   occur	  with	   old	   lesions	   (Kolappan	   et	   al.,	   2009).	   This	   sensitivity	   is	   increased	   further	   by	  
using	  triple	  dose	  gadolinium	  (96%).	  (Hickman	  et	  al.,	  2004b)	  found	  that	  the	  acute	  enhancing	  
lesion	   length	  using	   triple	  dose	  gadolinium	  was	  associated	  with	  both	  baseline	  visual	   acuity	  
and	   final	   visual	   outcome.	   Duration	   of	   enhancement	   was	   not	   predictive	   of	   final	   visual	  
outcome.	  	  	  
Imaging	   studies	   have	   correlated	   breakdown	   of	   the	   blood	   brain	   barrier	   and	   optic	   nerve	  
inflammation	   with	   the	   initial	   clinical	   presentation.	   (Youl	   et	   al.,	   1991)	   demonstrated	   that	  
gadolinium	   leakage	  was	   a	   consistent	   early	   feature	   of	   the	   optic	   nerve	   lesion	   and	   lasted	   a	  
mean	  of	  31.2	  days.	  Gadolinium	  enhancement	  in	  the	  optic	  nerve	  lesion	  was	  associated	  with	  
the	  symptoms	  and	  signs	  of	  an	  optic	  neuropathy	  as	  well	  as	  prolonged	   latency	  and	  reduced	  
amplitude	   on	   VEPs.	   Conversely	   disappearance	   of	   gadolinium	   leakage	  was	   associated	  with	  
recovery	   of	   VEP	   amplitude	   to	   a	   mean	   of	   50%	   of	   the	   unaffected	   eye	   as	   well	   as	   clinical	  
improvement.	  Youl	  et	  al	  did	  not	  find	  a	  correlation	  between	  VEP	  changes	  acutely	  and	  lesion	  
length	  but	  follow	  up	  VEP	  amplitude	  was	  found	  to	  correlate	  inversely	  with	  lesion	  length.	  They	  
concluded	  that	   inflammation	  and	  oedema	  are	  crucial	   factors	   in	  determining	  the	  reversible	  
element	  of	  conduction	  block	  and	  visual	  impairment.	  
Demyelination	   also	   occurs	   during	   the	   active	   inflammatory	   phase.	   Halliday	   et	   al	   observed	  
delayed	   pattern	   evoked	   VEP	   responses	   in	   eyes	   affected	   by	   optic	   neuritis	   with	   a	   mean	  
latency	   of	   155ms	   +/-­‐	   20.0ms	   compared	   to	   121.1	   +/-­‐	   5.9	   in	   healthy	   controls	   due	   to	  
demyelination	  and	  slowing	  of	  conduction	  in	  the	  affected	  optic	  nerve	  (Halliday	  et	  al.,	  1972)	  
Other	  studies	  have	  also	  demonstrated	  that	  reduced	  amplitude	  and	  prolonged	  latency	  occurs	  
acutely	  during	  an	  episode	  of	  optic	  neuritis.	  
It	  is	  therefore	  likely	  that	  an	  important	  cause	  of	  functional	  loss	  in	  the	  initial	  presentation	  of	  
optic	   neuritis	   is	   axonal	   conduction	   block.	   Conduction	   block	   occurs	   at	   the	   site	   of	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inflammatory	   demyelination	   but	   is	   unimpaired	   on	   either	   side	   of	   this.	   The	   likelihood	   of	  
conduction	   block	   depends	   on	   the	   amount	   of	   myelin	   that	   is	   lost.	   In	   experimentally	  
demyelinated	   central	   axons	   conduction	   block	   invariably	   occurs	   if	   a	   whole	   internode	   of	  
myelin	  is	  lost	  and	  lasts	  for	  several	  days	  (Smith	  and	  McDonald,	  1999).	  
Demyelination	  widens	   the	   nodal	   distance	   thereby	   increasing	   the	   electrical	   capacitance	   of	  
the	   node	   that	   reduces	   its	   safety	   factor	   for	   conduction	   (Smith	   and	   McDonald,	   1999).	   In	  
normal	   axons	   the	   safety	   factor	   of	   nerve	   conduction	   is	   around	   3-­‐5	   times	   greater	   than	  
required	  to	  produce	  an	  impulse.	  Demyelinated	  axons	  have	  an	  inherently	  lower	  safety	  factor	  
that	  is	  typically	  near	  unity.	  As	  such	  even	  small	  changes	  in	  environment	  can	  have	  significant	  
effects	  on	  axonal	  conduction	  and	  clinical	  symptoms.	  
Inflammation	  may	  play	  also	  contribute	   to	  conduction	  block	  via	  proinflammatory	  cytokines	  
e.g.	   tumour	   necrosis	   factor-­‐a,	   interferon–y,	  which	   are	   potent	   stimulators	   of	   the	   inducible	  
form	  of	  nitric	  oxide	  synthetase.	  Nitric	  oxide	  has	  been	  shown	  to	  induce	  conduction	  block	  in	  
demyelinated	  axons	  within	  minutes	  and	  its	  effects	  can	  last	  for	  hours	  (Smith	  and	  McDonald,	  
1999).	   This	   may	   be	   due	   to	   an	   effect	   on	   sodium	   channels	   and	  mitochondrial	   metabolism	  
(Bolaños	  et	  al.,	  1997).	  	  
In	  addition	  to	  the	  resolution	  of	  inflammation,	  restoration	  of	  current	  along	  the	  demyelinated	  
axon	   may	   also	   contribute	   to	   resolution	   of	   symptoms.	   In	   experimental	   models	   of	  
demyelinated	  central	  axons	  current	  can	  be	  restored	  within	  2-­‐3	  weeks	  of	  demyelination	  even	  
in	   the	   absence	   of	   remyelination	   (Felts	   et	   al.,	   1997).	   There	   is	   evidence	   to	   suggest	   that	  
functional	   recovery	   is	   possible	   despite	   complete	   demyelination	   of	   axons	   within	   plaques	  
(Wisniewski	  et	  al.,	  1976)	  and	  normal	  visual	  acuity	  can	  be	  preserved	  in	  MS	  patients	  despite	  
significant	  delays	  in	  VEP	  latency	  (Halliday	  et	  al.,	  1972)	  	  
	  Restoration	   of	   current	   involves	   upregulation	   of	   sodium	   channels	   along	   the	   demyelinated	  
segment	  and	  the	  adoption	  of	  a	  microsaltatory	  mode	  of	  conduction.	  Although	  conduction	  is	  
restored	  across	  the	  demyelinated	  segment	  it	  is	  not	  as	  fast	  as	  normal	  resulting	  in	  increased	  
latency	  of	  conduction.	  Remyelination	  may	  not	  play	  a	  big	  role	  in	  the	  initial	  stages	  of	  recovery.	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Fading	  of	  Vision	  
The	   ability	   of	   demyelinated	   axons	   to	   conduct	   trains	   of	   impulses	   is	   restricted	   due	   to	   the	  
gradual	  accumulation	  of	  the	  refractory	  period	  between	  repeated	  activation.	  This	  means	  that	  
the	   maximum	   frequency	   of	   conduction	   of	   action	   potentials	   can	   be	   quite	   significantly	  
reduced	  after	  relatively	  short	  periods	  of	  activity.	  This	  phenomenon	  is	  likely	  to	  contribute	  to	  
the	  fading	  of	  vision	  in	  bright	  environments	  that	  sometimes	  occurs	  after	  an	  episode	  of	  optic	  
neuritis.	  	  
Uhtoff's	  Phenomenon	  
This	  symptom	  was	  initially	  described	  by	  Uhtoff	  (1890)	  as	  the	  transient	  deterioration	  in	  vision	  
that	   occurred	   during	   exercise	   in	   patients	   with	   optic	   neuritis.	   Young	   and	   Bennett	   first	  
described	   the	  exacerbation	  of	  visual	   symptoms	  by	   increased	   temperature.	   It	   is	  a	  common	  
symptom	  after	  optic	  neuritis	  and	  can	  occur	  in	  up	  to	  33%	  of	  patients	  (Perkin	  and	  Rose,	  1976).	  
Although	  it	  can	  be	  apparent	  acutely	  during	  optic	  neuritis	  it	  is	  generally	  characteristic	  of	  the	  
recovery	  phase.	   It	  can	  occur	   for	  several	  months	  to	  years	  after	  an	  episode	  of	  optic	  neuritis	  
and	   its	   resolution	   may	   suggest	   remyelination.	   In	   a	   study	   by	   (Selhorst	   et	   al.,	   1982)	   VEP	  
amplitude	  was	  found	  to	  be	  reduced	  or	  absent	  during	  exercise	  in	  4	  patients	  following	  optic	  
neuritis	  and	  this	  was	  accompanied	  by	  a	  reduction	  in	  visual	  acuity.	  Vision	  recovered	  within	  5-­‐
15	  minutes	  after	  exercise	  cessation	  and	  was	  accompanied	  by	  a	  return	  in	  VEP	  amplitude	  to	  
pre-­‐exercise	  levels.	  	  
Uhtoff's	  Phenomenon	  can	  be	  explained	  by	  the	  reduced	  safety	  factor	  in	  demyelinated	  axons	  
that	  renders	  them	  susceptible	  to	  increases	  in	  temperature	  with	  transient	  conduction	  block.	  	  
Conversely	   ingestion	   of	   ice	   and	   reduced	   temperature	   has	   been	   shown	   to	   transiently	  
improve	  symptoms.	  	  
Phosphenes	  
This	  is	  a	  perception	  of	  flashes	  of	  lights	  provoked	  by	  eye	  movements.	  They	  are	  believed	  to	  be	  
the	  optical	  equivalent	  of	  Lhermitte's	  phenomenon.	  Their	  pathophysiology	  can	  be	  explained	  
by	   the	   electrophysiological	   properties	   of	   demyelinated	   axons	   that	   render	   them	   hyper	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excitable	   to	   mechanical	   stimuli	   generating	   spontaneous	   bursts	   of	   spurious	   (ephaptic)	  
impulses.	  	  
Pulfrich's	  Phenomenon	  
This	   is	   the	  anomalous	  perception	  of	   the	  directionality	  of	   the	  movement	  of	   an	  object	   that	  
occurs	   after	   an	   episode	   of	   unilateral	   optic	   neuritis.	   It	   is	   due	   to	   the	   asymmetry	   in	   the	  
conduction	  velocity	  of	  the	  optic	  nerves	  that	   leads	  to	  a	  difference	   in	   latency	  of	  the	  cortical	  
response	  to	  stimulation	  in	  the	  two	  eyes.	  In	  clinical	  practice	  it	  usually	  occurs	  in	  the	  recovery	  
period	  after	  optic	  neuritis	  but	  is	  not	  as	  common	  as	  Uhtoff's	  phenomenon.	  
2.10 Remyelination.	  	  
	  Initially	   thought	  not	   to	   take	  place,	   it	   is	  now	  well	  established	   that	  extensive	   remyelination	  
may	   occur	   within	   plaques	   in	   optic	   neuritis	   and	   MS.	   This	   is	   particularly	   true	   in	   early	   MS	  
lesions	  occurring	  within	   the	   first	   few	  years	  of	  disease	  onset	   (Lassmann,	  1998).	   It	  accounts	  
for	   the	   appearance	   of	   shadow	   plaques	   (completely	   remyelinated	   plaques).	   The	   mature	  
nervous	   system	   retains	   a	   pool	   of	   undifferentiated	   oligodendrocyte	   precursors.	   These	  
precursor	  cells	  are	  recruited	  to	  the	  site	  of	  tissue	  injury	  and	  surround	  lesions	  in	  MS	  and	  new	  
myelin	   is	  formed.	   	   	  Remyelinated	  plaques	  are	  characterized	  by	  decreased	  myelin	  thickness	  
to	   axonal	   diameter	   ratio	   with	   short	   internodal	   distances	   (Bogdan	   et	   al.	   2013).	  
Oligodendrocytes	  expressing	  myelin	  proteins	  in	  their	  cytoplasm	  are	  found	  in	  close	  proximity	  
to	   these	  myelin	   sheaths.	   Remyelination	  may	   be	   complete	   or	   incomplete.	   If	   incomplete	   it	  
mostly	   occurs	   at	   the	   lesion	   edge.	   Shadow	   plaques	   are	   characterized	   by	   sharply	  
circumscribed	  areas	  of	  myelin	  pallor	   in	   the	  normal	  appearing	  white	  matter.	   The	   timing	  of	  
remyelination	  is	  unknown	  but	  demyelination	  and	  remyelination	  may	  occur	  at	  the	  same	  time	  
and	   the	   two	   processes	   may	   occur	   in	   a	   dynamic	   equilibrium.	   The	   extent	   to	   which	  
remyelination	   occurs	   is	   thought	   to	   depend	   upon	   the	   availability	   of	   oligodendrocyte	  
progenitor	   precursor	   cells	   as	   well	   as	   the	   pro	   or	   anti-­‐inflammatory	   balance	   and	  may	   vary	  
from	   patient	   to	   patient	   (Bogdan	   et	   al.	   2013).	   The	   degree	   of	   axonal	   loss	   and	   glial	   scar	  
formation	  may	  also	  be	  important	  factors.	   	  Remyelinated	  plaques	  may	  be	  more	  susceptible	  
to	  second	  hit	  inflammatory	  demyelination.	  Remyelination	  of	  MS	  lesions	  may	  have	  important	  
functions	  including	  protection	  of	  axons	  and	  restoration	  of	  conduction	  velocity.	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Remyelination	   is	   thought	   to	   occur	   after	   an	   episode	   of	   optic	   neuritis	   as	   suggested	   by	   the	  
progressive	   shortening	   of	   VEP	   latency	   over	   time.	   Normalisation	   of	   VEP	   latency	   has	   been	  
shown	  to	  occur	  in	  up	  to	  38%	  of	  cases	  after	  optic	  neuritis.	  Brusa	  et	  al.,	  2001	  demonstrated	  
that	   VEP	   latency	   decreased	   significantly	   for	   the	   first	   year	   post	   optic	   neuritis	   and	   less	  
strikingly	   during	   the	   second	   year.	   The	   most	   marked	   reduction	   in	   VEP	   latency	   occurred	  
between	   3	   and	   6	   months.	   This	   was	   not	   accompanied	   by	   a	   significant	   functional	  
improvement.	   They	   postulated	   that	   remyelination	   was	   the	   most	   likely	   cause	   for	   the	  
progressive	   shortening	   although	   reorganisation	   of	   ion	   channel	   distribution	   and	   synaptic	  
plasticity	  may	   also	   contribute.	   They	   suggested	   that	   the	   dissociation	   between	   VEP	   latency	  
and	   visual	   function	   is	   that	   final	   visual	   outcome	   is	   dependent	   on	   axonal	   loss	   rather	   than	  
remyelination.	  	  
Non-­‐conventional	  MRI	  techniques	  have	  been	  used	  to	  image	  the	  extent	  of	  myelination	  within	  
the	  optic	  nerve	  after	  optic	  neuritis	   in	  vivo.	  Magnetisation	   transfer	   indirectly	  measures	   the	  
amount	  of	  macromolecular	  structure,	  e.g.	  myelin	  that	  is	  present	  in	  the	  tissue	  (Kolappan	  et	  
al.,	   2009).	   Thorpe	   et	   al.,	   1995	   demonstrated	   that	   MTR	   was	   significantly	   reduced	   in	   the	  
affected	   optic	   nerves	   of	   20	   patients	  with	   optic	   neuritis	  when	   compared	   to	   controls.	  MTR	  
reduction	  was	  negatively	  correlated	  with	  VEP	  latency	  suggesting	  it	  might	  be	  an	  indicator	  of	  
demyelination.	  Inglese	  et	  al.,	  2002	  measured	  MTR	  in	  the	  whole	  optic	  nerves	  in	  a	  cohort	  of	  
patients	   with	   previous	   optic	   neuritis.	   Mean	   MTR	   correlated	   with	   visual	   acuity	   and	   was	  
significantly	  reduced	  in	  the	  optic	  nerves	  of	  patients	  with	  worse	  visual	  outcome	  compared	  to	  
those	  with	   good	   recovery.	  MTR	   values	   did	   not	   correlate	  with	  VEP	   latency.	   This	  may	  have	  
been	  because	   the	  cohort	  of	  patients	   studied	  was	  biased	   towards	  poorer	  vision	  with	  more	  
pronounced	  axonal	  loss.	  In	  a	  study	  of	  serial	  MTR	  imaging	  in	  acute	  optic	  neuritis	  (Hickman	  et	  
al.,	  2004b)	  found	  that	  the	  mean	  MTR	  of	  the	  affected	  nerve	   lesion	  progressively	  decreased	  
until	  reaching	  a	  nadir	  at	  240	  days	  with	  a	  minimum	  value	  of	  44	  pu.	  After	  this	  point	  mean	  the	  
mean	   MTR	   of	   the	   affected	   optic	   nerve	   increased	   to	   a	   value	   of	   45	   pu	   at	   1	   year.	   Time	  
averaged	   MTR	   and	   mean	   VEP	   latency	   was	   related.	   The	   subsequent	   rise	   in	   MTR	   may	   be	  
attributable	  to	  remyelination.	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2.11 Axonal	  loss	  
Axonal	  loss	  is	  now	  recognised	  as	  a	  major	  cause	  of	  irreversible	  disability	  in	  MS	  and	  impaired	  
visual	  function	  after	  optic	  neuritis.	  	  Axonal	  transection	  and	  degeneration	  occur	  in	  the	  setting	  
of	   acute	   inflammatory	   demyelination	   and	   the	   extent	   of	   axonal	   loss	   correlates	   with	   the	  
magnitude	  of	  inflammation	  (Trapp	  et	  al.,	  1998).	  Axonal	  loss	  also	  occurs	  as	  a	  result	  of	  chronic	  
demyelination	  (Ganter	  et	  al.,	  1999).	   It	   is	   likely	  that	  progression	  in	  MS	  is	  due	  to	  cumulative	  
axonal	  loss.	  	  
Various	  mechanisms	  for	  axonal	  loss	  have	  been	  proposed	  including:	  
Acute	  
1) Proteolytic	  enzymes,	  cytokines	  and	  free	  radical	  produced	  by	  activated	  immune	  and	  
glial	  cells	  
2) Cytotoxic	  CD8+	  T	  cells	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3) Oxidative	  stress	  due	  to	  nitric	  oxide	  and	  mitochondrial	  dysfunction	  	  
Sub	  acute	  
4) Glutamate	  excitotoxicy	  
5) Alterations	  in	  the	  expression	  or	  activity	  of	  axonal	  ion	  channels	  
Chronic	  
6) Lack	  of	  trophic	  support	  from	  myelin	  and	  oligodendrocytes	  
7) Wallerian	  degeneration	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MRI	   studies	   have	   correlated	   axonal	   loss	  with	   a	   reduction	   in	   N-­‐acetyl	   aspartate	   and	   hypo	  
intensity	  on	  T1	  weighted	   images	  (T1	  black	  holes)	  and	  brain	  atrophy	  (Bjartmar	  et	  al.,	  2000;	  
van	  Waesberghe	  et	  al.,	  1999).	  
Alterations	   in	   axonal	   cytoskeleton	   and	   fast	   axonal	   transport	   have	   been	   used	   to	   indirectly	  
demonstrate	  pathology	  in	  demyelinated	  axons.	  Amyloid	  precursor	  protein	  is	  transported	  by	  
fast	   axonal	   transport	   and	   accumulates	   when	   this	   is	   disrupted.	   Ferguson	   et	   al.,	   1997	  
demonstrated	  accumulation	  of	  APP	   in	  active	  MS	   lesions,	  particularly	  occurring	   in	   terminal	  
axonal	   swellings	   suggesting	   axonal	   transection.	   They	   were	   found	   to	   correlate	   with	   the	  
degree	  of	  inflammation.	  Trapp	  et	  al.,	  1998	  demonstrated	  that	  acute	  lesions	  contained	  more	  
than	  11,000	  transected	  axons	  per	  mm3	  compared	  to	  1	  transected	  axon	  per	  mm3	  in	  controls.	  	  
Despite	  the	  fact	  that	  axonal	   loss	  is	  extensive	  in	  acute	  lesions	  the	  plasticity	  of	  the	  CNS	  may	  
compensate	   for	   this	   and	   in	   the	   early	   stages	   of	   MS	   axonal	   loss	   may	   not	   associated	   with	  
significant	   disability	   initially.	   However,	   cumulative	   loss	   of	   axons	   over	   time	   as	   a	   result	   of	  
inflammatory	   demyelination	   is	   likely	   to	   lead	   to	   irreversible	   disability.	   There	   may	   be	   a	  
threshold	  of	  axonal	  loss	  beyond	  which	  the	  brain	  can	  no	  longer	  compensate	  that	  marks	  the	  
transition	  from	  the	  relapsing	  to	  the	  progressive	  phase	  of	  MS.	  	  
After	  optic	  neuritis	   several	   studies	  have	  demonstrated	  that	  VEP	  amplitude	  correlates	  with	  
visual	   outcome	   (Halliday	   et	   al.,	   1973).	   This	   suggests	   that	   amount	   of	   axonal	   loss	   after	   an	  
episode	  of	  optic	  neuritis	   is	  predictive	  of	  visual	  outcome	  although	  a	  component	  of	  reduced	  
VEP	  amplitude	  may	  reflect	  conduction	  block	  due	  to	  demyelination.	  	  	  
Quantifying	   atrophy	   of	   the	   optic	   nerve	   using	  MRI	   gives	   an	   indication	   of	   axonal	   loss	   after	  
optic	  neuritis,	  although	  atrophy	  of	  tissue	  in	  MS	  could	  potentially	  result	  from	  demyelination	  
or	  axonal	  loss.	  However,	  axons	  contribute	  twice	  as	  much	  bulk	  to	  white	  matter	  than	  myelin	  
(Miller	  et	  al.,	  2002)	  and	  are	  therefore	  likely	  to	  be	  the	  important	  determinant	  of	  atrophy.	  	  
In	  a	  cross-­‐sectional	  study	  of	  17	  patients	  with	  a	  previous	  episode	  of	  unilateral	  optic	  neuritis,	  
Hickman	  et	  al.,	  2001	  were	  reliably	  able	  to	  demonstrate	  optic	  nerve	  atrophy	  following	  optic	  
neuritis.	   A	   subsequent	   serial	   MRI	   study	   in	   acute	   optic	   neuritis	   found	   initial	   optic	   nerve	  
 74 
swelling	  at	  baseline	   that	  was	   followed	  by	  progressive	  atrophy	  over	   time.	  At	  52	  weeks	   the	  
mean	   cross-­‐sectional	   are	   of	   the	   affected	   nerve	  was	   11.3	  mm2	   compared	   to	   13.1	  mm2	   in	  
controls.	   They	   found	   that	   there	   was	   an	   association	   with	   baseline	   optic	   nerve	  mean	   area	  
(when	  there	  was	  swelling	  of	  the	  nerve	  reflecting	  inflammation)	  and	  logMAR	  visual	  acuity	  but	  
there	  was	  no	  evidence	  of	   an	  association	  at	  1	   year	   (Hickman	  et	   al.,	   2004b).	  However,	   in	   a	  
different	   study	   of	   a	   cohort	   of	   patients	   with	   more	   severe	   visual	   loss,	   visual	   acuity	   was	  
associated	   with	   the	   degree	   of	   optic	   nerve	   atrophy	   as	   well	   as	   reduced	   VEP	   amplitudes	  
(Hickman	  et	  al.,	  2002a).	   Inglese	  et	  al.,	  2002	   imaged	  the	  optic	  nerves	  of	   thirty	  MS	  patients	  
with	  a	  previous	  episode	  of	  unilateral	  optic	  neuritis	  and	  found	  that	  optic	  nerve	  volume	  on	  T1	  
weighted	  images	  correlated	  with	  visual	  acuity	  and	  VEP	  latency.	  	  
Henderson	  et	  al.,	  2011	  looked	  at	  early	  factors	  associated	  with	  axonal	  loss	  after	  optic	  neuritis	  
as	  measured	  by	  RNFL	   thickness	   on	  OCT.	   They	  performed	   clinical,	   electrophysiological	   and	  
MRI	  assessments	  at	  baseline	  and	  3	  months.	  They	  found	  only	  VEP	  latency	  and	  colour	  vision	  
at	   baseline	   and	   3	   months	   were	   significantly	   and	   independently	   associated	   with	   RNFL	  
thinning.	  	  
Even	   though	  most	  patients	  make	  a	  good	   recovery	   there	   is	  an	  average	  a	  20%	  reduction	  of	  
RNFL	   thickness	   in	   the	   affected	   eye	   following	   an	   episode	   optic	   neuritis	   (Henderson	   et	   al.,	  
2010).	   	   Similarly,	   normal	   visual	   acuity	   is	   possible	   despite	   an	   abnormal	   VEP.	   	   This	  may	   be	  
explained	  by	  a	  redundancy	  of	  axons	  in	  the	  optic	  nerve.	  A	  threshold	  level	  of	  axonal	  loss	  may	  
be	   required	   to	   produce	   clinically	   significant	   visual	   loss.	   In	   a	   study	   by	   Frisen	   and	   Quigley	  
(1984)	  nerve	  fibre	  counts	  were	  obtained	  from	  the	  temporal	  quadrants	  of	  optic	  nerve	  with	  
optic	  atrophy.	  They	  found	  that	  normal	  visual	  acuity	  is	  possible	  despite	  loss	  of	  40%	  of	  neural	  
substrate	  (Frisen	  and	  Quigley,	  1984).	  	  	  
Visual	  acuity	  depends	  on	  the	  quality	  of	  the	  optics	  of	  the	  eye	  and	  the	  processing	  of	  the	  image	  
in	   the	  neural	  pathway	  from	  the	  retina	  to	  the	  brain.	  Altered	  optics	  of	   the	  eye	  can	  degrade	  
the	  quality	  of	  the	  image,	  the	  retina	  has	  anatomical	  and	  physiological	  limits,	  and	  higher	  order	  
neural	   processing	   can	  alter	   the	  perception	  of	   an	   image	   (Amesbury	   and	   Schallhorn,	   2003).	  
Consequently	  visual	  acuity	  depends	  not	  only	  on	  the	  number	  of	  functioning	  neural	  channels	  
but	  is	  also	  significantly	  limited	  by	  other	  factors	  such	  as	  the	  optics	  of	  the	  eye	  and	  spacing	  of	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photoreceptors.	  It	  is	  therefore	  not	  surprising	  that	  acuity	  presents	  a	  relatively	  insensitive	  and	  
pathologically	  nonspecific	  measure	  of	  visual	  dysfunction	  after	  optic	  neuritis.	  	  
Another	  factor	  that	  may	  contribute	  to	  visual	  recovery	  after	  optic	  neuritis	  despite	  structural	  
damage	  is	  cortical	  adaptation.	  Werring	  et	  al	  (2000)	  demonstrated	  extra-­‐occipital	  activation,	  
suggesting	   functional	   reorganisation	   of	   the	   cerebral	   response	   to	   a	   photic	   stimulus,	   after	  
optic	  neuritis	  in	  patients	  with	  a	  good	  visual	  recovery	  (normal	  visual	  acuity	  and	  colour	  vision)	  
when	   compared	   to	   normal	   controls.	   They	   suggested	   that	   the	   change	   in	   distribution	   of	  
cortical	   activation,	   with	   activation	   of	   areas	   involved	   in	   visual	   processing	   and	   multimodal	  
sensory	   integration,	   occurred	   in	   response	   to	   persistently	   abnormal	   afferent	   input	   to	   the	  
visual	  cortex	  and	  could	  possibly	  have	  contributed	   to	  visual	   recovery.	  They	  postulated	   that	  
activation	   of	  multimodal	   regions	   could	   contribute	   to	   suppression	   of	   abnormal	   input	   from	  
the	  affected	  eye	  or	  alternatively	  could	   reflect	   increased	  attention	  and	  perhaps	  perceptual	  
enhancement	  of	  a	  pathogically	  degraded	  stimulus	  (Werring	  et	  al.,	  2000).	  
	  Toosy	  et	  al	  (2005)	  prospectively	  performed	  functional	  MRI	  on	  20	  patients	  with	  acute	  optic	  
neuritis	  at	  baseline,	  1,	  3,	  6	  and	  12	  months	  and	  correlated	  it	  with	  clinical	  function	  and	  optic	  
nerve	  function.	  They	  found	  that	  baseline	  gadolinium	  enhanced	  lesion	  length	  was	  associated	  
with	  lower	  functional	  activation	  within	  the	  visual	  cortex	  and	  worse	  vision.	  They	  also	  found	  
significant	   fMRI	   changes	  within	   the	   right	   peristriate	   cortex	   and	   bilaterally	   in	   the	   occipital	  
cortices	  when	   either	   affected	   or	   unaffected	   eyes	  were	   stimulated	   at	   baseline	   even	  when	  
accounting	   for	   confounding	   structural	   pathology.	   These	   changes	   subsided	   after	   a	   few	  
months.	   They	   concluded	   that	   these	   findings	  were	   suggestive	  of	   cortical	   adaptation	  within	  
the	  extrastriate	  areas	  occurring	  early	  on	  after	  optic	  neuritis	  (Toosy	  et	  al.,	  2005)	  .	  	  
In	  a	  longitudinal	  study	  of	  patients	  with	  acute	  optic	  neuritis	  over	  12	  months,	  Jenkins	  et	  al	  
(2010)	  investigated	  the	  role	  of	  neuroplasticity	  in	  higher	  visual	  areas	  in	  recovery	  after	  acute	  
optic	  neuritis.	  They	  found	  that	  greater	  baseline	  fMRI	  responses	  in	  the	  lateral	  occipital	  
complex	  were	  predictive	  of	  better	  visual	  outcome	  and	  vice	  versa.	  This	  affect	  was	  
independent	  of	  measures	  of	  demyelination	  and	  neuroaxonal	  loss.	  They	  concluded	  that	  early	  
neuroplasticity	  in	  higher	  cortical	  areas	  appears	  to	  be	  an	  important	  determinant	  of	  visual	  
outcome	  (Jenkins	  et	  al.,	  2010).
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Chapter	  3 Clinical,	  Imaging	  and	  Electrophysiological	  Methods	  of	  Assessing	  
Anterior	  Visual	  Pathway	  in	  Optic	  Neuritis	  
3.1 Visual	  function	  
High	   contrast	   visual	   acuity	   (HCVA)	   refers	   to	   the	   spatial	   resolving	   ability	   of	   the	   eye	   and	  
measures	  the	  smallest	  size	  black-­‐on	  white	  letters	  that	  can	  be	  read.	  	  Although	  theoretically	  a	  
test	  of	   foveal	   function,	   in	  reality	   it	   is	  reflective	  of	  the	   integrity	  of	  the	  entire	  anterior	  visual	  
system	  and	   is	   in	   fact	   a	   very	   crude	  way	  of	  measuring	   visual	   function.	   The	  most	   commonly	  
used	  HCVA	   charts	   in	   research	   are	   the	   early	   treatment	   diabetic	   retinopathy	   study	   (ETDRS)	  
charts,	  the	  gold	  standard	  used	  in	  ophthalmology	  clinical	  trials.	  Unlike	  Snellen	  charts	  each	  line	  
contains	   an	   equal	   number	   of	   letters	   and	   change	   between	   the	   lines	   occurs	   in	   equal	  
logarithmic	   steps	   thereby	   providing	   continuous	   data	   in	   the	   form	   of	   LogMAR	   visual	   acuity	  
that	   is	   amenable	   to	   statistical	   analysis.	   Although	   visual	   acuity	   provides	   a	   reasonable	  
assessment	  of	  the	  quantity	  of	  vision	  it	  is	  not	  a	  good	  measure	  of	  the	  quality	  of	  vision.	  	  
3.2 Low	  contrast	  letter	  acuity	  
Contrast	   is	   defined	   as	   the	   quantity	   of	   lightness	   or	   darkness	   contained	   by	   an	   object	   with	  
respect	   to	   its	   background.	   	   Contrast	   threshold	   is	   the	   smallest	   difference	   in	   lightness	   and	  
darkness	   between	   an	   object	   and	   its	   background	   that	   can	   be	   distinguished.	   This	   is	   usually	  
reported	  as	  contrast	  sensitivity	   that	   is	   the	  reciprocal	  of	  contrast	   threshold	   (Richman	  et	  al.,	  
2013).There	  are	  numerous	  different	  charts	  available	  to	  assess	  contrast	  sensitivity	  but	  Sloan	  
low	   contrast	   letter	   acuity	   charts	   are	   the	  main	   type	   used	   in	  MS	   and	   optic	   neuritis	   clinical	  
trials.	  	  
Low	  contrast	   letter	   acuity	   (LCLA)	   is	   the	   identification	  of	   grey	   letters	  on	  a	  white	  background	  
and	  is	  assessed	  using	  Sloan	  charts	  These	  charts	  have	  gray	  letters	  on	  a	  white	  background	  and	  
have	   a	   standardized	   format	   based	   on	   ETRDS	   visual	   acuity	   charts.	   Each	   line	   of	   letters	   gets	  
progressively	  smaller	  whilst	   the	  contrast	   remains	   the	  same.	  Patients	  are	  seated	  at	  2	  metres	  
from	  the	  chart	  and	  asked	  to	  read	  as	  many	  letters	  as	  they	  can	  from	  top	  to	  bottom.	  Charts	  at	  
varying	   contrast	   levels	   are	   available	   e.g.	   1.25%,	   2.5%.	   Letter	   scores	   indicate	   the	   number	   of	  
letters	  at	  a	  particular	  contrast	  level	  the	  patient	  can	  identify	  correctly	  with	  a	  maximum	  score	  of	  
70.	   This	   method	   of	   assessing	   contrast	   sensitivity	   has	   advantages	   in	   that	   it	   is	   easily	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administered,	   time	   efficient	   and	   inexpensive.	   It	   is	   however	   important	   to	   control	   for	   factors	  
that	   can	   affect	   LCLA	   assessment	   including	   refractory	   error	   and	   lighting	   levels	   of	   the	   testing	  
environment.	  (Balcer	  et	  al.,	  2015).	  	  
Figure	  3-­‐1:	  Low	  contrast	  letter	  acuity	  chart	  
	  
Measures	  of	  low	  contrast	  vision	  in	  optic	  neuritis	  and	  MS	  have	  been	  shown	  to	  be	  reliable	  and	  
sensitive	   to	   visual	   impairment	   even	   among	   patients	   with	   good	   high	   contrast	   visual	   acuity	  
(Balcer	  and	  Frohman,	  2010).	  Low	  contrast	   letter	  acuity	   is	  more	  sensitive	  to	  subjective	  visual	  
complaints	   and	   is	   predictive	   of	   ‘real	   world’	   visual	   tasks	   such	   as	   reading	   rate	   and	   facial	  
recognition	  (Sakai	  et	  al.,	  2011).	  
The	  Optic	  Neuritis	  Treatment	  trial	  was	  important	  in	  establishing	  the	  role	  of	  low	  contrast	  vision	  
as	  an	  outcome	  measure	  after	  optic	  neuritis.	  It	  demonstrated	  that	  contrast	  sensitivity	  was	  able	  
to	  elucidate	  persistent	  visual	  abnormalities	  despite	  recovery	  of	  high	  contrast	  vision	  (Beck	  et	  
al.,	  2004).	  Subsequently,	  low	  contrast	  letter	  acuity	  was	  incorporated	  into	  several	  MS	  trials	  as	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an	   exploratory	   outcome	   measure	   and	   visual	   function	   is	   now	   recognized	   as	   an	   important	  
aspect	  of	  outcome	  assessment	  in	  MS	  trials.	  
A	   substudy	  of	   the	   IMPACT	   trial	   (which	  evaluated	   the	  efficacy	  and	   safety	  of	   interferon-­‐1b	   in	  
patients	  with	  secondary	  progressive	  MS)	  demonstrated	  that	  mean	  low	  contrast	  acuity	  scores	  
were	  lower	  in	  MS	  patients	  than	  normal	  controls	  (Baier	  et	  al.,	  2005).	  This	  and	  other	  studies	  of	  
patients	  with	   RRMS	   and	   secondary	   progressive	  MS	   also	   demonstrated	   that	   LCLA	   correlates	  
with	  MSFC	   (positively)	   and	  EDSS	   (negatively).	   In	   the	   IMPACT	   trial	   the	  use	  of	   LCLA	   imparted	  
additional	  value	  to	  the	  MSFC	  with	  regards	  to	  predicting	  changes	  in	  EDSS	  (Balcer	  et	  al.,	  2003).	  	  
In	  addition	  to	  disability,	  LCLA	  scores	  have	  been	  associated	  with	  T2	  lesion	  volume	  and	  in	  one	  
study	  for	  every	  one	  line	  (5	  letters)	  worsening	  of	  LCLA	  was	  associated	  with	  a	  3	  mm3	  increase	  in	  
whole	  brain	  T2	  lesion	  volume	  (Wu	  et	  al.,	  2007).	  
Fischer	  et	  al	  found	  that	  there	  was	  a	  modest	  but	  highly	  significant	  correlation	  between	  mean	  
RNFL	   thickness	   and	   visual	   function	   (p=0.0001);	   after	   adjusting	   for	   age	   there	  was	   a	   3-­‐4	  µm	  
decrease	  in	  RNFL	  thickness	  for	  every	  1	  line	  reduction	  in	  LCLA	  (Fisher	  et	  al.,	  2006)	  .	  	  
In	  another	  study	  by	  Talman	  et	  al	  (2010),	  2.5%	  LCLA	  was	  significantly	  associated	  with	  RNFL	  
thinning.	  Scores	  from	  1.25%	  chart	  correlated	  less	  well.	  They	  postulated	  that	  floor	  effects	  may	  
limit	  the	  capacity	  of	  1.25%	  chart	  to	  capture	  changes	  in	  acuity	  as	  many	  MS	  patients	  had	  zero	  or	  
close	  to	  zero	  scores	  limiting	  their	  capacity	  to	  demonstrate	  change	  over	  time.	  This	  may	  also	  be	  
because	  the	  amount	  of	  variability	  in	  this	  measurement	  means	  it	  lacks	  precision.	  In	  addition	  
they	  suggested	  that	  changes	  in	  LCLA	  at	  1.25%	  contrast	  level	  might	  be	  more	  reflective	  of	  
disease	  in	  the	  brain	  and	  posterior	  visual	  pathway	  (Talman	  et	  al.,	  2010).	  When	  considering	  the	  
advantages	  of	  2.5%	  versus	  1.25%	  Sloan	  charts	  it	  is	  important	  to	  consider	  potential	  ceiling	  and	  
floor	  effects.
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Table	  3-­‐1	  Mean	  reference	  values	  for	  visual	  and	  OCT	  assessments	  in	  MS	  	  
(Taken	  from	  Sakai	  et	  al	  2011,	  table	  1)	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Several	   phase	   III	   trials	   in	  MS	   have	   shown	   that	   LCLA	   was	   able	   to	   demonstrate	   treatment	  
affects.	  In	  the	  AFFIRM	  trial	  of	  natalizumab	  versus	  placebo	  for	  RRMS	  binocular	  low	  contrast	  
letter	  acuity	  was	  measured	  using	  1.25	  and	  2.5%	  charts	  Sloan	  charts.	  Patients	   in	   the	  active	  
group	   demonstrated	   a	   reduction	   of	   cumulative	   probability	   of	   sustained	   visual	   loss	   (47%	  
p=<0.001	   at	   2.5%)	   in	   addition	   to	   a	   sustained	   clinically	  meaningful	   improvement	   in	   vision	  
(57%	  p=0.01).	  No	  treatment	  effect	  was	  demonstrated	  for	  high	  contrast	  visual	  acuity	  (Balcer	  
et	   al.,	   2007;	   Balcer	   et	   al.,	   2012).	   Similar	   treatment	   effects	   on	   LCLA	   were	   shown	   in	   the	  
SENTINAL	  trial	  (natalizumab	  plus	  IFNB-­‐1a	  versus	  placebo	  plus	  IFNB-­‐1a).	  
Measuring	  patient	  reported	  vision	  related	  quality	  of	  life	  can	  provide	  evidence	  for	  the	  clinical	  
meaningfulness	  of	  structural	  and	  functional	  measurements.	  The	  NEI-­‐VFQ-­‐25	  is	  a	  well	  
validated	  vision	  related	  quality	  life	  measure	  and	  has	  been	  supplemented	  with	  a	  10-­‐item	  
Neuro-­‐opthalmic	  questionnaire	  specifically	  designed	  for	  MS	  patients	  for	  use	  in	  clinical	  trials	  
(Ma	  et	  al.,	  2002;	  Raphael	  et	  al.,	  2006)	  	  
The	   issue	  of	  defining	  what	   is	  a	   ‘clinically	  significant’	   improvement	  or	  deterioration	  of	  LCLA	  
has	  been	  tackled	  recently	  and	  it	  is	  now	  well	  established	  that	  reductions	  in	  LCLA	  are	  reflected	  
in	  worse	  vision-­‐related	  quality	  of	  life	  scores	  (Mowry	  et	  al.,	  2009).	  Balcer	  et	  al	  looked	  at	  the	  
inter-­‐rater	  and	  test-­‐retest	  reliability	  of	  LCLA	  and	  demonstrated	  that	  7	  letters	  corresponds	  to	  
two	   standard	  deviations	  of	  difference	   (Balcer	  et	   al.,	   2000).	  A	  7-­‐letter	   reduction	   in	   LCLA	   IS	  
associated	  with	  significant	  worsening	  of	  NEI-­‐VFQ-­‐25	  scores	  as	  well	  as	  RNFL	  thickness	  by	  OCT	  
(Talman	   et	   al.,	   2010)	   and	   was	   used	   in	   the	   AFFIRM	   trial	   to	   define	   clinically	   meaningful	  
improvement	  or	  deteri	  oration	  (Balcer	  et	  al.,	  2007).	  
More	  recently	  measures	  of	  visual	  function	  have	  been	  used	  as	  the	  primary	  outcome	  measure	  
in	  trials	  assessing	  potential	  neuroprotective	  therapies	  to	   improve	  visual	  recovery	  following	  
optic	  neuritis	  (Tsakiri	  et	  al.,	  2012).	  
3.3 Colour	  Vision	  
Colour	   vision	   involves	   the	  detection	  of	  different	   spectra	  of	   light	  by	   colour	   sensitive	   cones	  
(red,	   green,	   blue	   light)	   these	   project	   to	   the	   retinal	   ganglion	   cells.	   Colour	   vision	   is	  mainly	  
served	   by	   the	   macula.	   RGC	   axons	   then	   project	   to	   the	   parvocellular	   and	   koniocellular	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neurons	   in	   the	   LGN.	   In	   primate	   optic	   nerves,	   small	   axons	   transmit	   colour	   information.	  
Smaller	  axons	  are	  concentrated	  in	  the	  fovea	  and	  larger	  axons	  extrafoveally	  
Acquired	   dyschromptopsia	   can	   result	   from	   injury	   anywhere	   along	   the	   visual	   system	   from	  
photoreceptors	  to	  the	  visual	  cortex.	  Most	  standard	  bedside	  tests	  in	  neurology	  are	  optimized	  
for	  detection	  of	  congenital	  colour	  deficits.	  Given	  the	  complexity	  of	  colour	  vision,	  methods	  
have	   been	   developed	   for	   converting	   colour	   vision	   performance	   using	   the	   organization	   of	  
coloured	  caps	  into	  a	  quantitative	  score.	  The	  Farnsworth	  Munsell	  100	  hue	  test	  is	  an	  example.	  
The	  patient	  is	  asked	  to	  place	  85	  coloured	  caps	  in	  perceived	  order	  of	  hue	  and	  an	  error	  score	  
is	  calculated.	  	  
Abnormalities	  in	  colour	  vision	  are	  common	  in	  MS	  in	  particular	  following	  optic	  neuritis.	  Even	  
without	  a	  history	  of	  optic	  neuritis	  deficits	   in	  colour	  vision	  can	  be	  detected	  in	  up	  to	  70%	  of	  
MS	  patients	  (Gundogan	  et	  al.,	  2013).	  	  	  
Although	   traditionally	   optic	   neuritis	   has	   been	   thought	   to	   cause	   defects	   in	   red/green	  
discrimination	  the	  optic	  neuritis	  treatment	  trial	  showed	  that	  no	  single	  type	  of	  colour	  vision	  
defect	  was	  consistently	  associated	  with	  ON	  (Beck	  et	  al.,	  1992b).	  Katz	  et	  al	  analysed	  the	  raw	  
colour	   vision	  data	   from	   the	  optic	   neuritis	   treatment	   trial.	   They	   suggested	   that	   the	   spatial	  
organization	   of	   the	   visual	   field	   defect	   might	   be	   the	   primary	   determinant	   of	   the	   type	   of	  
colour	   vision	   defect	   present.	   Central	   field	   defects	   were	   more	   likely	   to	   cause	   red/green	  
dyschromatopsia	  and	  patients	  with	  preserved	  central	  vision	  more	  likely	  to	  have	  blue	  green	  
dyschromatopsia	  (Katz,	  1995)	  
A	  study	  by	  Villoslada	  et	  al	  confirmed	  and	  extended	  observations	  on	  abnormalities	  of	  colour	  
vision	   in	   patients	  with	  MS.	   They	  were	  present	   in	   all	   disease	   subtypes	   but	  more	   severe	   in	  
patients	  with	   progressive	   disease	   and	   visual	   function	  was	  weakly	   correlated	  with	   disease	  
duration.	  They	  found	  a	  strong	  correlation	  between	  colour	  vision	  and	  mean	  RNFL	  thickness,	  
temporal	  quadrant	  RNFL	  thickness	  and	  macular	  volume.	  Colour	  vision	  measurements	  were	  
more	   strongly	   associated	   with	   OCT	   scores	   than	   other	   measurements	   of	   visual	   function	  
(HCVA/LCLA).	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They	   found	  colour	  visual	   function	   tests	  were	  strongly	  correlated	  with	  OCT	  measures	  at	  all	  
stages	  of	  the	  disease	  strongly	  suggesting	  colour	  vision	  impairment	  in	  MS	  is	  a	  consequence	  of	  
injury	  to	  the	  anterior	  visual	  pathway	  rather	  than	  post	  chiasmatic	  or	  posterior	  visual	  pathway	  
structures.	  Different	  visual	  outcomes	  	  (HCVA,	  LCLA	  and	  colour	  vision)	  were	  partially	  but	  not	  
completely	  correlated	  suggesting	  they	  may	  measure	  different	  aspects	  of	  the	  anterior	  visual	  
pathway	   function	   but	   this	   could	   equally	   be	   due	   to	   the	   imprecision	   of	   measurements	   of	  
visual	  function	  (Villoslada	  et	  al.,	  2012).	  
Martínez-­‐Lapiscina	  et	   al	   found	   impaired	   colour	   vision	   in	  MS	  eyes	  without	   a	  history	  of	  ON	  
was	   associated	   with	   increased	   disability	   in	   addition	   to	   OCT	   (RNFL	   thickness	   and	  macular	  
volume)	   and	  MRI	   measures	   (normalized	   brain	   parenchymal	   volume	   and	   normalized	   grey	  
matter	   volume)	   of	   neuroaxonal	   loss.	   Interestingly	   they	   found	   that	   inflammatory	   disease	  
activity	  did	  not	  differ	  between	  patients	  with	  colour	  vision	  abnormalities	  and	  those	  without	  
perhaps	   suggesting	   that	   colour	   vision	   abnormalities	   are	   more	   indicative	   of	   diffuse	  
neuroaxonal	  loss	  than	  inflammatory	  activity	  (Martínez-­‐Lapiscina	  et	  al.,	  2014).	  
In	   support	   of	   this	  Henderson	  et	   al	   found	   that	   colour	   vision	   at	   baseline	   and	   three	  months	  
after	  optic	  neuritis	  were	  independently	  associated	  with	  the	  final	  degree	  of	  RNFL	  thinning	  as	  
measured	   by	   OCT.	   They	   suggested	   that	   neurons	   with	   small	   axons	   in	   the	   parvocellular	  
pathway	  are	  selectively	  vulnerable	  to	  damage	  after	  demyelinating	  optic	  neuritis	  (Henderson	  
et	   al.,	   2011).	   This	   is	   consistent	   with	   the	   study	   by	   Evangelou	   et	   al	   that	   found	   selective	  
atrophy	  of	  smaller	  neurons	   in	  the	  parvocellular	   layer	  of	  the	  LGN	  in	  a	  pathology	  study	  of	  8	  
patients	  with	  MS	  (and	   is	  discussed	   in	  more	  detail	   in	  sections	  2.8)	   (Evangelou	  et	  al.,	  2001).	  
Post	  mortem	  studies	  examining	  the	  spinal	  cord	  In	  MS	  patients	  have	  also	  demonstrated	  that	  
small	  axons	  of	  <	  3	  µm2	  are	  particularly	  affected	  with	  large	  fibres	  remaining	  relatively	  intact	  
(DeLuca	  et	  al.,	  2004;	  Lovas	  et	  al.,	  2000)	  	  
This	  is	  in	  accordance	  with	  the	  findings	  by	  Flanagon	  et	  al	  (2005)	  who	  demonstrated	  that	  
MS/ON	  selectively	  affects	  processing	  in	  colour	  pathways	  rather	  than	  the	  magnacellular	  
pathway	  and	  within	  colour	  pathways	  neurons	  with	  opposed	  L-­‐	  and	  M-­‐	  cone	  inputs	  are	  more	  
damaged	  than	  neurons	  from	  S	  cones.	  (Flanagan	  and	  Markulev,	  2005).	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3.4 Visual	  Evoked	  Potentials	  
Electrophysiological	  measures	  allow	  us	  to	  assess	  the	  function	  of	  the	  anterior	  visual	  pathway.	  
Visual	  evoked	  potentials	  (VEPs)	  have	  been	  shown	  to	  be	  highly	  sensitive	  but	  not	  specific	  test	  
for	   optic	   neuritis	   (Petzold,	   2014).	   Conventional	   VEPs	   measure	   the	   cortical	   response	   to	  
monocular	  stimulation	  with	  a	  single	  checkerboard	  pattern	  in	  the	  central	  30	  degrees	  of	  the	  
visual	   field.	   The	   major	   component	   of	   the	   VEP	   is	   the	   large	   positive	   peak	   at	   about	   100	  
milliseconds	  (P100)	  and	  is	  reliable	  between	  individuals	  and	  stable	  between	  the	  ages	  of	  5	  and	  
60.	  The	  amplitude	  of	  the	  P100	  peak	  can	  also	  be	  measured.	  	  
Demyelination	  causes	  delay	  of	  VEP	  latency	  and	  conduction	  block.	  VEP	  amplitude	  is	  generally	  
preserved	  but	   a	   reduction	   in	   amplitude	   acutely	   can	   reflect	   conduction	  block	   and	   later	   on	  
axonal	  loss.	  The	  P100	  amplitude	  may	  also	  remain	  attenuated	  due	  to	  temporal	  dispersion.	  	  
	  A	  positive	  P100	  elicited	  by	  pattern	  reversal	  stimulation	  has	  been	  shown	  to	  originate	  from	  
the	   V1	   striate	   visual	   cortex	   by	   the	   combined	   activity	   of	   postsynaptic	   potentials.	   The	  
magnitude	   of	   the	   VEP	   reflects	   the	   number	   of	   functioning	   afferents	   that	   reach	   the	   striate	  
cortex.	  VEPs	  test	  pathway	  function	  with	  a	  temporal	  precision	  of	  milliseconds.	  	  
Small	  check	  sizes	  preferentially	  stimulate	  the	  fovea	  and	  activate	  mostly	  contrast	  channels.	  
Large	   check	   sizes	   stimulate	   the	   fovea	   and	   extrafoveal	   region	   and	   activate	   a	   mixture	   of	  
contrast	  and	  luminance	  channels.	  
Halliday	   et	   al	   were	   the	   first	   to	   demonstrate	   a	   delay	   in	   pattern	   reversal	   VEPs	   after	   optic	  
neuritis	  and	  that	  the	  delay	  persisted	  for	  many	  years	  after	  the	  attack	  (Halliday	  et	  al.,	  1972).	  A	  
normal	  VEP	  during	  acute	  optic	  neuritis	  has	  been	  reported	  in	  up	  23%	  of	  patients	  (Frederiksen	  
and	  Petrera,	  1999).	  
Within	   a	   month	   of	   onset	   of	   optic	   neuritis	   visual	   symptoms,	   remyelination	   by	  
oligodendrocytes	   commences	   at	   the	   edges	   of	   the	   plaque	   this	   is	   compatible	   with	   the	  
subsequent	  shortening	  of	  P100	   latency.	   In	  a	   longitudinal	  study	  by	  Brusa	  et	  al,	  VEP	   latency	  
decreased	   significantly	   during	   the	   first	   year	   post	   ON	   with	   the	   most	   marked	   reduction	  
occurring	   between	   3	   and	   6	  mths,	   and	   continued	   for	   up	   to	   2	   yrs.	   This	   was	   not,	   however	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accompanied	  by	  a	  significant	  functional	  improvement	  (Brusa	  et	  al.,	  2001).	  	  
Youl	  et	  al	  demonstrated	  that	  gadolinium	  enhancement	  of	  the	  optic	  nerve	  lesion	  on	  MRI	  was	  
associated	   with	   prolonged	   VEP	   latency	   and	   reduced	   amplitude	   and	   that	   its	   subsequent	  
resolution	   coincided	   with	   a	   recovery	   of	   VEP	   amplitude	   (but	   not	   VEP	   latency)	   and	   visual	  
function.	  They	  concluded	  that	  inflammation	  was	  a	  crucial	  factor	  in	  the	  reversible	  element	  of	  
conduction	  block	  and	  and	  visual	   impairment	  and	  that	  functional	  recovery	  can	  occur	   in	  the	  
presence	  of	  demyelination	  (Youl	  et	  al.,	  1991a).	  
Hickman	  et	  al	  in	  a	  serial	  longitudinal	  study	  of	  22	  patients	  after	  optic	  neuritis	  did	  not	  find	  an	  
association	   between	   any	   of	   the	   baseline	   VEP	   variables	   and	   final	   visual	   outcome.	   Average	  
vision	   scores	   over	   the	   follow	   up	   period	   tended	   to	   be	   better	   in	   patients	  with	   higher	   time	  
averaged	   whole	   and	   central	   field	   VEP	   amplitudes	   and	   higher	   VEP	   amplitudes	   were	  
associated	  with	  a	  better	  prognosis	  (Hickman	  et	  al.,	  2004b).	  
Several	   studies	   have	   demonstrated	   an	   association	   between	   VEP	   amplitude	   and	   RNFL	  
thickness	  (Trip	  et	  al.,	  2005;	  Klistorner	  et	  al.,	  2008),	  and	  in	  a	  study	  by	  Henderson	  et	  al	  looking	  
at	  early	  factors	  associated	  with	  axonal	  loss	  after	  optic	  neuritis	  VEP	  latency	  at	  baseline	  and	  3	  
months	  was	  significantly	  and	  independently	  associated	  with	  RNFL	  thinning.	  They	  postulated	  
that	   more	   extensive	   and	   prolonged	   demyelination	   leads	   to	   a	   greater	   propensity	   to	  
inflammatory-­‐mediated	  axonal	  damage	  (Henderson	  et	  al.,	  2011).	  	  
3.4.1 Pattern	  electroretinogram	  
The	   ERG	   provides	   a	   measure	   of	   functional	   integrity	   of	   the	   retinal	   photoreceptors	   and	  
ganglion	  cells.	  The	  PERG	  is	  the	  electrophysiological	  response	  obtained	  by	  stimulation	  of	  the	  
central	   retina	   and	  provides	   an	  objective	  measure	   of	  macular	   function.	   The	   PERG	  has	   two	  
components	   a	   positive	   response	   at	   about	   50ms	   referred	   to	   as	   P50	   and	   a	   later	   negative	  
response	  N95	  at	   approximately	  95	  ms.	  Current	  data	   suggests	   that	   the	  N95	   component	  of	  
the	  human	  PERG	   is	   a	   contrast	   related	   component	   generated	  by	   the	   retinal	   ganglion	   cells.	  
The	  P50	  is	  in	  part	  ganglion	  cell	  derived	  but	  also	  has	  retinal	  origins	  distal	  to	  the	  ganglion	  cells	  
(although	  these	  have	  yet	  to	  be	  fully	  elucidated,	  (Holder	  et	  al.,	  2010)).	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Optic	  disc	  oedema	  spreading	  in	  to	  the	  macula	  can	  affect	  ganglion	  cell	  function	  and	  the	  PERG	  
P50	  and	  N95	  waves	  can	  be	  reduced	  acutely	  in	  optic	  neuritis.	  During	  the	  recovery	  phase	  P50	  
amplitude	  recovers	  to	  within	  normal	   limits	  but	  this	  may	  not	  be	  the	  case	  for	  the	  PERG	  N95	  
wave.	   Selective	   reduction	  of	   PERG	  N95	  wave	   at	   4-­‐6	  weeks	   after	   optic	   neuritis	   can	   reflect	  
retrograde	  degeneration	  of	  retinal	  ganglion	  cells.	  PERGs	  are	  abnormal	  in	  approximately	  40%	  
of	  eyes	  with	  optic	  nerve	  demyelination	  and	   in	  85%	  of	   these	   the	  abnormality	   is	   a	   reduced	  
N95	  (Brecelj,	  2014).	  PERG	  P50	  amplitudes	  at	  presentation	  may	  have	  prognostic	  significance	  
after	  optic	  neuritis	  as	  in	  a	  case	  series	  of	  17	  eyes	  with	  acute	  optic	  neuritis	  the	  two	  eyes	  with	  
poor	  visual	  recovery	  (≤	  6/12)	  had	  PERG	  P50	  amplitudes	  of	  <	  0.5uV	  at	  presentation.	  However	  
larger	  series	  are	  required	  to	  confirm	  this	  (Holder,	  2001).	  
3.4.2 Multifocal	  VEP	  
Due	   to	   cortical	   overrepresentation	   the	   full	   field	   VEP	   is	   greatly	   dominated	   by	   the	  macular	  
region.	   They	   do	   not	   provide	   topographical	   detail	   of	   optic	   nerve	   dysfunction	   but	   rather	   a	  
single	  global	  response.	  Multifocal	  VEPs	  allow	  the	  topographic	  study	  of	  optic	  nerve	  function	  
with	  measurement	  of	  amplitude	  and	   latency	   from	  multiple	   locally	  derived	  VEP	   responses.	  
Averaged	  multifocal	   VEPs	   have	   a	   significant	   contribution	   from	   the	   peripheral	   part	   of	   the	  
visual	   field	   and	   take	   recordings	   from	   60	   locations	   simultaneously	   over	   44	   degrees	   of	   the	  
visual	  field	  (Laron	  et	  al.,	  2010).	  They	  therefore	  allow	  for	  assessment	  of	  a	  much	  larger	  cross-­‐
sectional	  area	  of	  the	  optic	  nerve.	  Multifocal	  VEPs	  have	  been	  found	  to	  correlate	  with	  visual	  
field	   perimetry	   results.	   In	   a	   study	   of	   patients	   with	   recovered	   optic	   neuritis,	   73	   %	   of	   the	  
affected	   eyes	   were	   identified	   as	   abnormal	   according	   to	   the	   VEP	   P100	   amplitude	   and/or	  
latency,	  while	  89%	  had	  abnormal	  multifocal	  VEPs,	  which	  revealed	  superior	  performance	  in	  
detecting	   small	   or	   peripheral	   defects	   (Klistorner	   et	   al.,	   2008).	   Responses	   from	   peripheral	  
areas	   can	   be	   recorded	   on	   multifocal	   VEPs	   even	   when	   the	   central	   field	   has	   no	   signal	   on	  
conventional	  VEPs.	  
Multifocal	  VEPs	  demonstrated	  a	   strong	   topographical	  association	  between	  RNFL	   thickness	  
and	  VEP	   amplitude	   in	   the	   affected	   eye	   after	   optic	   neuritis.	   The	   largest	   reduction	  of	   RNFL	  
thickness	  was	  seen	  in	  the	  temporal	  sector	  and	  this	  corresponded	  with	  the	  biggest	  reduction	  
of	  mfVEP	  amplitude	  in	  the	  central	  part	  of	  the	  visual	  field.	  Superior	  and	  inferior	  RNFL	  sector	  
thinning	  also	  correlated	  highly	  with	  the	  mfVEP	  derived	  from	  the	  corresponding	  areas	  of	  the	  
 86 
visual	  field	  (Klistorner	  et	  al.,	  2009).	  
The	  same	  group	  identified	  electrophysiological	  evidence	  of	  heterogeneity	  of	  lesions	  in	  optic	  
neuritis.	  They	  performed	  mfVEPS	  in	  27	  pts	  at	  1,	  3,	  6	  and	  12	  months	  post	  optic	  neuritis	  and	  
found	   two	  distinct	   subgroups	   in	   terms	  of	   recovery	  of	  mfVEP	   latency	  with	  63%	  of	  patients	  
demonstrating	  significant	   latency	  shortening	  over	  the	  follow	  up	  period	  and	  37%	  of	  patient	  
whose	  latency	  remained	  unchanged.	  They	  suggested	  that	  this	  difference	  in	  recovery	  may	  be	  
attributable	   to	   the	   different	   histopathologic	   patterns	   of	   MS	   lesions	   that	   have	   previously	  
been	  described,	  postulating	  that	  the	  63%	  of	  patients	  with	  the	  subsequent	  shortening	  of	  VEP	  
latency	   had	   type	   1	   and	   2	   lesion	   patterns	   of	   demyelination/remyelination	   and	   those	  with	  
little	  or	  no	  recovery	  of	  latency	  had	  type	  3	  and	  4	  (Klistorner	  et	  al.,	  2007).	  
Multifocal	  VEP	  latency	  has	  also	  been	  shown	  to	  correlate	  negatively	  with	  total	  and	  temporal	  
RNFL	  thickness	  in	  MS	  patient	  without	  a	  history	  of	  optic	  neuritis	  suggesting	  that	  patients	  with	  
subclinical	  ON	  demyelination	  also	  have	  RNFL	  thinning	  (Sriram	  et	  al.,	  2014).	  
3.5 Optic	  Nerve	  Magnetic	  Resonance	  Imaging	  
3.5.1 Conventional	  Imaging	  
Although	  MRI	  of	  the	  optic	  nerve	  is	  not	  routinely	  used	  for	  the	  diagnosis	  of	  optic	  neuritis	  it	  has	  
been	  used	  in	  research	  studies	  to	  identify	  and	  monitor	  the	  evolution	  of	  the	  lesion	  in	  the	  optic	  
nerve	  as	  well	  as	  performing	  atrophy	  measurements.	   Imaging	  of	   the	  optic	  nerve	   is	  difficult	  
because	   of	   its	   small	   size	   and	   mobility,	   which	   means	   that	   high-­‐resolution	   images	   are	  
essential.	   In	  addition	  to	   this,	  artifacts	  caused	  by	  surrounding	  CSF	  and	  orbital	  bone	  and	  fat	  
due	  to	  its	  anatomical	  location	  are	  problematic.	  	  
Pathological	   studies	   have	   demonstrated	   that	   demyelinating	   optic	   nerve	   lesions	   are	  more	  
diffuse	  and	   less	  well	  demarcated	  than	  brain	   lesions	  and	  are	  often	  associated	  with	  atrophy	  
(Rocca	   et	   al.,	   2005).	   Lesions	  may	   be	   complete	   are	   partial	   in	   cross-­‐section	   often	   sparing	   a	  
peripheral	  ring.	  	  
The	   most	   effective	   MR	   imaging	   sequences	   of	   the	   optic	   nerve	   are	   short	   tau	   inversion	  
recovery,	  (STIR)	  fast	  spin	  echo	  T2	  weighted	  fat	  suppressed	  images	  and	  spin	  echo	  T1	  pre	  and	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post	  Gad	  fat-­‐suppressed	  sequences.	  Periorbital	  fat	  gives	  a	  high	  signal	  on	  FSE	  images	  that	  are	  
not	  heavily	  T2	  weighted	  and	  a	  very	  high	  signal	  on	  T1	  weighted	  images.	  	  
The	  first	  MRI	  studies	  in	  optic	  neuritis	  used	  short	  tau	  inversion	  recovery	  sequences	  (STIR)	  to	  
null	   the	   signal	   from	   orbital	   fat.	   In	   a	   study	   of	   37	   patients	   with	   acute	   optic	   neuritis,	   STIR	  
sequences	   detected	   84%	   of	   lesions	   in	   the	   symptomatic	   eye	   (Miller	   et	   al.,	   1988a).	  
Subsequently	   faster	   imaging	   techniques	   with	   the	   addition	   of	   fat	   saturation	   impulses	   (to	  
suppress	  the	  signal	  arising	  from	  orbital	  fat)	  were	  developed.	  Fast	  spin	  echo	  sequences	  allow	  
increased	  resolution	  with	  reduced	  acquisition	  times	  when	  compared	  to	  spin	  echo	  imaging.	  
FSE	  images	  have	  been	  shown	  to	  be	  superior	  in	  detecting	  optic	  nerve	  lesions	  than	  STIR	  (Gass	  
et	  al.,	  1996).	  
On	  FSE	  and	  STIR	  sequences	  CSF	  gives	  a	  high	  signal	  possibly	  obscuring	  signal	  from	  the	  optic	  
nerves.	  With	   fluid	  attenuated	   inversion	   recovery	   (FLAIR)	   imaging	   it	   is	  possible	   to	   suppress	  
the	   signal	   from	   CSF	   and	   can	   be	   combined	  with	   other	   sequences	   to	   allow	  more	   accurate	  
optic	   nerve	   cross-­‐sectional	   area	   measurements	   High	   signal	   in	   the	   optic	   nerve	   persists	  
despite	   visual	   recovery.	  However	  unlike	   the	  brain,	   T1	  hypointense	   lesions	  are	  not	   seen	   in	  
the	  nerve;	  this	  may	  be	  due	  to	  the	  different	  architecture	  of	  the	  optic	  nerve	  compared	  to	  the	  
white	  matter	  in	  the	  brain.	  	  
Gadolinium	  enhancement	   in	   the	  optic	  nerve	  occurs	  due	   to	  breakdown	  of	   the	  blood	  brain	  
barrier	   in	  association	  with	  acute	  optic	  neuritis	  and	  is	  a	  consistent	  feature	  during	  the	  acute	  
phase	   (Kupersmith	   et	   al.,	   2002).	   Hickman	   et	   al	   demonstrated	   that	   dilatation	   of	   the	   optic	  
sheath	   immediately	   posterior	   to	   the	   globe	   and	   optic	   nerve	   sheath	   enhancement	   are	   also	  
common	   but	   not	   specific	   findings	   on	   conventional	   MR	   sequences	   in	   acute	   optic	   neuritis	  
(Hickman	  et	  al.,	  2005).	  	  
The	  disappearance	  of	  gadolinium	  enhancement	  after	  around	  4	  weeks	  coincides	  with	  visual	  
recovery	  and	  an	  increase	  in	  VEP	  amplitude	  (Youl	  et	  al.,	  1991a).	  A	  study	  by	  Kuppersmith	  et	  al	  
(2002)	  demonstrated	  that	  abnormal	  enhancement	  of	  the	  affected	  optic	  nerve	  is	  a	  sensitive	  
finding	   in	   acute	   optic	   neuritis	   and	   was	   present	   in	   94.4%	   of	   patients.	   There	   was	   no	  
enhancement	   in	   clinically	   unaffected	   optic	   nerves,	   nor	  was	   enhancement	   seen	   in	   chronic	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lesions	   of	   the	   optic	   nerve.	   The	   length	   of	   gadolinium	   enhancement	   was	   correlated	   with	  
baseline	  visual	   function	  and	  canilicular	   lesions	  were	  associated	  with	  worse	  baseline	  colour	  
vision	   (Kupersmith	   et	   al.,	   2002).	   Hickman	   et	   al	   (2004)	   used	   triple	   dose	   gadolinium	   in	   a	  
prospective	   cohort	   of	   22	   patients	   with	   acute	   optic	   neuritis.	   They	   found	   an	   association	  
between	   baseline	   gadolinium	   enhanced	   lesion	   length	   and	   visual	   outcome	   and	   reported	   a	  
worsening	  of	  0.02	  logMAR	  units	  for	  every	  additional	  3mm	  increase	  in	  baseline	  gadolinium–
enhancing	   lesion	   length	   (Hickman	   et	   al.,	   2004b).	   Neither	   the	   Kupersmith	   nor	   Hickman	  
studies	   found	   an	   association	   between	   the	   gadolinium	   enhanced	   lesion	   length	   and	   final	  
visual	  recovery.	  	  
Quantifying	  atrophy	  of	  the	  optic	  nerve	  using	  MRI	  gives	  an	  indication	  of	  axonal	  loss.	  Hickman	  
et	   al	   were	   reliably	   able	   to	   demonstrate	   atrophy	   of	   the	   intraorbital	   segment	   of	   the	   optic	  
nerve	  using	  fat	  saturated	  sTE-­‐FLAIR	  sequences,	  allowing	  cross-­‐sectional	  area	  measurements	  
using	  a	  semi-­‐automated	  contouring	  technique	  (Hickman	  et	  al.,	  2001).	  	  In	  a	  subsequent	  serial	  
MRI	   study	   in	   acute	   optic	   neuritis	   there	   was	   initial	   optic	   nerve	   swelling	   followed	   by	  
progressive	   atrophy.	   At	   52	  weeks	   the	  mean	   cross-­‐sectional	   area	   of	   the	   affected	   eye	  was	  
11.3	  mm2	  compared	  to	  13.1	  mm2	  in	  controls.	  They	  found	  an	  association	  between	  baseline	  
optic	  nerve	  mean	  cross-­‐sectional	  area	  and	  logMAR	  visual	  acuity	  but	  there	  was	  no	  evidence	  
of	  an	  association	  at	  1	  year	  (Hickman	  et	  al.,	  2002a).	  	  
Trip	  et	  al	  (2005)	  studied	  a	  cohort	  of	  patients	  with	  incomplete	  recovery	  after	  an	  episode	  of	  
optic	   neuritis.	   Optic	   nerve	   cross-­‐sectional	   area	   was	   reduced	   by	   30%	   when	   compared	   to	  
controls	  and	  correlated	  with	  affected	  eye	  RNFL	  thickness	  and	  macular	  volume	  as	  measured	  
by	   OCT.	   Optic	   nerve	   cross-­‐sectional	   area	   was	   also	   correlated	   with	   measures	   of	   visual	  
function	   and	   whole	   field	   VEP	   amplitude	   (but	   not	   latency).	   The	   correlations	   with	   VEP	  
amplitude	   and	   OCT	  measures	   would	   suggest	   optic	   nerve	   atrophy	   on	  MRI	   is	   reflective	   of	  
axonal	  loss	  (Trip	  et	  al.,	  2005).	  
3.5.2 Non-­‐conventional	  imaging	  –	  Magnetisation	  transfer	  ratio	  
Magnetisation	  transfer	  ratio	  (MTR)	  is	  a	  measure	  of	  the	  degree	  of	  proton	  exchange	  between	  
free	   water	   and	   macromolecules	   and	   indirectly	   measures	   the	   amount	   of	   macromolecular	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structure,	   e.g.	  myelin,	   that	   is	   present	   in	   tissues.	   As	  would	   be	   expected,	  MTR	   is	   higher	   in	  
white	  matter	  than	  grey	  matter	  and	  is	  reduced	  in	  acute	  MS	  plaques.	  	  
Thorpe	  et	  al	  (1995)	  demonstrated	  that	  MTR	  was	  significantly	  reduced	  in	  the	  affected	  optic	  
nerves	   of	   20	   patients	   with	   optic	   neuritis	   compared	   to	   controls.	   MTR	   was	   negatively	  
correlated	  with	  VEP	   latency	  suggesting	   it	  may	  be	  an	   indicator	  of	  demyelination	  (Thorpe	  et	  
al.,	  1995).	  
Inglese	   et	   al	   (2002)	  measured	  MTR	   in	   the	  whole	   optic	   nerve	   in	   a	   cohort	   of	   patients	  with	  
previous	   optic	   neuritis.	   Mean	   MTR	   correlated	   with	   visual	   acuity	   and	   was	   significantly	  
reduced	  in	  the	  optic	  nerves	  of	  patients	  with	  worse	  visual	  outcome	  compared	  to	  those	  with	  
good	  recovery	  (Inglese	  et	  al.,	  2002).	  	  	  	  
In	  a	   longitudinal	  study	  of	  patients	  with	  acute	  optic	  neuritis,	  Hickman	  et	  al	  found	  that	  MTR	  
values	  were	  initially	  unchanged	  during	  the	  acute	  phase	  and	  then	  subsequently	  declined	  until	  
it	  reached	  a	  nadir	  at	  8	  months.	  After	  this	  point	  the	  mean	  MTR	  began	  to	  increase	  but	  had	  not	  
returned	  to	  normal	  at	  1	  year.	  They	  suggest	  the	  increase	  in	  MTR	  after	  8	  months	  may	  be	  due	  
to	  remyelination	  (Hickman	  et	  al.,	  2004a).	  
In	   their	   cohort	   of	   patients	  with	   incomplete	   recovery	   post	   optic	   neuritis,	   Trip	   et	   al	   (2005)	  
demonstrated	   that	  whole	   nerve	   affected	   eye	  MTR	   and	   lesional	   nerve	  MTR	  were	   reduced	  
compared	  to	   the	   fellow	  eye	  and	  controls.	  Mean	  whole	  nerve	  MTR	  and	   lesional	  MTR	  were	  
significantly	   correlated	  with	  central	   field	  VEP	   latency	  as	  well	   as	  RNFL	   thickness	   suggesting	  
that	  MTR	  is	  a	  measure	  of	  both	  axonal	  loss	  and	  demyelination	  (Trip	  et	  al.,	  2005).	  
This	   was	   supported	   by	   a	   study	   by	   Wang	   et	   al	   who	   found	   that	   affected	   nerve	   MTR	   was	  
significantly	  reduced	  compared	  to	  the	  unaffected	  eye	  at	  three,	  6	  and	  12	  months	  after	  optic	  
neuritis.	  3	  and	  12	  month	  MTR	  was	  associated	  with	  RNFL	  thinning	  at	  12	  months	  suggesting	  a	  
reduction	  in	  MTR	  is	  associated	  with	  axonal	  loss	  (Wang	  et	  al.,	  2012).	  
Further	   studies	   are	   required	   to	   elucidate	   the	   exact	   contribution	   of	   axonal	   loss	   and	  
demyelination	  to	  reduced	  MTR.	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Ongoing	   developments	   in	   optic	   nerve	   imaging	   including	   increased	   field	   strengths	   (7	   Tesla	  
MRI),	   surface	  coils	  adjacent	   to	   the	  optic	  nerves	  and	   faster	  acquisition	  times	  may	   in	   future	  
enable	   higher	   resolution	   images,	   with	   increased	   signal	   to	   noise	   ratio	   and	   reduction	   in	  
motion	  artifact	  improving	  the	  quality	  of	  these	  images	  
3.6 Optical	  coherence	  tomography	  
Optical	   coherence	   tomography	   (OCT)	  was	   first	  described	  by	  Huang	  et	  al.	   in	  1991	  and	  was	  
first	   used	   to	   image	   the	   retina	   in	   1991	   (Huang	   et	   al.,	   1991).	   OCT	   technology	   has	   evolved	  
rapidly	   enabling	   the	   production	   of	   in	   vivo	   high-­‐resolution	   cross-­‐sectional	   and	   three-­‐
dimensional	   images	   of	   the	   retinal	  microstructure	   in	   real	   time.	   	   These	  OCT	   images	   closely	  
reflect	   histological	   sections	   of	   the	   macula	   and	   fovea,	   hence	   the	   term	   “optical	  
biopsy.”(Blumenthal	  et	  al.,	  2009)	  
The	   technique	   was	   initially	   used	   for	   the	   diagnosis	   and	   management	   of	   ophthalmological	  
diseases	   but	   over	   the	   last	   decade	   has	   been	   increasingly	   recognized	   for	   its	   applications	   in	  
multiple	  sclerosis.	  	  
3.6.1 Basic	  principles	  of	  OCT	  
OCT	   is	   the	   optical	   analogue	   of	   B	  mode	   ultrasound,	   except	   that	   instead	   of	   using	   acoustic	  
waves	   it	   uses	   light	   reflections	   to	   acquire	   images.	   A	   broad	   band	   width	   laser	   or	   super	  
luminescent	   diode	   low	   coherence	   light	   source	   is	   scanned	   across	   the	   retina	   and	   the	  
magnitude	  and	  echo	  time	  delay	  of	  backscattered	  light	  is	  measured.	  	  In	  contrast	  to	  standard	  
ultrasound,	  direct	  detection	  of	   light	  echoes	   is	  not	  possible	  because	  of	  their	  high	  speed.	   	  A	  
correlation	  technique	  is	  therefore	  required	  and	  OCT	  systems	  are	  based	  on	  the	  principle	  of	  
low	  coherence	  tomography	  that	  was	  first	  described	  by	  Sir	  Isaac	  Newton.	  	  Acquisition	  of	  the	  
OCT	  signal	   is	  based	  on	  splitting	  of	  the	  coherent	   light	  beam	  into	  two	  parts:	  a	  sample	  and	  a	  
reference	  beam	  which	  are	  the	  same	  length	  but	  follow	  two	  different	  paths.	  	  When	  reflected	  
light	   from	   each	   of	   the	   two	   paths	   reaches	   the	   detector	   at	   the	   same	   time	   they	   induce	   an	  
interference	  signal.	  	  The	  image	  is	  acquired	  by	  measuring	  the	  amplitude	  of	  this	  interference	  
signal.	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3.6.2 Spectral	  Domain	  OCT	  
The	  first	  retinal	  images	  with	  spectral	  domain	  OCT	  were	  reported	  in	  2002	  and	  the	  technique	  
became	  commercially	  available	  in	  2006.	  	  Imaging	  is	  approximately	  60-­‐110	  times	  faster	  than	  
time	  domain	  OCT	  with	  an	  acquisition	  speed	  of	  approximately	  25,000	  axial	  scans	  per	  second	  
and	  an	  axial	  image	  resolution	  of	  approximately	  5-­‐7µm.	  	  There	  is	  also	  a	  significant	  reduction	  
of	  artifact	   from	  ocular	  movements.	   	  Spectral	  domain	  also	  exceeds	   time	  domain	  OCT	   in	   its	  
ability	  to	  form	  3	  dimensional	  maps	  of	  the	  retina	  and	  optic	  nerve.	  
It	  is	  based	  on	  fast	  Fourier	  transformation	  and	  it	  allows	  all	  echoes	  of	  light	  from	  the	  different	  
retinal	   layers	   to	   be	  measured	   simultaneously	   and	   the	   interference	   signal	   is	   a	   function	   of	  
their	  wavelength.	  	  This	  eliminates	  the	  need	  for	  a	  moving	  reference	  mirror.	  	  
New	   spectral	   domain	   OCT	   devices	   include	   automated	   eye	   centering,	   longitudinal	   co-­‐












Figure	  3-­‐2:	  Schematic	  diagram	  demonstrating	  basic	  principles	  of	  OCT	  	  
Taken	  from	  (Frohman	  et	  al.,	  2008)(Figure	  1)	  
	  
	  
A:	  Low	  coherence	  infrared	  light	  is	  transmitted	  into	  the	  eye	  through	  the	  pupil	  
B:	   Near	   infra	   red	   light	   is	   scanned	   across	   the	   retina	   and	   the	   magnitude	   and	   echo	   time	   delay	   of	  
backscattered	  light	  is	  measured	  from	  the	  interference	  signal	  
C:	  An	  algorithm	  mathematically	  transforms	  this	  information	  into	  a	  grey	  scale	  image	  
The	   first	   applications	   of	   OCT	   were	   in	   ophthalmology	   and	   it	   is	   now	   validated	   for	   the	  
longitudinal	  assessment	  of	  glaucoma	  and	  macular	  degeneration.	  However,	  over	  the	  past	  15	  
years	  there	  has	  been	  an	  exponential	  increase	  in	  the	  literature	  on	  its	  application	  in	  MS.	  
3.6.3 Optical	  coherence	  tomography	  in	  Optic	  Neuritis	  and	  MS	  
The	   retina	   has	   often	   been	   described	   as	   the	  window	   into	   the	   CNS	   and	   the	   afferent	   visual	  
system	  represents	  an	  exciting	  prospect	   for	  MS	  researchers	  specifically	  with	  regards	   to	   the	  
processes	  of	  neurodegeneration	  and	  repair.	  This	  is	  because	  the	  retina	  is	  unique	  in	  the	  CNS	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in	  that	  it	  contains	  unmyelinated	  axons,	  which	  comprise	  the	  retinal	  nerve	  fibre	  layer	  (RNFL),	  
the	  most	   proximal	   part	   of	   the	   afferent	   visual	   system	   and	   therefore	   thinning	   of	   the	   RNFL	  
primarily	   represent	   axonal	   loss.	   	   OCT	  measurements	   of	   RNFL	   thickness	   in	  MS	   have	   been	  
shown	  to	  be	  reliable	  and	  reproducible	  (Cettomai	  et	  al.,	  2008;	  Syc	  et	  al.,	  2010).	  	  
The	  anterior	  visual	  system	  is	  a	  frequent	  target	  of	  the	  disease	  process	  in	  MS.	  When	  an	  acute	  
lesion	   affects	   the	   optic	   nerve	   during	   an	   episode	   of	   optic	   neuritis	   there	   is	   transection	   of	  
axons	   followed	   by	   retrograde	   axonal	   degeneration	   culminating	   in	   loss	   of	   retinal	   ganglion	  
cells	  and	  axons	  in	  the	  RNFL,	  which	  manifests	  as	   loss	  of	  macular	  volume	  and	  RNFL	  thinning	  
(Figure	  3-­‐3).	  RNFL	  thinning	  and	  reduced	  macular	  volume	  can	  also	  occur	  as	  a	  result	  of	  trans-­‐
synaptic	  retrograde	  degeneration	  from	  lesions	  in	  the	  posterior	  visual	  pathway.	  In	  reality	  it	  is	  
likely	   that	   axonal	   injury	   always	   leads	   to	   bi-­‐directional	   trans-­‐synaptic	   axonal	   degeneration	  
(Petzold	  et	  al.,	  2010).	  
Figure	  3-­‐3:	  Schematic	  diagram	  demonstrating	  mechanisms	  of	  RNFL	  thinning	  




A:	  Schematic	  diagram	  of	  normal	  visual	  pathway	  in	  humans	  
B:	  Optic	  neuritis	   causes	  acute	  axonal	   loss	  within	   the	  optic	  nerve	   (red	  dotted	   line)	   leading	   to	  RNFL	  
thinning	  
C.	   	   In	  MS	  lesions	  with	  the	  optic	  radiations	  can	  cause	  transynaptic	  axonal	   loss	  through	  the	  LGN	  that	  
eventually	  over	  time	  leads	  to	  RNFL	  thinning.	  
D	  In	  MS	  chronic	  subclinical	  changes	  in	  the	  anterior	  visual	  system	  can	  lead	  to	  a	  small	  amount	  of	  RNFL	  
thinning.	  	  
	  OCT	  provides	  a	  non-­‐invasive	  means	  of	  quantifying	  the	  structural	  effects	  of	  an	  inflammatory	  
lesion	   in	   the	   optic	   nerve	   that	   can	   be	   compared	   to	   functional	   outcomes	   to	   construct	   a	  
structural-­‐functional	   paradigm	   of	   CNS	   injury.	   In	   this	   way	   it	   is	   hoped	   that	   the	  
neurodegenerative	   process	   occurring	   in	   the	   retina	   can	   be	   extrapolated	   to	   the	   processes	  
occurring	   in	   the	   rest	  of	   the	  brain	  and	   spinal	   cord	   in	  patients	  with	  multiple	   sclerosis.	   	   This	  
would	  allow	  the	  retina	  to	  be	  used	  as	  a	  biomarker	  for	  monitoring	  neurodegeneration	  in	  MS	  
and	  also	  for	  measuring	  the	  therapeutic	  efficacy	  of	  neuroprotective	  drugs.	  	  
	  Parisi	   et	   al	   reported	   the	   earliest	   study	   of	   OCT	   in	   MS.	   They	   demonstrated	   that	   RNFL	  
thickness	  was	  46%	   lower	   in	  14	  MS	  eyes	  with	  a	  prior	  history	  of	  optic	  neuritis	  compared	  to	  
controls.	   Importantly	   they	   also	   demonstrated	   even	   in	  MS	   eyes	  without	   a	   history	   of	   optic	  
neuritis	   RNFL	   thickness	  was	   26%	   lower	   than	   controls	   (Parisi	   et	   al.,	   1999).	   This	   innovative	  
work	  was	  the	  catalyst	  for	  further	  OCT	  studies	  in	  optic	  neuritis	  and	  MS.	  	  
Subsequently	  Trip	  et	  al.	  investigated	  25	  patients	  after	  a	  single	  episode	  of	  optic	  neuritis	  (with	  
an	   intentional	   bias	   towards	   poor	   visual	   recovery)	   in	   a	   retrospective	   cross-­‐sectional	   study.	  	  
The	  mean	  RNFL	  thickness	  and	  total	  macular	  volume	  of	  affected	  eyes	  was	  reduced	  by	  33%	  
and	   11%	   respectively	   compared	   with	   controls.	   	   Greater	   RNFL	   thinning	   predicted	   worse	  
LogMAR	   visual	   acuity,	   visual	   field	   abnormality,	   colour	   vision	   and	   visual	   evoked	   potential	  
(VEP)	  amplitudes,	   consistent	  with	  axonal	  degeneration	   (Trip	  et	   al.,	   2005).	   	   The	  group	  also	  
looked	  at	   the	  cross-­‐sectional	  area	  of	   the	  optic	  nerve	  as	  measured	  by	  magnetic	   resonance	  
imaging	   (MRI)	   and	   found	   that	   the	   optic	   nerve	   area	   of	   the	   affected	   eye	   was	   significantly	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reduced	   when	   compared	   with	   fellow	   eyes	   and	   controls	   and	   that	   the	   RNFL	   and	   macular	  
volume	  of	  the	  affected	  eye	  correlated	  significantly	  with	  optic	  nerve	  area.(Trip	  et	  al.,	  2006)	  	  
In	  2006	  Costello	  et	  al	  reported	  that	  75%	  of	  patients	  with	  MS	  will	  sustain	  10-­‐40	  µm	  of	  RNFL	  
loss	   within	   a	   period	   of	   3-­‐6	   months	   following	   acute	   optic	   neuritis	   (AON)	   (Costello	   et	   al.,	  
2006).	  	  	  
Subsequently	  in	  a	  meta-­‐analysis	  by	  Petzold	  including	  the	  results	  from	  12	  studies	  there	  was	  
an	   estimated	   average	   loss	   of	   -­‐20.38	  µm	   (CI	   -­‐22.86	   to	   -­‐17.91)	   in	  MSON	  eyes	   compared	   to	  
controls	  (Petzold	  et	  al.,	  2010).	  This	  is	  particularly	  striking	  as	  the	  general	  population,	  (without	  
concomitant	   eye	   disease)	   will	   only	   lose	   about	   0.017%	   per	   yr	   or	   approximately	   10-­‐20	  µm	  	  
over	  60	  yrs.	  (Sakai	  et	  al.,	  2011).	  
Figure	  3-­‐4:	  RNFL	  thickness	  of	  MSON	  eyes	  versus	  controls	  




In	  the	  same	  meta-­‐analysis,	  15	  studies	  comparing	  MS	  eyes	  without	  a	  history	  of	  optic	  neuritis	  
to	   controls	   the	  mean	   estimated	  RNFL	   loss	  was	   -­‐7.8	  µm	   (CI	   -­‐8.65	   to	   -­‐5.52)	   (Petzold	   et	   al.,	  
2010).	  	  
Figure	  3-­‐5:	  RNFL	  thickness	  of	  MS	  non-­‐ON	  eyes	  versus	  controls	  
(Taken	  from	  Petzold	  et	  al	  2010,	  Figure	  4)	  
	  
In	   a	   12-­‐month	   longitudinal	   study,	   Costello	   et	   al.	   demonstrated	   that	   74%	   of	   patients	   had	  
RNFL	   thinning	   after	   acute	   optic	   neuritis	   and	   the	  majority	   of	   this	   occurred	  within	   the	   first	  
three	  to	  six	  months,	  the	  temporal	  sector	  being	  the	  earliest	  involved	  at	  two	  months	  (Costello	  
et	   al.,	   2008).	   The	   temporal	   sector	   of	   the	   RNFL	   receives	   fibres	   from	   the	   papillomacular	  
bundle	  and	  is	  reduced	  by	  25-­‐34%	  compared	  to	  controls	  Noval	  et	  al	  (Noval	  et	  al.,	  2011).	  	  
	  
The	   development	   of	   validated	   measures	   of	   visual	   functioning	   has	   greatly	   facilitated	   the	  
exploration	   for	   a	   structural	   biomarker	   for	   neurodegeneration	   and	   one	   of	   the	   most	  
important	  findings	  from	  OCT	  in	  studies	  of	  patients	  with	  MS	  is	  the	  correlation	  between	  RNFL	  
thickness	  and	  visual	  function.	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3.6.4 RNFL	  thickness	  and	  visual	  function	  
In	  a	  cross-­‐sectional	  study	  Fisher	  et	  al.	  demonstrated	  low	  contrast	  letter	  acuity	  scores	  were	  
significantly	   correlated	   with	   average	   RNFL	   thickness	   and	   every	   one	   line	   decrease	   in	   low	  
contrast	  letter	  acuity	  was	  associated	  with	  an	  average	  4	  µm	  thinning	  of	  the	  RNFL	  (Fisher	  et	  
al.,	  2006).	  
This	   finding	  was	  also	  confirmed	   in	  a	  cohort	  of	  patients	  with	  MS	  by	  a	   longitudinal	  study	  by	  
Talman	   et	   al..	   They	   found	   a	   significant	   association	   between	   low	   contrast	   letter	   acuity	   at	  
2.5%	  and	  RNFL	  thickness	  (Talman	  et	  al.,	  2010).	  
	  Costello	  et	   al	   recruited	  54	  patients	  with	  acute	  unilateral	  optic	  neuritis	  within	  1	  month	  of	  
symptom	   onset	   and	   performed	   assessments	   including	   Humphrey	   visual	   fields	   (using	   30-­‐2	  
full	   threshold	   strategy	   testing)	  as	  well	   as	  RNFL	  measurements	  at	  3	  monthly	   intervals	  over	  
the	   period	   of	   a	   year.	   Regression	   analyses	   were	   performed	   to	   assess	   the	   relationship	  
between	  mean	  RNFL	   thickness	  and	  visual	   field	  mean	  deviation	   (VFMD,	   (dB))	  as	  well	  mean	  
RNFL	   thickness	   and	   logMAR	   visual	   acuity	   in	   54	   patients.	   Two	   regression	   lines	  were	   fitted	  
using	  RNFL	  to	  predict	  visual	  field	  function.	  The	  RNFL	  measure	  of	  75	  µm	  was	  used	  as	  the	  cut	  
off	  between	  the	  two	  regression	  lines	  because	  above	  this	  level	  the	  predictive	  effect	  of	  RNFL	  
thickness	  on	  VFMD	  was	  not	  significant.	  Below	  this	   level	  there	  was	  a	  significant	  association	  
between	  RNFL	  thickness	  and	  VFMD	  such	  that	  for	  every	  10	  µm	  reduction	  in	  RNFL	  thickness	  
there	  was	  a	  6.46	  dB	  reduction	  in	  VFMD.	  For	  logMAR	  visual	  acuity	  the	  cutoff	  point	  was	  70	  µm	  
below	  which	  RNFL	  thickness	  was	  significantly	  associated	  with	  logMAR	  visual	  acuity.	  Costello	  
et	  al	  suggested	  that	  a	  threshold	  RNFL	  thickness	  of	  75	  µm	  needs	  to	  be	  reached	  before	  visual	  
function,	   as	  measured	  by	  automated	  perimetry,	  declines	   linearly.	   They	   reasoned	   that	   this	  
was	   due	   to	   the	   ‘functional	   reserve”	   of	   the	   visual	   system	  whereby	   that	   visual	   function	   is	  
preserved	  until	  a	  critical	  level	  of	  axonal	  loss	  is	  reached	  (Costello	  et	  al.,	  2006).	  	  	  
However	  others	  have	  argued	  against	  the	  concept	  of	  ‘functional	  reserve’	  reasoning	  that	  the	  
impression	   of	   functional	   reserve	   is	   due	   to	   the	   logarithmic	   nature	   of	   of	   the	   decibel	   scale	  
VFMD	  and	  that	  there	  is	  actually	  a	  linear	  relationship	  between	  RNFL	  thickness	  and	  the	  anti-­‐
log	  of	  VFMD.	  In	  addition	  they	  argue	  that	  the	  structural	  test	  (e.g.	  RNFL	  thickness)	  can	  show	  a	  
statistically	   significant	   reduction	   before	   functional	   tests	   (e.g.	   VFMD)	   due	   to	   the	   smaller	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confidence	   intervals	   of	   structural	  measures	   that	   have	   less	   variability	   than	   functional	   tests	  
(Hood	  and	  Kardon,	  2007;	  Garway-­‐Heath	  et	  al.,	  2002).	  
	  
3.6.5 RNFL	  thickness	  and	  MS	  subtypes	  and	  disability	  
Several	   studies	   have	   shown	   that	   average	   RNFL	   thickness	   can	   differentiate	   between	   MS	  
subtypes	  with	  lower	  values	  in	  progressive	  forms	  of	  MS	  when	  compared	  with	  patients	  with	  
clinically	   isolated	  syndromes	  suggestive	  of	  MS	  (Costello	  et	  al.,	  2010;	  Pulicken	  et	  al.,	  2007).	  
The	  lowest	  values	  may	  be	  in	  patients	  with	  SPMS.	  (Costello	  et	  al.,	  2010;	  Pulicken	  et	  al.,	  2007)	  
In	  a	  study	  by	  Burkholder	  et	  al	  a	  10	  µm	  reduction	  in	  peripapillary	  RNFL	  was	  associated	  with	  a	  
0.2mm2	   reduction	   in	   macular	   volume.	   Total	   macular	   volume	   differed	   for	   different	   sub	  
groups	  of	  patients	  with	  lower	  values	  in	  secondary	  progressive	  MS	  than	  PPMS.	  Reductions	  in	  
inner	   total	   and	  outer	  macular	   volumes	  were	  associated	  with	   lower	  high	  and	   low	  contrast	  
letter	   acuity	   scores.	   Inner	  macular	   volume	   remained	   a	   significant	   predictor	   of	   visual	   loss	  
even	  when	   peripapillary	   RNFL	   thickness	  was	   taken	   into	   account	   suggesting	   that	   neuronal	  
loss	   is	   associated	   with	   impaired	   visual	   function.	   These	   findings	   are	   significant	   because	  
tracking	   macular	   volumes	   in	   ON	   patients	   may	   help	   determine	   the	   temporal	   relation	  
between	   primary	   neuronal	   cell	   death	   and	   axonal	   loss	   after	   a	   CNS	   inflammatory	   event	  
(Burkholder	  et	  al.,	  2009).	  
There	  are	  conflicting	  data	  on	  the	  correlation	  between	  overall	  disability,	  as	  measured	  by	  the	  
expanded	  disability	  status	  scale	  and	  RNFL	  thickness.	  In	  a	  meta-­‐analysis	  by	  Petzold	  et	  al	  of	  12	  
studies	   investigating	   the	   relationship	   between	   RNFL	   and	   EDSS	   an	   inverse	   correlation	  was	  
reported	   in	   6.	   Findings	   from	   these	   trials	   were	   consistent	   with	   two	   further	   studies	   which	  
described	  a	  reduction	  of	  RNFL	  thickness	  with	  EDSS	  percentiles	  (Petzold,	  2014).	  The	  strongest	  
relationships	  appear	  to	  be	   in	  cohorts	  of	  patient	  with	  relapsing	  remitting	  MS	  and	  generally	  
low	  EDSS	   and	   is	   has	   been	  proposed	   that	  OCT	   is	  more	   reflective	   of	   pathology	   in	   early	  MS	  






Figure	  3-­‐6:	  RNFL	  thickness	  and	  EDSS	  
(Taken	  from	  Fischer	  et	  al	  2006,	  Figure	  3)	  
 	  
In	  a	  longitudinal	  study	  of	  299	  MS	  patients	  with	  and	  without	  a	  prior	  history	  of	  optic	  neuritis	  
(median	  follow	  up	  of	  18	  months)	  Talman	  et	  al	  demonstrated	  a	  reduction	  of	  RNFL	  thickness	  
from	  baseline	  of	  1.7%	  at	  1-­‐2yrs,	  3.2%	  at	  2-­‐3yrs	  and	  6.7%	  at	  >3yrs	  of	  follow	  up	  This	  was	   in	  
contrast	  to	  mean	  RNFL	   loss	  of	  0.5%	  over	  3	  yrs	   in	  disease	  free	  control	  eyes.	   (Talman	  et	  al.,	  
2010).	  	  
Sepuclre	  et	  al	  found	  a	  decrease	  in	  average	  RNFL	  thickness	  of	  4.8	  µm	  after	  2	  yrs	  in	  a	  cohort	  of	  
MS	  patients	  with	  early-­‐	   intermediate	  disease.	  Patients	  with	  more	  active	  disease	  had	  more	  





3.6.6 RNFL	  thickness	  and	  brain	  atrophy	  
Significant	  correlations	  between	  RNFL	  thickness	  and	  brain	  global	  and	  regional	  atrophy	  have	  
also	  been	  demonstrated	  (Gordon-­‐Lipkin	  et	  al.,	  2007;	  Saidha	  et	  al.,	  2013).	  It	   is	   important	  to	  
note	   that	  a	  previous	  history	  of	  optic	  neuritis	  may	   interfere	  with	   the	  correlations	  between	  
MRI	  parameters	  and	  RNFL	  thickness	  in	  patients	  with	  MS	  (Zimmermann	  et	  al.,	  2013).	  
	  
3.6.7 Establishing	  the	  time	  course	  of	  axonal	  loss	  after	  optic	  neuritis	  for	  neuroprotection	  
trials	  
Establishing	   the	   time	   course	   of	   axonal	   loss	   after	   optic	   neuritis	   is	   important	   for	   future	  
neuroprotection	  trials	  and	  OCT	  has	  helped	  to	  elucidate	  this	  in	  detail.	  In	  2010,	  Henderson	  et	  
al.	  performed	  a	  prospective	  study	  on	  23	  patients	  with	  acute	  unilateral	  optic	  neuritis	  within	  a	  
median	  of	  16	  days	  from	  onset.	  	  Patients	  underwent	  OCT,	  visual	  assessments	  and	  VEPs	  at	  3,	  
6,	  12	  and	  18	  months.	  	  The	  evolution	  of	  retinal	  nerve	  fibre	  layer	  changes	  over	  time	  fitted	  well	  
with	  an	  exponential	  model	  (Figure 3-7)	  with	  RNFL	  thinning	  appearing	  a	  mean	  of	  1.6	  months	  
from	  symptom	  onset	   (compared	   to	   the	  baseline	  unaffected	  eye).	   They	   found	   that	  90%	  of	  
the	  retinal	  nerve	  fibre	  degeneration	  occurred	  within	  a	  mean	  2.38	  months	  from	  onset	  of	  the	  
disease	   and	   that	   poorer	   visual	   function	   was	   associated	   with	   greater	   decline	   in	   RNFL	  
thickness	   during	   the	   first	   three	  months.	   They	   also	   performed	   sample	   size	   calculations	   for	  
placebo-­‐controlled	   trials	   of	   acute	   neuroprotection.	   They	   found	   that	   smaller	   numbers	   of	  
patients	  were	  required	  after	  6	  months	  follow	  up	  than	  three	  and	  study	  power	  was	  improved	  
by	  investigating	  differences	  between	  affected	  and	  fellow	  eyes	  rather	  than	  changes	  in	  RNFL	  
thickness	   of	   the	   affected	   eye	   alone	   due	   to	   swelling	   of	   the	   affected	   eye	   at	   baseline.	  
(Henderson	  et	  al.,	  2010)	  
This	   study	   has	   paved	   the	   way	   for	   future	   neuroprotection	   trials	   using	   OCT	   as	   a	   primary	  






Figure	   3-­‐7:	   Affected	   minus	   baseline	   fellow	   eye	   RNFL	   thinning	   over	   time	   after	  
demyelinating	  optic	  neuritis	  
(Taken	  from	  Henderson	  et	  al	  2010,	  Figure	  2)	  
	  	  
.	  
3.6.8 Retinal	  Segmentation	  in	  optic	  neuritis	  and	  MS	  
With	   the	   introduction	   of	   high	   resolution,	   spectral	   domain	  OCT	   images	   and	   novel	   analysis	  
techniques	  it	  is	  now	  possible	  to	  segment	  and	  quantify	  individual	  retinal	  layers.	  	  The	  macular	  
is	  neuronally	  enriched	  and	  34%	  of	   its	  volume	  consists	  of	  RGCs	  and	  their	  axons.	  Given	  that	  
neuronal	   loss	   is	   recognized	   as	   an	   important	   cause	   of	   disability	   in	   MS	   measurements	   of	  
retinal	  ganglion	  cell	   layer	  thickness	  have	  emerged	  as	  a	  potential	  biomarker.	   	  Post	  mortem	  
ganglion	  cell	  drop	  out	  is	  described	  in	  >70%	  of	  MS	  patients	  (Kerrison	  et	  al.,	  1994).	  A	  recent	  
pathology	  study	  on	  eyes	  of	  82	  patients	  with	  MS	  demonstrated	  atrophy	  of	   retinal	  ganglion	  
cells	  and	  their	  axons	  as	  well	  as	  of	  the	  inner	  nuclear	  layer	  (Green	  et	  al.,	  2010).	  Subsequently	  
retinal	  ganglion	  cell	  layer	  loss	  has	  been	  demonstrated	  in	  vivo	  using	  OCT	  both	  in	  acute	  optic	  
neuritis	  and	  in	  MS.	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In	  a	  longitudinal	  study	  of	  20	  acute	  optic	  neuritis	  patients	  recruited	  within	  4	  weeks	  of	  visual	  
symptoms	  there	  was	  no	  significant	  difference	  in	  ganglion	  cell/inner	  plexiform	  layer	  (GC/IPL)	  
thickness	  when	  compared	  to	  the	  fellow	  eye	  at	  baseline	  whereas	  average	  retinal	  nerve	  fibre	  
layer	   thickness	   was	   significantly	   higher	   in	   the	   affected	   eye.	   There	   was	   no	   significant	  
difference	   in	  any	  of	   the	  other	   retinal	   layers	  compared	   to	   the	   fellow	  eye.	  At	   three	  months	  
there	  was	   significant	   thinning	   of	   the	  GC/IPL	   and	   the	   RNFL	   compared	   to	   baseline	   and	   the	  
fellow	  eye.	  GC/IPL	  and	  RNFL	  thinning	  then	  remained	  stable	  throughout	  the	  12	  month	  follow	  
up	   period	   and	   there	   were	   no	   changes	   in	   any	   of	   the	   deeper	   retinal	   layers.	   The	   authors	  
suggested	  that	  as	  there	  was	  no	  demonstrable	  oedema	  of	  the	  GC/IPL	  during	  the	  acute	  phase	  
of	  optic	  neuritis	  that	  it	  could	  be	  a	  superior	  outcome	  measure	  for	  neuroprotection	  trials	  than	  
RNFL	   thickness	   as	   it	   would	   allow	   true	   measures	   of	   the	   baseline	   affected	   eye	   instead	   of	  
surrogate	  measures	  of	  the	  contralateral	  eye	  (Syc	  et	  al.,	  2012).	  	  
In	   support	   of	   this	   Saidha	   et	   al	   demonstrated	   a	   superior	   structure-­‐function	   correlation	  
between	  GC/IPL	  thickness	  and	  other	  measures	  of	  visual	  function	  suggesting	  that	  it	  may	  be	  a	  
superior	   biomarker	   to	   assess	   the	   processes	   of	   neurodegeneration.	   They	   suggested	   that	  
astrogliosis	  may	  contribute	   to	   falsely	   increased	  measures	  of	  RNFL	   thickness	   (Saidha	  et	  al.,	  
2011a)	  and	  this	  is	  supported	  by	  pathological	  studies	  as	  discussed	  in	  section	  1.2.	  	  
Walter	  et	  al	  found	  that	  clinically	  meaningful	  reductions	  in	  high	  and	  low	  contrast	  letter	  acuity	  
were	   associated	  with	   thinning	   of	   peripapillary	   and	  macular	   RNFL	   and	  GC/IPL.	   They	   found	  
that	  retinal	  GC/IPL	  thickness	  was	  most	  strongly	  related	  to	  visual	  dysfunction	  and	  QOL	  in	  MS	  
(Walter	  et	  al.,	  2012).	  	  
Tatrai	  et	  al	  recruited	  39	  patients	  with	  relapsing	  remitting	  MS	  and	  found	  a	  strong	  correlation	  
between	   EDSS	   and	   peripapillary	   nerve	   fibre	   layer	   and	   GC/IPL.	   	   There	   was	   no	   correlation	  
between	  any	  of	  the	  other	  retinal	   layers.	  Peripapillary	  RNFL	  correlated	  strongly	  with	  GC/IPL	  
in	   the	   macula.	   They	   demonstrated	   that	   macular	   GC/IPL	   measurements	   had	   the	   highest	  
sensitivity	  and	   specificity	   to	  detect	  axonal	   loss	   independent	  of	  optic	  neuritis	   (Tatrai	  et	  al.,	  
2012)	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Garcia	  Martin	   et	   al	   evaluated	  204	  patients	  with	   relapsing	   remitting	  multiple	   sclerosis	   and	  
compared	   them	   to	  healthy	   controls;	   they	  obtained	  automated	   segmentation	  of	  10	   retinal	  
layers	  using	  a	  single	  parafoveal	  scan.	  They	  found	  reduced	  thickness	  in	  all	  retinal	  layers	  in	  the	  
MS	   patients	   when	   compared	   to	   controls.	   The	   inner	   retinal	   layers	   (RNFL,	   GC/IPL	   and	   INL)	  
were	  significantly	  thinner	  in	  patients	  with	  a	  history	  of	  optic	  neuritis	  than	  those	  without	  but	  a	  
history	  of	  optic	  neuritis	  had	  no	  significant	  effect	  on	  the	  outer	  retinal	  layers.	  RNFL	  and	  GC/IPL	  
correlated	  inversely	  to	  EDSS	  (Garcia-­‐Martin	  et	  al.,	  2014).	  	  
Albrecht	  et	  al	  (2012)	  segmented	  retinal	  layers	  on	  high	  resolution,	  horizontal	  and	  parafoveal	  
scans	   on	   41	   RRMS,	   42	   SPMS	   and	   12	   PPMS	   patients.	   GC/IPL	   thickness	   was	   reduced	   in	   all	  
subgroups	  of	  MS	  patients	  when	  compared	  to	  controls.	   INL	  thickness	  was	  only	  significantly	  
reduced	   in	   PPMS	   patients.	   This	   was	   independent	   of	   a	   history	   of	   optic	   neuritis	   and	   they	  
postulated	  may	  represent	  primary	  retinal	  pathology.	  They	  found	  no	  significant	  difference	  in	  
ONL/OPL	   thickness	   between	   any	   of	   the	   MS	   groups	   and	   controls.	   They	   found	   significant	  
correlations	  of	  mean	  RNFL,	  macular	  and	  OPL	  thickness	  with	  EDSS.	  Interestingly	  in	  contrast	  to	  
RNFL	   and	   macular	   thickness,	   OPL	   thickness	   was	   positively	   correlated	   with	   EDSS.	   They	  
suggested	  that	  thickening	  of	  this	  layer	  occurs	  due	  to	  reorganization	  following	  degeneration	  
of	  other	  retinal	  layers	  (Albrecht	  et	  al.,	  2012).	  
3.6.9 Microcystic	  macular	  oedema	  
It	  has	  been	  reported	  that	  approximately	  5%	  of	  patients	  with	  early	  MS	  will	  have	  evidence	  of	  
microcystic	  macular	  oedema	  (MME)	  and	  inner	  nuclear	  layer	  thickening.	  MME	  is	  defined	  as	  
two	   or	   more	   limited,	   insular	   and	   cystoid	   areas	   of	   hyporeflectivity	   in	   two	   or	   more	  
consecutive	  B	  scans.	  Shadowing	  in	  the	  retinal	  layers	  below	  the	  cystoid	  areas	  may	  occur.	  The	  
pathophysiology	  of	  MME	  is	  unknown	  and	  inflammatory	  processes,	  retrograde	  degeneration	  
of	  inner	  retinal	   layers	  and	  vitreous	  traction	  have	  been	  postulated	  to	  play	  a	  role.	  In	  MS	  the	  
presence	  of	  microcystic	  macular	  oedema	  and	  INL	  thickening	  are	  associated	  with	   increased	  
inflammatory	  disease	  activity,	  including	  gadolinium-­‐enhancing	  lesions	  and	  new	  T2	  lesions	  on	  
brain	  MRI	  and	  relapses	  (Gelfand	  et	  al.,	  2012;	  Saidha	  et	  al.,	  2012)	  
However,	  microcystic	  macular	  oedema	  might	  not	  be	  specific	  to	  MS	  but	  may	  be	  optic	  neuritis	  
dependent.	   Kaufhold	   et	   al	   (2013)	   found	   that	  MME	  was	   associated	  with	   a	   history	   of	   optic	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neuropathy	  (of	  any	  cause)	  in	  95	  %	  of	  cases	  Eyes	  with	  MME	  had	  reduced	  RNFL	  and	  macular	  
volume	  and	  reduced	  visual	  acuity	  compared	  to	  eyes	  unaffected	  by	  MME.	  Eyes	  with	  an	  RNFL	  
thickness	   below	   the	   first	   quartile	   categorised	   as	   having	   a	   history	   of	   severe	   optic	   neuritis	  
were	  at	  greatest	   risk	   for	  development	  of	  MME	  odds	  ratio=13.6.	  SLO	   images	  showed	  dark,	  
dotted	   patterns	   in	   the	   ocular	   fundus	   of	   all	   patients	   affected	   by	   MME	   and	   generally	  
presented	  in	  a	  crescent	  shape	  around	  the	  fovea.	  They	  found	  that	  MME	  was	  more	  common	  
in	   patients	   with	   NMO	   and	   CRION	   than	   MS	   and	   suggested	   a	   strong	   pathophysiological	  
correlation	   between	   the	   development	   of	   MME	   and	   the	   extent	   of	   optic	   nerve	   damage	  
(Kaufhold	  et	  al.,	  2013).	  	  
Another	  study	  by	  Abegg	  et	  al	  also	  demonstrated	  that	  MME	  is	  not	  specific	  for	  demyelinating	  
disease.	   They	   found	   that	  MME	  was	   restricted	   to	   retinal	   areas	  with	   nerve	   fibre	   layer	   and	  
ganglion	  cell	   loss	  and	  hypothesized	  that	  MME	  is	  caused	  by	  retrograde	  degeneration	  of	  the	  
inner	  retinal	  layers	  resulting	  in	  impaired	  fluid	  resorption	  (Abegg	  et	  al.,	  2014).	  .	  	  
3.6.10 Macular	  thinning	  predominant	  phenotype	  
Saidha	   et	   al	   (2011)	   described	   a	   group	   of	   macular	   thinning	   predominant	   (MTP)	   patients	  
defined	  as	  having	  a	  macular	   thickness	  of	  <	  5th	  percentile,	   ipsilateral	  normal	   average	  RNFL	  
thickness	  and	  in	  the	  absence	  of	  a	  history	  of	  acute	  optic	  neuritis.	  In	  MTP	  patients	  all	  retinal	  
layers	   were	   lower	   when	   compared	   to	   controls.	   Compared	   to	   other	   MS	   patients	   without	  
MTP,	   MTP	   patients	   had	   significantly	   reduced	   INL	   and	   ONL	   thickness.	   They	   found	   that	  
average	  MS	  severity	  score	  was	  significantly	  higher	  in	  patients	  with	  MTP	  and	  it	  appeared	  to	  
be	   associated	   with	   a	   more	   aggressive	   form	   of	   MS.	   In	   the	   MTP	   patients,	   multifocal	   ERG,	  
which	  predominantly	  reflects	  the	  function	  of	  the	  outer	  retina,	  was	  diffusely	  abnormal	  with	  
attenuated	  amplitudes	  of	  the	  P1	  waveform.	  The	  authors	  suggest	  that	  patients	  with	  the	  MTP	  
phenotype	  may	  have	  a	  distinct	  pathological	  process	  of	  primary	  neuronal	  loss.	  These	  findings	  





Table	  3-­‐2:	  Methods	  for	  assessment	  of	  the	  anterior	  visual	  system	  in	  MS.	  
(Adapted	  from	  Frohman	  et	  al	  2006,	  Table	  2)	  
	  
	   Information	   Limitation	  
Visual	  acuity	   Global	  high-­‐contrast	  acuity	   Crude	   measure	   of	   visual	  
function	  
Insensitive	   to	   other	   visual	  
system	  abnormalities	  
	   	   Subjective	  
	   	   Subject	  cooperation	  
	   	   Potentially	  affected	  by	  
fatigue,	  temperature	  
	  and	  other	  factors	  such	  as	  
infection,	  stress	  
Low-­‐contrast	   letter	  
acuity/sensitivity	  
Sensitive	  measure	  of	  visual	  function	  




	   Predictive	  of	  ‘real	  world’	  tasks	   Subject	  cooperation	  
	   	   Potentially	  affected	  by	  
fatigue,	  temperature	  
and	  other	  factors	  such	  as	  
infection,	  stress	  
Colour	  vision	   Cone	  vision	   Subjective	  
	   Small	  axons	  of	  parvocellular	  pathway	  
selectively	  affected	  by	  demyelination	  
Subject	  cooperation	  
	   Correlates	  with	  structural	  changes	   Potentially	  affected	  by	  
fatigue,	  	  
temperature,	  and	  other	  
factors	  such	  as	  infection,	  	  
stress	  
	   	  	   	  
Visual	   Evoked	  
potentials	  
Transmission	  characteristics	  of	  
anterior	  visual	  system	  	  
Potentially	  affected	  by	  
temperature,	  infection	  
	   Provides	  measure	  of	  magnitude	  and	  
latencies	  of	  responses,	  reflecting	  
axonal	  and	  myelin	  integrity	  
Cortical	  
overrepresentation	  
MRI	  techniques	   Structural	  measures	  of	  tissue	  
architecture.	  Sensitive	  to	  changes	  in	  
myelin,	  axons,	  gliosis,	  and	  
inflammation	  
Long	  imaging	  times	  
Requires	  high	  resolution	  
images	  
Image	  quality	  limited	  by	  
motion	  artifact	  
Not	  as	  reproducible	  as	  OCT	  
	   	   Not	  entirely	  specific	  for	  
each	  pathological	  process	  
OCT	   Measures	  retinal	  architecture.	  RNFL	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contains	  axons	  and	  glia	  but	  no	  myelin	   	  
Dependent	   on	   accurate	  
disc	  centering	  and	  	  
adequate	  signal	  strength	  
	   Non	  invasive,	  sensitive	  and	  
reproducible	  
Fast	  acquisition	  times	  
Patients	   cooperation	   +	  
must	  be	  able	  to	  fixate	  


















Chapter	  4 A	  Phase	  II	  Placebo	  Controlled	  Trial	  of	  Neuroprotection	  with	  
Phenytoin	  in	  Optic	  Neuritis	  
	  
4.1 Background	  and	  rationale	  for	  neuroprotection	  with	  sodium	  channel	  blockade	  
Acute	  demyelinating	  optic	  neuritis	  is	  a	  common,	  often	  presenting	  manifestation	  of	  Multiple	  
Sclerosis	  (MS).	  During	  long	  term	  follow	  up	  around	  75%	  of	  patients	  presenting	  with	  clinically	  
isolated	  optic	  neuritis	  go	  on	  to	  develop	  multiple	  sclerosis	  (MS)(Beck	  et	  al	  1993).	  The	  acute	  
inflammatory	   lesion	   in	   the	  optic	  nerve	   resembles	   the	  demyelinating	  plaques	  elsewhere	   in	  
the	  CNS.	  	  
Although	  in	  general	  visual	  recovery	  after	  a	  single	  episode	  of	  optic	  neuritis	  is	  good,	  10-­‐15%	  of	  
patients	  will	  be	  left	  with	  significant	  permanent	  visual	  deficits	  (Beck	  et	  al	  1993).	  Axonal	  loss	  
and	   subsequent	   neurodegeneration	   is	   now	   recognized	   as	   a	   major	   cause	   of	   persistent	  
disability	  both	  in	  optic	  neuritis	  and	  multiple	  sclerosis.	  Imaging	  of	  the	  retinal	  nerve	  fibre	  layer	  
(RNFL)	   with	   optical	   coherence	   tomography	   (OCT),	   and	   of	   the	   optic	   nerve	   with	  MRI	   both	  
demonstrate	  significant	  tissue	  loss	  which	  correlates	  with	  impaired	  visual	  function	  after	  optic	  
neuritis	  (Kolappan	  et	  al.,	  2009).	  
As	  with	  other	  MS	  relapses,	  corticosteroids	  have	  no	  or	  little	  impact	  on	  the	  extent	  that	  vision	  
recovers,	  nor	  do	  they	  prevent	  optic	  nerve	  atrophy	  on	  MRI	  or	  improve	  VEP	  latency	  after	  an	  
attack	  of	  optic	  neuritis	  (Spoor	  and	  Rockwell,	  1988;	  Beck	  et	  al.,	  1992b;	  Kapoor	  et	  al.,	  1998).	  	  
Also,	   immunomodulation	   with	   disease	   modifying	   therapies	   has	   been	   only	   partially	  
successful	   in	   preventing	   disability	   in	   MS	   that	   occurs	   following	   relapses.	   With	   this	  
background,	  neuroprotection	  remains	  a	  major	  unmet	  need.	  Treatments	  that	  protect	  against	  
acute	   neuroaxonal	   loss	   should	   not	   only	   prevent	   disability	   after	   optic	   neuritis	   but	   also	   by	  
implication,	  relapses	  of	  MS	  in	  general.	  
Optic	   neuritis	   represents	   an	   attractive	   model	   to	   investigate	   the	   effects	   of	   potential	  
neuroprotective	  treatments	  in	  MS	  as	  1)	  it	  occurs	  in	  a	  structurally	  eloquent	  region	  of	  the	  CNS	  
that	   is	   commonly	   affected	  by	   the	  disease	  process;	   2)	   it	   presents	  with	   a	   clinical	   syndrome	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which	   is	   relatively	  easy	   to	   recognize	   (although	  acutely	   this	   can	  be	  more	  challenging	  when	  
symptoms/signs	  have	  not	  fully	  developed)	  and	  prompts	  patients	  to	  seek	  help	  early;	  3)	  it	  can	  
be	  reliably	  studied	  with	  a	  combination	  of	  validated	  clinical,	  electrophysiological	  and	  imaging	  
techniques	  thereby	  allowing	  a	  structure-­‐function	  paradigm	  of	  CNS	  injury	  to	  be	  constructed;	  
4)	  the	   lesion	  in	  the	  optic	  nerve	   leads	  to	  retrograde	  degeneration	  of	  the	  retinal	  nerve	  fibre	  
layer	  (RNFL),	  a	  relatively	  pure	  compartment	  of	  unmyelinated	  axons	  the	  thickness	  of	  which	  
can	  be	  measured	  sensitively	  and	  noninvasively	  using	  optical	  coherence	  tomography	  (OCT);	  
5)	  the	  natural	  history	  of	  optic	  neuritis	  has	  been	  well	  defined.	  
Progress	  in	  the	  development	  of	  potential	  neuroprotective	  therapies	  in	  optic	  neuritis	  and	  MS	  
relies	   upon	   the	   identification	   of	   key	   mechanisms	   and	   treatment	   targets.	   Amongst	   the	  
possible	   mechanisms,	   there	   is	   growing	   evidence	   for	   the	   role	   of	   sodium	   channels	   in	  
neurodegeneration	  in	  multiple	  sclerosis.	  	  
Pathological	  studies	  have	  demonstrated	  that	  significant	  axonal	  loss	  occurs	  even	  in	  the	  early	  
stages	  of	  MS	  and	   the	  extent	  of	   axonal	   loss	   correlates	  with	   the	  magnitude	  and	   severity	  of	  
inflammation	  at	  different	  sites	  within	  the	  CNS	  (Trapp	  et	  al.,	  1998;	  Bitsch	  et	  al.,	  2000).	  Early	  
axonal	   transection	   is	   thought	   to	   be	   due	   to	   the	   vulnerability	   of	   demyelinated	   axons	   to	  
inflammation.	   	   The	   extent	   of	   axonal	   degeneration	   in	   MS	   lesions	   is	   partly	   related	   to	   the	  
number	   of	   cytotoxic	   T	   cells	   and	   activated	   macrophages	   that	   can	   be	   found	   in	   close	  
opposition	  with	   injured	  axons	   (Smith	  and	  Lassmann,	  2002).	  Thus	   inflammatory	  mediators,	  
particularly	  nitric	  oxide,	  may	  play	  a	  key	  role	  in	  the	  mechanism	  of	  injury.	  	  In	  support	  of	  this	  
the	  production	  of	  nitric	  oxide	   is	  significantly	  raised	  within	  MS	  lesions	  and	   its	  expression	   in	  
EAE	  models	  coincides	  temporally	  and	  quantitatively	  with	  clinical	  signs	  (Smith	  and	  McDonald,	  
1999).	   Moreover,	   nitric	   oxide	   can	   promptly	   and	   reversibly	   cause	   conduction	   block	   and	  
demyelinated	   axons	   are	   particularly	   vulnerable	   to	   this	   effect	   (Redford	   et	   al.,	   1997).	   The	  
mechanisms	  by	  which	  NO	  can	  cause	  conduction	  block	  are	  not	  entirely	  clear	  but	  it	  is	  thought	  
that	  NO	  can	  directly	  impair	  the	  function	  of	  sodium	  channels	  
The	   ‘sodium	   hypothesis’	   postulates	   that	   axonal	   injury	   results	   from	   a	   combination	   of	   1)	  
excessive	   energy	   demands	   from	   ionic	   imbalances	   due	   to	   increased	   sodium	   loading	   in	  
partially	  demyelinated	  axons	  and	  (Waxman,	  1998;	  Craner	  et	  al.,	  2004;	  Bechtold	  and	  Smith,	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2005)and	  2)	  from	  inhibition	  of	  mitochondrial	  respiration	  by	  inflammatory	  mediators	  such	  as	  
NO	  (Bolaños	  et	  al.,	  1997;	  Smith	  et	  al.,	  2001;	  Garthwaite	  et	  al.,	  2002).	  
To	   expand	   these	   points:	   demyelinated	   axons	   exhibit	   increased	   expression	   of	  Na	   channels	  
along	  the	  denuded	  axolemma	  that	   is	  an	  adaptive	  response	  to	  allow	  restoration	  of	  current	  
along	   the	   demyelinated	   segment.	   Specifically,	   studies	   have	   demonstrated	   upregulated	  
expression	  of	  Nav	  1.2	  and	  Nav	  1.6	  along	  extensive	  regions	  of	  demyelinated	  axons	  in	  EAE	  and	  
in	  acute	  MS	  plaques	  (Craner	  et	  al.,	  2004).	  Nav	  1.6	  channels	  produce	  a	  persistent	  current	  as	  
well	  as	  rapidly	  activating	  -­‐inactivating	  currents.	  
	  Whereas	  in	  normal	  myelinated	  axons	  action	  potential	  generation	  is	  confined	  to	  nodal	  zones	  
some	   chronically	   demyelinated	   axons	   develop	   a	   continuous	   mode	   of	   action	   potential	  
supported	  by	  a	  more	  diffuse	  distribution	  of	  channels.	  
Figure	  4-­‐1:	  Diagram	  illustrating	  sodium	  channel	  reorganisation	  in	  the	  demyelinated	  axon	  
Taken	  from	  Waxman	  2006	  (Figure	  1)	  
	  
a	  	  In	  normal	  myelinated	  axons	  there	  is	  clustering	  of	  Nav	  1.6	  channels	  at	  the	  nodes	  of	  Ranvier	  	  
b	  	  The	  acutely	  demyelinated	  axon	  has	  a	  low	  Na+	  channel	  density	  due	  to	  their	  scarcity	  in	  the	  exposed	  
internodal	  region	  this	  leads	  to	  conduction	  failure	  
 110 
c	  	  Demyelinated	  axons	  exhibit	  increased	  expression	  of	  Na	  channels	  along	  the	  denuded	  axolemma,	  an	  
adaptive	  response	  to	  allow	  restoration	  of	  current	  	  
d	   	   Chronically	  demyelinated	  axons	   can	  develop	  a	   continuous	  mode	  of	   conduction	   that	   can	   lead	   to	  
sodium	  overloading	  and	  axonal	  degeneration	  
This	   leads	   to	   excessive	   intraxonal	   sodium	   loading	   thereby	   increasing	   the	   energy	   demand	  
required	   to	  operate	   the	  NA+/K+	  ATPase	   to	  allow	   repolarization	   (Bostock	  and	  Sears,	   1978;	  
Foster	   et	   al.,	   1980).	   This	  mismatch	   between	   energy	   supply	   and	   demand	   in	   demyelinated	  
axons	  creates	  a	  state	  of	  ‘virtual	  hypoxia’	  (Stys	  et	  al.,	  1992).	  
Because	  Na/K	  ATPase	  is	  required	  for	  extrusion	  of	  Na+	  an	  inadequate	  supply	  of	  ATP	  may	  be	  
expected	  to	  exacerbate	  the	  effects	  of	  persistent	  Na+	  influx.	  
Nitric	  oxide	  is	  known	  to	  impair	  mitochondrial	  metabolism	  reducing	  ATP	  production	  leading	  
to	  energy	  failure.	  Axons	  are	  particularly	  vulnerable	  to	  the	  effects	  of	  nitric	  oxide	  if	  they	  are	  
electrically	  active	  (Smith	  and	  Lassmann,	  2002;	  Kapoor	  et	  al.,	  2003).	  
This	  energy	  failure	  inhibits	  the	  activity	  of	  the	  Na+/K+ATPase	  to	  extrude	  sodium	  which	  in	  turn	  
leads	   to	   the	   reverse	   operation	   of	   the	   Na+/Ca+	   exchanger	   promoting	   injurious	   levels	   of	  
intraxonal	   calcium,	   thereby	   activating	   degradative	   enzymes	   and	   promoting	   axonal	  
degeneration	  (Kapoor	  et	  al.,	  2003).	  	  
Nav	  1.6	  has	  been	  shown	  to	  be	  coexpressed	  with	  the	  Na/Ca2+	  exchanger	  along	  degenerating	  
axons	  in	  EAE	  (Craner	  et	  al.,	  2004)	  and	  would	  be	  expected	  to	  predispose	  demyelinated	  axons	  






	  Figure	  4-­‐2:	  Schematic	  diagram	  of	  the	  role	  of	  sodium	  channels	   in	  axonal	  degeneration	   in	  
multiple	  sclerosis	  	  (taken	  from	  Raftopoulos	  and	  Kapoor,	  2013	  Figure	  1)	  
	  
Nitric	   oxide	   production	   impairs	   mitochondrial	   metabolism	   leading	   to	   reduced	   ATP	   production	   and	   energy	  
failure.	  This,	   in	   turn	   leads	   to	   failure	  of	   the	  sodium/potassium	  ATPase	  and	  reduced	  ability	   to	  extrude	  sodium	  
with	   subsequent	   depolarisation	   and	   inability	   to	   maintain	   transmembrane	   ion	   gradients.	   Depolarisation	  
activates	  voltage	  gated	  sodium	  channels	  that	  provide	  a	  conduit	  for	  persistent	  sodium	  influx.	  This	  subsequently	  
drives	  the	  reverse	  operation	  of	  the	  sodium/calcium	  exchanger	  leading	  to	  injurious	  levels	  of	  intraxonal	  calcium	  
and	  axonal	  degeneration	  
The	  premise	  that	  sodium	  loading	  may	  be	  an	  important	  cause	  of	  axonal	  degeneration	  raises	  
the	  possibility	  that	  axons	  may	  gain	  protection	  from	  partial	  sodium	  channel	  blockade.	  Indeed	  
partial	   sodium	   channel	   blockade	   has	   been	   shown	   to	   be	   neuroprotective	   in	   several	  
experimental	  models	   of	   inflammatory	   axonal	   injury.	   For	   example,	  Garthwaite	   et	   al	   (2002)	  
demonstrated	  partial	  blockade	  of	  sodium	  channels	  prevented	  nitric	  oxide	  mediated	  axonal	  
degeneration	   in	   rat	   optic	   nerves	   (Garthwaite	   et	   al.,	   2002).	   Subsequently	   Lo	   et	   al	   (2003)	  
demonstrated	  that	  oral	  phenytoin	  taken	  for	  a	  28-­‐30	  day	  period	  in	  CF7B1	  mice	  with	  EAE	  was	  
protective	  against	  axonal	  loss	  and	  improved	  clinical	  outcome.	  Importantly	  neuroprotection	  
with	  sodium	  channel	  blockade	  could	  be	  achieved	  at	  concentrations	  that	  didn’t	  compromise	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Sodium	  channels	  also	  occur	  in	  cells	  in	  the	  immune	  system	  and	  may	  have	  a	  regulatory	  effect	  
on	   their	   function	   and	   the	   subsequent	   immune	   response.	   Nav	   1.6	   sodium	   channels	   are	  
present	   in	  macrophages	   and	  microglia	  within	   acute	  MS	   lesions	   and	   their	   expression	   is	   up	  
regulated	  when	  these	  cells	  are	  activated.	  Macrophages	  and	  microglia	  are	  closely	  associated	  
with	   degenerating	   axons	   in	   MS	   and	   produce	   axonal	   injury	   via	   CD4+T	   cell	   proliferation,	  
production	  of	  inflammatory	  cytokines	  and	  NO.	  In	  one	  study	  sodium	  channel	  blockade	  with	  
phenytoin	   reduced	   inflammatory	   infiltrate	   in	   EAE	   by	   75%	   (Craner	   et	   al.,	   2005).	   The	  
expression	  of	  Nav	  1.6	  channels	  has	  also	  been	  shown	  to	  be	  upregulated	  in	  macrophages	  and	  
microglia	  upon	  activation	  in	  acute	  MS	  lesions	  (Craner	  et	  al.,	  2005).	  Sodium	  channel	  blockade	  
may	  therefore	  have	  immunomodulatory	  effects	  in	  addition	  to	  the	  directly	  protective	  effects	  
on	  axons	  described	  above.	  	  
In	  EAE	  models	  the	  sudden	  withdrawal	  of	  phenytoin	  resulted	  in	  acute	  clinical	  deterioration	  in	  
association	  with	  an	  increased	  CNS	  inflammatory	  infiltrate	  and	  ultimately	  death	  in	  over	  50%	  
of	  mice.	  (Black	  et	  al.,	  2007).	  There	  is	  currently	  no	  evidence	  that	  this	  occurs	  in	  humans.	  	  
4.2 The	  Lamotrigine	  Trial	  in	  Secondary	  Progressive	  Multiple	  sclerosis	  
The	  experimental	  evidence	  in	  animal	  models	  of	  a	  neuroprotective	  effect	  of	  sodium	  channel	  
blockade	  led	  to	  a	  clinical	  trial	  of	  lamotrigine	  trial	  in	  secondary	  progressive	  MS.	  120	  patients	  
were	   randomly	   assigned	   to	   receive	   lamotrigine	   or	   placebo	   for	   two	   years.	   The	   primary	  
outcome	  measure	  was	  the	  rate	  of	  reduction	  in	  central	  cerebral	  volume	  over	  two	  years	  and	  
the	  trial	  was	  powered	  to	  detect	  a	  60%	  treatment	  effect.	  The	  prediction	  was	  that	  lamotrigine	  
would	  preserve	  brain	  volume,	  but	   in	  fact	  the	  opposite	  effect	  was	  observed,	  at	   least	   in	  the	  
first	  year	  of	  treatment,	  when	  loss	  of	  partial	  and	  whole	  brain	  volume	  occurred	  at	  a	  greater	  
rate	  in	  the	  active	  arm.	  Specifically,	  the	  mean	  change	  in	  central	  cerebral	  volume	  was	  -­‐3.8mls	  
in	   the	   lamotrigine	   group	   and	   -­‐2.48	  mls	   in	   the	   placebo	   group.	   The	   volume	   loss	  was	   partly	  
reversible	   after	   treatment	   was	   withdrawn.	   The	   trial	   was	   therefore	   regarded	   as	   having	   a	  




Figure	  4-­‐3:	  Mean	  central	  cerebral	  volume	  in	  the	  lamotrigine	  and	  placebo	  groups	  measured	  









The	   interpretation	   of	   these	   findings	   was	   complex,	   partly	   due	   to	   the	   possible	   reversible	  
treatment	  effects	  on	  fluid	  shifts	  and	  a	  reduction	  in	  inflammation	  (so	  called	  pseudo-­‐atrophy).	  
Also	   non–adherence	   in	   the	   lamotrigine	   group	   approached	   50%	   as	   the	   drug	   was	   poorly	  
tolerated.	   This	  may	  be	  because	   the	   significant	   pre-­‐existing	   level	   of	   disability	   in	   secondary	  
progressive	   MS	   patients	   renders	   them	   particularly	   susceptible	   to	   axonal	   block	   due	   to	  
reduced	  conduction	  of	  sodium	  channels	  in	  chronically	  demyelinated	  axons.	  	  
Despite	  these	  limitations,	  some	  potentially	  positive	  treatment	  effects	  emerged.	  Namely,	  the	  
rate	  of	  decline	  of	  walking	  speed,	  a	   secondary	  outcome	  measure,	  was	  halved	   in	   the	  active	  
group	   compared	   to	   placebo	   and	   the	   active	   group	   had	   significantly	   lower	   serum	  
concentrations	  of	  neurofilament	  (Gnanapavan	  et	  al.,	  2013)	  a	  potential	  biomarker	  of	  axonal	  
degeneration.	  	  
Consideration	   of	   the	   trial	   design	   suggested	   a	   number	   of	   weaknesses,	   including	   limited	  
compliance	   with	   treatment	   due	   to	   poor	   tolerability	   of	   sodium	   channel	   blockade	   in	  
secondary	   progressive	   MS,	   and	   a	   premature	   read	   out	   which	   may	   have	   missed	   the	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emergence	   of	   a	   beneficial	   effect	   of	   treatment	   on	   brain	   atrophy	   after	   the	   first	   year	   of	  
treatment.	   Moreover,	   the	   wrong	   disease	   subtype	   may	   have	   been	   targeted	   given	   that	  
neuroprotection	   may	   be	   more	   effective	   in	   relapses	   than	   in	   progressive	   MS	   because	   the	  
higher	  level	  of	  inflammation	  in	  the	  acute	  plaque	  is	  closer	  to	  the	  experimental	  models	  from	  
which	  the	  sodium	  hypothesis	  arose	  (Kapoor	  et	  al.,	  2010).	  Additionally	  a	  study	  by	  Black	  et	  al	  
looked	  at	  the	  expression	  of	  Nav	  1.2	  and	  Nav	  1.6	  channels	  and	  the	  sodium	  calcium	  exchanger	  
(NCX)	  in	  chronic	  MS	  plaques.	  Unlike	  in	  acute	  lesions,	  axonal	  injury,	  as	  evidenced	  by	  B-­‐	  APP	  
accumulation,	  did	  not	  occur	  at	  sites	  of	  coexpression	  of	  Nav	  1.6	  and	  NCX	  and	  there	  was	  no	  
expression	   of	  Nav	   1.2	   channels	   along	   demyelinated	   axons.	   They	   suggested	   therefore	   that	  
different	  mechanisms	  underlie	  axonal	  degeneration	  in	  chronic	  plaques	  and	  this	  may	  account	  
for	  the	  lack	  of	  efficacy	  of	  sodium	  channel	  blockade	  in	  secondary	  progressive	  MS	  (Black	  et	  al.,	  
2007).	  	  
We	  believe	  the	  limitations	  of	  the	  lamotrigine	  trial	  have	  been	  addressed	  in	  the	  design	  of	  this	  
trial	   of	   neuroprotection	   with	   phenytoin	   in	   optic	   neuritis.	   Namely	   that	   treatment	   was	  
commenced	  at	  an	  early	  stage	  of	  the	  evolution	  of	  an	  acute	  inflammatory	  lesion	  (in	  the	  optic	  
nerve),	  which	  is	  more	  comparable	  to	  the	  experimental	  models	  on	  which	  the	  theory	  is	  based,	  
and	  was	  continued	  beyond	  the	  resolution	  of	  inflammation.	  	  
Secondly,	   the	  trial	   targets	  people	  with	   isolated	  optic	  neuritis	  or	  early	  multiple	  sclerosis,	   in	  
which	  sodium	  channel	  blockade	  is	  likely	  to	  be	  much	  better	  tolerated.	  This,	  in	  addition	  to	  the	  
shorter	  trial	  design	  increased	  the	  likelihood	  of	  adherence.	  	  
Thirdly,	  Henderson	  et	  al	  (2010)	  demonstrated	  mean	  time	  to	  90%	  loss	  of	  RNFL	  thickness	  after	  
an	  episode	  of	  acute	  optic	  neuritis	  was	  2.38	  months	  and	  that	  the	  earliest	  detectable	  atrophy	  
in	   the	   affected	   compared	   to	   the	   baseline	   fellow	   eye	   was	   1.64	   months.	   Therefore,	   the	  
readout	  of	  the	  trial,	  which	  was	  timed	  at	  three	  months	  after	  cessation	  of	  treatment	  (and	  6	  
months	  after	  onset	  of	  optic	  neuritis),	  allows	  the	  resolution	  of	  any	  treatment	  related	  volume	  
changes,	  and	  incorporates	  the	  delay	  that	  occurs	  in	  the	  development	  of	  atrophy	  in	  the	  optic	  
nerve	  and	  retina	  after	  the	  onset	  of	  inflammation	  (Henderson	  et	  al.,	  2010).	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Finally	   the	   anterior	   visual	   system	   presents	   an	   opportunity	   to	   implement	   a	   sensitive	   and	  
clinically	  relevant	  measure	  of	  neuroprotection,	  by	  using	  OCT	  to	  quantify	  the	  thickness	  of	  the	  
retinal	  nerve	  fibre	  layer,	  in	  which	  thinning	  primarily	  reflects	  axonal	  loss.	  
Table	  4-­‐1:	  Advantages	  of	  the	  neuroprotection	  with	  phenytoin	  in	  acute	  optic	  neuritis	  over	  
the	  lamotrigine	  trial	  in	  SPMS	  patients	  
Lamotrigine	  Trial	  (SPMS)	   Phenytoin	  Trial	  (Acute	  Optic	  Neuritis)	  
Significant	  pre-­‐existing	  disability	  
renders	  patients	  particularly	  sensitive	  to	  
axonal	  conduction	  block	  with	  Na	  
channel	  blockade	  
	  
CIS	  or	  early	  MS	  patient	  less	  disabled.	  
Na	  channel	  blockade	  likely	  to	  be	  better	  
tolerated.	  
Lower	  levels	  of	  inflammation,	  no	  longer	  
actively	  relapsing.	  	  
	  
Early	  inflammatory	  lesion	  more	  
comparable	  to	  EAE	  model.	  
Cerebral	  volume	  changes	  confounded	  
by	  reversible	  fluid	  shifts	  and	  reduced	  
inflammation.	  
	  
Clinically	  significant	  primary	  outcome	  
measure	  in	  the	  retina	  which	  primarily	  
reflects	  axonal	  loss	  
Premature	  read	  out	  time	  may	  have	  
missed	  emergence	  of	  beneficial	  
treatment	  effects	  after	  the	  first	  year	  
Delayed	  read	  out	  time,	  three	  months	  
after	  cessation	  of	  treatment,	  to	  
incorporate	  lag	  in	  RNFL	  atrophy	  
Longer	  trial	  design	  with	  poor	  
compliance	  
Shorter	  trial	  design	  increases	  likelihood	  
of	  compliance	  
	  
4.3 Trial	  objectives	  
We	   undertook	   a	   phase	   II	   double	   blind	   placebo	   controlled	   trial	   of	   neuroprotection	   with	  
phenytoin	  in	  acute	  demyelinating	  optic	  neuritis.	  
The	  primary	   aim	  of	   the	   trial	  was	   to	   determine	  whether	   immediate	   and	   sustained	   sodium	  
channel	   blockade	   with	   phenytoin	   is	   neuroprotective	   in	   acute	   optic	   neuritis	   (given	   that	  
phenytoin	   is	   a	   selective	   sodium	   channel	   inhibitor	   in	   the	   concentrations	   used	   in	   the	   trial	  
(Yaari	  et	  al.,	  1986)).	  	  
Secondary	  aims	  were	  to	  assess	  whether	  sodium	  channel	  blockade	  with	  phenytoin	  improves	  
visual	  outcome	  and	  promotes	   remyelination	  of	   the	  optic	  nerve.	  Additionally,	  we	  assessed	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the	  safety	  profile	  of	  phenytoin	  in	  acute	  demyelinating	  optic	  neuritis	  and	  the	  occurrence	  of	  
any	  unexpected	  adverse	  events.	  	  
4.4 Trial	  design	  
This	   investigator	   led	   trial	   had	   a	   multi-­‐centre	   double	   blind,	   parallel	   group,	   randomized	  
controlled	  design.	  There	  were	  two	  trial	  sites	  in	  London	  and	  Sheffield.	  
Patients	   aged	  between	  18-­‐	   60	   years	  were	  eligible	   if	   they	  had	   a	   clinical	   diagnosis	   of	   acute	  
unilateral	  optic	  neuritis	  (confirmed	  by	  a	  neuro-­‐ophthalmologist)	  with	  a	  visual	  acuity	  of	  ≤	  6/9	  
(and	  ≥	  6/6	  in	  the	  fellow	  eye)	  and	  an	  interval	  of	  ≤	  14	  days	  between	  onset	  of	  visual	  loss	  and	  
randomization.	  Patients	  with	  a	  previous	  diagnosis	  of	  relapsing	  MS	  were	  eligible	  if	  they	  had	  ≤	  
10	  years	  of	  disease	  duration	  and	  an	  EDSS	  of	  ≤	  3.	  Prior	  or	  ongoing	  treatment	  with	  glatiramer	  
acetate	  and	  B	   interferon	  was	  permitted	  and	   the	  decision	   to	  administer	  corticosteroids	   for	  
treatment	  acute	  optic	  neuritis	  was	  left	  to	  the	  discretion	  of	  the	  treating	  physician.	  	  
Patients	  were	  excluded	  if	  they	  had	  a	  history	  of	  previous	  optic	  neuritis	  (in	  either	  eye)	  or	  any	  
co-­‐morbid	   ocular	   disease,	   clinical	   or	   biochemical	   evidence	   of	   cardiac,	   hepatic	   or	   renal	  
abnormalities,	   contraindications	   to	   phenytoin	   use	   (including	   pregnancy)	   and	   disabling	  
temperature	  dependent	  MS	  symptoms.	  	  
Patients	  were	  also	  excluded	  if	  they	  had	  taken	  drugs	  that	  block	  sodium	  or	  calcium	  channels	  
in	   the	  preceding	   two	  weeks	  and	   if	   corticosteroids	   (with	   the	  exception	  of	   for	   treatment	  of	  
their	  optic	  neuritis)	  or	  any	  other	  immunomodulatory	  drugs	  had	  been	  taking	  in	  the	  preceding	  
two	  months.	  	  	  
The	  study	  was	  approved	  and	  by	  the	  London-­‐South	  East	  UK	  Research	  and	  Ethics	  Committee	  
and	  was	  monitored	  by	  an	   independent	  data	  monitoring	  and	  ethics	  committee.	  The	  trial	   is	  
registered	   with	   Clinical.Trials.gov	   (NCT	   01451593)	   and	   with	   EUDRACT.	   All	   patients	   gave	  
written	  informed	  consent	  before	  entry.	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4.5 Screening	  assessments	  
Participants	   were	   referred	   from	   a	   number	   of	   patient	   identification	   centres	   across	   the	  
country.	   In	   particular,	   ophthalmologists	   in	   eye	   casualties	   were	   included	   in	   the	   trial	  
infrastructure.	  Each	  participating	  centre	  was	  visited	  to	   increase	  awareness	  of	   the	  trial	  and	  
encourage	  referrals.	  Each	  centre	  was	  provided	  with	  posters	  outlining	  the	  main	  inclusion	  and	  
exclusion	  criteria	  and	  the	  contact	  details	  of	  the	  trial	  team.	  	  
Potential	   trial	   participants	   were	   screened	   clinically	   at	   one	   of	   the	   two	   trial	   sites	   for	   a	  
diagnosis	   of	   acute	  optic	   neuritis.	  A	   full	  medical	   history	   and	  ophthalmological	   examination	  
• Acute	  unilateral	  demyelinating	  optic	  neuritis	  
• ≤	  14	  days	  since	  onset	  of	  visual	  loss	  (since	  axonal	  injury	  is	  dependent	  on	  
coincident	  inflammation	  neuroprotection	  most	  likely	  to	  be	  effective	  if	  
commenced	  as	  soon	  as	  possible)	  
• Age	  18-­‐60	  (upper	  limit	  chosen	  to	  avoid	  including	  patients	  with	  
cerebrovascular	  disease	  on	  MRI)	  
• Visual	  acuity	  ≤	  6/9	  in	  the	  affected	  eye	  
• A	  	  pre-­‐existing	  diagnosis	  of	  	  relapsing	  MS	  were	  eligible	  within	  10	  years	  of	  
disease	  onset	  providing	  	  they	  had	  an	  EDSS	  of	  ≤	  3.	  (Patients	  with	  early	  MS	  
are	  less	  disabled	  and	  more	  likely	  to	  tolerate	  sodium	  channel	  blockade)	  
• Previous	  history	  of	  optic	  neuritis	  or	  ocular	  disease	  in	  either	  eye	  	  (as	  
this	  would	  interfere	  with	  outcome	  assessment)	  
• Use	  of	  sodium	  channel	  or	  calcium	  blockers	  in	  the	  previous	  two	  weeks	  
• Use	  of	  corticosteroids	  in	  the	  previous	  two	  months	  (with	  the	  exception	  
of	  for	  treatment	  of	  the	  optic	  neuritis)	  
• Clinical	  or	  biochemical	  evidence	  of	  cardiac,	  hepatic	  or	  renal	  
abnormalities	  
• Contraindications	  to	  phenytoin	  (including	  pregnancy	  and	  breast	  
feeding	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was	   undertaken.	   Screening	   investigations	   included	   full	   blood	   count,	   urea	   and	   electrolytes	  
and	  liver	  function	  tests,	  aquaporin	  4	  antibodies,	  urinalysis	  and	  urinary	  pregnancy	  test,	  ECG	  
and	  OCT	  to	  ensure	  that	  phenytoin	  could	  be	  given	  safely.	  Eligible	  patients	  were	  provided	  with	  
a	   detailed	   patient	   information	   leaflet	   and	   were	   given	   adequate	   time	   to	   consider	  
participation	  in	  the	  trial.	  Appropriate	  follow	  up	  was	  arranged	  for	  patients	  who	  were	  either	  
ineligible	  or	  declined	  to	  participate	  in	  the	  trial.	  
Participants	  who	  were	  randomised	  and	  enrolled	  but	   later	   found	  not	  to	  have	  optic	  neuritis	  
and	  those	  with	  positive	  aquaporin	  4	  antibodies	  were	  withdrawn	  from	  the	  trial	  and	  excluded	  
from	  the	  ITT	  cohort.	  	  	  
188	  patients	  were	  screened	  in	  total	  across	  the	  two	  sites	  (157	  London	  and	  31	  Sheffield).	  The	  
tables	  below	  outline	  the	  reasons	  for	  screening	  failure.	  
Table	  4-­‐2:	  Reasons	  for	  screening	  failure	  
Reason	  for	  screening	  failure	   Number	  of	  patients	  
Visual	  acuity	  ‘too	  good’	   28	  
Declined	   25	  
Alternative	  diagnosis	  (see	  table	  below)	   20	  
>14	  days	  since	  onset	  of	  visual	  loss	   11	  
Bilateral	  optic	  neuritis	   5	  
Previous	  history	  of	  optic	  neuritis	   3	  
On	  long	  term	  immunosuppression	  	   1	  
Diagnosis	  unclear	   4	  
Other	   5	  
	  
Table	  4-­‐3:	  Alternative	  diagnoses	  
Central	  serous	  retinopathy	   1	  




Optic	  nerve	  meningioma	   1	  
Cavernoma	  compressing	  optic	  chiasm	   1	  
Posterior	  scleritis	   2	  
Sarcoidosis	   3	  
Uveitis	   1	  
Leber’s	  hereditary	  optic	  neuropathy	   2	  
Toxic	  optic	  neuropathy	   1	  
Neuroretinitis	   1	  
Optic	  disc	  drusen	   1	  
Functional	  visual	  loss	   4	  
	  
4.6 Randomization	  and	  Procedures	  
Patients	   were	   randomly	   assigned	   (1:1)	   to	   phenytoin	   or	   placebo	   via	   a	   website	  
(www.sealedenvelope.com)	   by	   minimization,	   with	   time	   from	   onset	   (≤7	   days,	   >7	   days),	  
Center	   (London,	   Sheffield),	   prior	   MS	   diagnosis	   (yes/no),	   disease	   modifying	   treatment	  
(yes/no),	   and	   corticosteroids	   for	   optic	   neuritis	   (yes/no),	   as	   binary	  minimization	   variables.	  	  
Patients	  were	  allocated	  a	  randomization	  code	  that	  was	  matched	  to	  a	  confidential	  treatment	  
list	  by	  the	  study	  pharmacist	  to	  assign	  patients	  either	  to	  phenytoin	  or	  placebo	  (which	  were	  
identical	  in	  appearance)	  for	  3	  months.	  Throughout	  the	  study	  only	  the	  pharmacist	  was	  aware	  
of	   treatment	   allocation.	   Treating	   and	   assessing	   physicians	   as	   well	   as	   patients	   remained	  
masked	  to	  treatment	  allocation.	  
Patients	   were	   loaded	   with	   a	   total	   dose	   of	   15mg/kg	   divided	   in	   three	   equal	   doses,	   each	  
rounded	   up	   to	   the	   nearest	   50mg,	   over	   three	   days.	   A	   daily	   maintenance	   dose	   (4mg/kg,	  
rounded	   up	   to	   the	   nearest	   50mg,	   with	   a	   maximum	   of	   350mg)	   was	   given	   for	   13	   weeks,	  
increased	   to	   6	  mg/kg	   from	   at	   the	   recommendation	   of	   the	   DMEC	   due	   to	   sub-­‐therapeutic	  
serum	   phenytoin	   levels,	   the	   protocol	   was	   amended	   from	   17	   July	   2013.	   Patients	   were	  
recruited	  between	  February	  2012	  and	  May	  2014.	  58	  participants	  were	  randomised	  before	  
17	  July	  2013,	  29	  of	  whom	  were	  assigned	  to	  the	  lower	  daily	  maintenance	  dose	  of	  phenytoin	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and	   28	   were	   randomised	   after	   this	   date	   13	   of	   who	   were	   assigned	   the	   higher	   daily	  
maintenance	  dose.	  Final	  assessments	  were	  performed	  in	  December	  2014.	  	  
The	  rationale	  for	  the	  timing	  and	  duration	  of	  treatment	  was	  that	  because	  axonal	  injury	  may	  
be	   driven	   both	   by	   inflammation	   and	   by	   increased	   expression	   of	   axonal	   sodium	   channels,	  
neuroprotection	  would	  be	  expected	  to	  be	  most	  effective	  if	  treatment	  is	  commenced	  as	  soon	  
as	  possible	  after	  the	  onset	  of	  a	  relapse	  and	  continued	  until	  after	  inflammation	  (as	  inferred	  
by	  presence	  of	  gadolinium	  enhancement	  of	  the	  lesion)	  and	  axonal	  membrane	  readaptation	  
has	   subsided.	   	   In	   support	   of	   this	   Al-­‐Izki	   et	   al	   (2013)	   found	  Nav	   blocking	   compounds	  were	  
most	  effective	  during	   lesion	   formation	  and	  periods	  of	  blood	  barrier	  breakdown	   in	  an	  EAE	  
model	  of	  optic	  neuritis.	  Beyond	  this	  once	  the	  natural	  regulatory	  mechanisms	  were	  initiated,	  
Nav	  blockage	  failed	  to	   improve	  recovery	   (Al-­‐Izki	  et	  al.,	  2014).	   In	  view	  of	   this	  patients	  were	  
recruited	   and	   treatment	   commenced	   in	   ≤	   14	   days	   from	   onset	   of	   visual	   symptoms	   and	  
continued	  for	  3	  months.	  During	  this	  period	  there	  was	  also	  a	  possibility	  that	  surviving	  axons	  
undergo	  a	  degree	  of	  remyelination	  providing	  further	  protection	  from	  longer-­‐term	  injury.	  	  
A	   treating	   physician	   assessed	   patients	   after	   1	   and	   3	   months,	   when	   blood	   samples	   were	  
obtained	  to	  measure	  phenytoin	  concentrations,	  blood	  counts	  and	  liver	  function	  tests.	  	  
4.7 Study	  end	  points	  
The	  primary	  outcome	  measure	  was	  active	  versus	  placebo	  difference	  in	  mean	  retinal	  nerve	  
fibre	   layer	   thickness	   in	   the	   affected	   eye	   at	   6	   months,	   adjusted	   for	   the	   corresponding	  
baseline	   measurement	   in	   the	   unaffected	   eye.	   Mean	   retinal	   nerve	   fibre	   layer	   thickness	  
(RNFL)	   was	   chosen	   as	   the	   primary	   outcome	   measure	   due	   to	   the	   large	   body	   of	   data	  
supporting	  its	  use	  as	  a	  surrogate	  outcome	  measure	  of	  axonal	   loss	  in	  multiple	  sclerosis	  and	  
optic	   neuritis	   (Petzold	   et	   al.,	   2010;	   Balcer	   et	   al.,	   2015;	   Henderson	   et	   al.,	   2010).	   RNFL	  
measurements	  have	  been	  shown	  to	  correlate	  with	  measures	  of	  visual	   function	   in	  patients	  
with	  and	  without	  a	  history	  of	  optic	  neuritis	  as	  well	  as	  more	  general	  disability	  (Fisher	  et	  al.,	  
2006),	  brain	  atrophy	  and	  T2	  lesion	  load	  in	  patients	  with	  MS	  (Saidha	  et	  al.,	  2013).	  Additonally	  
the	  timeframe	  of	  RNFL	  loss	  after	  optic	  neuritis	  has	  been	  well	  defined.	  For	  these	  reasons	  it	  
was	   felt	   that	   RNFL	   thickness	   measurements	   would	   provide	   information	   about	   clinically	  
relevant	   treatment	   effects	   within	   feasible	   a	   timeframe	   for	   a	   clinical	   trial.	   At	   the	   time	   of	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designing	   the	   trial	   relatively	   little	   data	   was	   available	   on	   the	   use	   of	   ganglion	   cell	   layer	  
thickness	  measurements	  as	  a	  surrogate	  outcome	  in	  neuroprotection	  trials.	  Also,	  at	  the	  time	  
segmentation	  algorithms	  had	  yet	  to	  be	  fully	  optimized	  and	  were	  not	  commercially	  available.	  	  
Secondary	   imaging	   outcomes	   included	   macular	   volume	   as	   measured	   by	   OCT,	   and	   MRI	  
measures	  including	  lesional	  optic	  nerve	  cross-­‐sectional	  area	  and	  MTR	  (an	  indirect	  measure	  
of	  optic	  nerve	  myelination)	  in	  addition	  to	  lesion	  length.	  
Visual	  function	  was	  not	  chosen	  as	  the	  primary	  outcome	  measure	  as	  the	  redundancy	  in	  the	  
anterior	  visual	  system	  would	  make	  treatment	  effects	  more	  difficult	  to	  demonstrate.	  	  
Secondary	  clinical	  outcomes	   included	  affected	  eye	  visual	   function	  as	  measured	  by	   logMAR	  
visual	   acuity,	   low	   contrast	   letter	   score	   (1.25%	   and	   2.5%	   Sloan	   charts)	   and	   Farnsworth-­‐
Munsell	  100	  Hue	  test.	  In	  addition	  whole	  and	  central	  field	  VEP	  amplitudes	  and	  latencies	  were	  
performed	   to	   give	   independent	   inferential	  measures	   of	   axonal	   conduction	   block/loss	   and	  
demyelination/remyelination	  respectively	  of	  the	  optic	  nerve.	  
Primary	   and	   secondary	   endpoints	  were	  measured	   at	   baseline	   and	   6	  months	   later.	   The	   3-­‐
month	  gap	  between	  cessation	  of	  treatment	  and	  this	  final	  assessment	  was	  designed	  to	  allow	  
any	  artefactual	  effects	  of	  sodium	  channel	  inhibition	  (e.g.	  pseudoatrophy)	  to	  reverse	  before	  
the	   final	   readout.	   Brain	  MRI	   sequences	  were	   obtained	   at	   baseline	   for	   patients	  without	   a	  
prior	  diagnosis	  of	  multiple	  sclerosis.	  This	  was	  done	  to	  detect	  the	  presence	  of	  demyelinating	  
lesions	   for	   prognostication	   or	   diagnosis	   of	  MS.	  MS	   was	   diagnosed	   using	   2010	  McDonald	  
criteria	  (Polman	  et	  al.,	  2011).	  
Optical	  coherence	  tomography	  
OCT	   images	   were	   acquired	   with	   spectral	   domain	   OCT	   (Spectralis	   Heidelberg	   engineering,	  
Germany,	  Software	  V	  5.4B).	  Identical	  OCT	  protocols	  were	  performed	  at	  both	  sites	  by	  trained	  
technicians	  blinded	  to	  treatment	  allocation.	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Mydriatics	   were	   not	   used	   if	   pupils	   were	   large	   enough	   to	   permit	   scanning	   (>5mm).	  
Automated	   real	   time	   a	   method	   for	   maintaining	   OCT	   B	   scan	   alignment	   and	   registration	  
during	  image	  acquisition	  was	  employed.	  	  	  
Retinal	   nerve	   fibre	   layer	   measurements	   were	   performed	   using	   3.45	   mm	   diameter	   circle	  
scan.	   The	  mean	   and	   sectoral	   (nasal,	   temporal,	   superior	   and	   inferior)	   RNFL	  measurements	  
were	  recorded.	  	  
In	  addition	  a	  fast	  macular	  volume	  scan	  (20	  x20°	  field,	  25	  horizontal	  B	  scans,	  ART	  9)	  centered	  
on	  the	  fovea	  was	  performed.	  
Internal	   fixation	  was	  used	  unless	   this	  was	  not	  possible	  due	   to	  poor	   visual	   acuity	   in	  which	  
case	  an	  external	  fixation	  light	  using	  the	  unaffected	  eye	  was	  employed.	  	  
The	  software	  assisted	  retest	  function	  was	  applied	  to	  the	  baseline	  scans.	  This	  uses	  landmarks	  
in	  the	  baseline	  image	  to	  re-­‐centre	  the	  SD-­‐OCT	  beam	  in	  the	  follow	  up	  scan	  to	  the	  previously	  
scanned	  location.	  
Scans	  were	  excluded	  if	  they	  had	  a	  signal	  strength	  of	  <25	  or	  violated	  international	  consensus	  
quality	  control	  criteria	  (Schippling	  et	  al.,	  2015).	  
Low	  contrast	  letter	  scores	  
Low	   contrast	   letter	   scores	   were	   measured	   using	   retro-­‐illuminated	   Sloan	   letter	   charts	   at	  
1.25%,	   2.5%	   contrast	   levels	   for	   each	   eye	   at	   2	  meters	   (Precision	   Vision,	   La	   Salle,	   IL)	   using	  
standard	   fluorescent	  office	   lighting.	  Numbers	  of	   letters	   identified	  were	   recorded	   for	   each	  
eye.	  	  
LogMAR	  Visual	  Acuity	  
High	  contrast	   logMAR	  visual	  acuity	  was	  performed	  using	  retro-­‐illuminated	  ETRDS	  charts	  at	  
4m.	  When	   no	   letters	   could	   be	   correctly	   identified	   a	   score	   of	   1.7	   was	   assigned.	   Standard	  
lighting	   levels	   were	   established	   using	   fluorescent	   office	   lighting.	   Best-­‐corrected	   acuities	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were	   obtained	   with	   prescription	   spectacles	   and	   pinhole	   occluder.	   In	   addition	   to	   logMAR	  
visual	  acuity	  taken	  at	  baseline	  and	  six	  months,	  Snellen	  visual	  acuity	  was	  also	  performed	  at	  
one	  and	  three	  months	  for	  safety	  reasons	  (to	  ensure	  that	  treatment	  with	  phenytoin	  did	  not	  
have	  a	  deleterious	  effect	  on	  vision)	  
Colour	  Vision	  
To	  assess	  colour	  vision	  the	  Farnsworth	  Munsell	  Hue	  100	  test	  was	  performed	  as	  previously	  
described	   (Farnsworth,	   1943).	   85	   coloured	   caps	   of	   different	   hues	   were	   presented	   under	  
standard	  daylight	  conditions	  (colour	  temperature	  6500K)	  in	  numerical	  order.	  Each	  eye	  was	  
tested	   separately.	   Patients	   with	   a	   logMAR	   acuity	   of	   1.0	   or	   worse	   were	   deemed	   to	   have	  
insufficient	   visual	   acuity	   to	   perform	   the	   test	   and	   were	   assigned	   an	   error	   score	   of	   2000.	  
Otherwise	  a	  computer	  program	  calculated	  the	  total	  error	  score.	  
Magnetic	  resonance	  imaging	  
MRI	  images	  were	  obtained	  on	  a	  two	  3	  T	  scanner	  and	  identical	  scanning	  protocols	  performed	  
at	  both	  sites.	  Each	  optic	  nerve	  was	   imaged	  separately	  and	   for	  all	  acquisitions	   the	   imaging	  
plane	   for	   the	   optic	   nerves	  was	   set	   orthogonal	   to	   the	   longitudinal	   axis	   of	   the	   optic	   nerve	  
itself.	  
	  The	  following	  sequences	  were	  performed	  using	  identical	  scan	  geometry:	  
1)	   A	   multi-­‐dynamic	   fat-­‐suppressed	   heavily	   T2-­‐weighted	   multi-­‐slice	   “single-­‐shot”	   two-­‐
dimensional	  (2D)	  turbo	  spin	  echo	  (TSE)	  with	  field	  of	  view	  (FOV)	  =	  160	  x	  160	  mm2;	  repetition	  
time	   (TR)	   =	   16	   s;	   echo	   time	   (TE)	   =	   74	   ms;	   voxel	   size	   =	   0.5	   ×	   0.5	   ×	   3	   mm3;	   number	   of	  
excitations	  (NEX)	  =	  1;	  20	  contiguous	  slices;	  number	  of	  repeated	  dynamic	  scans	  =	  15	  (32s	  per	  
dynamic	  scan;	  to	  minimize	  the	  effect	  of	  motion	  patients	  were	  asked	  to	  fixate	  on	  a	  marker	  
attached	  to	  the	  coil;	  the	  individual	  volumes	  acquired	  were	  then	  co-­‐registered	  and	  averaged	  
to	  produce	  the	  final	  image,	  (Yiannakas	  et	  al.,	  2013).	  
2)	  A	  conventional	  fat-­‐suppressed	  T2-­‐weighted	  2D-­‐TSE	  with	  FOV	  =	  160	  x	  160	  mm2;	  TR	  =	  3	  s;	  
TE	  =	  80	  ms;	  voxel	  size	  0.5	  x	  0.5	  x	  3	  mm3;	  NEX	  =	  3;	  20	  contiguous	  slices;	  scan	  time	  6	  min	  30	  s	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3)	  A	  T1-­‐weighted	  fluid	  attenuated	  inversion	  recovery	  (FLAIR)	  2D-­‐TSE	  with	  FOV	  =	  160	  x	  160	  
mm2;	  	  TR	  =	  2.1	  s;	  TE	  =	  10	  ms;	  inversion	  time	  (TI)	  =	  1	  s;	  voxel	  size	  0.5	  x	  0.5	  x	  3	  mm3;	  NEX	  =	  2;	  
20	  contiguous	  slices;	  scan	  time	  6	  min	  26	  s	  .	  
4)	   For	   MTR	   imaging,	   a	   3D	   slab-­‐selective	   FFE	   sequence	   with	   two	   echoes	   (TR	  =	  49	  ms,	  
TE1/TE2	  =	  3.6/6	  ms,	  flip	  angle	  α	  =	  9°),	  performed	  with	  and	  without	  Sinc-­‐Gaussian	  shaped	  MT	  
saturating	  pulses	  of	  nominal	  α	  =	  360°,	  offset	  frequency	  1	  kHz,	  duration	  16	  ms.	  Twenty	  slices	  
were	  acquired	  with	  FOV	  =	  160	  ×	  160	  mm2;	  voxel	  size	  0.75	  ×	  0.75	  ×	  5	  mm3	  (reconstructed	  to	  
0.5	  ×	  0.5	  ×	  5	  mm3),	  NEX	  =	  2,	  SENSE	  acceleration	  factor	  =	  2,	  scanning	  time	  =	  7	  min.	  
Three	   independent	   assessors	   blinded	   to	   treatment	   allocation	   identified	   lesion	   length	   and	  
position	  and	  patient	  identity	  using	  a	  combination	  of	  the	  conventional	  and	  multidynamic	  T2	  
weighted	  sequences.	  
The	   length	  of	   the	   lesion	   (in	  millimeters)	  was	  determined	  as	   the	  number	  of	   slices	   involved	  
multiplied	  by	  3.The	  globe–lesion	  distance	  (in	  millimeters)	  was	  calculated	  by	  multiplying	  the	  
number	  of	  slices	  between	  the	  globe	  and	  the	  anterior	  edge	  of	  the	  lesion	  by	  3.	  
A	  blinded	  assessor	  using	  semi-­‐	  automated	  contouring	  technique	  on	  the	  T1	  weighted	  images	  
performed	  mean	   lesional	   cross-­‐sectional	   area.	  A	   lesion	  mask	  was	   created	  on	   the	  baseline	  
affected	  eye	  T2	  images.	  Affected	  eye	  baseline	  T2	  and	  6	  month	  T1	  images	  were	  subsequently	  
registered	   together.	   The	   T2	   lesion	  mask	  was	   then	   applied	   to	   the	   registered	   6	   -­‐month	   T1	  
images	   and	   mean	   ‘lesional’	   cross-­‐sectional	   area	   calculated.	   Measurements	   were	   then	  
corrected	   for	   the	   corresponding	   baseline	  mean	   ‘non	   –lesional’	   cross-­‐sectional	   area	   in	   the	  
unaffected	  eye	  (by	  applying	  the	  T2	  lesion	  mask	  to	  baseline	  unaffected	  eye	  T1	  images)	  
	  
The	  MTR	  analysis	  was	  performed	  as	  follows:	  
Two	   MToff	   and	   two	   MTon	   images	   were	   acquired	   for	   each	   optic	   nerve	   within	   the	   same	  
acquisition.	   MTon	   and	  MToff	   represent	   acquisitions	   with	   and	   without	   the	   pre-­‐saturation	  
pulse	  respectively.	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Lesional	   MTR	   values	   for	   the	   affected	   optic	   nerves	   (corresponding	   MTR	   values	   for	   the	  
unaffected	  nerves)	  were	  derived	  as	  follows	  for	  baseline	  and	  6	  month	  follow	  up	  MRI	  scans.	  
FSL	  flirt	  was	  used	  for	  registration	  (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT).	  
1)	  Calculation	  of	  optic	  nerve	  MTR	  maps	  
All	  four	  MT	  images	  were	  registered	  (using	  FSL)	  to	  one	  of	  the	  MToff	  images.	  The	  two	  MToff	  
and	   two	  MTon	   images	  were	   respectively	   averaged	   to	   produce	   one	  MToff	   and	   one	  MTon	  
image	   for	   each	   nerve.	  MTR	   optic	   nerve	  maps	   were	   calculated	   using	   the	   formula	   (MToff-­‐
MTon/MToff)	  x100.	  
2)	  Extraction	  of	  optic	  nerve	  MTR	  values	  
Jim	  (Xinapse	  systems)	  was	  used	  to	  delineate	  ROIs	  within	  the	  optic	  nerves.	  Initially,	  T1	  optic	  
nerve	   maps	   were	   registered	   to	   the	   MToff	   maps	   using	   FSL	   flirt.	   Circular	   ROIs	   (diameter	  
1.5mm,	  area	  1.76	  mm	  sq)	  were	  then	  applied	  to	  centres	  of	  the	  optic	  nerves	  on	  the	  registered	  
T1	  maps	  (using	  MToff	  and	  registered	  MTon	  maps	  as	  visual	  reference).	  The	  optic	  nerve	  MTR	  
values	  were	  then	  extracted	  on	  a	  slice-­‐by-­‐slice	  basis	  for	  each	  optic	  nerve	  (left	  and	  right).	  
3)	  Determining	  lesion	  extent	  on	  optic	  nerve	  MTR	  map	  
The	  acute	   lesion	  was	  previously	   identified	  on	   the	  baseline	  optic	  nerve	  T2	   images	   (e.g.	   the	  
lesion	  could	  extend	  from	  slice	  numbers	  4-­‐8	  inclusive).	  A	  crude	  baseline	  T2	  lesion	  mask	  was	  
created	  based	  on	  the	  longitudinal	  extent	  of	  the	  lesion.	  The	  baseline	  optic	  nerve	  T2	  images	  
were	   registered	   to	   baseline	   MToff	   space	   (this	   is	   in	   the	   same	   space	   as	   MTR)	   and	   the	  
transformation	  matrix	  was	  applied	  to	  the	  T2	  lesion	  mask	  to	  determine	  the	  MTR	  equivalent	  
lesion	  mask	  at	  baseline.	  This	  was	  binarized	  with	  an	  intensity	  threshold	  of	  0.9.	  
Baseline	  MToff	  images	  were	  registered	  to	  follow-­‐up	  MToff	  images.	  A	  transformation	  matrix	  
was	   applied	   to	   the	   baseline	   T2	   lesion	  mask	   to	   convert	   it	   to	   follow-­‐up	  MToff	   space.	   This	  
transformed	  mask	  was	  binarized	  with	  an	  intensity	  threshold	  of	  0.9.	  The	  baseline	  and	  follow-­‐
up	  MT	  lesion	  masks	  were	  overlaid	  onto	  the	  optic	  nerve	  MTR	  maps	  and	  the	  longitudinal	  slice	  
extent	  of	  the	  lesion	  was	  recorded.	  A	  similar	  algorithm	  was	  followed	  for	  the	  unaffected	  optic	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nerve	   with	   T2	   lesion	   masks	   initially	   created	   for	   the	   unaffected	   side	   before	   being	  
transformed	  into	  baseline	  and	  follow-­‐up	  MT	  space.	  Hence	  the	  lesional	  MTR	  values	  could	  be	  
determined	   for	   affected	   and	   fellow	   optic	   nerves	   and	   these	   were	   entered	   into	   statistical	  
analysis.	  
Visual	  evoked	  potentials	  
VEPs	  were	  performed	  at	  both	   sites	   following	   International	   Federation	  of	  Neurophysiology	  
guidelines	  (Holder	  et	  al.,	  2010)	  on	  a	  Synergy	  system.	  Monocular	  stimuli	  were	  applied	  using	  
reversal	   of	   achromatic	   checks	   with	   a	   luminance	   of	   61.2cd/m2	   (55.6cd/m2	   in	   Sheffield),	  
(Michelson)	  contrast	  of	  96.9%	  (93.1%	  in	  Sheffield),	  a	  reversal	  rate	  of	  2.1/s	  (1.9/s	  in	  Sheffield)	  
of	  a	  32	  x	  32	  array	  with	  a	  check	  size	  of	  15.6’	  arc	  min/0.25°	  (18.0’	  arc	  min/0.3°	   in	  Sheffield)	  
and	   a	   stimulus	   field	   of	   15.6°	   (19.1°	   x	   14.4°	   in	   Sheffield)	   in	   standard	   background	   office	  
lighting.	   Responses	   were	   recorded	   from	   Oz	   using	   Fz	   as	   reference	   and	   Cz	   as	   ground	   at	   a	  
sweep	   duration	   of	   250	  ms	   and	   filters	   at	   1	   Hz	   (high	   pass)	   and	   100	   Hz	   (low	   pass)	   without	  
notch.	  At	  least	  100	  responses	  were	  averaged	  per	  trial	  using	  automatic	  artefact	  rejection	  and	  
at	   least	   2	   replicates	   were	   obtained.	   Replicates	   were	   averaged	   and	   VEP	   latencies	   were	  
measured	  to	  the	  nadir	  of	  the	  P100	  and	  amplitudes	  from	  N75	  to	  P100	  to	  an	  accuracy	  of	  one	  
decimal	  place.	  	  
	  
	  Patients	   with	   absent	   VEP	   latencies	   or	   amplitudes	   were	   assigned	   a	   value	   of	   200	   and	   0	  
respectively.	  At	  baseline	  20	  affected	  eyes	  in	  each	  group	  had	  their	  absent	  VEP	  latencies	  and	  
amplitudes	  replaced	  this	  way	  (this	  was	  not	  used	  in	  the	  main	  analysis	  given	  that	  the	  baseline	  
fellow	  rather	  than	  the	  affected	  eye	  measurements	  were	  used	  in	  the	  statistical	  analysis	  (see	  
section	  4.8)	  and	  none	  at	  baseline	  unaffected	  eye.	  At	  6	  months	  this	  replacement	  was	  made	  in	  
three	  patients,	  all	  three	  in	  the	  active	  group.	  Although	  the	  200	  value	  is	  arbitrary,	  it	  is	  higher	  
than	  the	  highest	  measured	  value	  in	  the	  study	  –	  188.	  It	  is	  therefore	  conservative	  to	  include	  
these	  values	  at	  6	  months	  rather	  than	  to	  exclude	  them	  that	  would	  have	  reduced	  the	  mean	  
latency	   of	   the	   active	   group.	   Substituting	   values	   of	   220	   had	   no	   effect	   on	   the	   statistical	  
significance	  level	  when	  comparing	  active	  vs.	  placebo	  difference.	  	  
	  
Trained	  staff	  blinded	  to	  treatment	  allocation	  performed	  all	  outcome	  assessments.	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4.8 Statistical	  analysis	  
The	  target	  sample	  size	  of	  45	  per	  arm	  was	  chosen	  to	  give	  80%	  power	  to	  detect	  a	  treatment	  
effect	  in	  RNFL	  thickness	  of	  50%	  (inferred	  from	  a	  50%	  reduction	  in	  the	  amount	  of	  RNFL	  loss	  
compared	  to	  the	  fellow	  eye	  in	  a	  trial	  comparing	  active	  and	  placebo	  arms)	  at	  5%	  significance	  
level,	   whilst	   allowing	   for	   a	   20%	   combined	   rate	   of	   loss	   to	   follow-­‐up	   and	   non-­‐adherence.	  
Sample	   size	   was	   calculated	   from	   longitudinal	   OCT	   data	   on	   23	   patients	   with	   acute	  
demyelinating	  optic	  neuritis	  using	  the	  mean	  follow	  up	  affected	  eye	  RNFL	  thickness	  adjusted	  
for	   baseline	   fellow	   eye	   RNFL	   thickness	   (calculated	   using	   the	   follow	   up	   affected	   eye	   RNFL	  
standard	  deviation	   (18.32)	   and	   the	   follow	  up	   affected	   versus	   baseline	   fellow	  eye	  Pearson	  
correlation	  coefficient	  (0.63)	  (Henderson	  et	  al.,	  2010).	  	  
	  
Adjusting	   for	   the	   fellow	   eye	   maximised	   power	   by	   overcoming	   the	   large	   inter-­‐subject	  
variability	  in	  normal	  RNFL	  thickness	  The	  fellow	  eye	  was	  chosen	  because	  acute	  swelling	  in	  the	  
affected	  eye	  makes	  this	  eye	  a	  poor	  predictor	  of	  follow-­‐up	  thickness,	  and	  makes	  affected	  eye	  
change	  uninterruptable.	  	  Accordingly,	  an	  ANCOVA	  analysis	  method	  was	  used,	  using	  multiple	  
linear	   regression	   of	   the	   follow-­‐up	   affected	   eye	   RNFL	   on	   a	   trial	   arm	   indicator	   with	   the	  
following	  pre-­‐specified	  covariates:	  baseline	  fellow	  eye	  value,	  center	  (binary),	  days	  between	  
onset	  and	  baseline	  assessment,	  and	  whether	  the	  patient	  was	  prescribed	  corticosteroids	  at	  
the	  time	  of	  baseline	  assessment	  (3	  categories:	  no/	  1-­‐5	  days	  prior	  to	  assessment/	  6-­‐30	  days	  
prior).	  	  Two	  planned	  binary	  covariates	  were	  not	  used	  because	  of	  a	  pre-­‐specified	  minimum	  of	  
10	  for	  their	  smallest	  category:	  “Prior	  MS”	  (4	  yes,	  82	  no)	  and	  “Prescribed	  disease-­‐modifying	  
treatment”	   (1	   yes,	   85	   no).	   	   Secondary	   outcomes	   were	   analyzed	   similarly,	   with	   the	  
corresponding	   baseline	   fellow-­‐eye	   value	   and	   the	   same	   pre-­‐specified	   covariates.	   An	  
exception	   was	   lesion	   length,	   for	   which	   the	   baseline	   fellow	   eye	   was	   not	   specified	   as	  
covariate;	  also,	  due	  to	  only	  3	  patients	  at	  one	  MRI	  site	  (Sheffield),	  center	  was	  not	  used	  as	  a	  
covariate	  in	  the	  analyses.	  	  	  	  	  	  
	  	  
The	   primary	   intention-­‐to-­‐treat	   (ITT)	   analyses	   included	   all	   randomized	   patients	   who	   were	  
followed	   up.	   	   Secondary	   per	   protocol	   (PP)	   analyses,	   after	   excluding	   patients	   with	   a	  
subsequent	   further	   episode	   of	   optic	   neuritis,	   compared	   all	   placebo	   patients	   with	   just	  
adherent	  active	  patients,	  defined	  as	  having	  phenytoin	  present	  in	  their	  one-­‐month	  blood.	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Where	   regression	   residuals	   showed	   signs	   of	   non-­‐normality	   and/or	   heteroscedasticity,	   p-­‐
values	  were	  calculated	  with	  a	  permutation	   test.	  Statistical	   significance,	  where	   referred	   to,	  





Chapter	  5 Baseline	  Results	  
5.1 Introduction	  
Optic	  neuritis	  is	  one	  of	  the	  most	  common	  causes	  of	  acute	  visual	  loss	  in	  young	  adults	  (Jin	  et	  
al.,	  1998).	  It	  may	  occur	  in	  isolation,	  so	  called	  ‘idiopathic	  optic	  neuritis’	  or	  in	  association	  with	  
multiple	   sclerosis.	   It	   usually	  presents	  with	   subacute	  monocular	   visual	   loss	   associated	  with	  
retro-­‐orbital	  pain,	  dyschromatopsia	  and	  reduced	  low	  contrast	  vision.	  	  
At	   baseline	   visual	   evoked	   potentials	   typically	   demonstrate	   a	   delayed	   P100	   latency	   and	  
acutely	  amplitude	  may	  be	  reduced	  or	  there	  may	  even	  be	  complete	  conduction	  block.	   	  The	  
lesion	  in	  the	  optic	  nerve	  may	  be	  visualized	  by	  orbital	  MRI	  using	  fat-­‐saturated	  fast	  spin	  echo	  
sequences	  and	  imaging	  of	  the	  retinal	  nerve	  fibre	  layer	  using	  optical	  coherence	  tomography	  
may	  demonstrate	  RNFL	  swelling.	  	  
In	   this	   chapter	   I	   aimed	   to	   look	   at	   the	   baseline	   clinical,	   electrophysiological	   and	   imaging	  
profile	   of	   our	   cohort	   of	   patients	   with	   acute	   optic	   neuritis	   recruited	   within	   2	   weeks	   of	  
symptom	   onset	   and	   investigate	   whether	   there	   were	   any	   significant	   correlations	   with	  
baseline	  visual	  function	  and	  RNFL	  swelling.	  
5.2 Methods	  
The	   baseline	   data	   of	   all	   86	   patients	   recruited	   into	   the	   study	  was	   analyzed.	   Clinical	   visual	  
function	   testing,	   VEPS	   and	   optical	   coherence	   tomography	  measurements	   (RNFL	   thickness	  
and	  macular	   volume)	  were	   performed	  within	   2	  weeks	   of	   symptom	   onset	   as	   described	   in	  
Chapter	  4.7.	  Orbital	  MRI	  was	  performed	  and	  optic	  nerve	  cross-­‐sectional	  area	  measurements	  
obtained	  as	  described	  in	  Chapter	  4.7.	  Lesion	  length	  was	  obtained	  using	  the	  conventional	  fat	  
suppressed	   T2	   weighted	   2D-­‐TSE	   images	   by	   calculating	   the	   number	   of	   consecutive	   slices	  
involved	  and	  multiplying	  by	  3.	  	  The	  globe–lesion	  distance	  (in	  millimeters)	  was	  calculated	  by	  




5.3 Summary	  of	  baseline	  results	  
86	   patients	   were	   included	   in	   the	   baseline	   analysis,	   of	   these	   63	  were	   female	   (73%).	   	   The	  
mean	  time	  from	  onset	  of	  visual	   loss	  to	  being	  enrolled	   into	  the	  trial	  was	  8.2	  days	  (+/-­‐	  3.2).	  
The	  majority	  of	  patients	  (79%)	  were	  prescribed	  steroids	  as	  treatment	  for	  their	  optic	  neuritis.	  
Only	  4	  patients	  had	  a	  pre-­‐existing	  diagnosis	  of	  Multiple	  sclerosis	  and	  just	  one	  of	  these	  was	  
prescribed	  a	  disease-­‐modifying	  drug	  (B	  interferon).	  	  
A	  baseline	  brain	  MRI	  was	  performed	  in	  80	  patients.	  Three	  patients	  had	  a	  known	  diagnosis	  of	  
MS	   and	   did	   not	   require	   brain	   imaging,	   two	   were	   lost	   to	   follow	   up	   before	   the	   MRI	   was	  
performed	  and	  one	  was	  unable	  to	  have	  the	  scan	  due	  to	  metalwork.	  
At	   baseline	  74%	  had	  ≥	  1	  T2	  hyper-­‐intense	   lesions	  on	  brain	  MRI,	   53%	  of	   patients	   satisfied	  
McDonald’s	   2010	   criteria	   for	   dissemination	   in	   space	   and	   30%	   satisfied	  McDonald’s	   2010	  
criteria	  for	  MS.	  
81	   patients	   underwent	   optic	   nerve	   imaging	   and	   the	   symptomatic	   optic	   nerve	   lesion	  
visualized	   in	   all	   except	   three	   at	   baseline.	  Mean	   lesion	   length	  was	   17.6mm	   (+/-­‐	   7.60).	   The	  
majority	  of	  patients	  had	  involvement	  of	  the	  intra-­‐orbital	  segment	  of	  the	  optic	  nerve	  (84%).	  
Canalicular	   involvement	   was	   seen	   in	   59%	   of	   patients	   and	   the	   intracranial	   segment	   was	  
involved	  in	  31%	  of	  patients.	  25%	  of	  patients	  had	  long	  lesions	  involving	  all	  three	  segments	  of	  
the	  optic	  nerve.	  Only	  1	  patient	  had	  involvement	  of	  the	  optic	  chiasm.	  	  
82	  patients	  had	  baseline	  electrophysiology	  performed.	  VEPs	  were	  absent	  in	  the	  affected	  eye	  
in	  40	  (49%)	  for	  the	  small	  check	  size	  and	  35	  (43%)	  for	  the	  large	  check	  size	  at	  baseline.	  






Table	  5-­‐1:	  Baseline	  clinical,	  electrophysiological	  and	  MRI	  characteristics	  for	  all	  patients	  





Age	  (yrs)	   34	  (8.7)	   	  
Women	   63	  (73%)	   	  
Days	  from	  onset	  to	  
randomization	  	  
8.2	  (3.2)	   	  
Prescribed	  corticosteroids	   68	  (79%)	   	  
Prior	  diagnosis	  of	  multiple	  
sclerosis	  
4(5%)	   	  
≥	  1	  T2	  hyperintense	  MRI	  brain	  
lesions	  
64(74%)	   	  
RNFL	  thickness	  affected	  eye	  
(μm)	  
127.9	  (44.9)	   98.2	  (11.0)	  
Macular	  volume	  (mm3)	   8.7	  (0.5)	   8.7	  (0.4)	  
LogMAR	  visual	  acuity	   1.09	  (0.57)	   -­‐0.03	  (0.09)	  
1.25%	  low	  contrast	  letter	  
score	  	  
0.26	  (1.74)	   27.91	  (10.13)	  
2.5%	  low	  contrast	  letter	  score	  	   0.49	  (2.53)	   33.69	  (9.76)	  
FM	  100-­‐Hue	  total	  error	  score	   	  1103	  (770.1)	   89.54	  (52.85)	  
VEP	  small	  check	  latency	  (ms)	   167.7	  (35.5)	   104.4	  (6.1)	  
VEP	  small	  check	  amplitude	  
(μV)	  	  
2.9	  (3.8)	   10.5	  (5.45)	  
Optic	  nerve	  cross-­‐sectional	  
area	  (mm2)	  
	  7.54(1.49)	   5.42	  (0.82)	  
Lesion	  length	  (mm)	   17.6	  (7.6)	   n/a	  
	  
Data	  are	  mean	  (SD)	  for	  the	  affected	  eye,	  or	  number	  (%)	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5.4 Statistical	  analysis	  
Univariable	  (pairwise)	  associations	  between	  baseline	  variables	  were	  assessed	  using	  Pearson	  
correlation	   coefficients.	  In	   order	   to	   determine	   which	   measures	   were	   independently	  
predictive	   of	   baseline	   visual	   function	   and	   RNFL	   swelling,	  multiple	   linear	   regressions	  were	  
used,	  with	  visual	  function	  or	  RNFL	  as	  response	  (dependent)	  variables.	  	  Where	  normality	  of	  
residuals	  could	  not	  be	  assumed,	  non-­‐parametric,	  bias-­‐corrected	  and	  accelerated	  bootstrap	  
confidence	   intervals	   were	   obtained	   using	   1000	   replicates,	   to	   confirm	   or	   correct	   the	  
regression	  results	  
5.5 Correlations	  with	  baseline	  visual	  function	  
Mean	  baseline	  corrected	  (with	  patients’	  spectacles	  and	  pin	  hole)	  logMAR	  visual	  acuity	  of	  the	  
affected	   eye	   was	   not	   significantly	   correlated	   with	   mean	   lesion	   length	   or	   distance	   of	   the	  
lesion	   from	   the	   globe	   	   (p=0.34,	   r=0.11	   and	   p=0.53,	   r=0.07	   respectively).	   There	   was	   no	  
significant	  difference	  in	  baseline	  logMAR	  visual	  acuity	  in	  patients	  with	  long	  lesions	  of	  ≥	  17.5	  
mm	  and	  those	  with	  shorter	  lesions	  <17.5	  mm	  (p=	  0.28).	  	  
Likewise	  there	  was	  no	  significant	  association	  between	  baseline	  affected	  eye	  logMAR	  visual	  
acuity	  and	  affected	  eye	  lesional	  optic	  nerve	  cross-­‐sectional	  area.	  	  
Baseline	   mean	   lesional	   optic	   nerve	   cross-­‐sectional	   area	   was	   significantly	   correlated	   with	  
mean	  lesion	  length	  (p=0.005,	  r=	  0.32).	  
Baseline	   low	   contrast	   letter	   score	   (1.25%	   and	   2.5%)	  was	   not	   significantly	   associated	  with	  
lesion	   length,	   distance	   of	   the	   lesion	   from	   the	   globe	   or	   optic	   nerve	   cross-­‐sectional	   area.	  
Similarly	  there	  was	  no	  significant	  association	  between	  baseline	  FM	  hue	  100	  score	  and	  lesion	  
length	   and	  optic	   nerve	   cross-­‐sectional	   area.	  However	   patients	  with	   long	   lesions	   of	   ≥	   17.5	  
mm	   had	   borderline	   significantly	   worse	   FM	   hue	   100	   error	   score	   than	   those	   with	   shorter	  
lesions	  <17.5	  mm	  (p=0.07)	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There	  was	  a	  significant	  correlation	  between	  baseline	  corrected	  with	  patients’	  spectacles	  and	  
pin	  hole)	   logMAR	  visual	  acuity	  and	  affected	  eye	  RNFL	  swelling	  (baseline	  affected	  eye	  RNFL	  
thickness-­‐baseline	  unaffected	  eye	  RNFL	  thickness0	  (p=0.04,	  r=0.23)	  (Figure	  5-­‐1)	  
Figure	  5-­‐1:	  Baseline	  LogMAR	  visual	  acuity	  was	  significantly	  correlated	  with	  RNFL	  swelling	  
 (in	  patients	  with	  recordable	  VEPs)	  
	  
Similarly,	  baseline	  affected	  eye	  RNFL	  thickness	  was	  predictive	  of	  a	  higher	   (worse)	  baseline	  
logmar	  when	  adjusted	  for	  the	  baseline	  unaffected	  eye	  RNFL	  thickness	  in	  a	  regression	  model	  
(p=0.02)	  	  
There	  was	  no	  significant	  correlation	  between	  baseline	  corrected	   logMAR	  visual	  acuity	  and	  
either	   affected	   eye	   macular	   volume	   or	   macular	   volume	   swelling	   (baseline	   affected	   eye	  
macular	  volume-­‐	  baseline	  unaffected	  eye	  macular	  volume)	  (p=0.23,	  r=	  -­‐0.13	  and	  p=	  0.13,	  r=	  
0.17	  respectively).	  
Patients	   with	   conduction	   block	   and	   absent	   affected	   eye	   VEPs	   (small	   check)	   had	   logMAR	  
visual	  acuity	  0.65	  higher	  (worse)	  than	  those	  with	  recordable	  VEPs	  at	  baseline	  (p=<0.001).	  
Amongst	   patients	  with	   recordable	  VEPs	   a	   1	  ms	   increase	   in	  VEP	   latency	   (small	   check)	  was	  




















There	   was	   no	   significant	   association	   between	   baseline	   logMAR	   visual	   acuity	   and	   VEP	  
amplitude	  (small	  check)	  (p=0.09).	  	  
Figure	  5-­‐2:	  Baseline	  LogMAR	  visual	  acuity	  was	  significantly	  associated	  with	  VEP	  latency	  
 
	  
Table	  5-­‐2:	  Univariate	  correlations	  with	  best	  corrected	  LogMAR	  visual	  acuity	  (affected	  eye)	  
MRI	  measures	   No.	  	   P	  value	   r	  =	  
Lesion	  length	   78	   0.34	   0.11	  
Optic	  nerve	  cross-­‐
sectional	  area	  (mm2)	  
73	   0.48	   -­‐0.08	  
Globe	  lesion	  distance	  
(T2weighted)	  (mm)	  
78	   0.53	   0.07	  
OCT	  measures	   	   	   	  
	  	  RNFL	  thickness	  (μm)	   86	   0.08	   0.19	  
	  	  RNFL	  swelling	  (μm)	   86	   0.04	   0.23	  
	  	  Macula	  volume	  (mm3)	   86	   0.23	   -­‐0.13	  
	  	  Macula	  swelling	  (mm£)	   86	   0.13	   0.17	  
VEP	  measures	   	   	   	  





















Small	  check	  VEP	  
amplitude*	  (μV)	  
42	   0.09	   0.07	  
Absent	  VEPS	   40	   <0.001	   0.31	  
	  
• In	  patients	  with	  recordable	  baseline	  VEPs	  
	  
Therefore,	  at	  baseline	   the	  predictors	  of	   logMAR	  visual	  acuity	  were	  baseline	  RNFL	   swelling	  
and	  absent	  VEPs	  as	  well	  as	  prolonged	  VEP	  latency	  in	  patients	  with	  recordable	  VEPs.	  	  
When	   both	   baseline	   RNFL	   swelling	   and	   absent	   affected	   eye	   VEPs	   were	   included	   in	   a	  
multivariate	   regression	  model	  only	  absent	  VEPs	  were	   independently	  predictive	  of	   logMAR	  
visual	  acuity	  at	  baseline	  (p=<0.001).	  	  	  
Likewise	  when	  both	  baseline	  RNFL	  swelling	  and	  baseline	  VEP	  latency	  (small	  check)	  for	  those	  
with	   recordable	   VEPs	   were	   included	   in	   the	   regression	   model,	   only	   VEP	   latency	   was	  
independently	  predictive	  of	  logMAR	  visual	  acuity	  at	  baseline	  (p=0.04).	  
In	   the	   regression	   model	   absent	   VEPs	   (small	   check)	   explained	   31%	   of	   the	   variability	   in	  
LogMAR	   visual	   acuity	   at	   baseline	   where	   as	   VEP	   latency	   in	   those	   with	   recordable	   VEPs	  
explained	   11%	   of	   the	   logMAR	   variability	   suggesting	   that	   absence	   of	   VEPs	   are	   the	   better	  
predictor	  of	  logMAR	  visual	  acuity	  at	  baseline.	  
There	  was	  no	  significant	  difference	  in	  low	  contrast	  letter	  scores	  (1.25%	  and	  2.5%)	  between	  
patients	  with	  absent	  and	  those	  with	  recordable	  VEPs.	  However	  mean	  affected	  eye	  FM-­‐Hue-­‐	  
100	  error	  score	  in	  patients	  with	  absent	  baseline	  VEPs	  was	  more	  than	  double	  that	  of	  patients	  
with	  recordable	  VEPs	  at	  baseline	  (1554	  versus	  679,	  p=<0.001).	  	  	  
In	  patients	  with	  recordable	  VEPs	  there	  was	  a	  significant	  negative	  correlation	  between	   low	  
contrast	   letter	   score	  at	  1.25%	  (p=0.03,	   r=-­‐0.33)	  and	  2.5%	  (p=0.02,	   r-­‐0.37)	  and	  VEP	   latency	  
but	  no	  significant	  correlation	  with	  VEP	  amplitude.	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Mean	   VEP	   latency	   and	   amplitude	   in	   patients	   with	   recordable	   VEPs	   were	   significantly	  
correlated	  with	   FM-­‐hue	   100	   error	   scores	   at	   baseline	   (p=0.008,	   r=0.41	   and	   p=0.02,	   r-­‐0.36	  
respectively).	  
5.6 Correlations	  with	  baseline	  RNFL	  swelling	  
There	  was	  a	  significant	  positive	  correlation	  between	  RNFL	  swelling	  with	  optic	  nerve	   lesion	  
length	  and	  lesional	  optic	  nerve	  cross-­‐sectional	  area	  at	  baseline	  (p=	  0.001,	  r=0.36	  and	  p=0.02,	  
r=0.28	   respectively)	   (See	   Figure 5-3	   and	   Figure 5-5).	   Conversely,	   there	   was	   a	   significant	  
negative	   correlation	   between	   baseline	   RNFL	   swelling	   and	   distance	   of	   the	   lesion	   from	   the	  
globe	  (p=0.002,	  r=-­‐0.34)	  (See	  Figure 5-4).	  
There	  was	  no	  significant	  association	  between	  baseline	  low	  contrast	  letter	  score	  (1.25%	  and	  
2.5%)	  and	  RNFL	  thickness/RNFL	  swelling/Macular	  volume.	  However,	  baseline	  FM-­‐Hue	  error	  
score	  was	  significantly	  associated	  with	  RNFL	  thickness	  and	  RNFL	  swelling	  (baseline	  affected	  
eye	  RNFL	   thickness	   –	   unaffected	   eye	  RNFL	   thickness)	   (p=0.05,	   r=0.21	   and	  p=0.03,	   r=	   0.23	  
respectively).	  
Table	  5-­‐3:	  Univariate	  correlations	  with	  RNFL	  swelling	  (affected	  eye)	  
MRI	  measures	   No.	  	   P	  value	   r	  =	  
Lesion	  length	  (mm)	   81	   0.001	   0.36	  
Optic	  nerve	  cross-­‐sectional	  
area	  (mm2)	  
73	   0.02	   0.28	  
Globe	  lesion	  distance	  (mm)	  
(T2weighted)	  
81	   0.002	   -­‐0.34	  
Visual	  function	  measures	   	   	   	  
	  	  LogMAR	  visual	  acuity	   86	   0.04	   0.23	  
	  2.5%	  low	  contrast	  letter	  
score	  
86	   0.40	   -­‐0.09	  
	  1.25%	  low	  contrast	  letter	  
score	  	  
86	   0.21	   -­‐0.14	  
	  	  FM-­‐100	  Hue	  total	  error	   86	   0.03	   0.23	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score	  
VEP	  measures	   	   	   	  
Absent	  VEPS	   40	   0.005	   0.3	  
	  
	  
Figure	  5-­‐3:	  Baseline	  RNFL	  swelling	  was	  significantly	  associated	  with	  lesion	  length	  
  
Figure	  5-­‐4:	  Baseline	  RNFL	   swelling	  was	  negatively	  associated	  with	  distance	  of	   the	   lesion	  





































Distance	  of	  lesion	  from	  the	  globe	  (mm)	  
 138 




Patients	  with	   absent	   baseline	   VEPs	   (small	   check)	   had	   on	   average	   a	   25	   μms	   greater	   RNFL	  
thickness	  than	  those	  with	  recordable	  VEPs	  (p=0.002)	  at	  baseline.	  	  
When	  lesion	  length,	  lesional	  optic	  nerve	  cross-­‐sectional	  area,	  distance	  of	  the	  lesion	  from	  the	  
globe	  and	  absent	  VEPs	  were	  all	   included	   in	  a	  multivariate	   regression	  model	   (adjusting	   for	  
the	   unaffected	   eye)	   the	   strongest	   independent	   predictor	   of	   baseline	   RNFL	   swelling	   was	  
lesion	  length	  (p=0.003	  r=0.28).	  Distance	  of	  the	  lesion	  from	  the	  globe	  and	  absent	  VEPs	  was	  
also	   independently	  predictive	  of	  RNFL	   swelling	  at	  baseline	   (p=0.02	   r=	   -­‐0.21	  and	  p=0.05	   r=	  
0.17	  respectively).	  
Patients	  with	  absent	  VEPs	  at	  baseline	  had	  borderline	  significantly	  longer	  symptomatic	  optic	  
nerve	  lesion	  by	  3.2	  mm	  than	  patients	  with	  recordable	  VEPs	  (p=0.06)	  
5.7 Discussion	  
Inflammation	   and	   conduction	   block	   appear	   to	   be	   the	  main	   determinants	   of	   visual	   loss	   at	  
baseline	   in	   acute	   optic	   neuritis	   as	   suggested	   by	   the	   significant	   associations	   of	   both	   RNFL	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affected	  eye.	  The	  degree	  of	  demyelination	  also	  appears	  to	  be	  an	  important	  determinant	  of	  
baseline	   visual	   function	   given	   the	   association	   between	   prolonged	   VEP	   latency	   in	   those	  
patients	  with	  recordable	  VEPs	  and	   logMAR	  visual	  acuity	  and	  colour	  vision.	  The	   lack	  of	  any	  
significant	   baseline	   associations	   between	   any	  of	   the	  MRI,	  OCT	  or	  VEP	  measurements	   and	  
low	   contrast	   letter	   scores	   is	   likely	   due	   to	   the	   floor	   effect	   of	   performing	   these	   tests	   at	  
baseline	  when	  visual	  function	  is	  most	  impaired.	  Conduction	  block	  on	  baseline	  VEP	  was	  the	  
best	  independent	  predictor	  of	  visual	  loss	  at	  baseline	  explaining	  31	  %	  of	  the	  variability	  and	  is	  
likely	   to	  be	  due	   to	  a	   combination	  of	   inflammation	  and	   inflammatory	  mediators	  as	  well	   as	  
demyelination.	  	  
The	  results	  are	  supportive	  of	  the	  findings	  by	  Youl	  et	  al	  1991	  who	  found	  that	  inflammation	  -­‐	  
as	  demonstrated	  by	  Gd-­‐DTPA	  leakage	  across	  the	  blood	  optic	  nerve	  barrier	  -­‐	  was	  associated	  
with	  conduction	  block	  and	  the	  clinical	  deficit	  (Youl	  et	  al.,	  1991a).	  	  
More	  surprisingly	  none	  of	  the	  MRI	  characteristics	  (including	  lesion	  length)	  were	  associated	  
with	   baseline	   visual	   acuity	   although	   patients	  with	   longer	   lesions	   on	  MRI	   (≥	   17.5mm)	   had	  
borderline	  worse	  colour	  vision	  at	  baseline.	   It	   should	  be	  noted	   that	   in	  my	  study	   the	   lesion	  
length	  was	   identified	  using	  a	  combination	  of	  the	  conventional	   fat-­‐suppressed	  T2-­‐weighted	  
2D-­‐TSE	   images	   and	   multi-­‐dynamic	   fat-­‐suppressed	   heavily	   T2-­‐weighted	   multi-­‐slice	   “single-­‐
shot”	   two-­‐dimensional	   TSE	   images	   rather	   than	   using	   gadolinium	   enhanced	   images	   of	   the	  
optic	  nerves.	  Previous	  studies	  have	  demonstrated	  an	  association	  between	   lesion	   length	  as	  
measured	   by	   the	   length	   gadolinium	   enhancement	   of	   the	   optic	   nerve	   and	   baseline	   visual	  
acuity	   (Hickman	   et	   al.,	   2004b;	   Kupersmith	   et	   al.,	   2002).	   In	   concordance	   with	   my	   results	  
Hickman	   et	   al	   2004	   did	   not	   find	   a	   significant	   association	   between	   lesion	   length	   on	   the	  
baseline	  FSE	  images	  and	  logMAR	  visual	  acuity.	  In	  that	  study	  the	  median	  lesion	  length	  was	  6	  
mm	   longer	   on	   the	   gadolinium-­‐enhanced	   images	   than	   the	   FSE	   images	   perhaps	   suggesting	  
that	   gadolinium	   enhancement	   of	   the	   optic	   nerve	   is	   a	   more	   sensitive	   method	   of	   imaging	  
acute	  inflammation	  in	  the	  optic	  nerve.	  Gadolinium	  enhancement	  may	  also	  be	  more	  specific	  
for	   inflammation	   and	   has	   been	   shown	   to	   correlate	   with	   the	   inflammatory	   infiltrate	   and	  
expansion	  of	  the	  extracellular	  space	  (Guy	  et	  al.,	  1992);	  on	  the	  other	  hand,	  fat	  saturated	  T2	  
weighted	   images	   demonstrate	   high	   signal	   as	   a	   result	   not	   only	   of	   vasogenic	   oedema	   and	  
inflammation	  but	  also	  axonal	  loss,	  extracellular	  water	  and	  gliosis.	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The	  location	  of	  the	  lesion	  did	  not	  appear	  to	  be	  an	  important	  determinant	  of	  baseline	  visual	  
loss	  as	  there	  was	  no	  association	  between	  distance	  of	  the	  lesion	  from	  the	  globe	  and	  baseline	  
visual	  acuity.	  	  
Despite	   the	   lack	   of	   association	   between	   MRI	   characteristics	   and	   baseline	   visual	   acuity,	  
longer	   and	  more	   anterior	   lesions	   on	   T2	   weighted	  MRI	   were	   significantly	   associated	   with	  
RNFL	  swelling	  at	  baseline.	  Longer	   lesions	  may	  be	  more	   likely	  to	  cause	  stasis	  of	  axoplasmic	  
flow	  leading	  to	  RNFL	  swelling	  proximal	  to	  the	  lesion.	  Equally,	  the	  more	  proximal	  the	  lesion	  
to	  the	  optic	  nerve	  head	  the	  more	   likely	  the	  extension	  of	   inflammation/oedema	  across	  the	  
lamina	  cribrosa	  into	  the	  RNFL.	  	  
Conduction	  block	  on	  baseline	  VEPs	  was	  also	  significantly	  associated	  with	  RNFL	  swelling	  and	  
there	  was	  also	  a	  borderline	  significant	  association	  with	  lesion	  length,	  again	   implicating	  the	  
degree	  of	  inflammation	  in	  the	  acute	  lesion	  with	  loss	  of	  function	  and	  conduction	  block.	  The	  
strongest	   independent	   predictor	   of	   RNFL	   thickness	   at	   baseline	  was	   lesion	   length,	   and	   the	  
extent	  of	  the	  lesion	  was	  more	  important	  than	  its	   location	  in	  predicting	  RNFL	  swelling.	  This	  
perhaps	   suggests	   that	   RNFL	   swelling	   is	   more	   often	   due	   to	   a	   secondary	   phenomenon	  






Chapter	  6 Trial	  results	  –	  Primary	  outcome	  measure	  
6.1 Patients	  
Patients	   were	   recruited	   between	   February	   2012	   and	   May	   2014,	   and	   final	   assessments	  
performed	   in	   December	   2014.	   86	   patients	   were	   randomly	   assigned	   to	   receive	   phenytoin	  
(n=42)	  or	  placebo	  (n=44)(Figure	  6-­‐1).	  The	  groups	  had	  similar	  baseline	  characteristics	  (Table	  
6-­‐1)	  There	  were	  however	  a	   slightly	  higher	  proportion	  of	  patients	   in	   the	  active	  group	  who	  
were	  prescribed	  corticosteroids.	  This	  may	  be	  due	  to	  the	  slightly	  worse	  baseline	  visual	  acuity	  
in	   the	   phenytoin	   compared	   the	   placebo	   group.	   There	  were	   only	   four	   patients	  who	   had	   a	  
pre-­‐existing	   diagnosis	   of	   multiple	   sclerosis;	   3	   of	   these	   were	   in	   the	   placebo	   group.	   One	  
patient	   from	   the	   placebo	   group	   was	   on	   disease	   modifying	   medication	   at	   the	   time	   of	  
randomization.	  Amongst	  the	  remainder	  of	  patients	  similar	  proportions	  of	  patients	  had	  ≥	  1	  
T2	   hyperintense	   MRI	   brain	   lesions	   in	   the	   phenytoin	   and	   placebo	   groups	   (73%	   and	   76%	  
respectively).	  	  13	  patients	  in	  the	  active	  group	  and	  11	  in	  the	  placebo	  group	  fulfilled	  McDonald	  
2010	  criteria	  for	  the	  diagnosis	  of	  MS	  on	  presentation.	  	  A	  further	  16	  went	  on	  to	  have	  relapses	  
during	  the	  trial	  follow	  up	  period	  (13	  of	  these	  were	  MS	  defining	  (7	  active,	  9	  placebo).	  
Only	  screening	  data	  was	  available	   for	  the	  patients	  who	  declined	  to	  participate	   in	  the	  trial.	  
However	   they	  were	   of	   similar	   age	   (mean	   age	   32)	   and	   sex	   (76%	   female)	  with	   comparable	  
visual	  acuity	  in	  the	  affected	  eye	  (mean	  logMAR	  visual	  acuity	  1.0)	  to	  the	  patients	  who	  were	  
recruited	   into	   the	   trial.	   	   Given	   the	   similar	   screening	   characteristics	   it	   is	   likely	   that	   the	  
findings	  of	  the	  trial	  are	  generalisable	  to	  all	  patients	  who	  matched	  the	  eligibility	  criteria.	  
The	  mean	  time	  from	  onset	  of	  visual	  loss	  to	  recruitment	  was	  8.2	  and	  8.1	  days	  respectively	  in	  
the	  phenytoin	  and	  placebo	  groups	  respectively.	  Given	  the	  mounting	  evidence	  that	  vitamin	  D	  
deficiency	  may	   be	   one	   of	   the	   environmental	   factors	   associated	  with	   an	   increased	   risk	   of	  
developing	  MS	  (Martinelli	  et	  al.,	  2014),	  baseline	  vitamin	  D	  levels	  were	  taken	  in	  41	  patients	  
(18	  phenytoin	  and	  23	  placebo).	  Baseline	  mean	  vitamin	  D	  levels	  were	  38.83	  nmol/L	  (active)	  
and	  40.22	  nmol/L	  (placebo)	  respectively.	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  Table	  6-­‐1:	  Baseline,	  clinical,	  structural	  and	  electrophysiological	  data	  
	   Phenytoin	  (n=42)	   Placebo	  (n=44)	  
Age	  (yrs.)	   33	  (8.2)	   35	  (9.1)	  
Women	   31	  (74%)	   32	  (73%)	  
Days	  from	  onset	  to	  
randomization	  	  
8.2	  (3.1)	   8.1	  (3.2)	  
Prescribed	  corticosteroids	   35	  (83%)	   33	  (75%)	  
Prior	  diagnosis	  of	  
multiple	  sclerosis	  
1	  (2%)	   3	  (7%)	  
≥	  1	  T2	  hyperintense	  MRI	  
brain	  lesion	  
32	  (73%)	   32	  (76%)	  
RNFL	  thickness	  affected	  
eye	  (μm)	  
130.6	  (46.4)	   125.2	  (43.4)	  
Macular	  volume	  (mm3)	   8.7	  (0.5)	   8.6	  (0.4)	  
LogMAR	  visual	  acuity	   1.11	  (0.54)	   1.07	  (0.6)	  
1.25%	  low	  contrast	  letter	  
score	  	  
0.07	  (0.5)	   0.45	  (3.0)	  
2.5%	  low	  contrast	  letter	  
score	  	  
0.21	  (1.2)	   0.77	  (3.8)	  
FM	  100-­‐Hue	  total	  error	  
score	  
1066	  (764.6)	   1139	  (775.5)	  
VEP	  P100	  latencya	  
	  (Small	  check,	  ms)	  
167.9	  (35.2)	   167.6	  (35.8)	  
VEP	  P100	  amplitudea	  
(small	  check,	  μV)	  	  
2.8	  (3.8)	   3.0	  (3.8)	  
Optic	  nerve	  cross-­‐
sectional	  area	  (mm2)	  
7.60	  (1.55)	   7.48	  (1.43)	  
Lesion	  length	  (mm)	   17	  (8.1)	   18	  (7.1)	  
Data	  are	  mean	  (SD)	  for	  the	  affected	  eye,	  or	  number	  (%)	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aTwenty	  subjects	   in	  each	  group	  had	  affected	  eye	  vision	  too	  poor	   to	  measure	  VEP,	  but	   the	  
baseline	  affected	  eye	  VEP	  was	  not	  used	  in	  analyses.	  
5	  patients	  were	   lost	   to	   follow	  up,	   leaving	  81	  who	  attended	   for	  assessment	  of	   the	  primary	  
outcome	  at	  6	  months	  (39	  phenytoin,	  42	  placebo).	  Of	  these,	  10	  in	  the	  phenytoin	  group	  were	  
withdrawn	  from	  treatment	  due	  to	  rash	  after	  a	  mean	  of	  18.4	  (SD	  14.98)	  days,	  but	  continued	  
to	   be	   followed	   up	   (Figure	   6-­‐1).	   The	   remaining	   29	   in	   the	   phenytoin	   group	   were	   serum	  
adherent	  (mean	  serum	  phenytoin	  concentration	  8.57	  (SD	  5.40)mg/L).	  The	  combined	  overall	  




























188	  were	  screened	  
77	  did	  not	  meet	  inclusion	  
criteria	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
28	  visual	  acuity	  better	  than	  
6/9	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11	  more	  than	  14	  days	  since	  
symptom	  onset	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  bilateral	  optic	  neuritis	  	  	  	  	  	  	  	  	  	  	  
3	  had	  previous	  optic	  
neuritis	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  on	  long-­‐term	  
immunosuppression	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9	  diagnosis	  unclear	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20	  had	  an	  alternative	  
diagnosis	  *	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25	  did	  not	  consent	  
86	  underwent	  randomization	  
42	  assigned	  to	  
receive	  phenytoin	  
44	  assigned	  to	  
receive	  placebo	  
42	  included	  in	  
the	  intention	  to	  
treat	  analysis	  
39	  included	  in	  
the	  intention	  to	  
treat	  analysis	  
10	  discontinued	  
study	  treatment	  	  





treatment,	  	  	  
2	  were	  lost	  
to	  follow	  up	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Alternative	  diagnosis	  were	  functional	  visual	  loss	  (n=4),	  sarcoidosis	  (n=3),	  migraine	  with	  aura	  
(n=2),	  posterior	  scleritis	   (n=3),	  Leber	  hereditary	  optic	  neuropathy	  (n=2),	  compressive	  optic	  
nerve	  lesions	  (n=2),	  uveitis	  (n=1),	  toxic	  optic	  neuropathy	  (n=1),	  neuroretinitis	  (n=1)	  central	  
serous	  retinopathy	  (n=1)	  and	  optic	  nerve	  drusen	  (n=1)	  
6.2 Intention	  to	  treat	  comparison	  –	  Primary	  outcome	  measure	  
Measurements	  of	  the	  thickness	  of	  the	  RNFL	  and	  of	  macular	  volume	  remained	  stable	  in	  the	  
unaffected	  eye,	  with	  no	  significant	  change	  between	  baseline	  and	  6	  months	  (Table	  6-­‐2)	  
Table	  6-­‐2:	  Stability	  of	  measurements	  in	  the	  unaffected	  eye	  in	  the	  phenytoin	  and	  placebo	  
groups	  
	   Phenytoin	   Placebo	  






































































Data	  are	  means	  and	  SD.	  
In	  the	  placebo	  group,	  the	  mean	  thickness	  of	  the	  RNFL	  in	  the	  affected	  eye	  fell	  by	  24.1	  μm	  (or	  
24%)	   after	   6	   months	   when	   compared	   with	   the	   baseline	   unaffected	   eye	   (Figure	   6-­‐2).	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Proportionately,	   at	   6	   months,	   the	   temporal	   sector	   RNFL	   had	   the	   greatest	   reduction	   in	  
thickness	  compared	  to	  the	  unaffected	  eye	  in	  the	  placebo	  group. 
Figure	  6-­‐2:	  Atrophy	  of	  overall	  and	  sectoral	  RNFL	  thickness	  at	  6	  months	  in	  the	  affected	  eye	  
(placebo	  arm	  only)	  
 	  
	  In	  the	  phenytoin	  group	  the	  mean	  affected-­‐eye	  thickness	  fell	  16.7	  μm	  (17%)	  after	  6	  months	  
compared	   with	   the	   baseline	   unaffected	   eye,	   giving	   a	   significantly	   higher	   mean	   6-­‐month	  
affected	  eye	  RNFL	  thickness	  in	  the	  phenytoin	  group	  compared	  to	  placebo	  (Figure	  6-­‐3).	  	  The	  
ITT	  adjusted	  phenytoin	  -­‐	  placebo	  mean	  6-­‐month	  affected	  eye	  RNFL	  difference	  was	  7.2	  μm	  














Mean	  RNFL	   Temporal	  RNFL	   Nasal	  RNFL	   Superior	  RNFL	   Inferior	  RNFL	  
Mean	  percentage	  reduclon	  in	  6	  mth	  mean	  and	  sectoral	  
RNFL	  thickness	  compared	  to	  corresponding	  
measurements	  in	  the	  baseline	  unaﬀected	  eye	  in	  the	  
placebo	  group	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Figure	   6-­‐3:	   Scatter	   plots	   of	   RNFL	   thickness	   in	   the	   baseline	   unaffected	   eye	   and	   6	  month	  
affected	  eye	  in	  the	  phenytoin	  and	  placebo	  groups	  
	  
	  
At	  6	  months	  superior	  and	  nasal	  sector	  RNFL	  thicknesses	  were	  significantly	  greater	  the	  active	  
group	   (p=0.005	   and	   p=0.058	   respectively)	   There	   was	   no	   significant	   difference	   in	   the	  
temporal	  sector	  or	  inferior	  sectors	  (p=0.39	  and	  p=0.22	  respectively	  (Table	  6	  -­‐3)	  
Mean	  6-­‐month	  affected	  eye	  MV	  fell	  compared	  to	  the	  baseline	  unaffected	  eye	  by	  0.6	  mm3	  
(7%)	  and	  0.4	  (4%)	  in	  placebo	  and	  phenytoin	  groups	  respectively,	  giving	  a	  significantly	  higher	  
mean	  6-­‐month	  affected	  eye	  MV	  in	  the	  phenytoin	  group	  compared	  to	  placebo	  (Figure	  6-­‐4)	  
The	   ITT	   adjusted	   phenytoin-­‐placebo	   mean	   6-­‐month	   affected	   eye	   difference	   in	   macular	  
volume	  was	  0.2	  mm3	   (95%	  CI	  0.1,	  0.3;	  p=0.005),	   a	  34%	  beneficial	   treatment	  effect.	   There	  
was	  a	  significant	  phenytoin-­‐placebo	  treatment	  effect	  on	  macular	  volume	  when	  adjusted	  for	  
the	  baseline	  affected	  eye.	   	   Segmentation	  of	   the	   retinal	   layers	  had	  not	  been	  performed	  at	  
the	  time	  of	  writing	  this	  thesis	  but	  will	  be	  performed	  retrospectively	  and	  will	  be	  the	  subject	  
























Figure	   6-­‐4:	   Scatter	   plots	   of	   macular	   volume	   in	   the	   baseline	   unaffected	   and	   6	   month	  
affected	  eye	  in	  the	  active	  and	  placebo	  groups	  
	  
Exploratory	  analyses	  	  
Mean	  adjusted	  active-­‐placebo	  difference	  in	  RNFL	  thickness	  in	  the	  affected	  eye	  was	  similar	  in	  
patients	   who	   discontinued	   treatment	   due	   to	   rash	   compared	   to	   those	   who	   continued	  
treatment	  for	  the	  full	  three	  months	  (8.3	  µm,	  95%	  CI	  1.96,18.52).	  	  
There	  was	  no	  statistical	  difference	  in	  the	  treatment	  effect	  (on	  the	  primary	  analysis)	  between	  
participants	  with	   normal	   (within	   normal	   limits	   for	   patient’s	   age)	   and	   abnormal	   brain	  MRI	  

































Table	  6-­‐3:	  Intention	  to	  treat	  comparison	  of	  primary	  endpoints	  at	  six	  months	  
	  















































































Data	  are	  mean	  (SD)	  
¶	  Pre-­‐specified	  adjustment	   for	  baseline	  unaffected	  value,	  centre,	  days	  between	  onset	  and	  
baseline,	  days	  between	  steroid	  and	  baseline	  
6.3 Relapses	  
In	  the	  intention	  to	  treat	  comparison	  seven	  patients	  (17%)	  suffered	  a	  further	  demyelinating	  
relapse	  during	  the	  6-­‐month	  follow	  up	  period	  in	  the	  phenytoin	  group	  and	  nine	  in	  the	  placebo	  
group	   (21%).	   This	   difference	   was	   not	   statistically	   significant	   (p=	   0.65).	   There	   was	   no	  
significant	   difference	   in	   time	   to	   second	   demyelinating	   relapse	   between	   the	   two	   groups	  
(logrank	  test	  p=	  0.608)	  (Figure	  6-­‐5).	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Figure	  6-­‐5:	  Kaplan	  Meier	  curves	   for	   time	  to	  second	  demyelinating	   relapse	  during	   the	  six	  
month	  follow	  up	  period	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6.4 Per	  protocol	  comparison	  -­‐	  primary	  end	  point	  	  
	  29	   of	   the	   42	   patients	   in	   the	   phenytoin	   patients	   in	   the	   phenytoin	   group	   were	   serum	  
compliant	  as	  defined	  by	  a	  1	  month	  serum	  phenytoin	   level	  of	  >0.	  For	   the	  29	  patients	  who	  
were	   serum	   compliant	   the	  mean	   phenytoin	   concentration	  was	   7mg/L,	   SD	   5.9.	   Below	   is	   a	  
histogram	  of	  serum	  phenytoin	  levels	  at	  1	  month.	  
Figure	  6-­‐6:	  Histogram	  of	  1-­‐month	  serum	  phenytoin	  levels	  in	  the	  active	  group	  
 
	  
*	  The	  first	  bar	  contains	  one	  patient	  with	  a	  level	  of	  1	  mg/L	  and	  seven	  with	  0mg/L	  
**	  6	  patients	  in	  the	  active	  group	  had	  missing	  serum	  phenytoin	  levels	  at	  one	  month	  (3	  were	  
lost	  to	  follow	  up	  and	  3	  results	  were	  missing)	  
Treatment	  effects	  on	  the	  primary	  outcome	  measure	  of	  the	  per	  protocol	  comparison	  echoed	  
those	  of	   the	   intention	   to	   treat	   analysis	   and	   the	   adjusted	   active–placebo	  difference	   in	   the	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mean	   6	  month	   affected	   eye	   RNFL	   thickness	   of	   7.4	   μm	   (p=0.03)(Table	   6-­‐4).	   Sectoral	   RNFL	  
analysis	  demonstrated	  similar	  significant	   treatment	  effects	  on	  the	  superior	  RNFL	  quadrant	  
thickness	   (p=	   0.007)	   in	   the	   phenytoin	   adherent	   group.	   There	   were	   also	   near	   significant	  
treatment	  effects	  on	  nasal	   quadrant	  RNFL	   thickness	   (p=0.07)	  but	  no	   significant	  effects	  on	  
temporal	  or	  inferior	  quadrant	  RNFL	  thickness	  (p=0.36	  and	  0.26	  respectively)	  (Table	  6-­‐4).	  
	  Similarly,	  treatment	  affects	  on	  mean	  total	  macular	  volume	  in	  the	  per	  protocol	  comparison	  
mirrored	  the	  ITT	  analysis	  with	  an	  adjusted	  active-­‐placebo	  6-­‐month	  macular	  volume	  was	  0.2	  
mm3	  higher	  in	  the	  phenytoin	  group	  compared	  to	  placebo	  (p=0.01)	  (Table	  6-­‐4)	  
Table	  6-­‐4:	  Per	  protocol	  comparison	  of	  the	  primary	  endpoints	  at	  6	  months	  




























































































Data	  are	  mean	  (SD)	  
¶	  Pre-­‐specified	  adjustment	   for	  baseline	  unaffected	  value,	  centre,	  days	  between	  onset	  and	  
baseline,	  days	  between	  steroid	  and	  baseline	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There	  was	  no	  significant	  correlation	  between	  time	  to	  initiation	  of	  treatment	  and	  mean	  six-­‐
month	  RNFL	  thickness	  in	  the	  phenytoin	  adherent	  patients(r=0.07,	  p=0.73).	  
Figure	  6-­‐7:	  Scatter	  plot	  of	  mean	  RNFL	  atrophy	  at	  6	  months	  in	  the	  affected	  eye	  against	  1-­‐
month	  serum	  phenytoin	  	  
	  
6.5 Relapses	  
In	  the	  per	  protocol	  comparison	  5	  patients	  in	  the	  phenytoin	  group	  (17%)	  and	  9	  in	  the	  placebo	  
group	   (21%)	   suffered	   a	   further	   demyelinating	   relapse.	   Again	   this	   difference	   was	   not	  
statistically	  significant	  (p=0.7).	  The	  per	  protocol	  log	  rank	  test	  for	  time	  to	  relapse	  was	  p=0.58	  
6.6 Adverse	  Events	  
Treatment	   with	   phenytoin	   was	   generally	   well	   tolerated	   and	   was	   not	   associated	   with	  
abnormalities	  in	  the	  blood	  count	  or	  liver	  function.	  We	  did	  not	  note	  any	  acute	  deterioration	  
of	  vision	  or	  other	  neurological	   function	  that	  might	  be	  attributed	  to	  conduction	  block	  from	  
inhibition	   of	   sodium	   currents,	   or	   any	   rebound	   deterioration	   upon	   withdrawal	   of	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treatment—effects	   that	  had	  previously	  been	   thought	   to	  potentially	   limit	   the	  use	  of	   drugs	  
acting	  on	  this	  target	  in	  demyelinating	  disorders.	  Only	  one	  participant	  had	  a	  severe	  adverse	  
reaction—a	  skin	  rash—attributable	  to	  phenytoin,	  but	  a	  further	  nine	  participants	  developed	  
minor,	  self-­‐limiting	  skin	  rashes	  and	  were	  withdrawn	  from	  treatment	  by	  the	  investigators	  as	  
stipulated	  by	  the	  trial	  protocol.	  Similar	  proportions	  of	  patients	  in	  the	  phenytoin	  and	  placebo	  
groups	  had	  adverse	  events,	  and	  serious	  adverse	  events	  were	  not	  attributable	  to	  phenytoin	  
with	  the	  exception	  of	  a	  severe	  rash	   in	  one	  patient.	   (Table	  6-­‐5,Table	  6-­‐6)	  A	  higher,	  but	  not	  
significant	   proportion	   of	   patients	   discontinued	   the	   study	   medication	   due	   to	   an	   adverse	  
event	  in	  the	  active	  group	  (due	  to	  skin	  rash	  in	  all	  cases).	  	  
Table	  6-­‐5:	  Adverse	  events	  
	  
Adverse	  Events	   Phenytoin	   Placebo	  
At	  least	  one	  adverse	  event	   34	  (81)	   40	  (91)	  
	  
At	  least	  one	  adverse	  event	  
leading	  to	  discontinuation	  
of	  study	  medication	  
10	  (24)	   3	  (7)	  
	  
Any	  serious	  adverse	  event	   5	  (12)	   2	  (5)	  
	  
Any	  event	  leading	  to	  
death	  
0	   0	  
Mean	  number	  (range)	  of	  












Table	  6-­‐6:	  Serious	  adverse	  events	  
	  
	   Phenytoin	   Placebo	  
	  
Breast	  Malignancy	   1	   0	  
Dilated	  superior	  
ophthalmic	  vein	  seen	  on	  






Appendicitis	   2	   0	  
Cellulitis	   0	   1	  
Severe	  rash	   1	   0	  
Congenital	  malformation	   0	   1	  
	  
Data	  are	  number	  of	  serious	  adverse	  events	  
6.7 Discussion	  
The	  main	  finding	  in	  this	  phase	  2	  clinical	  trial	   is	  that	  treatment	  with	  phenytoin	  protects	  the	  
RNFL	   and	  macula	   from	   degeneration	   after	   acute	   optic	   neuritis.	   The	   characteristics	   of	   the	  
placebo	  and	  phenytoin	  groups	  at	  baseline	  were	  comparable	  and	  were	  typical	  of	  acute	  optic	  
neuritis.	   Measures	   of	   visual	   function	   at	   baseline,	   in	   particular	   low	   contrast	   letter	   scores,	  
were	   worse	   in	   the	   phenytoin	   group	   and	   baseline	   RNFL	   swelling	   was	   greater	   than	   in	   the	  
placebo	  group.	  This	  could	  be	  interpreted	  in	  several	  ways	  1)	  Firstly,	  given	  that	  lower	  baseline	  
low	  contrast	  acuity	  is	  predictive	  of	  lower	  RNFL	  thickness	  at	  6	  months	  (Henderson	  et	  al	  2010)	  
our	   results	   could	   actually	   be	   conservative	   and	   therefore	   all	   the	   more	   consistent	   with	   a	  
neuroprotective	   treatment	   effect	   of	   phenytoin	   2)	   Secondly,	   that	   higher	   levels	   of	  
inflammation	  at	  baseline	  (as	  reflected	  by	  greater	  RNFL	  swelling)	  in	  the	  phenytoin	  group	  lead	  
to	  greater	  levels	  of	  astrogliosis	  at	  6	  months	  which	  was	  reflected	  in	  a	  ‘falsely’	  higher	  6	  month	  
RNFL	  thickness	  in	  the	  phenytoin	  group.	  Nevertheless,	  if	  this	  had	  occurred	  one	  would	  expect	  
baseline	  RNFL	  thickness	  in	  the	  affected	  eye	  to	  be	  correlated	  with	  6	  month	  affected	  eye	  RNFL	  
thickness	  and	   this	  was	  not	   the	   case	   (r=0.13	  p=	  0.25)	  3)	  Thirdly	   that	  phenytoin	  exerted	  an	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anti-­‐inflammatory	  effect	  that	  reduced	  inflammatory	  axonal	  transaction	  and	  thus	  conferred	  
secondary	  protection	  of	  axons.	  However,	  in	  this	  case	  one	  would	  also	  expect	  corticosteroids	  
to	  be	  neuroprotective	  in	  optic	  neuritis	  and	  results	  of	  previous	  studies	  have	  suggested	  they	  
are	  not	  (Naismith	  et	  al.,	  2009a;	  Hickman	  et	  al.,	  2003).	  	  	  
The	  loss	  of	  thickness	  of	  the	  RNFL	  in	  the	  placebo	  group	  after	  6	  months	  was	  consistent	  with	  
previous	  natural	   history	   studies	   (Henderson	  et	   al.,	   2010;	  Costello	   et	   al.,	   2008).	   Treatment	  
with	  phenytoin	  reduced	  this	  loss	  by	  30%,	  and	  there	  was	  a	  34%	  treatment	  effect	  on	  the	  loss	  
of	   macular	   volume.	   These	   results	   suggest	   that	   phenytoin	   protects	   the	   compartment	  
comprising	   the	  retinal	  ganglion	  cells	   (which	  make	  up	  34%	  of	  macular	  volume	  (Sakai	  et	  al.,	  
2011)	  and	  their	  axons	  in	  the	  RNFL.	  It	  should	  be	  noted	  that	  OCT	  measures	  of	  RNFL	  thickness	  
do	   not	   allow	   us	   to	   directly	   visualize	   the	   surviving	   axons	   therefore	  we	   can	   only	   infer	   that	  
increased	   RNFL	   thickness	   in	   the	   phenytoin	   group	  was	   due	   to	   a	   neuroprotective	   effect	   on	  
axonal	  loss.	  An	  alternative	  explanation	  could	  be	  that	  the	  increased	  mean	  RNFL	  thickness	  at	  6	  
months	   in	   the	   phenytoin	   group	   was	   due	   to	   higher	   levels	   of	   astrogliosis	   given	   that	   the	  
phenytoin	  group	  had	  worse	  visual	  function	  and	  more	  RNFL	  swelling	  at	  baseline.	  However	  as	  
discussed	  above	  if	  we	  were	  to	  assume	  that	  higher	  levels	  RNFL	  inflammation	  at	  baseline	  led	  
to	   increased	  astrogliosis	  at	  6	  months	   then	  there	  should	  be	  a	  positive	  correlation	  between	  
the	  baseline	  and	  6	  month	  affected	  eye	  RNFL	  thickness	  which	  was	  not	  the	  case	  (see	  above).	  	  
In	   the	   future	   it	  may	  be	  possible	   to	  use	  techniques	  such	  as	  detection	  of	  apoptosing	  retinal	  
cells	  (DARC)	  to	  directly	  visualise	  the	  amount	  of	  retinal	  ganglion	  cell	   loss.	  This	  could	  give	  us	  
pathological	   insights	   into	   the	   timing	   of	   RGC	   loss	   after	   optic	   neuritis	   as	   well	   as	   allowing	  
greater	  pathological	  specificity	  when	  testing	  neuroprotective	  treatments	  (Normando	  et	  al.,	  
2015).	  	  
These	  results	  are	  consistent	  with	  the	  neuroprotective	  effect	  of	  sodium	  channel	  blockade	  in	  
experimental	  models	  of	  optic	  neuritis	  and	  EAE	  (Garthwaite	  et	  al.,	  2002;	  Lo	  et	  al.,	  2003)	  and	  
support	  the	  ‘sodium	  hypothesis’	  of	  neuroaxonal	  loss	  within	  the	  context	  of	  acute	  relapses	  in	  
vivo.	  Based	  on	  these	  results	  it	  is	  not	  possible	  to	  elucidate	  whether	  treatment	  with	  phenytoin	  
had	  an	  additional	  anti-­‐inflammatory	  effect	  by	  blocking	  Nav1.6	  channels	  on	  macrophages	  and	  
microglia	  as	  well	  as	  along	  retinal	  ganglion	  cell	  axons	  but	  could	  have	  conceivably	  done	  both.	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Although	   there	  were	   significant	   treatment	   effects	   on	   superior	   (p=0.005)	   and	   nasal	   sector	  
RNFL	   thickness	   (p=0.058),	   the	   temporal	   (p=0.37)	   and	   inferior	   sector	   thicknesses	   (p=0.26)	  
were	  not	  significantly	  preserved.	  Costello	  et	  al	   found	  that	  the	  rate	  of	  RNFL	  thinning	  varies	  
between	  different	  sectors	  with	  significant	  thinning	  in	  the	  temporal	  sector	  occurring	  as	  early	  
as	  2	  months	  after	  optic	  neuritis	  (Costello	  et	  al.,	  2008).	  Reductions	  in	  superior	  RNFL	  thickness	  
occurred	  after	   longer	  periods	  of	   three	  months	  or	  more.	   The	   temporal	   sector	  of	   the	  RNFL	  
receives	  small	  diameter	  nerve	  fibres	  from	  the	  fovea	  via	  the	  papillomacular	  bundle	  and	  may	  
be	  more	  susceptible	  to	  early	  damage	  possibly	  due	  to	  the	  selective	  early	  loss	  of	  small	  axons.	  
In	   support	  of	   this	   Evangelou	  et	   al	   2001	   found	   selective	  atrophy	  of	   smaller	  neurons	   in	   the	  
parvocellular	  layer	  in	  the	  lateral	  geniculate	  nucleus	  in	  a	  post	  mortem	  study	  of	  eight	  patients	  
with	  multiple	  sclerosis.	  They	  postulated	  that	  smaller	  axons	  may	  be	  preferentially	  susceptible	  
to	  injury	  in	  multiple	  sclerosis	  (Evangelou	  et	  al.,	  2001).	  	  
The	  lack	  of	  treatment	  effect	  on	  temporal	  sector	  RNFL	  thickness	  could	  suggest	  that	  either	  1)	  
an	  even	  earlier	  time	  window	  of	  recruitment	  is	  required	  to	  prevent	  degeneration	  of	  smaller	  
axons	  in	  the	  parvocellular	  pathway	  or	  2)	  that	  the	  neuroprotective	  effect	  of	  sodium	  channel	  
blockade	   did	   not	  manifest	   during	   the	   initial	   hyper	   acute	   inflammatory	   period	   after	   optic	  
neuritis	  but	  rather	  during	  the	  subacute	  or	  even	  post-­‐inflammatory	  period.	  This	  could	  explain	  
the	   lack	   of	   correlation	   between	   RNFL	   thickness	   and	   time	   to	   initiation	   of	   treatment.	  
Alternatively,	   because	   all	   patients	  were	   recruited	  within	   a	   very	  narrow	   time	  window,	   this	  
may	  not	  have	  allowed	  for	  correlations	  with	  time	  to	  be	  seen.	  	  	  
There	   was	   one	   significant	   outlier	   in	   the	   phenytoin	   group	   who	   developed	   severe	   RNFL	  
thinning	  despite	  high	  phenytoin	  levels	  and	  it	  may	  be	  that	  some	  patients	  have	  a	  particularly	  
intense	  and	  destructive	   inflammatory	  period	   that	   is	  difficult	   to	   treat	  with	  neuroprotective	  
therapy	  even	  if	  instituted	  early.	  	  
It	  is	  also	  important	  to	  note	  that	  this	  particular	  patient	  did	  have	  some	  atypical	  features	  with	  
severe	   baseline	   visual	   loss	   (no	  perception	  of	   light)	   and	   virtually	   no	   visual	   recovery	  with	   a	  
normal	   MRI	   brain.	   Despite	   being	   investigated	   extensively	   no	   other	   cause	   for	   the	   optic	  
neuritis	  was	  found.	  Although,	  aquaporin	  4	  antibodies	  were	  negative	  it	  cannot	  be	  completed	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excluded	  that	  this	  patient	  had	  a	  different	  pathological	  process	  causing	  the	  optic	  neuritis	  not	  
amenable	  to	  neuroprotection	  with	  sodium	  channel	  blockade.	  
The	   fact	   that	   there	   was	   no	   significant	   difference	   in	   the	   occurrence	   of	   a	   second	  
demyelinating	   relapse	   between	   the	   groups	   would	   suggest	   that	   phenytoin	   did	   not	   exert	  
immunomodulatory	  effects	  in	  our	  cohort	  of	  patients.	  However,	  the	  relatively	  small	  number	  
of	   relapses	   and	   short	   follow	   up	   period	   of	   6	   months	   means	   that	   it	   is	   difficult	   to	   draw	  
definitive	  conclusions	  -­‐	  this	  would	  need	  to	  be	  investigated	  further	  in	  larger	  phase	  three	  trials	  
with	  longer	  follow	  up	  periods.	  
The	  conclusions	  in	  the	  present	  study	  may	  be	  affected	  by	  a	  relatively	  high,	  31%	  rate	  of	  loss	  to	  
follow	  up,	  withdrawal	  from	  treatment	  and	  non-­‐adherence	  in	  the	  phenytoin	  group.	  This	  was	  
largely	   due	   to	   an	   unusually	   high	   incidence	   of	   rashes	   in	   our	   cohort	   of	   patients.	  While	   this	  
figure	   may	   affect	   the	   statistical	   power	   of	   the	   study,	   the	   robustness	   of	   the	   results	   is	  
supported	  by	  the	  agreement	  between	  the	  intention	  to	  treat	  and	  per	  protocol	  analyses,	  and	  
the	   consistency	   of	   treatment	   effects	   in	   the	   macula,	   RNFL	   and	   optic	   nerve.	   Mean	   serum	  
phenytoin	  levels	  were	  7mg/L	  in	  the	  phenytoin	  group	  which	  may	  be	  ‘sub	  therapeutic’	  and	  are	  
lower	  than	  the	  levels	  that	  were	  neuroprotective	  in	  experimental	  models	  (Lo	  et	  al.,	  2003)	  as	  
well	  as	  the	  levels	  regarded	  as	  therapeutic	  in	  epilepsy	  (10-­‐20	  mgL/L).	  However,	  it	  should	  be	  
stated	   that	   the	   ‘therapeutic’	   level	   of	   phenytoin	   in	   optic	   neuritis	   has	   not	   yet	   been	   clearly	  
defined.	  It	  is	  possible	  that	  a	  greater	  treatment	  effect	  may	  have	  been	  observed	  if	  not	  for	  the	  
aforementioned	  problems.	  	  
	  It	   is	   also	   important	   to	   consider	   the	   relatively	   high	   percentage	   of	   patients	   who	   received	  
corticosteroids	   at	   presentation,	   in	   case	   this	   treatment	   affected	   the	   baseline	   OCT	  
measurements	   or	   the	   final	   outcome.	   Against	   this	   possibility	   are	   the	   facts	   that	  
measurements	  of	  the	  RNFL	  and	  of	  macular	  volume	  remained	  stable	  in	  the	  unaffected	  eye	  in	  
both	  the	  phenytoin	  and	  placebo	  groups,	  and	  that	  in	  previous	  reports	  corticosteroids	  did	  not	  
affect	  atrophy	  of	  the	  RNFL	  (Naismith	  et	  al.,	  2009b)	  or	  optic	  nerve	  (Hickman	  et	  al.,	  2003),	  nor	  
visual	   recovery	  after	  optic	  neuritis	   (Beck	  et	  al.,	  1992a).	   	  Care	  was	  also	   taken	  to	  adjust	   the	  
calculation	  of	  outcome	  for	  the	  use	  and	  timing	  of	  corticosteroids.	  	  
 159 
Another	  potential	  confounding	  factor	  is	  the	  slightly	  higher	  proportion	  of	  patients	  with	  a	  pre-­‐
existing	   diagnosis	   of	   MS	   in	   the	   placebo	   group.	   This	   could	   theoretically	   increase	   the	  
likelihood	  of	  a	  previous	  episode	  of	  subclinical	  optic	  neuritis	  and	  preexisting	  RNFL	  thinning	  in	  
the	  affected	  eye.	  However,	  the	  absolute	  numbers	  of	  patients	  were	  small	  (3	   in	  the	  placebo	  
group),	  all	  of	  whom	  had	  early	  relapsing	  remitting	  MS	  with	  no	  evidence	  of	  subclinical	  optic	  
neuritis	  in	  the	  fellow	  eye	  so	  the	  likelihood	  of	  this	  would	  seem	  low.	  Again	  care	  was	  taken	  to	  











Chapter	  7 Trial	  results-­‐	  Secondary	  Endpoints	  
7.1 Intention	  to	  treat	  comparison	  
7.1.1 	  MRI	  
Lesional	  Optic	  nerve	  cross-­‐sectional	  area	  
Consistent	   with	   previous	   longitudinal	   MRI	   studies	   there	   was	   initial	   swelling	   at	   baseline	  
followed	  by	  subsequent	  atrophy	  at	  6	  months	  in	  the	  affected	  eye	  (Table	  7.1).	  There	  was	  no	  
significant	   change	   in	   the	   mean	   cross-­‐sectional	   area	   of	   unaffected	   eye	   in	   either	   the	  
phenytoin	  (p=0.30)	  or	  placebo	  group	  (p=0.27).	  	  In	  the	  placebo	  group	  the	  mean	  affected	  eye	  
cross-­‐sectional	   area	   fell	   by	   0.84	  mm2	   compared	  with	   the	   baseline	   unaffected	   eye.	   	  Mean	  
cross-­‐sectional	  area	   in	   the	  unaffected	  eye	  was	  consistent	  with	   recent	  publications	  on	  MRI	  
measurements	  of	  the	  optic	  nerve	  (Yiannakas	  et	  al.,	  2013).	  
There	  was	  a	  borderline	  significant	  treatment	  effect	  on	  optic	  nerve	  cross-­‐sectional	  area,	  with	  
an	   adjusted	   active-­‐placebo	   difference	   of	   0.4	  mm2	   (p=0.061)	   (Table	   7-­‐2)	   a	   38%	   treatment	  
effect.	  	  




Bars	  are	  standard	  errors	  around	  unadjusted	  group	  means	  
A	  number	  of	  scans	  was	  excluded	  due	  to	  significant	  motion	  artifact	  that	  precluded	  accurate	  
cross-­‐sectional	   area	   measurements	   These	   were	   very	   plausibly	   missing	   at	   random	   and	  
unlikely	   to	   cause	   bias	   The	   outcome	   analysis	   included	   only	   patients	   with	   recordable	  
measurements	  in	  both	  the	  baseline	  unaffected	  eye	  and	  the	  six	  month	  affected	  eye.	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Data	  are	  mean	  (SD)	  (n=number	  of	  scans)	  
Optic	  nerve	  lesion	  length	  
The	  optic	  nerve	  lesion	  was	  identified	  at	  baseline	  in	  96%	  of	  the	  patients	  who	  had	  an	  MRI	  scan	  
using	  a	  combination	  of	   the	  two	  T2	  sequences.	   In	   the	  three	  patients	   in	  whom	  the	  baseline	  
optic	   nerve	   lesion	   was	   not	   visualized	   (1	   placebo	   and	   2	   phenytoin)	   clinical	   and	   VEP	  
measurements	  were	  consistent	  with	  acute	  demyelinating	  optic	  neuritis	  and	  in	  2	  of	  these	  the	  
lesion	  was	  subsequently	  seen	  at	  6	  months.	  Mean	  lesion	  length	  was	  17.23	  (SD	  8.11)	  mm	  in	  
the	  phenytoin	  group	  and	  18.00	  (SD	  7.11)	  in	  the	  placebo	  group	  at	  baseline	  	  (Table	  7-­‐1).	  	  
Intention	  to	  treat	  comparison	  showed	  no	  significant	  difference	  in	  lesion	  length	  between	  the	  
groups	   at	   6	   months	   (mean	   adjusted	   active-­‐placebo	   difference	   -­‐2.45	   mm,	   p=0.29)	   (Table	  
7-­‐1).	   This	   analysis	  did	  not	  adjust	   for	   the	  baseline	   lesion	   length	   in	   the	  affected	  eye	  due	   to	  
concerns	   about	   comparing	   treatment	   effects	   on	   an	   active	   lesion	   in	   progress	   but	   was	  
adjusted	  for	  the	  other	  minimization	  variables.	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In	  a	   secondary	  analysis	  baseline	   lesion	   length	  was	   included	  as	  an	  additional	  covariate	  and	  
the	  adjusted	  active	  –	  placebo	  difference	  was	  -­‐2.12	  (p	  =0.32,	  95%	  CI	  -­‐6.36	  to	  2.12)	  
Table	  7-­‐1:	  Intention	  to	  treat	  comparison	  of	  the	  secondary	  outcome	  measures	  at	  6	  months	  












































































































Data	  are	  mean	  (SD)	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¶	  Pre-­‐specified	  adjustment	   for	  baseline	  unaffected	  value,	  centre,	  days	  between	  onset	  and	  
baseline,	  days	  between	  steroid	  and	  baseline;	  centre	  was	  dropped	  for	  optic	  nerve	  area,	  and	  
centre	  and	  baseline	  unaffected	  value	  were	  dropped	  for	  lesion	  length	  
a	  Comparison	   includes	   three	  active	  patients	  with	  affected	  eye	  vision	   too	  poor	   to	  give	  VEP	  
values,	   for	   which	   amplitude	   0μV	   and	   latency	   200ms	   was	   used.	   (baseline	   affected	   eye	  
measurements	  were	  not	  used	  in	  the	  primary	  comparison)	  
Lesional	  Magnetisation	  Transfer	  Ratio	  (MTR)	  
At	  baseline	  mean	  lesional	  MTR	  was	  lower	  by	  a	  mean	  of	  5.92	  pcu	  in	  the	  phenytoin	  and	  6.78	  
pcu	  in	  the	  placebo	  group	  when	  compared	  to	  the	  unaffected	  eye.	  By	  6	  months	  mean	  lesional	  
MTR	   had	   increased	   slightly	   by	   1.75	   pcu	   in	   the	   active	   group	   and	   1.90	   pcu	   in	   the	   placebo	  
group	   but	   was	   still	   significantly	   lower	   than	   the	   baseline	   unaffected	   eye	   (Figure	   7-­‐2)
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Figure	   7-­‐2:	   Graph	   illustrating	   mean	   baseline	   and	   6	   month	   affected	   eye	   MTR	   values	  
compared	  to	  the	  baseline	  unaffected	  eye	  
	  
	  
There	  was	  no	  significant	  active-­‐placebo	  difference	  in	  mean	  adjusted	  lesional	  magnetization	  
ratio	  (p=	  0.43)	  at	  6	  months	  (Table	  7-­‐2).	  
7.1.2 Functional	  measurements	  	  
	  LogMAR	  visual	  acuity	  
Visual	   loss	   in	   the	   affected	  eye	   at	   baseline	  was	   slightly	   (but	   not	   significantly)	  worse	   in	   the	  
phenytoin	  group	  (mean	  logMAR	  acuity	  =	  1.11)	  compared	  to	  placebo	  (mean	  LogMAR	  acuity	  =	  
1.07).	  In	  general	  vision	  recovered	  well	  in	  both	  groups	  and	  the	  mean	  best-­‐corrected	  log	  MAR	  
visual	  acuity	  in	  the	  affected	  eye	  at	  6	  months	  was	  0.09	  (SD	  0.4)	  in	  the	  active	  group	  and	  0.04	  
(SD	  0.18)	  in	  the	  placebo	  group.	  There	  was	  no	  significant	  difference	  in	  mean	  adjusted	  active-­‐
placebo	   in	   best	   corrected	   Log	   MAR	   visual	   acuity	   at	   6	   months	   (p=0.728)	   (Table	   7-­‐1).
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Figure	  7-­‐3:	  LogMAR	  visual	  acuity	  in	  the	  baseline	  unaffected	  eye	  and	  6	  month	  affected	  eye	  
in	  the	  phenytoin	  and	  placebo	  groups	  
	  
Bars	  are	  standard	  errors	  around	  the	  unadjusted	  group	  means	  
At	  one	  month	  and	  three	  months	  visual	  acuity	  was	  measured	  using	  the	  Snellen	  chart	  but	  for	  
the	  purpose	  of	  statistical	  analysis	  this	  data	  was	  converted	  to	  the	  LogMAR	  scale	  by	  taking	  –
log10	  of	  the	  snellen	  fraction.	  The	  graph	  below	  demonstrates	  the	  trajectory	  of	  visual	  recovery	  







Figure	  7-­‐4:	  Trajectory	  of	  visual	  recovery	  in	  the	  ITT	  comparison	  
	  
There	  were	  no	  significant	  differences	  in	  mean	  adjusted	  active-­‐placebo	  logMAR	  visual	  acuity	  
at	  one	  month	  (p=0.95)	  or	  three	  months	  (p=0.50).	  	  
	  Low	  contrast	  letter	  score	  
Due	   to	   the	   severity	   of	   visual	   loss	   in	   the	   affected	   eye	   there	   were	   floor	   effects	   in	   the	  
measurements	   of	   low	   contrast	   letter	   scores	   at	   both	   1.25%	   and	   2.5%	   contrast	   levels	   at	  
baseline.	  	  
As	  would	  be	  expected	  low	  contrast	  letter	  acuity	  at	  both	  contrast	  levels	  recovered	  less	  well	  
than	  high	  contrast	  acuity	  in	  both	  the	  phenytoin	  and	  placebo	  groups	  at	  6	  months.	  
There	   was	   no	   significant	   treatment	   effect	   at	   either	   1.25%	   or	   2.5%	   contrast	   levels	   at	   6	  






Figure	  7-­‐5:	  Scatter	  plot	  of	  2.5%	  low	  contrast	  letter	  scores	  in	  the	  baseline	  unaffected	  and	  6	  
month	  affected	  eye	  by	  trial	  arm	  
	  
Bars	  are	  standard	  errors	  around	  unadjusted	  group	  means	  
Farnsworth	  Munsell-­‐100	  Hue	  test	  
At	  baseline	  38%	  in	  the	  active	  group	  and	  43%	  in	  the	  placebo	  group	  were	  unable	  to	  perform	  
the	  test	  as	  their	  visual	  acuity	  was	  too	  poor.	  	  
Colour	  vision	   recovered	   less	  well	   than	  high	  contrast	  acuity	   in	  both	   the	  active	  and	  placebo	  
groups	  (Table	  7-­‐1).	  
There	  was	  no	  significant	  difference	  in	  mean	  adjusted	  FM-­‐100	  Hue	  between	  the	  groups	  at	  6	  
months	  (p=	  0.71)	  (Table	  7-­‐1).	  
Visual	  evoked	  potential	  measures	  
46.15%	  of	  patients	  in	  the	  phenytoin	  group	  and	  40.45%	  of	  patients	  in	  the	  placebo	  group	  had	  
large	  check	  VEPs	  that	  were	  unrecordable	  at	  baseline.	  This	  increased	  to	  51.28%	  (phenytoin)	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46.51%	  (placebo)	   for	  small	  check	  VEPs.	  At	  6	  months	  no	  patients	   in	  the	  placebo	  group	  and	  
8.54%	  in	  the	  phenytoin	  group	  had	  unrecordable	  small	  and	  large	  check	  VEPs.	  	  
For	   those	  with	   recordable	  VEPS,	  as	  would	  be	  expected,	  VEP	   latencies	   for	  both	  check	  sizes	  
were	  prolonged	  and	  VEP	  amplitudes	  reduced	  at	  baseline	  compared	  to	  the	  unaffected	  eye	  in	  
both	   groups.	   Consistent	   with	   previous	   studies,	   there	   was	   shortening	   of	   VEP	   latency	   at	   6	  
months	   in	   the	   affected	  eye	   in	   both	   groups	   (Brusa	   et	   al.,	   2001).	  However	   latency	  was	   still	  
prolonged	  by	  an	  average	  of	  28.99	  ms	  in	  the	  phenytoin	  group	  and	  22.67	  ms	  in	  the	  placebo	  
group	  compared	  to	  the	  baseline	  unaffected	  eye	  (small	  check).	  	  At	  6	  months	  VEP	  amplitudes	  
in	  the	  affected	  eye	  had	  returned	  to	  within	  normal	  limits	  in	  both	  groups.	  	  
There	  was	  no	  significant	  difference	  in	  either	  small	  (p=0.27)	  or	  large	  (0.14)	  check	  VEP	  latency	  
between	  the	  two	  groups	  at	  6	  months.	  Similarly	  adjusted	  active-­‐placebo	  difference	  was	  not	  
significant	  for	  either	  small	  (p=0.83)	  or	  large	  check	  (p=0.52)	  amplitude	  (Table	  7-­‐2).	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7.2 Per	  Protocol	  Analysis	  (Table	  7-­‐3)	  
The	   per	   protocol	   analysis	   was	   consistent	   with	   intention	   to	   treat	   analysis	   for	   all	   the	  
secondary	  outcome	  measures.	  
7.2.1 MRI	  
Optic	  nerve	  lesion	  length	  
The	  adjusted	  active-­‐placebo	  difference	  in	  6	  month	  lesion	  length	  was	  -­‐3.06	  mm	  (See	  Table	  7-­‐
3)	   and	   there	   was	   no	   significant	   treatment	   effect	   (p=0.24)	   NB:	   as	   in	   ITT	   analysis	   baseline	  
lesion	  length	  was	  not	  adjusted	  for,	  however,	  when	  baseline	  lesion	  length	  was	  included	  as	  a	  
covariate	  the	  active	  –placebo	  difference	  reduced	  further	  to	  	  -­‐1.93	  mm.	  	  
There	  was	   no	   evidence	   of	   a	   relationship	   between	   1-­‐month	   phenytoin	   levels	   in	   the	   active	  
group	  and	  6	  month	  lesion	  length	  (r=0.09,	  p=0.65).	  
Lesional	  Optic	  nerve	  cross-­‐sectional	  area	  
The	  adjusted	  difference	  in	  mean	  cross-­‐sectional	  area	  was	  0.37	  mm2	  	  (p=0.11)	  (Table	  7-­‐3).	  
There	  was	  no	  evidence	  of	  a	  relationship	  between	  1-­‐month	  phenytoin	  levels	  in	  and	  6-­‐month	  
optic	  nerve	  cross-­‐sectional	  area	  in	  the	  active	  group	  (r=0.26,	  p=0.18).	  
Lesional	  Magnetisation	  transfer	  ratio	  
Adjusted	  active-­‐placebo	  difference	  in	  mean	  lesional	  MTR	  was	  0.39	  pcu	  with	  no	  evidence	  of	  a	  
significant	   treatment	  effect	   (p=0.82)	   (Table	  7-­‐3).	   There	  was	  no	  evidence	  of	   an	  association	  




7.2.2 Functional	  measurements	  
LogMAR	  visual	  acuity	  
At	   6	   months	   there	   was	   no	   significant	   difference	   in	   mean	   adjusted	   active	   –placebo	   best	  
corrected	  visual	  (p=	  0.91)	  (Table	  7-­‐3).	  
There	   was	   no	   significant	   association	   between	   1-­‐month	   phenytoin	   levels	   and	   6	   month	  
LogMAR	  visual	  acuity	  (r=	  0.105,	  p=	  0.55)(Figure	  7-­‐6).	  
Figure	  7-­‐6:	  A	  Scatter	  graph	  of	  1	  month	  phenytoin	  levels	  against	  6	  month	  LogMAR	  visual	  	  
	  
Snellen	   visual	   acuities	   taken	   at	   1	   and	   three	  months	   were	   converted	   as	   explained	   above.	  
There	  was	  no	  significant	  active-­‐placebo	  difference	  in	  LogMAR	  visual	  acuity	  at	  either	  1	  month	  
(p=0.87)	   or	   3	   months	   (p=0.57)	   (See	   Figure	   7-­‐7	   for	   trajectory	   of	   visual	   recovery	   in	   the	  
phenytoin	  adherent	  and	  placebo	  groups).	  
At	  one	  month	  and	  three	  months	  there	  was	  no	  significant	  association	  between	  logMAR	  visual	  
acuity	  and	  1-­‐month	  phenytoin	  levels	  (r=0.009,	  p=0.75	  and	  r=0.006,	  p=0.8	  respectively).	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There	  was	  no	  evidence	  of	  an	  association	  between	  time	  to	  initiation	  of	  treatment	  and	  mean	  
LogMAR	  visual	  acuity	  at	  1	  month	  (r=	  -­‐0.15,	  p=0.43),	  3	  months	  (r=	  -­‐0.13,	  p=	  0.50)	  or	  6	  months	  
in	  the	  phenytoin	  adherent	  patients	  (r=-­‐0.20,	  p=0.30).	  
Figure	  7-­‐7:	  Trajectory	  of	  visual	  recovery	  in	  the	  per	  protocol	  	  
	  
	  
Low	  contrast	  letter	  score	  
There	   was	   no	   significant	   difference	   between	   the	   groups	   in	   low	   contrast	   letter	   scores	   at	  
either	  1.25%	  and	  2.5%	  contrast	  levels	  at	  6	  months	  (p=	  0.67	  and	  p=0.48	  respectively)(Table	  
7-­‐3).	  	  
Equally	   there	   was	   no	   association	   between	   6-­‐month	   low	   contrast	   letter	   score	   at	   either	  
contrast	  level	  and	  1-­‐month	  phenytoin	  levels.	  	  
In	  the	  phenytoin	  adherent	  group	  there	  was	  no	  evidence	  of	  an	  association	  between	  time	  to	  
initiation	  of	  treatment	  and	  6-­‐month	  low	  contrast	  letter.	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Farnsworth	  Munsell	  100	  Hue	  total	  error	  score	  
There	  was	  no	  significant	  difference	  in	  adjusted	  active-­‐placebo	  FM	  100	  Hue	  total	  error	  score	  
at	  6	  months	  (p=	  0.57)	  (Table	  7-­‐3).	  
Visual	  evoked	  potentials	  
There	   were	   no	   significant	   between	   group	   differences	   in	   mean	   small	   or	   large	   check	   VEP	  
latencies	   at	   6	   months	   (p=0.39	   and	   p=	   0.21).	   Likewise	   treatment	   with	   phenytoin	   had	   no	  
significant	  effect	  on	   small	  or	   large	  check	  VEP	  amplitudes	  at	  6	  months	   (p=0.79	  and	  p=0.58	  
respectively)	  (Table7-­‐3).	  
Again	  there	  was	  no	  association	  between	  phenytoin	  levels	  at	  1	  month	  or	  time	  to	  initiation	  of	  














Table	  7-­‐2:	  Per	  protocol	  comparison	  of	  the	  secondary	  endpoints	  at	  6	  months	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¶	  Pre-­‐specified	  adjustment	   for	  baseline	  unaffected	  value,	  centre,	  days	  between	  onset	  and	  
baseline,	  days	  between	  steroid	  and	  baseline;	  centre	  was	  dropped	  for	  optic	  nerve	  area,	  and	  
centre	  and	  baseline	  unaffected	  value	  were	  dropped	  for	  lesion	  length	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7.3 Discussion	  
Consistent	   with	   the	   significant	   treatment	   effects	   on	   RNFL	   thickness	   and	  macular	   volume	  
there	  was	  also	  a	  near	  significant	  treatment	  38%	  treatment	  effect	  on	  the	  loss	  of	  optic	  nerve	  
cross-­‐sectional	   area	   (p=0.06).	   This	   follows,	   as	   protecting	   axons	   in	   the	   optic	   nerve	   should	  
result	  in	  preservation	  of	  axons	  and	  their	  cell	  bodies	  in	  the	  retina.	  	  
Despite	   the	  observed	  neuroprotective	  effect	  on	   the	   structural	  OCT	  and	  MRI	  measures	  we	  
did	  not	  demonstrate	  a	  corresponding	  significant	  treatment	  effect	  on	  any	  of	   the	  functional	  
outcomes.	  	  
In	  general,	  high	  contrast	  visual	  acuity	  recovered	  well	  in	  the	  both	  the	  phenytoin	  and	  placebo	  
groups	  with	  possible	  ceiling	  effects	  making	  any	  potential	  benefits	  of	   treatment	  difficult	   to	  
demonstrate.	   It	   is	   important	   to	   note	   that	   this	   proof	   of	   concept,	   phase	   II	   trial	   was	   not	  
powered	   to	   demonstrate	   significant	   treatment	   effects	   on	   visual	   function.	   Lack	   of	   power	  
meant	  that	  we	  did	  not	  dwell	  on	  the	  results	  of	  colour	  vision	  and	  low	  contrast	  acuity	  (LCVA),	  
which	  were	  actually	  better	  (albeit	  non-­‐significantly)	  in	  the	  group	  treated	  with	  phenytoin.	  To	  
establish	  significance,	  we	  calculated	  that	  the	  effect	  size	  on	  LCVA	  we	  found	  in	  our	  study	  (0.15	  
for	  2.5%	  LCVA	  vs	  0.45	  for	  the	  RNFL)	  would	  require	  a	  trial	  involving	  630	  participants.	  
Furthermore,	   there	   is	   a	   degree	  of	   redundancy	  of	   axons	   in	   the	   anterior	   visual	   system	   that	  
complicates	   the	   relationship	   between	   structural	   and	   functional	   outcomes.	   A	   threshold	   of	  
axonal	  loss	  may	  be	  required	  to	  produce	  clinically	  significant	  high	  contrast	  visual	  loss.	  This	  is	  
supported	  by	  a	   clinico	  pathological	   study	  by	  Frisen	  et	   al	  who	  obtained	  nerve	   fibre	   counts	  
from	  the	  temporal	  quadrant	  of	  optic	  nerves	  from	  14	  eyes	  with	  known	  optic	  atrophy	  (of	  any	  
cause).	   They	   found	   that	   normal	   visual	   acuity	   was	   possible	   despite	   a	   40%	   loss	   of	   neural	  
substrate(Frisen	  and	  Quigley,	  1984).	  More	  recently,	  Costello	  et	  al	  demonstrated	  a	  threshold	  
RNFL	   thickness	   of	   75μms	   below	   which	   RNFL	   measurements	   predicted	   persistent	   visual	  
dysfunction	  (Costello	  et	  al.,	  2006).	  Therefore,	  it	  may	  be	  that	  the	  level	  of	  axonal	  loss	  required	  
for	  a	  clinically	  significant	  reduction	  in	  high	  contrast	  visual	  acuity	  was	  not	  reached	  in	  either	  
group	  after	  a	  single	  episode	  of	  optic	  neuritis.	  	  
Reduced	   neuroaxonal	   loss	   may	   only	   translate	   into	   clinical	   benefit	   further	   down	   the	   line	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either	   after	   repeated	   ‘inflammatory	   hits’	   to	   the	   optic	   nerve	   or	   with	   the	   more	   insidious	  
axonal	   loss	  known	  to	  occur	  over	  time	  in	  MS.	   In	  support	  of	  this,	   in	  eyes	  affected	  by	  two	  or	  
more	   episode	   of	   optic	   neuritis	   retinal	   nerve	   fibre	   layer	   atrophy	   is	   more	   severe	   and	   the	  
corresponding	   impact	   on	   visual	   outcome	  much	  more	   evident.	   For	   example,	   in	   one	   study	  
eyes	   affected	   by	   recurrent	   optic	   neuritis	   (mean	   number	   of	   ON	   events	   2.2)	   had	   a	   mean	  
affected	   eye	   RNFL	   thickness	   of	   64.2	   μms	   and	   a	   median	   logMAR	   visual	   acuity	   of	   0.32	  
compared	  to	  those	  with	  a	  single	  episode	  of	  optic	  neuritis	  who	  had	  a	  mean	  RNFL	  thickness	  of	  
86.3	  μms	  and	  a	  median	  logMAR	  acuity	  of	  0.23	  (Costello	  et	  al.,	  2010).	  
However,	   it	   should	  be	  noted	  that	   the	  concept	  of	   functional	   reserve	   is	  controversial.	   It	  has	  
been	   argued	   that	   the	   impression	   of	   functional	   reserve	   is	   only	   given	   by	   the	   logarithmic	  
nature	   of	  measures	   of	   visual	   function	   such	   as	   logMAR	   visual	   acuity	   and	   visual	   field	  mean	  
deviation	  and	  that	  the	  relationship	  is	  actually	  linear	  (as	  opposed	  to	  curvilinear)	  if	  the	  anti-­‐log	  
of	  the	  measurement	  is	  used.	  Additionally	  due	  to	  the	  higher	  variability	  and	  wider	  confidence	  
intervals	   of	   functional	   tests	   statistically	   significant	   structural	   damage	   is	   identified	   before	  
functional	   loss	  adding	   to	   the	   impression	  of	   functional	   reserve	   (Garway-­‐Heath	  et	  al.,	  2002;	  
Hood	  and	  Kardon,	  2007).	  	  
Thirdly,	   neuroplasticity	   in	   higher	   cortical	   areas	  may	   also	   be	   an	   important	   determinant	   of	  
visual	  outcome	  after	  optic	  neuritis.	  Jenkins	  et	  al	  found	  that	  greater	  baseline	  fMRI	  responses	  
in	   the	   lateral	   occipital	   cortex	   were	   predictive	   of	   better	   visual	   outcome.	   This	   effect	   was	  
independent	  of	  measures	  of	  neuroxonal	  loss	  (RNFL	  thickness	  and	  optic	  nerve	  cross-­‐sectional	  
area)	  and	  demyelination	  (VEP	  latency)	  (Jenkins	  et	  al.,	  2010).	  Thus,	  this	  could	  also	  contribute	  
to	   the	   lack	   of	   any	   significant	   difference	   in	   visual	   outcome	   between	   the	   two	   groups,	   as	  
neuroprotection	  would	  not	  be	  expected	  to	  have	  an	  effect	  on	  cortical	  adaptation.	  
Whereas	  both	  groups	  recovered	  well	  in	  terms	  of	  high	  contrast	  visual	  acuity,	  recovery	  of	  low	  
contrast	  acuity	  and	  colour	  vision	  was	  not	  as	  good.	  There	  was	  a	  >	  7	   letter	  reduction	   in	   low	  
contrast	  letter	  scores	  (at	  1.25	  %	  and	  2.5%)	  in	  both	  groups	  when	  compared	  to	  the	  baseline	  
unaffected	  eye,	  which	  has	  been	  demonstrated	   to	  be	  clinically	  meaningful	   (as	   this	  exceeds	  
the	  amount	  of	  change	  that	  would	  be	  expected	  from	  repeated	  testing	  when	  there	  is	  no	  ‘real’	  
change	  and	  has	  been	  associated	  with	  significant	   reductions	   in	  vision	  related	  quality	  of	   life	  
scores	   (Talman	  et	  al.,	  2010).	   	  Given	   the	  greater	   sensitivity	  of	   low	  contrast	   letter	   scores	   to	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optic	  neuritis	   related	  visual	   loss	   it	   is	  surprising	  that	  we	  did	  not	  see	  a	  significant	  treatment	  
effect.	   This	   could	   have	   several	   interpretations:	   1)	   that	   although	   phenytoin	   protected	  
ganglion	   cells	   and	   their	   axons	   they	   remained	  non-­‐functioning	  and	   therefore	   the	  observed	  
improvement	   in	   structural	   outcomes	  was	   not	   translated	   into	   functional	   gains	   2)	   that	   the	  
significantly	  higher	  RNFL	  thickness	  and	  macular	  volume	  in	  the	  phenytoin	  group	  was	  not	  due	  
to	   preserved	   ganglion	   cells	   and	   their	   axons	   but	   rather	   due	   to	   increased	   astrogliosis	   and	  
therefore	  we	  did	  not	  see	  any	  functional	  gains	  (although	  perhaps	  in	  this	  case	  one	  would	  have	  
expected	   the	  phenytoin	  group	   to	  have	  worse	   low	  contrast	   letter	   scores	  at	  6	  months	   than	  
the	   placebo	   group)	   3)	   that	   due	   to	   the	   variability	   and	   greater	   subjectivity	   of	   low	   contrast	  
letter	  scores	  they	  are	  not	  as	  sensitive	  to	  treatment	  effects	  as	  the	  structural	  outcomes	  and	  
therefore	  may	  require	  either	  more	  potent	  neuroprotective	  agents	  with	  greater	  effect	  sizes	  
or	  larger	  number	  of	  patients	  to	  demonstrate	  significant	  treatment	  effects	  in	  the	  future.	  	  	  	  	  	  
There	   was	   also	   no	   significant	   treatment	   effect	   on	   colour	   vision.	   This	   may	   be	   due	   to	   the	  
greater	   susceptibility	   of	   smaller	   axons	   in	   the	   parvocellular	   pathway	   to	   inflammatory	  
demyelination.	   Smaller	   axons	   have	   a	   larger	   surface	   area	   that	   may	   make	   them	   more	  
susceptible	   to	   toxic	   diffusible	   substances	   such	   as	   nitric	   oxide	   and	   may	   also	   have	   less	  
mitochondria	   rendering	   them	   more	   vulnerable	   to	   energy	   failure.	   In	   keeping	   with	   this,	  
despite	   significant	   treatment	   effects	   on	   mean	   superior	   (p=0.005)	   and	   nasal	   sector	   RNFL	  
thickness	   (p=0.058)	  phenytoin	  had	  no	  significant	  effect	  on	  temporal	  sector	  RNFL	  thickness	  
(p=0.39).	   The	   temporal	   sector	   of	   the	   RNFL	   receives	   small	   diameter	   nerve	   fibres	   from	   the	  
fovea	  via	  the	  papillomacular	  bundle,	  responsible	  for	  colour	  and	  central	  vision.	  There	  was	  a	  
large	  amount	  of	  variability	  in	  the	  FM-­‐hue	  100	  error	  scores	  and	  this	  test	  can	  be	  quite	  arduous	  
for	  patients	   requiring	  a	  high	   level	  of	  attention	  and	  concentration.	   	   It	   is	   important	   to	  note	  
that	   measures	   of	   visual	   function	   are	   subjective	   and	   are	   affected	   by	   factors	   such	   as	  
temperature,	   stress	   and	   fatigue	   as	   well	   as	   being	   on	   reliant	   on	   patient	   attention	   and	  
cooperation	  and	  so	  may	  not	  be	  as	  reliable	  as	  structural	  measures	  such	  as	  RNFL	  thickness.	  
Visual	  fields	  were	  not	  assessed	  as	  part	  of	  the	  trial	  protocol	   largely	  due	  to	  time	  constraints	  
Assessment	   of	   visual	   fields	   could	   have	   potentially	   demonstrated	   better	   topographical	  
correlations	  with	  the	  different	  RNFL	  quadrants	  and	  perhaps	  demonstrated	  treatment	  effects	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on	   regions	   of	   the	   field	   corresponding	   to	   the	   superior	   and	   nasal	   sectors	   of	   the	   RNFL	   that	  
were	  significantly	  higher	  in	  the	  phenytoin	  group.	  	  
There	   was	   no	   significant	   difference	   in	   either	   VEP	   latency	   or	   amplitude	   between	   the	   two	  
groups.	  Delayed	  VEP	   latency	   is	   considered	   to	  be	   a	  measure	  of	   demyelination	   in	   the	  optic	  
nerve.	  Although	  demyelination	  is	  a	  likely	  an	  important	  harbinger	  of	  axonal	  loss	  in	  MS	  it	  does	  
not	   necessarily	   follow	   that	   reducing	   axonal	   loss	   promotes	   remyelination.	   Different	  
mechanisms	   unrelated	   to	   axonal	   survival	   such	   as	   the	   availability	   of	   oligodendrocyte	  
progenitor	  cells	  are	  likely	  to	  be	  required	  for	  the	  latter.	  	  
Previous	   studies	   have	   not	   demonstrated	   an	   association	   between	   RNFL	   thickness	   and	   VEP	  
latency	  after	  optic	  neuritis	  (Trip	  et	  al.,	  2005),	  (Henderson	  et	  al.,	  2010)	  and	  this	  may	  explain	  
why	   although	  phenytoin	   had	   a	   neuroprotective	   effect	   on	   axonal	   loss	   it	   did	   not	   appear	   to	  
improve	  remyelination.	  
Also	   although	   the	   time	   course	   of	   axonal	   loss	   in	   the	   retina	   and	   optic	   nerve	   has	   been	  well	  
studied	  the	  exact	  time	  course	  of	  remyelination	  is	  unclear.	  Brusa	  et	  al	  demonstrated	  that	  VEP	  
latencies	   -­‐	   and	  by	   inference	   remyelination	   -­‐	   can	   continue	   to	  decrease	  up	   to	  2	   years	   after	  
optic	   neuritis	   (Brusa	   et	   al.,	   2001).	   As	   our	   patients	  were	   only	   followed	   up	   for	   6	  months	   a	  
longer	   period	   of	   follow	   up	   may	   be	   necessary	   to	   demonstrate	   any	   beneficial	   effects	   on	  
remyelination.	  
In	   keeping	   with	   the	   lack	   of	   treatment	   effect	   on	   VEP	   latency	   there	   was	   no	   significant	  
between	  group	  differences	  in	  mean	  lesional	  MTR	  at	  6	  mths.	  MTR	  is	  a	  measure	  of	  the	  degree	  
of	  proton	  exchange	  between	  free	  water	  and	  macromolecules	  and	   is	  said	  to	  be	  an	   indirect	  
measure	  of	  myelin.	  At	  baseline	  there	  was	  a	  reduction	  in	  mean	  lesional	  MTR	  in	  both	  groups	  
compared	  to	  the	  unaffected	  eye.	  This	   is	  consistent	  with	  what	  occurs	  in	  acute	  brain	  lesions	  
and	   likely	   represents	   demyelination	   and	   oedema	   in	   the	   optic	   nerve	   (Chen	   et	   al.,	   2008).	  
There	  was	  a	  subsequent	  slight	  increase	  in	  lesional	  MTR	  by	  6	  months	  in	  both	  groups	  that	  may	  
be	   indicative	   of	   remyelination.	   The	   fact	   that	   there	  was	   no	   significant	   treatment	   effect	   on	  
lesional	  MTR	  supports	  the	  above	  conclusion	  that	  preservation	  of	  axons	  with	  sodium	  channel	  
blockade	  does	  not	  improve	  remyelination.	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Our	  baseline	  MTR	   results	  are	  not	   in	   concordance	  with	   the	   findings	  of	  Hickman	  et	  al.	  who	  
found	   there	  was	  no	  change	   in	  optic	  nerve	  MTR	  at	  baseline	   (median	   time	  of	  13	  days	   from	  
onset	  of	  optic	  neuritis)	  and	  on	  subsequent	  follow	  up	  imaging	  optic	  nerve	  MTR	  was	  reduced	  
until	  it	  reached	  a	  nadir	  at	  8	  months.	  By	  1	  year	  there	  had	  been	  a	  slight	  increase	  optic	  nerve	  
MTR	  (Hickman	  et	  al.,	  2004a).	  This	  study	  was	  performed	  on	  a	  smaller	  cohort	  of	  patients	  (29-­‐	  
although	   they	  were	   scanned	  more	   frequently)	   on	   a	   1.5	   T	   scanner	   and	   both	   optic	   nerves	  
were	  imaged	  at	  the	  same	  time.	  Also	  our	  patients	  were	  recruited	  earlier	  (mean	  8.1	  days	  after	  
optic	   neuritis)	   and	   the	  evolution	  of	  MTR	   in	   the	  present	   trial	   cohort	   of	   patients	  was	  more	  
consistent	  with	  that	  which	  occurs	  in	  acute	  MS	  brain	  lesions	  (Chen	  et	  al.,	  2008).	  	  
	  The	  lack	  of	  neuroprotective	  effect	  on	  VEP	  amplitude	  is	  perhaps	  more	  surprising	  given	  this	  is	  
thought	  to	  be	  a	  measure	  of	  axonal	  integrity.	  However	  conventional	  VEPs	  are	  dominated	  by	  
central	   vision	   and	   the	   VEP	   signal	   is	  mainly	   derived	   from	   the	  macular	   region.	   It	   has	   been	  
estimated	  that	  65%	  of	  the	  total	  VEP	  response	  represents	  the	  central	  two	  degrees	  of	  visual	  
field	   (Graham	   and	   Klistorner,	   1998)	   and	   therefore	   conventional	   VEPs	   are	   unable	   to	  
accurately	  record	  peripheral	  damage.	  Given	  that	  there	  was	  no	  significant	  treatment	  effect	  
on	   temporal	   RNFL	   thickness	   it	   is	   not	   surprising	   that	   there	   was	   significant	   effect	   on	   VEP	  
amplitude	   given	   that	   these	   fibres	   subserve	  macular	   function.	   VEP	   amplitude	  may	   also	   be	  
confounded	  by	  demyelination	  because	  of	  temporal	  dispersion.	  
On	  the	  other	  hand	  multifocal	  VEPs	  assess	  the	  VEP	  signal	  not	  as	  a	  single	  global	  response	  but	  
obtain	   simultaneous	   responses	   over	   multiple	   regions	   of	   the	   visual	   field	   at	   greater	  
eccentricities	  providing	  topographic	  measurement	  of	  optic	  nerve	  function.	  The	  mean	  RNFL	  
thickness	  samples	  the	  nerve	  fibre	  layer	  from	  the	  whole	  retina.	  Multifocal	  VEPs	  are	  likely	  to	  
have	  been	  a	  more	  accurate	  way	  of	  picking	  up	  focal	  deficits	  in	  the	  visual	  field	  as	  well	  as	  being	  
more	  comparable	  to	  RNFL	  thickness	  in	  terms	  of	  their	  coverage	  of	  the	  retina	  (Klistorner	  et	  al.,	  
2008).	  
The	  use	  of	  multifocal	  VEPs	  may	  also	  have	  allowed	  a	  greater	  proportion	  of	  recordable	  VEPs	  at	  
baseline,	  as	  they	  are	  capable	  of	  extracting	  responses	  from	  more	  peripheral	  locations.	  
For	   future	   trials,	   it	   is	   likely	   that	   better	   neuroprotection	   will	   be	   required	   to	   demonstrate	  
treatment	   effects	   on	   clinical	   outcomes	   in	   reasonably	   sized	   trials.	   For	   this,	   trials	   might	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consider:	   1)	   more	   potent	   and	   specific	   inhibitors	   of	   sodium	   channels;	   2)	   higher	   drug	  
concentrations	  (phenytoin	  concentrations	  in	  this	  trial	  were	  possibly	  sub	  therapeutic);	  and	  3)	  
an	  even	  earlier	  window	  of	   treatment	   in	   the	  evolution	  of	   relapse,	  although	   in	  practice	   this	  
may	   be	   difficult.	   The	   last	   two	   suggestions	   are	   consistent	   with	   the	   lack	   of	   correlation	  
between	  structural	  outcomes	  and	  the	  concentration	  of	  phenytoin	  and	  time	  to	   initiation	  of	  
treatment	   in	   the	   present	   study.	   	   A	   longer	   follow	   up	   period	   could	   also	   improve	   the	   trial	  
design	  as	  although	  6	  months	  is	  an	  adequate	  time	  lag	  to	  demonstrate	  treatment	  effects	  on	  
RNFL	  thinning,	  longer	  time	  periods	  may	  be	  required	  for	  other	  outcome	  measures.	  
Conversely,	   the	   results	   of	   the	   trial	   do	   not	   place	   a	   lower	   limit	   on	   the	   duration	   for	   which	  
treatment	   is	   required	   for	   successful	  neuroprotection.	  Patients	  were	   treated	   for	  3	  months,	  
i.e.	  well	  beyond	  the	   interval	  when	  gadolinium	  enhancement	   indicates	   inflammation	   in	  the	  
optic	  nerve	  (Youl	  et	  al.,	  1991b),	  yet	  an	  exploratory	  analysis	  favored	  improved	  OCT	  outcomes	  
in	  those	  who	  received	  treatment	  for	  only	  a	  mean	  of	  18.4	  days	  before	  it	  was	  withdrawn	  due	  
to	  a	  skin	  rash.	  
The	   results	   support	   the	   utility	   of	   OCT	   for	   measuring	   outcome	   in	   future	   trials	   of	  
neuroprotection	  in	  optic	  neuritis.	  In	  comparison,	  the	  specificity	  of	  MRI	  for	  estimating	  axonal	  
loss	   in	   the	  optic	  nerve	  with	  MRI	  may	  be	   limited	  by	   the	  confounding	  effects	  of	  myelin	  and	  
other	   supporting	   tissue,	   and	   there	   are	   inherent	   difficulties	   of	   imaging	   such	   a	   small	   and	  
mobile	  structure.	  OCT	  also	  has	  obvious	  advantages	  of	  ease	  of	  use	  and	  lower	  cost,	  and	  has	  
previously	  been	  used	   in	   three	  small	   trials	  of	  neuroprotection	   in	  optic	  neuritis.	  Memantine	  
reduced	   the	   loss	  of	   the	  RNFL	   (Esfahani	  et	  al.,	   2012),	  while	  erythropoietin	  was	  effective	   in	  
one	  trial	  (Suhs	  et	  al.,	  2012)	  but	  not	  in	  another	  (Shayegannejad	  et	  al.,	  2015).	  The	  present	  trial	  
addressed	   limitations	  of	  these	  studies	  by	  correcting	  measurements	   in	  the	  affected	  eye	  for	  
baseline	   measurements	   in	   the	   unaffected	   eye,	   and	   reporting	   MV	   data	   as	   well	   as	   more	  
detailed	  MRI	  data.	  
At	   the	   average	   concentration	   achieved	   in	   this	   trial,	   phenytoin	   is	   an	   almost	   pure	   activity-­‐
dependent	   inhibitor	  of	  voltage-­‐gated	  sodium	  channels	   (McLean	  and	  Macdonald,	  1983).	  By	  
analogy,	   other	   sodium	   channel	   inhibitors	   should	   also	   be	   neuroprotective	   in	   acute	   optic	  
neuritis	  and,	  given	  its	  similarities	  to	  other	  relapses	  of	  multiple	  sclerosis,	  in	  those	  relapses	  as	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well.	   In	   turn,	   the	   present	   trial	   design	   should	   enable	   proof	   of	   concept	   of	   neuroprotection	  
after	  relapse	  for	  treatments	  with	  other	  modes	  of	  action.	  	  
Implications	  for	  treating	  progressive	  MS	  are	  harder	  to	  define	  because	  of	  possible	  differences	  
in	  pathophysiology:	  microglial	  activation	  is	  likely	  to	  remain	  important	  in	  progressive	  disease	  
(Mahad	  et	  al.,	  2015),	  whereas	  sodium	  channel	  expression	  may	  change	  (Black	  et	  al.,	  2007).	  
A	   previous	   trial	   of	   neuroprotection	   with	   sodium	   channel	   inhibition	   used	   lamotrigine	   in	  
secondary	  progressive	  multiple	  sclerosis	   (Kapoor	  et	  al.,	  2010).	  Treatment	  had	  no	  effect	  on	  
the	   rate	   of	   cerebral	   atrophy,	   but	   interpretation	   was	   hampered	   by	   a	   high	   rate	   of	   non-­‐
adherence,	  and	  in	  retrospect	  there	  were	  a	  number	  of	  positive	  signals	  in	  the	  study,	  including	  
a	  significant	  positive	  treatment	  effects	  on	  the	  rate	  of	  deterioration	  of	  the	  timed	  walk	  and	  on	  
serum	  neurofilament	  concentrations	  in	  the	  adherent	  group	  of	  patients	  (Gnanapavan	  et	  al.,	  
2013).	  	  
In	  conclusion,	  the	  results	  of	  this	  clinical	  trial	  support	  the	  concept	  of	  neuroprotection	  using	  
phenytoin	   to	   inhibit	   voltage-­‐gated	   sodium	   channels	   in	   acute	   optic	   neuritis.	   These	   results	  
should	   encourage	   larger,	   phase	   3	   trials	   of	   sodium	   channel	   inhibitors	   in	   optic	   neuritis	   and	  
other	  relapses	  of	  multiple	  sclerosis.	  Future	  studies	  should	  also	  establish	  more	  precisely	  the	  








Chapter	  8 Conclusion	  
In	   conclusion,	   the	   results	   of	   this	   phase	   II	   clinical	   trial	   suggest	   that	   partial	   sodium	   channel	  
blockade	  with	  phenytoin	  (given	  that	   in	  the	  doses	  used	  in	  the	  trial,	  phenytoin	   is	  a	  selective	  
sodium	   channel	   blocker	   (Yaari	   et	   al.,	   1986))	   protects	   the	   RNFL	   and	   macula	   from	  
neurodegeneration	   after	   acute	   optic	   neuritis.	   However	   it	   should	   be	   noted	   that	   OCT	  
measurements	  only	  allow	  us	  to	  measure	  the	  thickness	  of	  retinal	  layers	  and	  do	  not	  give	  any	  
information	  about	  the	  cytological	  make	  up	  of	  these	  layers	  nor	  allow	  us	  to	  directly	  visualise	  
the	   retinal	   ganglion	   cells	   and	   their	   axons.	   Therefore,	   an	   alternative	   explanation	   for	   the	  
results	  would	  be	  that	  higher	  astrogliosis	  in	  the	  phenytoin	  group	  (due	  to	  more	  RNFL	  swelling	  
at	   baseline)	   led	   to	   “falsely’	   higher	   RNFL	   thickness	   measures	   at	   6	   months.	   However,	   as	  
discussed	   in	   section	   6.7	   if	   this	   were	   true	   one	   would	   have	   expected	   to	   see	   positive	  
correlations	  between	  the	  baseline	  and	  6	  month	  affected	  eye	  RNFL	  measurements	  and	  also	  
that	  increased	  levels	  of	  astrogliosis	  would	  have	  lead	  to	  worse	  visual	  function	  at	  6	  months	  in	  
the	  phenytoin	  group.	  This	  was	  not	  reflected	  in	  the	  results.	  Novel	  techniques	  such	  as	  DARC	  
may	   allow	   us	   to	   directly	   visualise	   retinal	   ganglion	   cell	   loss	   when	   testing	   neuroprotective	  
agents	   in	   the	   future	   and	   allow	   greater	   certainty	   about	   the	   efficacy	   of	   these	   treatments	  
(Normando	  et	  al.,	  2015).	  
Otherwise,	   at	   baseline	   the	   characteristics	   of	   the	   phenytoin	   and	   placebo	   groups	   were	  
generally	   comparable	   and	   typical	   of	   acute	   optic	   neuritis.	   Only	   three	   of	   the	   86	   patients	  
recruited	   had	   a	   pre-­‐existing	   diagnosis	   of	   multiple	   sclerosis.	   Thus	   the	   cohort	   of	   patients	  
studied	  consisted	  almost	  entirely	  of	  patients	  with	  clinically	  isolated	  optic	  neuritis,	  although	  
nearly	  three	  quarters	  had	  at	  least	  one	  hyperintense	  T2	  lesion	  on	  MRI	  brain	  (and	  are	  at	  high	  
risk	   of	   developing	   clinically	   definite	   MS	   in	   the	   future,	   indeed	   30%	   already	   satisfied	  
McDonald’s	  2010	  criteria	  for	  MS).	  	  
At	   baseline	   the	   best	   independent	   predictor	   of	   visual	   loss	   measured	   using	   logMAR	   visual	  
acuity	   was	   conduction	   block	   on	   VEPs.	   The	   significant	   positive	   association	   between	  
conduction	  block	  on	  VEPs	  and	  RNFL	  swelling	  as	  well	  as	  conduction	  block	  and	  lesion	  length	  
would	  support	  the	  findings	  of	  Youl	  el	  al	  1991	  that	  inflammation	  and	  inflammatory	  mediators	  
contribute	  to	  conduction	  block	  and	  loss	  of	  visual	  function	  initially	  (Youl	  et	  al.,	  1991a).	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The	  characteristics	  of	   the	   lesion	  on	  MRI	  were	   important	  determinants	  of	  RNFL	  swelling	  at	  
baseline	   with	   more	   anterior	   and	   longer	   lesions	   being	   associated	   with	   significantly	   more	  
RNFL	  swelling.	   	  Lesion	  length	  (rather	  than	  location)	  was	  the	  best	   independent	  predictor	  of	  
RNFL	   swelling	   perhaps	   suggesting	   that	   swelling	   in	   the	   retina	   is	   more	   often	   secondary	   to	  
axoplasmic	  stasis	  proximal	  to	  the	  lesion	  in	  the	  optic	  nerve	  (rather	  than	  to	  direct	  extension	  of	  
inflammation	  from	  an	  anteriorly	  located	  optic	  nerve	  lesion).	  	  
The	  lack	  of	  significant	  baseline	  associations	  between	  any	  of	  the	  MRI,	  OCT	  or	  VEP	  measures	  
and	  low	  contrast	  letter	  scores	  may	  be	  due	  to	  a	  floor	  effect.	  This	  could	  limit	  the	  usefulness	  of	  
low	   contrast	   letter	   scores	   during	   the	   acute	   phase	   of	   optic	   neuritis	   when	   vision	   is	   most	  
impaired.	  	  
The	  loss	  of	  RNFL	  thickness	  in	  the	  placebo	  group	  after	  6	  months	  was	  consistent	  with	  previous	  
natural	  history	  studies.	  Treatment	  with	  phenytoin	  reduced	  RNFL	   loss	  by	  30%,	  and	  MV	  loss	  
by	  34%.	  Together	  with	  a	  near	  significant	  38%	  decrease	  in	  loss	  of	  optic	  nerve	  cross-­‐sectional	  
area,	   these	   results	   suggest	   that	   phenytoin	   protects	   the	   compartment	   comprising	   retinal	  
ganglion	  cells	  (which	  make	  up	  34%	  of	  macular	  volume	  (Sakai	  et	  al.,	  2011)	  and	  their	  axons	  in	  
the	  RNFL	  and	  optic	  nerve.	   These	   results	   are	   consistent	  with	   the	  neuroprotective	  effect	  of	  
sodium	  channel	  blockade	   in	  experimental	  models	  of	  optic	  neuritis	  and	  EAE	  (Garthwaite	  et	  
al.,	  2002;	  Lo	  et	  al.,	  2003)	  and	  support	  the	  ‘sodium	  hypothesis’	  of	  neuroaxonal	  loss	  within	  the	  
context	  of	  acute	  relapses	  in	  vivo.	  
In	  contrast,	  we	  observed	  no	  significant	  treatment	  effects	  on	  visual	  outcomes	  or	  on	  the	  VEP.	  	  
High	  contrast	  visual	  acuity	  and	  VEP	  amplitude	  recovered	  well	  in	  both	  phenytoin	  and	  placebo	  
groups	  and	  this	  ceiling	  effect	  may	  have	  limited	  their	  ability	  to	  demonstrate	  any	  benefits	  of	  
treatment.	   Perhaps	   more	   surprisingly	   low	   contrast	   acuity	   and	   color	   vision	   were	   not	  
significantly	   improved	   with	   phenytoin	   despite	   significant	   effects	   on	   structural	   outcomes.	  
This	   could	   be	   interpreted	   in	   several	   ways	   including	   1)	   that	   treatment	   with	   phenytoin	  
resulted	   in	   the	   preservation	   of	   structurally	   intact	   but	   non-­‐functioning	   axons,	   2)	   that	   the	  
relative	   imprecision	  of	   visual	   outcomes	  measures	  makes	   them	   less	   sensitive	   to	   treatment	  
effects	   than	   structural	   outcomes	   or	   3)	   that	   improved	   structural	   outcomes	   did	   not	   reflect	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preservation	  of	  axons	  but	  rather	  increased	  levels	  of	  astrogliosis	  and	  therefore	  there	  was	  no	  
improvement	  in	  visual	  function.	  	  
Additionally,	   It	   may	   be	   that	   the	   small	   fibres	   of	   the	   parvocellular	   pathway	   are	   selectively	  
affected	  early	  on	  during	  the	  course	  of	  optic	  neuritis	  explaining	  the	  lack	  of	  treatment	  effect	  
on	  colour	  vision	  as	  well	  as	  on	  the	  temporal	  sector	  of	  the	  RNFL	  (Evangelou	  et	  al.,	  2001)	  and	  
may	  require	  even	  earlier	  intervention	  with	  neuroprotective	  therapies.	  	  	  
It	  should	  be	  noted	  that	  in	  our	  cohort	  of	  patients	  there	  was	  a	  highly	  significant	  but	  moderate	  
negative	   association	   between	   RNFL	   thickness	   and	   logMAR	   visual	   acuity	   at	   6	   months	  
(p=<0.0001,	  r=-­‐0.57)	  and	  similar	  moderate	  correlations	  with	   low	  contrast	   letter	  acuity	  at	  6	  
months	  perhaps	  suggesting	  that	  factors	  other	  than	  axonal	  loss	  contribute	  to	  visual	  outcome.	  
This	   could	   explain	   some	   of	   the	   discrepancy	   in	   the	   treatment	   effects	   on	   structural	   and	  
functional	  outcomes.	   In	   future,	   it	  may	  be	   important	   to	  gain	  a	  better	  understanding	  of	   the	  
mechanism	  of	  functional	  recovery	  after	  optic	  neuritis	  and	  their	  relationship	  with	  structural	  
outcomes	   in	   order	   to	   adequately	   power	   trials	   to	   demonstrate	   treatment	   effects	   on	  
functional	   outcomes.	   For	   example	   the	   visual	   cortex	   and	   LGN	   contain	   3-­‐400	   fold	   more	  
neurons	   than	   the	   retina	   and	   this	  may	   contribute	   to	   neuroplasticity	   in	   higher	   visual	   areas	  
which	  influences	  functional	  prognosis	  (Jenkins	  et	  al.,	  2010). 
The	  concept	  of	  ‘structural	  reserve’	  and	  ‘redundancy’	  of	  axons	  in	  the	  anterior	  visual	  system	  
needs	  to	  be	  explored	  further	  to	  establish	  if	  there	  is	  a	  threshold	  of	  axonal	  loss	  below	  which	  
clinically	  significant	  visual	  dysfunction	  manifests.	  If	  this	  is	  the	  case,	  then	  the	  clinical	  benefits	  
of	  neuroprotection	  may	  only	  become	  apparent	   later	  on	  after	  repeated	   ‘inflammatory	  hits’	  
on	  the	  optic	  nerve	  have	  a	  cumulative	  effect	  on	  axonal	  loss.	  
In	   future	   trials	   it	  will	   also	  be	   important	   to	   include	  patient	   reported	  outcomes	   such	  as	   the	  
NEI-­‐VFQ-­‐25	  quality	  of	  life	  score	  and	  to	  determine	  more	  precisely	  what	  are	  clinically	  relevant	  
improvements	  in	  visual	  outcome,	  particularly	  in	  trials	  such	  as	  ours	  with	  a	  short	  duration	  of	  
follow	  up.	  A	  composite	  visual	  score,	  comparable	  to	  the	  multiple	  sclerosis	  composite	  score	  
(Rudick	  et	  al.,	  2002)	  for	  physical	  disability,	  comprising	  measurements	  of	  several	  components	  
of	  visual	  function	  may	  be	  a	  better,	  more	  comprehensive	  functional	  outcome	  measure.	  This	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would	  require	  consensus	  from	  the	  MS	  community	  and	  need	  validation	  before	  being	  used	  in	  
clinical	  trials.	  	  
The	  lack	  of	  any	  significant	  reduction	  in	  VEP	  latency	  with	  phenytoin	  would	  suggest	  that	  the	  
greater	   preservation	   of	   axons	   in	   the	   retina	   and	   optic	   nerve	   was	   not	   due	   to	   enhanced	  
remyelination	   and	   that	   different	   biological	   processes	   are	   involved.	   However,	   clearly	   axon	  
preservation	   is	   a	   requirement	   to	   allow	   remyelination	   to	   occur	   and	   the	   time	   frame	   for	  
remyelination	  to	  occur	  may	  have	  exceeded	  the	  length	  of	  follow	  up	  in	  the	  trial.	  
The	  success	  of	  this	  trial	  would	  support	  the	  use	  of	  the	  anterior	  visual	  system	  as	  a	  model	  for	  
testing	  potential	   neuroprotective	   treatments	   in	  MS.	  Using	   a	   sentinel	   lesion	   approach,	   the	  
anterior	  visual	  system	  can	  be	  studied	  in	  detail	  thanks	  to	  the	  availability	  of	  validated,	  highly	  
sensitive	  clinical,	  imaging	  and	  electrophysiological	  techniques.	  The	  anterior	  visual	  system	  is	  
a	  structurally	  eloquent	  area	  of	  the	  CNS	  with	  biological	  traits	  that	  makes	  it	  ideal	  for	  modeling	  
the	  processes	  of	  neurodegeneration	  and	  repair.	  In	  particular,	  the	  retinal	  nerve	  fibre	  layer	  is	  
a	   relatively	   pure	   compartment	   of	   unmyelinated	   axons	  whose	   thickness	   can	   be	  measured	  
sensitively	  and	  non-­‐invasively	  using	  optical	   coherence	   tomography	  making	   it	   an	  attractive	  
biomarker	  of	  axonal	   loss.	   In	  addition	   to	   this	   the	  natural	  history	  of	  optic	  neuritis	  has	  been	  
well	   defined	   and	   the	   duration	   to	   outcome	   is	   relatively	   short	   meaning	   putative	  
neuroprotective	  treatments	  can	  be	  tested	  quickly	  and	  efficiently.	  
The	  effect	  sizes	  demonstrated	  in	  this	  trial	  support	  the	  use	  of	  OCT	  measures	  as	  primary	  end	  
points	  in	  future	  proof	  of	  concept	  optic	  neuritis	  trials.	  Our	  results	  would	  suggest	  that	  OCT	  is	  
superior	  to	  MRI	  of	  the	  optic	  nerve	  in	  demonstrating	  treatment	  effects.	  This	  may	  be	  due	  to	  
the	   confounding	   effects	   of	   myelin	   in	   the	   optic	   nerve.	   In	   addition	   to	   this,	   the	   inherent	  
difficulties	   in	   imaging	   such	   a	   small	   and	  mobile	   structure	  means	   that	   optic	   nerve	   imaging	  
with	  MRI	  involves	  longer	  scanning	  times	  and	  is	  very	  reliant	  on	  patient	  compliance	  during	  the	  
scan	   to	   reduce	   motion	   artifact.	   Moreover,	   as	   opposed	   to	   the	   quick,	   automated	   RNFL	  
measurements	  obtained	  with	  OCT,	  optic	  nerve	  cross-­‐sectional	  area	  measurements	  are	  more	  
labour	   intensive	   and	   currently	   not	   automated	   making	   them	   less	   reproducible.	   As	   a	  
biomarker,	  it	  may	  not	  add	  much	  value	  to	  the	  structural	  measurements	  of	  the	  retinal	  nerve	  
fibre	  layer.	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There	  may	  nevertheless	   be	   benefits	   in	   performing	  optic	   nerve	   imaging	  with	  MRI	   in	   acute	  
optic	   neuritis	   trials.	   Identification	   of	   the	   lesion	   in	   the	   optic	   nerve	   that	   can	   help	   with	  
diagnostic	   certainty,	   in	   particular	   when	   patients	   need	   to	   be	   recruited	   quickly	   within	   a	  
narrow	   time	  window.	  Additionally,	  measures	   such	   as	   lesion	   length	   and	   lesional	  MTR	  may	  
prove	  useful	  in	  future	  trial	  especially	  when	  the	  therapeutic	  focus	  is	  on	  repair.	  	  
The	  advantages	  of	  our	  trial	  design	  are	  1)	  we	  recruited	  a	  well-­‐defined	  cohort	  of	  patients	  with	  
early	  MS/	  CIS	  patients	  in	  whom	  sodium	  channel	  blockade	  with	  phenytoin	  was	  generally	  well	  
tolerated.	  2)	  Patients	  were	  recruited	  and	  loaded	  with	  phenytoin	  early,	  within	  two	  weeks	  of	  
symptom	   onset,	   and	   the	   read	   out	   time	   delayed	   until	   three	   months	   after	   cessation	   of	  
treatment	   to	   incorporate	   the	   lag	   in	  RNFL	  atrophy.	   	   3)	   There	  was	  a	   clear	   treatment	   target	  
with	  good	  experimental	  evidence	  for	  its	  rationale.	  4)	  The	  trial	  was	  properly	  powered	  using	  
longitudinal	  natural	  history	  data	  to	  inform	  sample	  sizes.	  	  
Despite	   these	   advantages,	   this	   was	   a	   small	   proof	   of	   concept	   trial,	   and	   definitive	  
confirmation	  of	  the	  findings	  would	  require	  a	  larger	  phase	  3	  trial;	  such	  a	  trial	  would	  also	  be	  
needed	   to	  determine	  whether	   there	   is	   a	  more	   subtle	  benefit	   to	   vision	   that	   could	  only	  be	  
detected	  in	  a	  large	  cohort.	  	  
Ten	   of	   the	   39	   active	   patients	   available	   at	   follow-­‐up	   were	   non-­‐adherent.	   While	   this	   may	  
affect	   the	   power	   of	   the	   ITT	   analysis,	   the	   robustness	   of	   the	   results	   is	   supported	   by	   the	  
agreement	  between	  the	  ITT	  and	  PP	  analyses	  as	  well	  as	  the	  consistency	  of	  treatment	  effects	  
in	   the	   macula,	   RNFL	   and	   optic	   nerve.	   Patients	   in	   the	   active	   group	   who	   discontinued	  
treatment	   (mainly	  due	   to	  a	   rash)	   remained	  on	   treatment	   for	  a	  mean	  of	  18.4	  days	  and	  an	  
exploratory	  analysis	  demonstrated	  improved	  OCT	  outcomes	  compared	  to	  the	  placebo	  group	  
even	  after	  this	  short	  length	  of	  time.	  	  
Regarding	  potential	  sources	  of	  bias	  care	  was	  taken	  to	  exclude	  patients	  with	  atypical	  acute	  
optic	   neuritis,	   and	   none	   of	   the	   participants	   developed	   features	   of	   disorders	   such	   as	  
neuromyelitis	   optica	   (for	   which	   antibodies	   were	   also	   tested	   at	   presentation)	   or	   chronic	  
relapsing	   inflammatory	   optic	   neuropathy.	   Since	   the	   study	   started,	   further	   immunological	  
subtypes	   of	   optic	   neuritis	   have	   been	   suggested	   (e.g.	   those	   with	   antibodies	   to	   myelin	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oligodendrocyte	  glycoprotein)	  and	  appropriate	  testing	  of	  these	  subtypes	  for	  any	  differences	  
in	  their	  response	  to	  neuroprotective	  therapies	  will	  be	  important	  to	  include	  in	  future	  studies.	  
It	   is	   unlikely	   that	   concomitant	   corticosteroid	   treatment	   would	   have	   influenced	   the	  
neuroprotective	   findings	   because	   care	   was	   taken	   to	   adjust	   the	   analysis	   for	   the	   use	   and	  
timing	  of	  corticosteroids.	  Also,	  measurements	  of	  the	  RNFL	  and	  of	  MV	  remained	  stable	  in	  the	  
fellow	   eye	   in	   both	   the	   phenytoin	   and	   placebo	   groups,	   and	   previous	   studies	   showed	   that	  
corticosteroids	  did	  not	  prevent	  atrophy	  of	  the	  RNFL	  (Naismith	  et	  al.,	  2009a)	  or	  optic	  nerve	  
(Hickman	  et	  al.,	  2003),	  or	  visual	  recovery	  after	  optic	  neuritis	  (Beck	  et	  al.,	  1992b).	  	  	  
	  
Although	   the	   read	   out	   time	   for	   our	   trial	   was	   timed	   to	   detect	   treatment	   effects	   on	   RNFL	  
atrophy	  it	  is	  unclear	  whether	  a	  six-­‐month	  follow	  period	  is	  long	  enough	  to	  detect	  beneficial	  
effects	   on	   other	   outcome	   measures.	   For	   example,	   the	   time	   course	   of	   remyelination	   is	  
unclear,	  with	  one	  study	  reporting	  a	  reduction	  in	  VEP	  latency	  up	  to	  2	  years	  post	  optic	  neuritis	  
(Brusa	  et	  al.,	  2001).	  Also,	  the	  visual	  system	  may	  compensate	  well	  in	  the	  short	  term	  but	  may	  
fail	   over	   longer	   periods	  with	   poorer	   functional	   outcome	   usually	   occurring	   after	   recurrent	  
episodes	  of	  optic	  neuritis.	  Therefore	  longer	  follow	  up	  periods	  may	  be	  required	  to	  evaluate	  
whether	   the	   increased	   structural	   reserve	   afforded	   by	   neuroprotection	   translates	   into	  
functional	  gain	  further	  down	  the	  line.	  	  
	  
Finally,	  a	  proportion	  of	  the	  patients	  recruited	  had	  a	  normal	  baseline	  brain	  MRI	  and	  it	  could	  
be	  argued	  that	  they	  should	  not	  have	  been	  included	  in	  the	  study	  given	  the	  relatively	  low	  risk	  
of	  them	  having	  an	  MS	  associated	  optic	  neuritis.	  However	  there	  was	  no	  statistical	  difference	  
in	   the	   treatment	   effect	   (on	   the	   primary	   analysis)	   between	   participants	   with	   normal	   and	  
abnormal	  brain	  MRI	  scans	  at	  baseline	  (p=0.629)	  and	  the	  pathological	  process	  may	  be	  similar	  
in	  idiopathic	  optic	  neuritis.	  
	  
Treatment	   with	   phenytoin	   was	   generally	   well	   tolerated	   and	   was	   not	   associated	   with	  
abnormalities	  in	  the	  blood	  count	  or	  liver	  function.	  We	  did	  not	  note	  any	  acute	  deterioration	  
of	  vision	  that	  might	  be	  attributed	  to	  conduction	  block	  from	  inhibition	  of	  sodium	  currents,	  or	  
any	  rebound	  deterioration	  upon	  withdrawal	  of	  treatment—effects	  that	  had	  previously	  been	  
thought	  to	  potentially	  limit	  the	  use	  of	  drugs	  acting	  on	  this	  target	  in	  demyelinating	  disorders.	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Only	  one	  participant	  had	  a	  severe	  adverse	  reaction—a	  skin	  rash—attributable	  to	  phenytoin,	  
but	   a	   further	   nine	   participants	   developed	   minor,	   self-­‐limiting	   skin	   rashes	   and	   were	  
withdrawn	   from	   treatment	   by	   the	   investigators	   according	   to	   protocol.	   Masking	   of	  
participants	  to	  treatment	  allocation	  failed	  in	  some	  cases	  as	  a	  result	  of	  skin	  rashes.	  Although	  
this	  unmasking	  might	  have	  had	  an	  effect	  on	  patient-­‐based	  clinical	  assessment,	  it	  should	  not	  
have	  affected	  the	  primary	  outcome	  
	  
Future	  trials	  should	  consider	  the	  use	  of	  more	  potent	  and	  specific	  sodium	  channel	  inhibitors	  
with	  better	   side	  effect	  profiles,	   even	  earlier	   treatment	  windows	   (although	   in	  practice	   this	  
may	  be	  very	  difficult	  to	  achieve)	  and	  higher	  drug	  concentrations.	  Using	  data	  from	  this	  trial	  
and	  other	  longitudinal	  studies	  of	  acute	  optic	  neuritis	  it	  may	  be	  possible	  to	  identify	  and	  select	  
patients	   at	   baseline	   with	   a	   poorer	   prognosis	   who	   have	   the	   most	   to	   gain	   from	  
neuroprotective	  treatments.	  Future	  studies	  should	  also	  establish	  more	  precisely	  the	  optimal	  
therapeutic	  window	  for	  neuroprotection	  in	  relapses.	  
	  
Some	  studies	  have	  suggested	  that	  the	  GC/IPL	  layer	  thickness	  in	  the	  macula	  may	  be	  a	  better	  
biomarker	   of	   axonal	   loss	   after	   optic	   neuritis	   as,	   unlike	   the	   RNFL,	   its	  measurement	   is	   not	  
affected	  by	  swelling	  acutely	  and	  GC/IPL	  layer	  thinning	  may	  occur	  earlier	  perhaps	  within	  days	  
of	   symptom	   onset	   (Gabilondo	   et	   al.,	   2015).	   Also,	   compared	   to	   RNFL	   thickness	   measures	  
there	   is	   less	   inter-­‐patient	  variability	   in	  GC/IPL	  measures	  and	  so	   it	  may	  be	  a	  better	  primary	  
outcome	  measure	  for	  future	  trials.	  	  
Also,	   new	   technology	   such	   as	   ultra	   high-­‐resolution	   OCT	   imaging	   may	   enable	   better	   and	  
more	  detailed	  and	  accurate	  measurements	  of	  the	  retinal	  layers	  in	  the	  macula	  (Zawadzki	  et	  
al.,	  2005;	  Choi	  et	  al.,	  2008)	  
Furthermore,	   in	   addition	   to	   the	   structural	   measurements	   obtained	   with	   OCT,	   techniques	  
such	   a	   ramen	   spectroscopy	   may	   allow	   us	   to	   obtain	   biochemical	   information	   on	   the	  
molecular	  processes	  of	  neurodegeneration	   in	  the	  retina	   in	  MS.	  Also,	   it	  may	  be	  possible	  to	  
make	  use	  of	   techniques	  such	  as	  detection	  of	  apoptosing	  retinal	  cells	   (DARC)	   that	  employs	  
fluorescently	   labeled	  annexing	  5	  and	   confocal	   laser	   scanning	  ophthalmoscopy0	   to	  directly	  
visualise	  the	  amount	  of	  retinal	  ganglion	  cell	  loss.	  This	  could	  give	  us	  pathological	  insights	  into	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the	  timing	  of	  RGC	  loss	  after	  optic	  neuritis	  as	  well	  as	  allowing	  greater	  pathological	  specificity	  
when	  testing	  neurprotective	  treatment	  (Normando	  et	  al.,	  2015).	  Advances	  in	  functional	  MRI	  
and	   electrophysiological	   techniques	   such	   as	   multifocal	   VEPs	   may	   also	   allow	   us	   to	   better	  
elucidate	  the	  pathophysiological	  mechanisms	  of	  functional	  recovery	  and	  its	  failure.	  
As	   the	   pathophysiology	   of	   optic	   neuritis	   resembles	   that	   of	   other	   relapses	   in	   MS	   sodium	  
channel	   blockade	   should	   be	   effective	   in	   these	   relapses	   as	   well.	   In	   turn,	   the	   present	   trial	  
design	  should	  enable	  proof	  of	  concept	  of	  neuroprotection	  after	  relapse	  for	  treatments	  with	  
other	  modes	   of	   action.	  However,	  whilst	   the	  mechanisms	  of	   neuroprotection	  with	   sodium	  
channel	   blockade	   would	   seem	   more	   applicable	   within	   the	   context	   of	   other	   acute	  
inflammatory	  lesions	  in	  relapsing	  MS,	  the	  implications	  for	  treating	  the	  more	  “slow	  burning”	  
neurodegeneration	  of	  progressive	  MS	  are	  harder	  to	  define	  because	  of	  possible	  differences	  
in	  pathophysiology.	  Microglial	  activation	  is	  likely	  to	  remain	  important	  in	  progressive	  disease,	  
whereas	  sodium	  channel	  expression	  might	  change	  (Black	  et	  al.,	  2007).	  	  	  
In	   summary,	   the	   results	  of	   this	   clinical	   trial	   support	   the	   concept	  of	   neuroprotection	  using	  
phenytoin	   to	   inhibit	   voltage-­‐gated	   sodium	   channels	   in	   acute	   optic	   neuritis.	   These	   results	  
should	   encourage	   larger,	   phase	   3	   trials	   of	   sodium	   channel	   inhibitors	   in	   optic	   neuritis	   and	  
other	   relapses	   of	   MS.	   The	   present	   trial	   design	   should	   also	   enable	   proof	   of	   concept	   of	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